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ABSTRACT
The s c ie n tif ic  lite ra tu re  indicates that the biotransformation of 
xenobiotics in man is more s im ilar to that observed in the non-human 
primate than to other laboratory animal species.
The main objective of the current investigation was to compare the 
a b il i ty  of 3 species of non-human primate, the rhesus monkey 
(Macaca m ulatta) ,  the cynomolgus monkey (Macaca fa s c ic u la ris ) and 
the baboon (Papio species), to conjugate xenobiotics with glutathione  
since such information is lacking in the lite ra tu re .
The metabolism and pharmacokinetics of ethacrynic acid, a d iu re tic  
known to be extensively metabolised by glutathione conjugation in 
several other animal species, was studied in the non-human primates.
The results indicate that the overall capacity fo r glutathione 
conjugation in the non-human primate is large, and demonstrate that 
various organs and tissues can simultaneously contribute to the 
detoxication and elim ination of various xenobiotics by this pathway.
In common with other laboratory animal species, the non-human 
primate excreted the major proportion of ra d io a c tiv ity , following  
administration of 14C-ethacrynic acid, in the b ile . The ra d io ac tiv ity  
in the b ile  was mainly associated with metabolites which had resulted  
from the in i t ia l  conjugation of ethacrynic acid with glutathione, 
and the subsequent metabolism of this conjugate via the mercapturic 
acid pathway. There were notable species differences, between the 
non-human primates and other laboratory animals, in the proportions
of the various metabolites which were excreted in the b ile .
Although the concentrations of glutathione in the various tissues 
of the non-human primate were s im ilar to those reported for other 
mamnals, species differences occurred in the rates of glutathione 
conjugation and the subsequent metabolism of the glutathione  
conjugate.
A s ig n ifican t finding concerned the extent to which various 
a£-unsaturated xenobiotics were conjugated with glutathione.
There were marked species differences between the non-human primate 
and the ra t in this respect.
The rhesus monkey, cynomolgus monkey and the baboon are s im ilar as 
regards ethacrynic acid metabolism, tissue glutathione concentrations, 
tissue glutathione S-transferase a c t iv it ie s , and the specific  
a c tiv it ie s  of the glutathione S-transferase isoenzymes. The rhesus 
monkey more closely resembles man in these respects, but both other 
species of non-human primate would appear to be suitable fo r use 
in metabolism and toxicological studies of compounds lik e ly  to be 
conjugated with glutathione.
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CHAPTER 1
HISTORICAL INTRODUCTION 
INTRODUCTION
During the la s t 3| decades there has been an enormous volume o f 
s c ie n tif ic  lite ra tu re  dealing with the metabolism of xenobiotics. 
Xenobiotics are defined as those compounds which are not endogenous 
to the species of in te res t. The apparent complexity of the metabolic 
reactions which are responsible fo r the metabolism of these compounds 
was . in it ia l ly  delineated by R.T. Williams and co-workers between 1947 
and 1959. Williams (1947; 1959) provided the c lass ifica tio n  which 
divided the major reaction pathways into 4 major groups. These groups 
were the processes of oxidation, reduction, hydrolysis and conjugation 
of the xenobiotics. The e ffec t of any of these reactions on an 
individual compound normally results in the product being more water 
soluble and, therefore,less lip o p h ilic  than the parent compound and 
thus more read ily  excreted. In recent years, however, a growing 
number of metabolic products which are not more water soluble and 
less lip o p h ilic  than the parent compound have been discovered.
The concept of m etabolically "activated" compounds which would have a 
greater potential to x ic ity  than the parent compound has attracted  much 
in te res t. For a review see Jollow et a l . (1977).
The c lass ifica tio n  of Williams (1959) grouped the oxidation, reduction 
and hydrolytic reactions together as phase I reactions and the 
usually subsequent conjugation reactions can be regarded as phase I I
reactions (Parke, 1968). By no means a ll  xenobiotic compounds 
undergo both phase I and phase I I  reactions in th is  biphasic manner, 
some compounds can form “conjugates" d irectly , w hilst others are 
metabolised By phase I reactions only.
Phase I reactions
As stated previously, the biotransformation reactions which co llective ly  
constitute the metabolic phase I reactions involve 3 main types o f  
chemical reaction, oxidation, reduction and hydrolysis. Of these 
the oxidation and reduction pathways are perhaps the major groups.
The former causes the addition of oxygen to e ith e r carbon, nitrogen 
or sulphur atoms, the N-, S- and O-dealkylation and oxidative  
deamination. These oxidation reactions are often , but not always, 
catalysed by enzymes present in the endoplasmic reticulum (microsomal 
frac tio n ) of the c e ll ,  Non-microsomal oxidases convert alcohols and 
aldehydes to carboxylic acids, and some amino acids are oxidised.
The m ajority of phase I oxidation reactions, catalysed by the enzymes 
present in the endoplasmic reticulum are mediated by the mixed 
function oxidases. This group of enzymes are widely d istributed  in 
most mammalian tissues, For these enzymes to function, a requirement 
exists fo r both molecular oxygen and the reduced dinucleotide NADPH 
to be availab le .
Examples o f the oxidation of xenobiotics which can occur in the 
microsomal frac tion  of ce lls  are,the oxidation of acetanilide to 
paracetamol (p-hydroxyacetanilide), the oxidation of an ilin e  to 
p-aminophenol or phenacetin to 2-hydroxyphenacetin (aromatic oxidation); 
the a lip h a tic  oxidation of tolbutamide to the corresponding hydroxymethyl 
compound. N- or S-oxidation reactions can occur with such compounds as
trim ethyl amine or ran itid in e  to y ie ld  the respective N-oxides, or with 
chlorpromazine to y ie ld  chlorpromazine sulphoxide. Phase I reactions 
are also responsible fo r the removal of alkyl groups attached to 
e ith e r nitrogen, sulphur or oxygen, fo r example the N-dealkylation  
of am itrip ty lin e  to produce n o rtr ip ty lin e , or the successive 
N-dealkylation of dimethyl an ilin e  yields an ilin e  via the monomethyl- 
intermediate. Aminopyrine can be metabolised by N-dealkylation to 
produce 4^methylaminoantipyrine. The S-dealkylation of such compounds 
as 6-methylthiopurine results in the formation of 6-mercaptopurine.
Alkyl groups attached vta oxygen can also be removed in a s im ilar  
manner, fo r example phenacetin to p-hydroxyacetanilide or the 
production of p-nitrophenol from p-n itroan iso le . Oxidative deamination 
can occur with such compounds as amphetamine to produce ammonia and 
phenyl acetone. Some additional reactions, such as the desulphuration 
of parathion to paraoxon,are mediated by microsomal enzymes.
Reactions involving reductions can be mediated by microsomal enzymes, 
examples of these reactions include the reduction of nitrobenzene 
to a n ilin e , the azoreducti/on of compounds such as protosil, and the 
dehalogenation of halothane to form trifluoroethane. Sulphur compounds 
can also be reduced,but usually by non-microsomal enzymes, to y ie ld  
th io ls  and sulphides. The hydrolytic reactions are catalysed by a 
numher of enzymes found in the cytosol but which also e x is t in blood 
plasma. Esters and amides are hydrolysed to th e ir  respective acids, 
procaineamide is  hydrolysed to p-aminobenzoic acid.
Some xenobiotics can be metabolised by phase I reactions to produce 
"active" metabolites. These are metabolites which have greater toxic  
potential and are capable of causing e ith e r c e llu la r  damage, e .g . necrosis,
or they can exert mutagenic or carcinogenic affects  (Jerina and Daly,
1974). There are numerous examples of such "active" intermediates.
One such group of compounds are those which undergo epoxide formation 
catalysed by the various microsomal enzymes. The metabolism of 
bromobenzene proceeds via the production of arene oxides mediated 
by the cytochrome Pi^ q system (Reid et- a l , 1971). One of the 2 
observed epoxides, the 3,4-oxide, is believed to be responsible fo r  
the liv e r  necrosis which occurs following bromobenzene administration  
(Jollow et a l , 1974). Epoxide hydrolase can hydrate the arene oxides 
to the respective dihydrodiols. A lte rn a tiv e ly , the epoxide can be 
conjugated with GSH (Chasseaud, 1969), glucuronic acid (Burke et a l , 
1977) or sulphate (Cohen et a l , 1976). Any modification of this  
pathway, fo r example by the depletion of GSH, or the in h ib itio n  of 
the glutathione S-transferases can therefore cause increased 
to x ic ity . Sim ilar metabolic "activation" has been observed with 
the polycyclic aromatic hydrocarbons, in which epoxide intermediates 
are also produced, together with the more reactive diol epoxides. 
Compounds which serve to i l lu s tra te  th is type of metabolism are 
naphthalene and benzo [a  Ipyrene (Holder et a l , 1974; Cooper et al, 1983). 
Aflatoxin Bi can also be "activated" (Wogan, 1975). The reactive metabol ites  
of these compounds can be conjugated with GSH (Boyland and Williams,
1965; W aterfall and Sims, 1972; Raj et a l , 1975; Moss et a l , 1983). 
Another compound which is converted to an "active" metabolite is 
paracetamol, in th is  case the reactive intermediate is believed 
to be qutnoneimine, formed by the dehydration of the N-hydroxylated 
compound produced by the cytochrome Pi^o system (Hinson et a l , 1977).
FIGURE I 
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Phase I I  reactions
Often, but not always, the metabolic products formed as a resu lt of 
phase I reactions are conjugated with an endogenous molecule. There 
are as least 8 major “conjugation '1 reactions through which endogenous 
molecules can be attached to xenobiotic substances depending on the 
functional groups availab le fo r such reactions. The conjugation 
reactions are summarised in Table I; from Caldwell (1982). In 
addition to the main conjugation reactions lis te d  in Table I ,  there 
are several other conjugation reactions which are less common. These 
reactions can resu lt in conjugates such as N-formyl (Boyland and 
Manson, 1966; Gothoskar e t a l , 1979):, N-succinyl (Caldwell, 1980), 
methylthio (S t i l lw e ll ,  1978 a&b; M uller e t a l , 1978), o-galactoside  
(Williamson et a l , 1972J, N-ribosides (Swartz e t a ! , 1973), fa t ty  
acid conjugates with p a lm itic , stearic- and lin o le ic  acids (Leighty  
e t a l , 1980). A recent review of unusual or less common conjugation 
reactions has appeared (Hawkins, 1981).
I t  should not be assumed that the formation of a conjugate automatically 
reduces the biological a c t iv ity  of a xenobiotic fo r there are examples 
where the reverse is  the case. There are 3 main types of "active"  
conjugates these are ( I }  conjugates that are chemically s tab le ,
(21 conjugates whose chemical re a c tiv ity  results in metabolic 
ac tiva tio n , and (31 conjugates which are not the end products of 
metabolism but which undergo fu rther metabolism. Morphine 
6-glucuronide, and N-acetylprocainamide, both conjugates, have 
been shown to possess the same or enhanced pharmacological a c t iv ity  
(Kalant and Macleod, 1980). The conjugation of ethylene dibromide 
with glutathione is an example of the second case (Van Bladeren e t a l ,
1979) where an S-2-bromoethyl glutathione can be formed which can act
as a sulphur mustard and be mutagenic. The glucuronides of 
benzo[ a ]pyrene may be deconjugated and converted into carcinogens 
in various tissues (Kinoshita and Gelboin, 1978). The N-glucuronide 
of N-hydroxy-2-acetamidofluorene is rapidly excreted in the urine 
but can be fu rther metabolised in the bladder where i t  can be 
carcinogenic. S im ila rly , the N-acetylation of isoniazid produces a 
conjugate which is  fu rther metabolised via hydrolysis to ison icotin ic  
acid and N-acetylhydrazine, a hepatotoxin.
TABLE I 
Conjugation reactions3
Conjugation
reaction High energy intermediates*
Functional groups 
involved
Glucuronidation Uridine diphosphate glucuronic 
acid (UDPEA)
-OH, -C00H, -NH2
-n r2 , -sh, 5 c-h
Glucose
conjugation
Uridine diphosphate glucose 
[UDPG] -OH, -C00H,-SH,r:NH
Sulphation Adenosine 3 '-phosphate 5 '-  
phosphosulphate (PAPS) -OH, -NH2 , -SH
Methylation S-Andenosylmethionine 
5-m ethyltetrahydrofolic acid -OH, -NH2
Acetylation Acetyl coenzyme A -OH, -NH2
Cyanide
detoxication
Thiosulphate + 3-mercapto- 
pyruvate CN~
Amino acid 
conjugation Coenzyme A thioesters -C00H •
Glutathione 
conjugation 
( *  See also 
Table I I )
Arene oxides, epoxides, a r y l, 
alkyl and aralkyl halides Various
a From Caldwell (1982).
*  The reactions with the sulDhane sulphur of thiosulphateand 
3-mercaptopyruvate, and the formation of glutathione conjugates 
are not normally classed as high energy intermediates.
Superimposed on the general phase I and phase I I  pathways of 
detoxication are the p ec u lia ritie s  of species differences in
metabolism. Individual species have been known fo r a long time to 
be defic ien t in one or more specific  pathways, fo r example, the 
members of the cat fam ily do not normally produce glucuronides with 
simple phenols. The dog and the fox do not read ily  N-acetylate  
various xenobiotics. The guinea-pig does not produce a mercapturic 
acid as an end product of glutathione conjugation due to deficiency  
in an acetyl CoA dependent N-acetylase. Of the conjugation reactions 
which occur, the conjugation of xenobiotics with glutamine appears 
to he^restricted to man and the non-human primates (Smith and Caldwell, 
1977}, the conjugation of aromatic acids with ornithine is s im ila r ly  
restric ted  to birds and re p tile s , and the conjugation with phenols 
to insects (Baldwin e t a l , 1960; Dutton, 1966; Smith, 1968). The 
conjugation of aryl acetic acids with taurine occurs to a major extent 
in carnivors (Caldwell, 1980) and taurine conjugates of c lo f ib r ic  
acid are only observed in the dog (Caldwell, 1982).
When a p articu la r xenobiotic or group of compounds are being studied, 
the choice of species in which the investigations are conducted 
should be governed by several factors which must be recognised.
For instance, does the species represent a relevant metabolic model 
fo r the class of compounds to be investigated? Is the species 
under examination m etabolically and pharmacologically typical of 
the species which w ill u ltim ately  be exposed to the xenobiotic?
There is also the consideration as to the a v a ila b il ity  of a 
p articu la r species. In a large number of cases the existing  
metabolic knowledge is in s u ffic ie n t to make a specific  choice as 
to the most suitable species fo r study.
-  r  -
This thesis is prim arily  concerned with the conjugation of xenobiotics 
with glutathione.
To-date there have been no major comparative studies conducted on 
glutathione conjugation in the non-human primate and man. The 
lim ited  data which ex is t tend-to suggest that the glutathione  
S-transferases of the non-human primate more closely'resemble those 
of man than those of the ra t ,  with respect to substrate s p e c ific ity  
and the physical characteristics of the individual isoenzymes. The 
non-human primate used in metabolic investigations, because of its  
s im ila r ity  to man in various metabolic respects, has mainly been the 
rhesus monkey (Macaca m ulatta). However, severe lim ita tio n s  are 
placed on the use of rhesus monkeys due to th e ir  lim ited  a v a ila b il ity .  
In th is thesis , 2 other "Old World" non-human primates were included 
to provide a broader base of comparison between the non-human primate 
and man. The 2 species of- "Old World" primate investigated were the 
baboon [Papio sp. ) and the cvnomolgus monkey (Macaca fa s c ic u la r is ) 
because these species are used extensively in metabolic and 
toxicological investigations.
GLUTATHIONE CONJUGATION
Glutath.ione
Glutathione (GSH} is a tripep tide  with the amino acid sequence of 
y-L-glutam yl-L-cysteinylg lycine (Figure I I ) .
NH2 ch2shI l
hooc-ch-ch2-ch2-conh-ch-conh-ch2-cooh
Glutathione 
FIGURE I I
Glutathione in crude form was isolated by De Rey-Pailhade in 1888
i n
from yeast (c ited  by Isherwood, 1959), but tlopkins (1921) was the f i r s t  
person to obtain a c rys ta llin e  preparation, which in 1929 he demonstrated 
was the trip ep tid e . The orig inal formula fo r glutathione was suggested 
by P ir ie  and Pinhey (1929). based on a physicochemical study of the 
tr ip e p tid e . Form these studies the following pKa values were obtained:
SH -  9 .66 , NHp^- 8 . 66 , COOH @  -  3.53 and ©  -  2.12. These values 
were subsequently re-examined by Cohn and Edsall [1943) and the 
following pKa values were determined: SH -  8.7 and NH3 ©  - 9 . 1  with 
the acid group v ir tu a lly  the same. Later studies by Jung et a l . (1972)
using nuclear magnetic resonance produced a value of 9.2 fo r the pKa
/
of the SH group.
Thiols in general may be reactive towards free rad ica ls , dona t ing hydrogen 
to most carbon, oxygen and nitrogen containing radicals e.g. GSH + H0<U»GS~+ H20 
Early observations of the re a c tiv ity  of the SH group were obtained 
with maleic acid (Friedmannet a l , 1949) and N-ethylmaleimide (Hanes e t a l , 
1951). Both these compounds are aB-unsaturated compounds and the 
nucleophilic suTphydryl group adds onto the double bond to y ie ld  
alkyl derivatives. Other reactions of the th io l group-are discussed 
la te r .
D istribution of glutathione
GSH is widely d istributed in animal tissues, and since the early  
estimations of tissue concentrations of GSH were made (Woodward and Fry,
1932; Woodward, 1935) there have been many reports concerning the 
concentrations of GSH which occur in various animal tissues 
(Davidson and Hird, 1964; Racker, 1951). GSH also occurs in plants 
(Crook and Hopkins, 1938) and in microorganisms (Jocelyn, 1972).
Of prime importance are the observations that GSH has been found 
in tra c e llu la r ly  in v ir tu a lly  a ll  mammalian ce lls  and tissues. GSH is 
also the most abundant of the c e llu la r  th io l compounds (M eister,
1975). In tra c e llu la r ly , GSH exists mainly in the reduced form 
[GSH ]  which is read ily  interchangeable with the oxidised form 
[  GSSG ] .  The concentrations of glutathione are re la t iv e ly  high in 
some tissues (up to 10 nM in live r). (Woodward, 1935; Bhattacharya et a l , 
1956; Shaker and Soliman, 1966) and numerous methods have been 
developed to measure the GSH in ce lls  (fo r a review of methodology 
see Jocelyn, 1972; Akerboom and Sies, 1981).
As w ith  any compound present in normal ce lls  GSH exists in equilibrium  
between synthesis and degradation. Of in teres t are the observations 
of Waelsch and Rittenberg (1941). Srivustava and Beutler (1968) 
and B arto li (1978), which reported that GSH has very fas t turnover 
ra tes , 5-24 h in various tissues.
Synthesis
Glutathione is synthesised from i ts  component ami noacids by a 2-stage 
process. The f i r s t  stage is  catalysed by the enzyme y-glutamylcysteine  
synthetase which, using a magnesium dependent reaction involving ATP, 
jo ins  L-glutamate and L^cysteine together to form y-glutamylcysteine  
(Orlowski and M eisters 1970). The second stage is catalysed by 
glutathione synthetase, which also requires magnesium and ATP to 
attach a molecule of L-glycine to the y-glutamlycysteine (Orlowski 
and M eister, 1970; Orlowski and W ilk, 1975). In some instances 
L-glycine can be replaced by L-a-aminobutyrate to y ie ld  opthalmic 
acid, or L-alanine to y ie ld  noropthalmic acid. The regulation of 
glutathione synthesis and degradation can be summarised and depicted
as the y-glutamyl cycle (Orlowski and M eister, 1970) (Figure I I I ) .
FIGURE I I I  
The y-glutamyl cyclea
Aminoacid 
(AA)
ATP
ATP
5-oxoproline
Cystein^
Cys-gly Glycine
Glutamate
Glutathione
v-glu-cys-gly
ATP
Enzymes are: ©  y-Glutamyltranspeptidase < D  y-Glutamyl 
cylotransferase; ©  Cysteinyl glycinase; ©  5-0xoprolinase;
(D y-Glutamyl synthetase; ( 6)  Glutathione synthetase.
a From Orlowski and Meister (1970).
The regulation of GSH synthesis is thought to be controlled by 
feedback in h ib itio n , and Richman and Meister (1975) have 
demonstrated that physiological concentrations of GSH in h ib it  the 
synthetic reactions. The level of the precursor amino acids, in
p articu la r cysteine, also lim its  the rate of synthesis (Tateishi e t a l , 
1974). The in tra c e llu la r  concentration of gluta.thione can be 
dependent also on such factors as the n u tritio n a l status (Tateishi 
et a l , 1974), the hormonal balance (Lazarow, 1954), and the growth 
of the organism (Jocelyn, 1959).
The biological and biochemical importance of maintaining a uniform 
concentration of glutathione is  due in part to the th io l group with 
which GSH can perform several protective functions. GSH provides 
protection of the S,H groups of proteins which may be of c a ta ly tic  
importance (Jocelyn, 1972; Flohe and Gunzler, 197-6). GSH can function  
as a regulator by the in teraction with proteins which require an SH 
group fo r th e ir  biological a c t iv ity  (Kosower and Kosower, 1976).
Lawrence et al ~. (1978) reported that GSH provides protection  
against oxidative stress, GSH also functions as a co-factor in many 
diverse enzyme reactions such as GSSG reductase (B eutler, 1974);
GSH peroxidase (Flohe and Gunzler, 1974); the dehydroascorbate 
dehydrogenase system of plants and micro-organisms (Mapson and Moustafa, 1956); 
formaldehyde dehydrogenase (S tr ittm a tte r  and B u ll, 1955; Rose and 
Racker, 1962; M eister, 1981J and the glutathione S-transferases 
(Boy!and e t a l , 1961; Booth et a l , 1961}. The formation of 
leukotriene C,the "slow reacting substance" of anaphalaxis 
(Brockelhurst, 1960)_, involves the addition of GSH to a leukotriene  
precursor epoxide of arachidonic acid (Orning e t a l , 1980). The l i s t  
is  by no means exhaustive [fo r  a review see Flohe and Gunzler, 1976).
Degradation
The in i t ia l  stage in the degradation of glutathione involves the loss 
of the y-glutamyl moiety [Hanes e tv a l, 1950; 1952), and a number of
research groups have studied the d is trib u tio n  and a c tiv ity  levels of 
y-glutamyltranspeptidase (y-GT), the enzyme responsible fo r the 
removal of the Y~9 l ‘utamyl residue. The tissue d is trib u tio n  of y“GT 
has been reviewed by Tate (1980). The involvement of y- GT has
been suggested in the glutathione dependent transport of amino acids 
(M eister, 1975). The involvement of y -GT in the biosynthesis of 
mercapturic acids could be in ferred as y~GT was noticeably  
more active with S-substituted glutathione (GSH conjugates) 
than with reduced GSH. The other enzymes responsible fo r the fu rther  
degradation of GSH are considered in the section dealing with 
mercapturic acid’ formation.
Conjugation with glutathione
Xenobiotics having a wide varie ty  of e lec tro p h ilic  groups can be 
conjugated with glutathione. These reactions can occur normally due 
to the in tr in s ic  nucleophilic re a c tiv ity  of the th io l group of GSH or 
be enzyme-mediated through the glutathione S-transferases (EC 2 .5 .1 .1 8 ) .
The GS-transferases can also form conjugates with endogenous compounds, 
fo r example, A-3-ketosteroids (Benson et a l , 1977), prostaglandin A 
(Cagen et a l , 1975), the endoperoxide intermediates o f the 
prostaglandins (Chri st-Hazelhof et a l , 1976), 15-ketoprostaglandins 
(Chaudhari et a l , 1978), thyroxine (Aykac, 1980). Lately there has 
been considerable in teres t in the formation of the leukotrienes 
involving in teraction of glutathione with the polyunsaturated fa t ty  
acid intermediates of the arachidonic acid cascade (Sammuelsson et a l , 
1982). The term leukotriene was used to describe both the 
characteris tic  structural featu re , i . e .  a conjugated tr ie n e , and
the observation that the conjugates were produced by several ce lls  
related to leukocytes. The major leukotriene (leukotriene C )^ 
(Figure IV) was shown to be (5S, 6R)-5-hydroxy-6-S-y-glutam yl-L- 
c y s te in y lg ly c in e -7 ,9 -tra n s -ll, 14-cis-etcosatetraenoic acid formed 
via an epoxide intermediate (leukotriene Ai*) (Murphy e t a l , 1979).
FIGURE IV
Leukotriene
The degradation of leukotriene Ci* proceeds via the loss of the 
y-glutamyl moiety (catalysed by y-GT) to give leukotriene Di* which 
then loses glycine catalysed by dipeptidase to y ie ld  leukotreine E^. 
Other leukotrienes C3 and C5 are known to arise from the corresponding 
tr ien o ic  and pentaenoic fa t ty  acids (Hammerstrom, 1983). The 
characterisation of the GS-transferase responsible fo r  leukotreine Ci* 
synthesis has been recently reported (Bach et a l , 1984).
The involvement of glutathione with xenobiotics was observed with the 
displacement of the halide group of several halogenonitrobenzenes 
(Knight and Young, 1958; Booth et a l , 1961). Although sulphur 
containing metabolites of bromobenzene and chlorobenzene had been 
reported over 10G years e a r lie r  by Baumann and Preusse (1879) and 
Jaffe (1879) (c ited  by Chasseaud, 1979) the d e fin ite  involvement of 
GSH was not appreciated u n til many years la te r  (Barnes et a l , 1959; 
Bray et a l , 1959), The 1960'S saw a rapid growth in the reported
number of compounds which are conjugated with GSH. Once the range of 
compounds shown to have the required e le c tro p h ilic ity  to react with 
the nucleophile GSH had began to expand the GS-transferases thought; 
to be responsible were prefixed with a descriptive term indicating  
type of compound involved.. Thus, the terms GS-aryltransferase (Grover and Sims 
1964], a lky1 transferase (Johnson, 1966), aralkyl transferase (Boyland 
and Chasseaud, 1969), epoxidetransferase (Boyland and W illiam s, 1965) 
and alkenetransferase (Boyland and Chasseaud, 1967 and 1973) became 
established. Demonstration of the overlapping substrate s p e c ific ity  
of each of these GS-transferases prompted a red e fin itio n  of the 
GS-transferases present in ra t  live rs  (Habig e t a l , 1974; Pabst e t a l , 
1974; Jakoby, 1976),
Some of the compounds known to be conjugated with GSH are shown in 
Table I I  and the group comprising the ag-unsaturated compounds is  
presented in expanded form as Table I I I ,  For comprehensive reviews 
of the conjugation of numerous compounds with glutathione see 
Chasseaud (1976; 1979),
The u tilis a t io n  of glutathione as the th io l donor fo r the glutathione  
S-transferases Is  specific  as regards endogenous th io ls . The 
endogenous th io ls  cysteine, N-acetylcysteine or pantotheine cannot 
replace GSH In the GS-transferase reaction. An apparent replacement 
of GSH by propylthiouracil has been observed (Yamada and Kaplowitz,
1980), but could not be confirmed (Habig e t a l , 1984). In addition to 
the ca ta ly tic  functions of the GS-transferases i t  must be remembered 
that these proteins can function as binding or c a rr ie r  proteins fo r  a 
large numher of lip o p h ilic  compounds such as stero ids, b iliru b in  and 
a varie ty  of exogenous organic anions (K etterer et a l , 1967; Litwack
et a l , 1971). The protein responsible, termed "ligandin'1, was f i r s t  
isolated as an aminoazodye binding protein by Ketterer and Whitehead 
(1965), and Ketterer e t a l . (1967). The aminoazodye carcinogen was 
shown to be bound covalently to the cysteinyl residues of the 
polypeptide (K etterer aind Christodoulides, 1969), as well as forming 
a glutathione conjugate (K etterer and Beale, 1971). This protein was 
shown to be iden tica l to the proteins which had been called the 
"Cortisol-m etabolite" binding protein (Morey and Litwack, 1969), 
b iliru b in  binding protein (Levi e t al, 1969) and glutathione S-transferase 
"B" (Habig et a l , 1974; K etleyxet a l , 1975).
Some evidence exists that ligandin can function as a storage protein  
(Jakoby and Habig, 1980), or i t  can function as a transport protein  
as indicated by Wol koff e t a l . (1978) ,
Occurrence of GS-transferase
The glutathione S-transferases ex is t in most mammals and other species 
of animals, birds (Grover and Sims, 1964; Husain et a l, 1981), fish  
(Bend et a l , 1977; Parker e t al, 1981; Nimmo et a l, 1979), and also in 
insects (Shishjdd et a l > 1972; Motoyama et a l , 1983). The 
GS-transferases are also found in plants (Lamoureaux and Frear, 1979; 
Moser et a l, 1983) and micro-organisms (Larson and Bakke, 1983). The 
GS-transferases ex ist p rim arily  as a cytosolic (soluble) enzyme 
system comprising approximately 10% of the cytosolic protein in  
ra t l iv e r  (Jakoby et a1, 1976) and 2% of the cytosolic protein in 
human liv e r  (Habig et a l , 1976). These enzymes also occur in the 
microsomal fraction  (endoplasmic reticulum ) of animals (Morgenstern e t a l, 
1979, 1983; Frledberg et a l , 1979; DePierre, 1983) and also in the 
microsomes of plants (Diesperger and Sandermann, 1979).
GS-transferase a c tiv ity  is  also present in the mitochondria of 
animal tissues (Wahllander e t a l , 1979; Kraus et a l , 1981) and also 
animal ce ll nuclei (Morgenstern e t a l , 1979).
The soluble GS-transferases are usually homo- or hetero-dimeric 
proteins with a sub-unit molecular weight of between 22,000 and 
25,000, and occur in numerous species of animals including ra t ,  
mouse, non-human primate and man (Jakoby and Habig, 1980).
Rat l iv e r  cytosol contains several GS-transferases (a t least 8 ) 
which have been shown to be homo- or hetero-dimeric proteins 
comprising 4 immunological!/ d ts tin c t sub-units (Pabst e t a l , 1973; 
Askelof et a l, 1975; Jakoby et al, 1976) . Several groups working with  
these proteins ascribed individual le tte rs  to indicate individual 
isoenzymes following the orig inal c lass ific a tio n  of the ra t l iv e r  
GS-transferases (Habig ert a l » 1974). The nomenclature was confused 
by the addition of new isoenzymes fo r which there was no consistent 
nomenclature. In an attempt to resolve the problems of nomenclature 
Jakoby e t a1 . (1984) published a set of guidelines following a 
Workshop on the GS-transferases held at Dundee in 1983 (Table IV) .
A s im ilar array of isoenzymes has also been observed in man 
(Kamisaka e t al , 1975 a,b), mouse (Benson et a l, 1978; Lee e t a l , 1981), 
guinea pig (Irw in e t a l , 1980) and monkey (Asaoka et a l , 1977).
TABLE I I
Glutathione conjugation
Compound conjugated 
with glutathione Reference
Halogenonitrobenzenes Bray e t aK  1957; Booth e t a l , 1961; 
Johnson, 1966; Suga e t a l , 1967
Aryl nitrocompounds Al-Kassab et a l , 1963
Aralkyl halides Suga e t a l , 1967; Bray e t a l , 1958
Aralkyl esters Clapp and Young, 1970; G ill ham, 1971
Epoxides ■ Boyland and W illiams, 1965;' 
F je lls te d t e t a l , 1973;
Sims and Grover, 1974
Aery1 amide Edwards, 1975; D ix it , 1981
Alkyl halides Booth et a l , 1961; Bray e t a l ,  1964
Organic n itra tes Needleman and Hunter, 1965; 
Keen and Jakoby, 1978
Organic thiocyanates Habig e t a l ,  1975; Keen, e t a l . 1976; 
Ohkawa et a l ,  19r t
ag-unsaturated compounds 
(see Table I I I )
Boyland and Chasseaud, 1967, 1968, 1969; 
Chasseaud, 1973, 1979
Nitrofurans Boyland and Speyer, 1970
Bromosulphthalein Coomhes and Stake!urn, 1961; 
J a v itt  e t a l ,  1960
Organophosphorus Fukami and Shishido, 1966
Sulphonamides Colucci and Buyske, 1965
TABLE M I
a3-Unsaturated compounds probably metabolised by glutathione
conjugation3
Class of 
compound
Ester
Aldehyde
ExamDle
Ethyl acrylate  
Cinnamaldehyde
Ketone Ethyl vinyl ketone 
*  Ethacrynic acid
*  trans-4-Phenyl -3-butene-l-one
*  Cyclohex-2-ene-l-one
Lactone
N it r i le  
Sul phone 
Amide
Parasorbic: acid
A cry lo n itr ile  
Methylvi nylsulphone 
Acrylamide
Structure
CH2=CHC00CH2CH3
CH=CHCH0
CH2=CHCOCH2CH3
Cl Cl
0CH2C00H
o
CH3 ^ 0 ^
ch2=chcn 
ch2=chso2ch3 
ch2=chconh2
0
a Adapted from Chasseaud, 1979.
*  Substrates fo r GS-transferase used in th is  thesis.
TABLE IV
Nomenclature fo r the ra t glutathione S-transferasesa
New designation
Previous nomenclature (Ref. )'&
O © © ® ©  © © ©
GS-transferase 1-1 \
Ligandin B
Ligandin ■ Bi Ya/Ya 1-2
1-2 * B b2 Ya/Yc BL
2-2 AA AA Yc/Yc b2
3-3 A A .YbVYb1- a2
3-4 C C Yb1/Yb2 AC
4-4 D "D" Yb: /Yb- C2
• 5-5 E E
6-6 mt
a Table adapted from Jakoby et a l , 1984.
 ^ Reference to each c la s s ific a tio n : (T ) Carne e t a l.  (1979); .
©  Habig e t a l . (19741; @  Hayes e t a l . (1981); ©  Ketterer e t al 
(1983); ( 5)  Scully and Mantle (1980); Mannervik and Jensson 
(1982); Diericks and De Beer (1981).
Rat glutathione S-transferases
Rat liv e r  was the tissue of choice fo r several research groups due to
2 main features, f i r s t ly  the a v a ila b il ity  of the animal species and 
secondly, ra t l iv e r  was known to contain a high concentration of 
GS-transferases, up to 10% of the cytosolic protein (Jakoby et a l ,
19761 ,^ The "basic" ra t hepatic GS-transferases can be separated from 
each other by means of CM-cellulose chromatography (Habig e t a l , 1974). 
The ra t l iv e r  GS-transferase isoenzymes were o r ig in a lly  designated,
D, E, C, B, A and AA in order of th e ir  elution from the CM-cellulose 
column. Using the new c las s ifica tio n  scheme of Jakoby e t a l . (1984), 
these enzymes would correspond to 4 -4 , 5 -5 , 3 -4 , 1-1 and 1 -2 , 3-3
and 2-2. Another isoenzyme with high a c tiv ity  towards the substrate 
menaphthyl sulphate has also been isolated (Gillham, 1971). The 
iso la tion  and p u rifica tio n  of the GS-transferases in ra t l iv e r  was 
in i t i a l l y  accomplished by Jakoby and co-workers (F je lls te d t e t a l , 
1973, Pabst e t a l , 1973, Habig et a l , 1974 and Jakoby et a l , 1976). 
The specific  a c t iv it ie s  of each of the Isolated isoenzymes were 
reported by Jakoby et a l . (1976 ) ,  and by Mannervik and Jensson
(1982). The re la tiv e  speciftc a c t iv it ie s  towards the p a rtic u la r  
substrates which are used in the studies described in th is  thesis  
are given in Table V,
TABLE V *
R elative specific  a c t iv it ie s 9 of ra t l iv e r  GS-transferase isoenzymes 
(Values calculated from Jakoby, 1976)
GS-transferase
Substrate0- A AA B C E
3-3b 2-2b 1-2 3-4b 5-5b
CDNB 100(62) 23 18 16 0.02
DCNB 100(4,2] 0,2 0.06 47 -
ENPP 2 - - 100(6.7)
EA - 100(0.3] 77 37 -
. t-PBO. 5. ........ —. . . . 0.3 100(0.4) —
9 Expressed as percentage of the specific  a c t iv ity  of the major 
isoenzyme w ith the individual substrate. The specific  a c t iv ity  
in yM/min/mg protein is  in parentheses.
b Nomenclature of Jakoby et a l , 1984.
0 Abbreviations used throughout the section: CDNB ( l-c h lo ro -2 ,4 -  
dinitrobenzene]; DCNB (1 ,2-d ich loro-4-n itrobenzene); ENPP (1 ,2 -  
epoxy-3-[p-nitrophenoxy] propane); EA (ethacrynic ac id ); 
t-PBO (tert-4-phenyl-3-buten-2-one).
I t  can be seen that although each isoenzyme possesses a broad and
overlapping substrate s p e c ific ity , the specific a c tiv ity  p ro file  fo r  
each isoenzyme is markedly d iffe re n t. There are also other 
characteristics which allow the various isoenzymes to be distinguished 
from each other; fo r instance, transferase 3-3 (A) as well as a high 
re a c tiv ity  towards CDNB and DCNB, also has a high re a c tiv ity  towards 
bromosulphthalein (Mannervik and Jensson, 1982), w hilst transferase
1-1 (B i) has a high level of isomerase a c tiv ity  towards A5- 
androstene-3,17 dione (Mannervik and Jensson, 1982). Transferase
2-2 (AA} has high glutathione peroxidase a c tiv ity  (Prohaska, 1980).
The isoenzymes can be fu rther characterised by th e ir  respective 
in h ib itio n  p ro files  with various compounds, fo r instance,
transferase 3-3 (A) is inhib ited By b iliru b in  and indocyanine
green as is transferase 3-4 (CJ (Ketley et a l , 1975). Triphenyl t in  
was shown to in h ib it  transferase 3-3 (A) to a greater extent than 
transferase 1-1 and 1-2 (B)., the respective Ki values being 3-3 :
0.08 yM and 1-1 and 1-2 : 0.27 yM (Henry and Byington, 1976). Other
in h ib itio n  characteristics fo r the ra t l iv e r  GS-transferases have been 
reported by Yalcin et a l . (1983).
GS-transferases 1-1 and 1-2 (B) is the most abundant isoenzyme present 
in ra t l iv e r  where the amount can reach 5% of the cytosolic protein .
The next most abundant is GS-transferase 3-4 (C) with = 2.5% of the 
cytosolic protein. The proportions of the other ra t l iv e r  enzymes 
have been reported as 3-3 (A l, 1%; 2-2 (AA), 0.5%; 5-5 (E ), 0.5% 
(Jakoby, 1976),
Some of the physical properties of the ra t l iv e r  transferases were 
determined by Habig et a l . (1974), Habig et a l . (1976) and Pabst et a l . 
(1974). Each isoenzyme is composed of 2 sub-units of approximately
equal size with the to ta l molecular weight of the isoenzyme being 
between 45,000 and 47,000. The is o e lec tric  points fo r each isoenzyme 
are 2 -2 , * 10; 3 -3 , 8 .9 ; 1-1 and 1-2 , 9 .8 ; 3 -4 , 8 .0 ; 5 -5 , 7 .3 .
Human glutathione S-transferases
Several "basic" GS-transferases designated a, p, y , 6 and e have been 
isolated from human liv e r  (Kamisaka et a l , 1975). These isoenzymes 
are immunologically. related and have very s im ilar amino acid 
composition. A ll the "basic" human GS-transferases apparently 
possess s im ilar substrate s p e c ific ity  p ro files  (Kamisaka et a t ,
1975). They d if fe r  from the ra t "basic". GS-transferases which are 
immunologically d iss im ila r, have d iffe r in g  substrate s p e c if ic it ie s ,  
and possess diverse amino acid composition. The human "basic" 
GS-transferase isoenzymes are d is tin c tly  d iffe re n t e n t it ie s . A 
hypothesis was advanced by Kamisaka et a l . (1975) that the basic 
human isoenzymes were charge isomers possibly the resu lt of 
deamidation of the asparagine or glutanrine residues of the 
GS-transferases. Post-translational changes were also proposed 
to account fo r the nature of the "basic" human GS-transferases 
(Strange et a l , 1984). In addition to these "basic" GS-transferases, 
2 "acidic" forms have been described and designated cd and ijj (Awasthi 
e t  a l , 1980). A s im ilar "acidic" transferase was isolated from 
human liv e r  by Koskelo and Valmet (1980). GS-transferase w appears 
to have some s im ila r it ie s  to the "basic" isoenzymes, as i t  also 
cross-reacts immunologically with antibodies prepared against the 
human "basic" isoenzymes. The existence of an approximately neutral 
isoenzyme was reported by Harholm et a l . (1980). This isoenzyme 
was only present in about 60% of the liv e r  samples examined and did 
not occur to any appreciable extent in foetal l iv e r  (Mannervik e t a l ,
1983). Warholm et a l. (1980), purified  the neutral isoenzyme (y) to 
apparent homogeneity and subsequently reported that the c a ta ly tic  
properties of th is  isoenzyme were d iffe re n t to those of the "basic" 
isoenzymes (Warholm e t a l , 1983). GS-transferase y was also reported 
as being a s lig h tly  larger protein (MW * 53,000) than the other human 
isoenzymes (MW between 47,000 and 51,000) (Guthenberg and Mannervik,
19811. Human GS-transferase y does not cross-react with antibodies 
against the known "basic" or "acidic" isoenzymes.
The acidic transferase w and \p isolated from human l iv e r  (Awasthi 
et a l , 1980). had pi values of 4.5 and 5.4 respectively. This compares 
with a pT value of 4.5 fo r an acidic GS-transferase isolated from 
human red blood ce lls  (GS-transferase p) (Marcus et a l , 1978), and 
a pi value of 4.5 fo r an acidic GS-transferase (i t), isolated from 
human placenta (Guthenberg et a l , 1979; Awasthi and Dao, 1981). 
GS-transferases p and tt appear to be s im ilar (Guthenberg and Mannervik, 
1981). I t  is probable, although s t i l l  to be proved, that the human 
acidic GS-transferases represent a d is tin c t group of isoenzymes, 
but recent results (Dao et a l , 1984) possibly indicate a shared 
sub-unit common to both "acidic" and "basic" isoenzymes. Genetic 
evidence points to the existence of 3 structural gene lo c i ,  which 
have been named GST 1, GST 2 and GST 3 (Board, 1981), and the gene 
products observed probably correspond to the 3 main groups of human 
GS-transferase isoenzymes (Warholm e t a l , 1983). The v irtu a l absence 
of GS-transferase y in human foetal l iv e r  is in teresting  as i t  also 
has a high capacity fo r epoxide conjugation in adult tissues. The 
p o ss ib ility  therefore exists that this GS-transferase may be 
produced by an inductive process (Warholm et a l , 1983). Induction 
of "basic" GS-transferases by phenobarbitone has been reported
(Fleischner et a l , 1976).
The substrate s p e c ific it ie s  w ithin each group of human GS-transferase 
isoenzymes are s im ila r , but there are d is tin c t differences between 
the isoenzyme groups (Jakoby and Habig, 1980; Guthenberg and Mannervik, 
1981; Warholm e t a l , 1983). The re la tiv e  specific  a c t iv it ie s  are 
given in Table V I.
TABLE VI
Relative specific  a c t iv it ie s  fo r human GS-transferasesa
Substrate^
Transferase
"Basic" "Neutral" "Acidic"
a -  e y P IT (? 0) & lf>)
CDNB 34 100(187) 56
DCNB 32.59 29 100(0.11)
ENPP - 30 100(0.37)
EA 2.5 9 100(0.86)
t-PBO <1 100(0.36) . . . \ 3 . . .
a Values calculated from Warholm et a l . (1983), plus values derived 
from Jakoby and Habig (1980) and Guthenberg and Mannervik (1981).
k Abbreviations as Table V..
Values are expressed as the percentrage of the specific  a c t iv ity  of 
the major isoenzyme towards the individual substrate. The specific  
a c tiv ity  (pM /m in /m g protein} is  given in parentheses.
Monkey glutathione S-transferases
The GS-transferase isoenzymes of non-human primates have been 
p a r t ia lly  investigated in the rhesus monkey (Macaca m ulatta) ,  the 
Japanese monkey (Macaca fuscata) and the crab-eating monkey (Macaca 
fa s c lc u la ris ). Individual basic isoenzymes have been isolated from 
the l iv e r  of the rhesus monkey ( l t d Ne t 'a l ,  1974; Asaoka et a l ,  1977;
Asaoka and Takahashi, 1977). These workers reported that 5 "basic" 
isoenzymes with GS-transferase a c tiv ity  towards DCNB were isolated  
a fte r  CM-cellulose chromatography. The major "basic" isoenzyme 
(Fraction IV) was further purified  and the properties of th is  isoenzyme 
were reported by Asaoka and Takahashi (1977). The specific  a c t iv it ie s  
of each of the fractions isolated towards several substrates, and the 
calculated re la tiv e  specific  a c t iv it ie s , are given in Table V I I .
TABLE V II
Relative specific  a c t iv it ie s  fo r the "basic" GS-transferase isoenzyme
of rhesus monkey l iv e r 9
Substrate^
Transferase
I I I . I I I IV V
CDNB 
DCNB 
t-PBO 
. . .  ENPP
8
9
25
17
47
63
24
56
88
100(90)
100(0.23)
100(0.008)
19
13
25
9 Values calculated from the data of Asaoka et a l . (1977). Values 
are expressed as the percentage of the specific  a c t iv ity  of the 
major isoenzyme w ith  the individual substrate. The specific  
a c tiv ity  (jjM/min/mg protein)' is given in parentheses.
k Abbreviations as Table V.
Further studies on fraction  IV showed that the isoenzyme has a 
molecular weight of approximately 48,000 and was composed of 2 
identical sub-units, as was GS-transferase I I I .  P a r t ia lly  p u rified  
isoenzymes I ,  I I  and V also had a major protein sub-unit of s im ilar  
size to that observed with isoenzyme IV , but traces of a minor 
component was evident (Asaoka and Takahashi, 1977). The amino acid 
composition was s im ilar to that observed with the human "basic" 
GS-transferases.
Tissue d is trib u tio n  of GS-transferases
GS-transferase a c tiv ity  can be measured in most organs obtained from 
an individual animal, but i t  is not certain that an individual 
isoenzyme is expressed in a p articu la r tissue. In most mammals, 
GS-transferase a c tiv ity  is  generally greatest in the l iv e r ,  but in 
birds renal GS-transferase a c t iv ity  often exceeds the hepatic levels  
(Husain et a l , 1981).
The most frequently studied tissue has been l iv e r ,  but extrahepatic  
tissues have also been extensively investigated, including kidney 
(Kaplowitz et a l , 1976; Fine et a l , 1978; Hales et a l , 1978; Bend et al 
1976; James et a l , 1977), small in testine  (Pinkus et a l , 1977; C lifto n  
and Kaplowitz, 1977), lung (Moron et a l , 1979; Bend et a l , 1976; 
L it te rs t  et a l , 1975; Guthenberg and Mannervik, 1979; Partridge et a l , 
1984; Gram et a l , 1974; Koskelo et a l , 1981). steroidogenic tissues (Bend 
et a l , 1976; Hales et a l , 1978; Meyer et a l , 1983), heart (Ishikawa 
and Sles, 1984; Kraus and K lo ft, 1980) and brain (D ix it et a l , 1981). Blood 
and blood cells  have been examined fo r GS-transferase a c tiv ity  
(Cagen et a l , 1976; Marcus et a l , 1978).
Comparative studies involving several tissues have been conducted by 
Booth et a l . (1961), Baars et a l . (J981), Datta (1973), Boyland and 
Chasseaud (1967), Chasseaud (1979), L it te rs t  et a l . (1975), Bend et a l . 
(1976) and James et a l . (1977).
Booth et a l . (1961) in th e ir  examination of various ra t organs found 
that GS-transferase a c tiv ity  towards DCNB in extrahepatic tissues 
were much lower than that in the liv e r . Boyland and Chasseaud (1967) 
indicated that there were d iffe rin g  levels of GS-transferase a c t iv ity
-  29 -
in extrahepatic tissues, depending- on the substrate used, fo r example, 
when diethylmaleate was used as the second substrate the a c tiv ity  
present in the kidney was much closer to that in the liv e r  than when
1 ,2-dichloro-4-nitrobenzene was used. The kidney appears well able 
to conjugate most of the popular GS-transferase substrates, 
fo r exampl-e, benzyl chloride (Suga et a l , 1967), and trans-4-
phenyl-3-butene-2-one (Boyland and Chasseaud, 1968), methyl iodide 
(Johnson, 1965) and 1,2-dichloro-4-nitrobenzene (Booth et a l , 1961; 
L it te rs t  et a l , 1975). C lifton  and Kaplowitz (1977) reported that 
the GS-transferase a c tiv ity  in ra t kidney toward various substrates 
were 5% (CDNB), 2% (DCNB), 7% (p-NBC), 68% (ENPP) and 128% (EA) of 
those in l iv e r . Baars et a l . (1981) in th e ir  investigation of the 
GS-transferase a c tiv ity  present in 27 ra t tissues, reported that 
when CDNB was used as substrate, the percentage of hepatic a c t iv ity  
present in an individual tissue was 12% (kidney), 43% (te s te s ), 9% 
(b ra in ), 6% (stomach), 4% (small in tes tin e , lung and h eart). Each 
of the remaining tissues had GS-transferase a c tiv ity  less than 4% 
of that of the l iv e r .  S im ila rly , Siegers et a l . (1983) found that 
human gastric mucosa contained 5% of the GS-transferase a c t iv ity  of 
human l iv e r .  Some of these results are d iffe re n t from those obtained 
in various portions of the gastro -in testina l tra c t mucosa, which were 
between 11% and 28% of the hepatic level (C lifto n  and Kaplowitz,
1977).
A comparative study of l iv e r ,  kidney and lung GS-transferase 
a c tiv ity  towards D’CNB in various species ( ra t ,  mouse, guinea pig, 
hamster and rabbit) (L itte rs t  et a l , 1975) showed that in most 
species the kidney contained between 5% and 33% of the hepatic 
a c t iv ity , although the mouse kidney contained approximately h a lf
that in the l iv e r .  In the lung of most species, a c t iv it ie s  were 
between 3% and 24% of those in the l iv e r ,  with mouse lung having 28% 
of the hepatic a c t iv ity . The GS-transferase a c tiv ity  in ra t Tung (3%) 
was the lowest in any of the species examined. Comparable figures  
fo r the rhesus monkey were 14% (kidney) and 10.5% (lung) (Asaoka et a l , 
1977). In a study using several substrates , Qesch et a l . (1983) found 
that GS-transferase a c t iv ity , when expressed as a percentage of 
hepatic a c t iv ity  towards the same substrate, were kidney 9%, 2%, 12%, 
23%, 65% and 18%, and lung 5%, 3%, 7%, 32%, 33% and 12%, using CDNB, 
DCNB, t-PBO, ENPP, menaphthyl sulphate and androstene-3,17-dione 
respectively.
GS-transferase a c tiv ity  in lung, towards styrene oxide, has been 
reported to be 20% o f that in the liv e r  (James et a l , 1977), but 
towards benzo[* a Jpyrene 5,6-oxtde the lung had higher levels of 
a c tiv ity  than the l iv e r  (Grover, 1974). In teres tin g ly , a non-human 
primate (cynomolgus monkey) also had lung GS-transferase a c t iv ity  
towards th is  substrate which was approximately twice i t s  hepatic 
a c tiv ity  (Chasseaud e t a1, 1980). Itfhen other epoxide substrates 
were examined using rodent lung, the GS-transferase a c t iv it ie s  were 
generally lower than those in the l iv e r .  The epoxides examined were 
naphthalene 1 ,2-oxide (Hayakawa et a l , 1974), benzo[ a jpyrene 4 ,5 -  
oxide and 11 ,12-oxide (Bend et a l , 1976; Cantforth et a l , 1979),
3-methylcholanthrene-11,12-oxide (Muhktar and Bresnick, 1976 a&b).
In the ra t , the testes have been reported to have s im ilar 
GS-transferase a c tiv it ie s  to those in the liv e r  (Guthenberg e t a l , 
1983). Other portions of the reproductive tra c t also have appreciable 
GS-transferase a c tiv ity  (Hales "et a l , 1978; Meyer et a l , 1983). In 
th e ir  study of the GS-transferase a c t iv ity  of the g astro -in tes tin a l
tra c t mucosa, C lifto n  and Kaplowitz (1977) showed that the a c t iv ity  
decreased with the distance from the pylorus. GS-transferase 
a c tiv ity  expressed as a percentage of the hepatic a c t iv ity  fo r  each 
of the portions of small in testin e  examined (proximal, mid and d is ta l)  
were DCNB 11%, 5% and 7%; CDNB 28%, 27% and 11%; p-nitrobenzyl 
chloride 10%, 7% and 6%; ENPP 60%, 37% and 28%; and EA 108%, 92% and 
67% respectively. In a study using various mucosal ce ll types,
Pinkus e t a l . (1977) reported that mucosal crypt ce lls  had less GS-transferase 
a c tiv ity  than the mature v il lu s  t ip  c e lls .
"The variations in GS-transferase a c tiv ity  in human tissues have been 
reported by Baars et a l . (1981). Their results show that 
GS-transferase a c t iv it ie s  present in kidney, adrenal and testes  
were s im ilar to that in the liv e r  towards CDNB. Values obtained 
in the same study fo r other tissues were stomach mucosa 40%, lung 
30%, small in testine  25% and the colon 15%. When concentrations of 
“basic" GS-transferases were measured by radioimmunoassay, i t  was 
shown that the kidney and testes contained approximately 30% o f  that 
in the l iv e r .  The duodenum contained 7% and the lung and stomach
0.5% of that in the l iv e r  (Sherman et a l , 1983).
These findings do not necessarily re fle c t  the actual glutathione  
conjugation capab ility  in v ivo , but more probably re fle c t  tissue  
differences with respect to individual isoenzyme composition.
Koskelo (1983), using several substrates to measure GS-transferase 
a c tiv ity  in various human tissues, showed that the measured a c t iv ity  
was dependent on the substrate used. The values obtained by Koskelo
(1983), when expressed as a percentage of the hepatic a c t iv ity ,  are
given in Table V I I I .
TABLE V I I I
Tissue GS-transferase a c tiv ity  towards various substrates
in human tissues9
Tissue
Substrate
CDNB DCNB p-NBCb' EA
Liver 
Kidney 
Lung 
Spleen 
. Placenta
100(1200)
76
40
26
................13 . .
100(2.1)
100
38
24
29
100(7.2)
49
33
24
15
100(3.6)
167
103
167
172
9 Values calculated from the data of Koskelo (1983). Figures in 
parentheses are specific  a c tiv it ie s  fo r liv e r  expressed as nmol/ 
min/mg protein.
Substrate p-nitrobenzyl chloride. Other abbreviations as Table V.
Several other groups have investigated the tissue d is trib u tio n  of 
the various human isoenzyme "fam ilies" ("basic", "neutral" and 
"ac id ic"), but a comparison of actual tissue specific  a c t iv it ie s  
is  d i f f ic u lt  because of the d iffe rin g  iso lation  procedures used, 
and the d iffe rin g  conditions used to assay the GS-transferase ac tiv ity . 
The specific tissues investigated were: adrenal and l iv e r  (Mannervik 
et a l , 1983), brain (Olsson et a l » 1983), eye (Polidoro et a l , 1980), 
and ovary (Guthenberg et a l , 1979; Polidoro et a l 1980).
The mQrcapturic acid Pathway
Once a glutathione conjugate has been produced with any of the 
miriad of compounds which can be conjugated, e ith er non-enzymically or 
enzymically with glutathione, its  degradation most often follows the 
"mercapturic acid pathway". The catabolic stages of th is  pathway 
are also used to metabolise GSH. The extent to which th is  metabolic
pathway is  involved and the speed at which i t  occurs can be species- 
dependent (James and Needham, 1973; Gorier et a l , 1982). The 
metabolites of the glutathione conjugate, and indeed the glutathione  
conjugate i t s e l f ,  can be excreted d ire c tly . Excretion can occur into  
the b ile  due to the increase in molecular weight (up to + 306) caused 
by conjugation often being s u ffic ie n t to exceed the b i l ia ry  excretion 
threshold (Smith, 19731, For example, nearly a ll  the metabolites of 
pentachlorothioanisole in the ra t are excreted in the faeces (Bakke 
et a l , 1981; Bakke, 1983), and a large proportion of the metabolites 
derived from the glutathione conjugation of ethacrynic acid are found 
inthe b ile  o f ra t and dog (Klaassen and F itzgera ld , 1974). The 
glutathione conjugates are converted into th e ir  respective mercapturic 
acids by 3 enzyme-catalysed reactions. These enzyme reactions and 
the mercapturic acid pathway are shown in Figure V. The f i r s t  enzyme 
mediated reaction involves the cleavage of the y-glutamyl portion of 
glutathione. This reaction, which is  catalysed by y-glutamyl 
transpeptidase, can proceed by e ith e r hydrolysis or transpeptidation. 
Once the cysteinylglycine conjugate is formed the next reaction  
involves the loss of the glycine moiety through the action of a 
dipeptidase (in  th is  instance referred to as cysteinylg lycine- 
dipeptidase), to produce a cysteine conjugate. This conjugate can 
be metabolised fu rther by a microsomal, acetyl CoA-dependent,
N-acetyl transferase to produce the N-acetylcysteine conjugate,
i . e .  the mercapturic acid. As mentioned e a r lie r  the la s t reaction  
does not occur to an appreciable extent in certain species, fo r  
instance the guinea pig, due to very low* a c tiv ity  of the enzyme 
(James and Needham, 19.73), The cysteine conjugate need not 
necessarily follow  the la s t stage of the mercapturic acid pathway, 
but can instead be metabolised by a C-S lyase to produce th io ls
which occurs during the metabolism of some halogenated olefins  
(Gandolfi, .1981; Green e t  a l , 1983), These th io ls  can subsequently 
be methylated (involving a th io l methyl transferase), or conjugated 
. w ith glucuronic acid. The S-^glucuronides can also be hydrolysed and 
undergo enterohepatic c ircu la tio n , Oxidation of the S-methyl compounds 
can resu lt in S-oxides pr sulphoxide formation (Bakke and Price, 1979). 
The a lte rn a tive  pathway of cysteine S-conjugate metabolism is given 
in Figure V I.
Enzymes involved in mercapturic acid synthesis 
y-Glutamyl transpeptidase (EC.2 .3 .2 .2 )
As previously mentioned y-glutamyltranspeptidase (y-GT) removes the 
y-glutamyi moiety from the glutathione conjugate. The reaction can 
take one of 3 forms (Tate, 1980), e ith er hydrolysis [  equation 1 2» 
transpeptidation [ equation 2 ] or autotranspeptidation [  equation 3 ] . '  
(Tate, 1980).
In each reaction, X represents the S-conjugate of cysteinyTglycine.
y^glu-X ± H20 —> glutamate + HX (1)
y-glu-X + acceptor -—#• y-glu-acceptor + HX (2)
(di ami no acid)
y - g l u - X  + y - g l u - X  — > y - g l u - y - g l u - X  + HX ( 3 )
y-GT is  widely d istributed in mammalian c e lls , and in several species, 
the highest levels of y-GT a c tiv ity  have been measured in the kidney 
(Revel and B a ll, 1959; Goldbarg et a l , 1960). The re la tiv e  y-GT  
a c tiv ity  values fo r various species, taking ra t kidney a c tiv ity  as 
100, are rabbit kidney 5 .7 , dog kidney 45, and human kidney 27
(Goldbarg et a l , 1960). Human l iv e r  has a re la tiv e  a c t iv ity  value of 
3, and human lung a value of 4 (Revel and B a ll, 1959), and ra t l iv e r
0 .2 , and ra t in tes tin a l mucosa between 1 and 3 (Tate, 1980). In the 
case of the in tes tin a l mucosa, the v illu s  ce lls  (mature c e lls ) have 
approximately 4-times the y-GT a c tiv ity  of the crypt c e lls . In 
general terms, high levels of y-GT a c t iv ity  are found in c e lls  which 
possess an absorption or secretory function (Meister e t a l , 1976). 
y-GT in common with several other enzymes is not a single enzyme, but 
is  composed of a "family" of isoenzymes (a t least 12) (Tate and 
M eister, 1976). The enzyme isolated from ra t kidney has an apparent 
molecular weight of 68,000 and is dimeric with sub-units- o f 46,000 and 
22,000. The amino acid composition of the smaller sub-unit from both 
ra t and human kidney are s im ilar (Tate and Ross, 1977). As y-GT is a 
membrane-bound enzyme, a ll iso lation  procedures involve the use of 
detergents to so lub ilise  the enzyme. Studies on the p a r t ia lly  
purified  enzyme have shown that several amino acids can serve as 
acceptor molecules in the transpeptidation reaction [eq u atio n  2 ] .
The best amino acid acceptors are the neutral L-amino acids such as 
cysteine, methionine, glutamine and alanine. Dipeptides of these 
amino acids with glycine also act as acceptors, but in general produce 
higher rates of transpeptidation (Thompson and M eister, 1977). As 
regards the rate of metabolism of glutathione conjugates, the a c t iv ity  
of y-GT has been shown to be greater towards S-substituted glutathiones 
than towards glutathione i t s e l f  (Tate and M eister, 1974). The presence 
of an acceptor molecule suppresses the hydrolytic function of y-GT  
[  equation 1 ] .  I t  has been shown that one of the functions of y-GT  
is the in tra c e llu la r  oxidation of glutathione to the disulphide GSSG 
(Tate et a l , 1979; Tate and Orlando, 1979).
Several compounds can modify or in h ib it the a c tiv ity  of y-GT, fo r  
example L-serine in the presence of borate (Revel and B a ll, 1959). 
y-GT is inhib ited  by y-glutamyl analogues such as 6-diazo-5-oxo-L- 
norleucine (DON), O-diazoacetylserine (Reed and E ll is ,  1980; Tate 
and M eister, 1977; Inoue e t a l , 1977), and by L-(aS, 5S) -2-amino-£r 
(-3 -ch loro-4 ,5-d ihydro-tsoxazo l-5-y l Jacetic acid (AT 125) (Neil e t a l , 
1979). The mechanism of in h ib itio n  occurs by the covalent binding of 
the in h ib ito r molecule of the y-glutamyl s ite  of the enzyme. Other 
compounds can a lte r  the c a ta ly tic  functions of y-GT, reducing the 
transpeptidation reaction [ equation 2 ] and stim ulating the hydrolytic 
function [ equation 1 . Maieic acid (Tate, and M eister, 1974; Curthoys.
and Kuhlenschmidt, 1975) and hippuric acid (Thompson, 1979; Thompson 
and M eister, 1980) appear to cause th is  e ffe c t. I t  is of in te res t 
that serum and urinary levels of benzoyl glycine are probably high 
enough to regulate the renal transpeptidase (Tate and Orlando, 1979). 
Some compounds such as a fla to x in  B1# when administered at very low 
levels (5 yM/kg), can cause induction of y-GT in the l iv e r ,  and th is  
may d ire c tly  a lte r  the metabolism of carcinogens (Moss e t a l , 1984).
Pipeptidase
There are a large number of peptidases, both in tra c e llu la r  and plasma- 
membrane bound, which can p o ten tia lly  mediate the removal o f the glycine  
moiety from cysteinylglycine conjugates. The occurrence of dipeptidases 
is  widespread, but of particu la r in te res t are the dipeptidases of 
l iv e r  (Stetson, 1975), kidney (George and Kenny, 1974), and intestinal 
mucosa (Das and Radhakrishnan, 1972). The in tes tin a l and renal enzymes 
•are prim arily  membrane-^bound, and are located in the brush border 
membranes of these tissues; however, s ig n ifican t amounts of cytosolic  
dipeptidase a c tiv ity  exists (Hughey et a l , 1978). Hughey et a l . (1978)
showed that an enzyme which was active towards S-derivatives of 
cysteinylglycine was localised along with y-GT and N-acetyltransferase 
in the proximal renal tubule. The peptidase had a broad substrate 
s p e c ific ity , but was p a rtic u la rly  active towards S-benzylcysteinylglyci 
Work by Wendel e t a l . (1977), which involved the microdissection of 
renal tubules, showed that perfusion of the isolated tubules with the 
glutathione conjugate of bromosulphthalein results in very fas t 
(T i -  3.5 sec .) degradation of th is  conjugate, and the ultim ate  
production of the cysteine conjugate. Dipeptidase a c tiv ity  is  
inh ib ited  by phosphate ions and th io ls .
N-Acetyltransferase
N-Acetyltransferases active towards amines are localised in the
cytosol (Tabor et a l , 1953), whereas the N-acetyltransferase probably
responsible fo r the fin a l stage of mercapturic acid biosynthesis, is
located in the endoplasmic reticulum (Elce, 1970; Green and Elce,
1975; Hughey et a l , 19781. Microsomal N-acetyltransferase has a
specific  requirement fo r acetyl CoA as the acetyl donor, and w ill act
on S-substituted cysteines (Green and Elce, 1975). The N-acetylation
of various cysteine conjugates of xenobiotics has been known fo r a
long time, and several researchers have shown that mercapturic acids
were produced by the tissues of various animal species in v itro
(Bray et a l , 1957, 1959; Bray et a l , 1964; James and White, 1967;
Brusewitz et a l , 19.77; James and Pheasant, 1978). The enzyme can
be inhib ited by p-chloromercuribenzoate and N-ethylmaleimide, and
has been p a r t ia lly  purified  and stab ilised  by Duffel and Jakoby
(1982). The enzyme was shown to have a s p e c ific ity  towards
lip o p h ilic  conjugates of L-cysteine, and th is  a c t iv ity  correlates well
with the e a r lie r  in Vivo metabolic studies in the ra t (Barnes e t a l , 
1959; Hughey et a l , 1978). Deacetylation of the mercapturic acid has 
been observed in ra t l iv e r  and kidney slices (Bray and James, 1960; 
Chasseaud, 1974).
FIGURE V
Mercapturic acid biosynthesis
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FIGURE VI
Metabolic degradation of mercapturic acids
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@  C-S lyase; ( ? )  th io l methyl transferase; (§ )  oxidase;
( 9)  glucuronyltransferase.
Metabolism of S-cysteine conjugates
C-S Lyase (a-lyase)
In mammals, C-S lyase has been demonstrated in several tissues but i t  
is  p a rtic u la rly  active in the liv e r  and kidney (Gandolfi e t a l , 1981; 
Doln and Anders, 1982). The presence of C-S lyase a c tiv ity  in the 
m icroflora of the gastro -in testina l tra c t has also been reported 
(Suzuki e t a l , 1982), which may be of considerable significance  
when i t  is  considered that glutathione conjugates and th e ir  S-cysteinyl 
derivatives are excreted into the b ile .
The reaction catalysed by C-S lyase is the removal of pyruvate and 
ammonia from the cysteine conjugate resulting in a free  th io l.  A 
purified  preparation of C-S lyase has been studied by Stevens and 
Jakoby (1983), in which study C-S lyase was shown to possess a. broad 
substrate s p e c ific ity .
Thiol S-methyltransferase
Once a th io l has been produced from the S-cysteine conjugate by the 
action of C-S lyase, the free th io l produced can be methylated by 
th io l S-methyltransferase. Thiol S-methyltransferase has a broad 
substrate s p e c ific ity  which includes hydrophobic th io ls  and hydrogen 
sulphide, w ith which i t  performs a detoxication function (Weisiger 
et a l , 1980). However, a large number of th io ls  derived from 
cysteine conjugates by the action of C-S lyase are also substrates 
(Tateishi et a l , 1978). Several methylthio metabolites of naphthalene 
have been reported (S t i l lw e ll ,  1978 a&b), and the metabolism of 
cloxapine also results in a methylthio compound presumably via a 
glutathione conjugate (Stock et a l , 1977). A recent review of 
methylthio and methyl sulphonyl metabolites has been reported by
Hawkins (1981).
Although the pathway fo r the degradation of cysteine conjugates by 
the sequential action of C-S lyase and th io l S-methyltransferase 
exis ts , i t s '  hiolocfical significance requires elucidation (Stevens and 
Jakoby, 1984).,
AIMS OF THE STUDY
The studies presented in th is  thesis are prim arily  concerned with 
glutathione conjugation in the non-human primate. The objectives 
were to obtain answers to the following questions:
1. How does the extent of conjugation with glutathione in non-human 
primates compare with that in man and other laboratory animal 
species?
2. What is the tissue d is trib u tio n  of glutathione, and what are the 
a c tiv it ie s  of the glutathione S-transferases responsible fo r  
glutathione conjugation in non-human primates?
3. Are there any apparent species differences in the glutathione  
S-transferases of the non-human primate species?
4. To what extent does the fu rther metabolism of glutathione  
conjugates occur in non-human primates?
The non-human primates used in th is  study were the rhesus monkey 
(Macaca m ulatta) , the baboon (Papio sp. ) and the cynomolgus monkey 
(Macaca fa s c ic u la rls ). The rhesus monkey was used,as i t  was u n til 
recently a common species fo r experimental studies of xenobiotics.
The baboon and cynomolgus monkey were included in the study in order 
to extend the range of knowledge of these 2 species in view of the 
now severe lim itations  on the a v a ila b il ity  of the rhesus monkey*
I t  was also the in tention to evaluate the metabolic s u ita b il ity  of 
these 2 species of non-human primate fo r experimental studies involving
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the conjugation of xenobiotics with glutathione, the results of which 
might be extrapolated to man.
In order to provide answers to the questions concerning the a b il i ty  
of the non-human primate to conjugate xenobiotics with g lutathione, 
consideration was given to the possible compounds which could be 
used. The model compound was required to be re la tiv e ly  non-toxic, 
and one which would, under normal circumstances, be metabolised 
prim arily  via the mercapturic acid pathway. The phenoxyacetic acid 
d iu re tic  -  ethacrynic acid -  was chosen fo r 5 main reasons:
F irs t ly , ethacrynic acid is a prescribed d iu re tic  in man and has 
been widely used fo r a number of years; secondly, the metabolism 
of ethacrynic acid has been studied in various species such as ra t 
and dog, but not in the non-human primate; th ird ly , the metabolism 
of ethacrynic acid is known to proceed via the mercapturic acid 
pathway; fourth ly ,, ethacrynic acid at the dose levels used appears 
to be without toxic s id e -e ffe c ts , and thus repeated use of the same 
experimental animal is acceptable; la s t ly , ethacrynic acid has been 
extensively used in v itro  as a substrate fo r the glutathione  
S-transferases in several species.
Ethacrynic acid, however, possesses 2 possible disadvantages: 
f i r s t ly ,  the compound has non-enzymic re a c tiv ity  with glutathione; 
secondly, some of the pharmacological actions of ethacrynic acid 
observed in man are less pronounced in the non-human primate. 
Nevertheless, th is second "disadvantage" can also be advantageous 
because s lig h tly  higher doses than are c lin ic a lly  used in man can 
be given to non-human primates without the e lec tro ly te  inbalance 
that would resu lt from excessive d iuresis.
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The tissue concentrations of glutathione were measured to provide 
background information as to the glutathione status of any p articu lar  
tissue in the non-human primates. The major tissues, which may be 
regarded as "portals" fo r the entry of xenobiotics into the body 
together with the tissues which possess major metabolic a c t iv ity ,  
were examined fo r th e ir  a b il i ty  to conjugate the various known 
substrates of the glutathione S-transferases with glutathione. The 
range of substrates fo r the GS-transferases included 1 ,2 -d ich lo ro -4 - 
nitrobenzene and 1-chioro-2,3-dinitrobenzene (both halogenonitrobenzenes);
1 ,2-epoxy-3-(p-nitrophenoxy)propane (an epoxide); diethylmaleate (an 
afr-unsaturated es ter, and a compound often used to deplete hepatic 
glutathione (Boyland and Chasseaud, 1968)), and ethacrynic acid (an 
a0-unsaturated ketone, which was also the model compound used fo r the 
in vivo investigations). Two additional ag-unsaturated ketones, 
trans-4-phenyl-3-butene-l-one,and cyclohex-2-en-l-one,were also 
employed. Information on the rates of degradation of the glutathione 
conjugate was provided by both in vivo and in v itro  investigations  
using ethacrynic acid, together with the assay of the tissue a c t iv it ie s  
of the 3 enzymes responsible fo r the synthesis of the mercapturic acid, 
namely y-glutamyltranspeotidase, cysteinlyglycine dipeptidase and 
N-acetyltransferase.
Ethacrynic acid
Ethacrynic acid (2 ,3 -d ic h lo ro -4 -[ methylenebutyryl ] phenoxyacetic 
acid] is a loop d iu re tic  which acts by reducing the re-absorption of 
sodium and chloride in the proximal renal tubule, the ascending loop 
of Hen!e,and to a lesser extent in the d ista l tubule (Beyer et a l ,
1965).
Ethacrynic acid
In man, the normal therapeutic dose of ethacrynic acid is between 
50 mg and 200 mg/day in divided doses. In man, the drug is rap id ly  
absorbed o ra lly  and causes an intense diuresis beginning w ithin  
30 min and reaching a maximum at about 2 h (Beyer et a l , 1965).
The pronounced diuresis observed with both man and dog was not 
observed to occur in "Old World" monkeys (Beyer et a l , 1965). Thus, 
although a normal human dose (50 mg) was given to non-human primates 
during the studies reported in th is thesis no major e lec tro ly te  
imbalance problems were encountered.
The aryloxyacetic acid derivative d iu re tics , including ethacrynic 
acid, were f i r s t  synthesised by Schultz et a l . (1962). These 
diuretics possess re a c tiv ity  with sulphydryl compounds and caused 
marked diuresis. The renotropic characteristics of ethacrynic acid 
were evaluated by Beyer et a l , 1965. These workers showed that when 
ethacrynic acid was administered to e ith er the ra t or the dog, up to 
35% of the dose (1-10 mg/kg) was excreted in the urine regardless of 
the route of adm inistration. A large proportion of the dose 
* (approximately 50%) was recovered in the faeces, thus suggesting 
extensive b ilia ry  excretion of the compound or its  metabolites.
The major urinary metabolite appeared to be the cysteine conjugate, 
which i t s e l f  is pharmacologically active as a d iu re tic  (Koechel and 
Cafruny, 1975). Klaassen and Fitzgerald  (1974) reported the b il ia ry
excretion of rad io a c tiv ity  following intravenous administration of 
1£*C-ethacrynic acid to the ra t and the dog. Their results showed 
that w ithin 4 h of drug administration to the ra t ,  between 60% and 
70% of the dose (5 or 50 mg/kg) had been excreted in the b ile . The 
major b il ia ry  metabolite appeared to be the glutathione conjugate 
(« 40%). The proportion of the mercapturate of ethacrynic acid 
produced was somewhat dependent on the dose level administered, and 
was between 18% (low dose) and 30% (high dose) of the b il ia ry  
ra d io a c tiv ity . The b il ia ry  excretion of ra d io ac tiv ity  in the dog 
during 4 h a fte r  dosing was 57% (5 mg/kg i . v . ) .  Ethacrynic acid 
appeared to be more extensively metabolised in the ra t than in the 
dog as ra t b ile  contained 25% of unchanged drug compared to 38% as 
unchanged drug in the dog b ile  during the same time period. There 
was, however, an additional metabolite present in the dog b ile  which 
was the cysteine conjugate of ethacrynic acid. In these experiments, 
approximately 20% of the b ilia ry - rad io ac tiv ity  was un iden tified .
The e ffec t of phenoharbitone, diethylmaleate,and probenecid 
pretreatment on the pharmacokinetics and metabolism of ethacrynic 
acid were investigated by Wallin e t a l . (19.78). Phenobarbitone 
pretreatment resulted in a s ig n ifican t increase in the metabolic 
clearance of ethacrynic acid together with an increase in 
GS-transferase a c tiv ity  in the hepatic cytosol. Diethylmaleate 
was observed to reduce the metabolic clearance. Examination of the 
b ilia ry  metabolite "p ro file"  indicated that both pretreatments 
altered the pattern of b ilia ry  metabolites, phenobarbitone increasing 
the amount of the glutathione conjugate produced, and diethylmaleate  
causing a reduction in the amount of the glutathione conjugate 
excreted.
The in i t ia l  h a l f - l i f e  of decline of plasma concentrations of 
1I+C-ethacrynic acid was reported as - 19 min, th is being s lig h tly  
reduced to 17 min a fte r  treatment with phenobarbitone. The results  
of these authors, c learly  show a biphasic plasma ra d io ac tiv ity  
concentration-time p ro f ile , but a h a l f - l i f e  fo r th is second phase 
was not reported (W allin et a l , 1978).
The conjugation of ethacrynic acid with glutathione, and its  
subsequent degradation, are presented in Figure V I I .
FIGURE V II
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CHAPTER 2
EXPERIMENTAL METHODS
Animals
Primates
A ll non-human primates used in th is  study were obtained from a 
commercial supplier (Shamrock Farms (GB) L td ., Henfield, Sussex, ' 
U .K .], and were subjected to both veterinary examination and a period 
of quarantine (12 weeks! p rio r to being housed in the primate fa c i l i ty  
a t Huntingdon Research Centre. The species used were rhesus monkey 
(Macaca mill a t ta ) , the cynomolgus monkey (Macaca fa s c ic u la ris ) and the
baboon (PapiO species). Three subspecies of baboons were used________
(Papio papio, Papio anubis and^Papio hamadryas). Animals were 
housed in individual cages designed to house non-human primates, 
constructed of aluminium and stainless steel and wall mounted in 
the primate f a c i l i t y  at Huntingdon Research Centre. The primate 
rooms were well ventilated and maintained at 22°C ± 1°C, and were 
re la tiv e ly  well isolated from external disturbances.
Individual animals were given free access to water and fed a 
controlled d ie t which was s lig h tly  varied fo r each species.
Rhesus monkey -  A d a ily  ration of 300 g per animal of mixed dry 
d ie t , containing 200 g F .P .I .  (Dixon and Sons L td ., Ware, U .K .);
50 g primate mazuri (Coopers N utritional Products, Witham, Essex)., 
and a 50 g Bonio dog biscuit (S p ille rs  L td ., Barking, Essex) was 
offered 200 g in the morning and a fu rther 100 g in the afternoon.
Cynomolgus monkey -  The d a ily  ration per animal was 50 g F .P .I .  and 
a 50 g Bonio b iscu it in the morning, and 50 g F .P .I .  and 50 g Mazuri 
in the afternoon.
Baboon -  The d a ily  ration per animal was 150 g F .P .I .  in the 
morning and 100 g F .P . I . ,  50 g Mazuri and a 50 g Bonio b iscu it in 
the afternoon.
The basic ration of a ll  non-human primates was supplemented on 
weekdays with one s lice  (35 g) of wholemeal bread, and d a ily  w ith  
fresh f r u i t  or vegetable produce. Blackcurrant ju ice  concentrate, 
containing vitamin C (approximately 53 mg) (Boots L td ., Nottingham) 
and Cytacon, a vitamin Bi 2 preparation containing 140 yg cyanocobalamin
B.P. (Glaxo L td ., Greenford, Middlesex), were added to the drinking____
water on one day each week.
Rats
Male rats of bodyweight approximately 200-250 g (Spra.gue-Dawley CD 
rats obtained from Charles River U .K .) were housed in the animal 
rooms of the Department of Metabolism at Huntingdon Research Centre. 
Before use they were housed under standard conditions and fed a 
balanced rodent d ie t (Spratts U .K .). Water was availab le ad 1ib ltum .
The rats were used to obtain tissues fo r determination of the tissue  
glutathione S-transferase a c tiv ity . The following tissues were removed 
as quickly as possible a fte r  an individual animal was k ille d  by 
cervical d islocation: L iver, kidney, lung, stomach, duodenum,
ileum and colon. The tissues were processed as detailed in the 
tissue fractionation  section. Rats were also used to study the
-  50 -
b ilia ry  excretion of ll+C-ethacrynic acid. The surgical procedure fo r  
the b ile  duct cannulation was conducted under general anaesthetic 
(halothane : oxygen). A fin e  polythene cannula ( i .d .  0.28 and
o.d. 0.61 mm) was inserted into the exposed b ile  duct and tied  in 
place. Once the flow of b ile  had been established, the abdominal 
incision was closed and the ra t placed in a Bollman restra in ing cage. 
The ra t was given access to food and its  drinking water was replaced 
by saline (0,18%) containing 4% dextrose. B ile collection was 
continued fo r up to 4 h. Rats, which in addition to the cannulation 
of the b ile  duct also had th e ir  renal blood vessels ligated,-.were held 
under general anaesthetic (Imobilon: Etorphine/methotrimeprazine)
fo r the duration of the experiment. At the end of the experimental 
period a ll rats were k ille d  by cervical d islocation.
Preparation of dosing material
ll*C-Ethacrynic acid ( lt+C methylene lab e l) was kindly supplied by 
Dr. J. Baer, Merck, Sharp & Dohme, Rahway, N .J ., U.S.A. A to ta l of
approximately 2 mCi was supplied in 2 separate lots ( I  and I I ) .
The specific  a c tiv ity  as supplied was e ither 15.873 yCi/mg ( I )  or 
21.277 yCi/mq ( I I ) .  For use, portions of the 14C-ethacrynic acid 
were diluted to a lower specific  a c t iv ity  with non-radioactive  
ethacrynic acid. To prepare the lower specific a c t iv ity  m ate ria l, 
a known amount of lt+C-ethacrynic acid and a known amount of non- 
radroactivematerial were dissolved in ethanol. A fter complete 
dissolution, the ethanol was removed by evaporation. The required 
amount used to dose individual animals was weighed into small 10 ml 
via ls  [intravenous dosing) or gelatin  capsules (oral doses). The 
individual doses and the specific a c t iv ity  of the lt+C-ethacrynic 
acid used are given in Appendices 1 and 2.
Intravenous doses
For an individual dose the required weight.of 14C-ethacrynic acid 
(ca. 50 mg) was dissolved in 2.5% aqueous sodium bicarbonate (2 m l).
The resultant solution was given as a bolus in jection  into a saphenous 
vein of the monkey via an indwelling cannula (size 18). The use of 
the indwelling catheter was chosen so that the dose could be flushed 
in with 10 ml of normal sa line. Any residual dose in the v ia l ,  syringe 
or cannula was measured a fte r  the completion of the dosing, and 
substracted from the to ta l amount of rad io ac tiv ity  present in the 
orig ina l dose v ia l.
Oral doses
Individual oral doses were prepared by weighing a known amount of 14C-
ethacrynic acid (ca. 50 mg) into a small (18 x 7 mm) soft ge la tin
capsule. The capsule was then placed in a glass container labelled  
with the number of the animal which was to receive the dose. For 
the administration of the capsule a so ft rubber stomach tube [diameter
ca. 7 mm) was used. The capsule was pushed into one end of the tube
[s u ffic ie n t only to hold the capsule) and the tube was passed o ra lly  
into the stomach.' The capsule was displaced from the end of the 
stomach tube by means of a ir  pressure generated by attaching a 20 ml 
syringe to the opposite end of the tube. This mode of oral 
administration reduced the p o ss ib ility  of the capsule rupturing 
in the mouth of the non-human primate.
Purity of dosing m aterials
The purity  of the ll+C-ethacrynic acid supplied by Dr. J. Baer was 
examined by th in -la yer chromatography in 2 solvent systems.
1. Butanol:acetic acid:water, 4:1:5 by volume (upper phase used) and,
2. Chloroform:methanol, 4:1 by volume.
The th in -la y e r separation was carried out using 5 x 20 x 0.2 mm 
prepared t ic  plates containing a bound fluorescent in h ib ito r  
(E. Merck A.G., Darmstadt, type 60 F254 I .  The rad io a c tiv ity  was 
located as a single "spot" which co-chromatographed with non-radioactive  
ethacrynic acid. To assess the p u rity , the t ic  plates were divided into  
zones, and the s ilic a  gel was scraped from the glass backi'ng-plate.
The zone containing the ra d io a c tiv ity  was removed la s t to minimise cross 
contamination. Each portion of the s ilic a  gel was placed into an 
individual s c in t il la t io n  v ia l and mixed with 4 ml water and 10 ml of - 
a s c in t il la t io n  cocktail [S c in t illa to r  "T", Fisons, U .K .). The gels 
were counted by liq u id  s c in t il la t io n  counting. The radioactive
purity  of the l l *C-ethacrynic acid was >98% in a ll  doses.
Preparation of conjugates of ethacrynic acid 
To investigate the metabolism of the glutathione conjugates of 
ethacrynic acid, the glutathione conjugate and the cysteine conjugate 
were synthesised w ith e ith er the sulphur atom of the conjugate 
labelled with 35S or the ethacrynic acid moiety, labelled with 1IfC.
Radiolabelled glutathione (_35S) specific  a c t iv ity  7.5 Ci/mmol was 
obtained from New England Nuclear, Boston, U.S.A. and radiolabelled cysteine ( 35S) 
93 mCi/mmol was obtained from Amersham In ternatio na l, U.K.
For the purpose of s ta b il i ty ,  35S-glutathione was supplied containing 
10 mM d ith io th re ito l. Before use the d ith io th re ito l was removed by 
extraction using the method of Butler et a l . (1976). For the
preparation of individual doses of 35S-labelled conjugates, equimolar 
amounts of sulphydryl compound were reacted with ethacrynic acid (as 
the sodium s a lt)  in d ilu te  sodium bicarbonate solution (pH 8 .0 ) .  For 
the incorporation of the 35S labels Into the respective conjugates, 
an aqueous solution containing the respective non-radioactive th io l 
was prepared (205 mg GSH; or cysteine HC1 = 43 mg cysteine) in a 
to ta l volume of approximately 10 ml. To these solutions was added 
e ith e r radioactive 35S-glutathione (ca. 200 yCi) or 35S-cysteine 
(ca. 50 yC i). To each solution non-radioactive ethacrynic acid 
dissolved in 2.5% sodium bicarbonate was added (202 mg to GSH 
solution and 107 mg to the cysteine so lu tion ). The reaction was 
allowed to proceed a t 25°C fo r 30 min, a fte r  which time the reaction  
had gone to completion (as judged by th in -la y e r chromatography in
butanolracetic acidrwater, 4 :1 :5 by volume). The respective^________
conjugates were purified  a fte r  freeze drying by preparative t ic  in  
a solvent system comprising the upper phase of a butanol:acetic  acid: 
water, 4:1:5 by volume. The conjugate was eluted from the s il ic a  gel 
by aqueous methanol (50%) and freeze dried. A s im ilar procedure 
using the ^ - la b e l le d  ethacrynic acid was used to obtain dosing 
material with the ethacrynic acid moiety labe lled . In most instances 
the overall y ie ld  was between 70 and 80% of the orig inal a c t iv ity .  
Aliquots (ca. 5 mg) of each conjugate were weighed and the amount 
of ra d io ac tiv ity  present quantified by liq u id  s c in t i l la t io n . Due 
to the lim ited a v a ila b il ity  of rhesus monkey, studies using these 
labelled  forms of ethacrynic acid conjugates were only conducted 
in baboons.
B ile duct cannulation of non-human primates
The cannulation of the b ile  duct of non-human primates was conducted
by a veterinary surgeon w hils t the monkey was held under general 
anaesthesia. A cholecystectomy was performed and a "T" tube cannula 
(s ize 6 or 8 FG) inserted into the common b ile  duct. The cannula 
was then passed through an incision in the abdominal wall of the 
monkey. Another tube was passed through a separate incision in the 
abdominal wall and secured into the fundus of the stomach. These 
tubes allowed both the collection and, i f  required, the return of 
b ile  to the monkey. A fter recovery from surgery, the monkeys were 
kept in restraining chairs (HRC design) in the Primate Department.
To re-establish  the normal physiological state of the animal, each 
monkey had 95% of the b ile  which i t  excreted returned to its  stomach 
via a "stream -splitting" device connected to the return tube. The 
b ilia ry  output of each animal was monitored by examination of the
b ile  (residual 5% samples) collected during each 12-h period. The__
b ile  was examined fo r volume, colour, and fo r the presence of blood. 
When the animal had recovered and was producing consistent amounts 
of normal b ile  the respective dose was administered.
Collection of samples : Intravenous doses
Following an intravenous dose of llfC-ethacrynic acid 2 separate 
collection procedures were followed.
1. Pharmacokinetic investigations -  Following adm inistration of
14C-ethacrynic acid blood samples (3-5 ml) were collected into  
heparinised tubes at the following times: Pre-dose, and 5, 10,
15, 30, 45 and 60 min post-dose, 1 .5 , 2, 2 .5 , 3, 4 , 5 , 6 , 7 , 8 , 
12, 24, 48 and 72 h post-dose. The blood cells  were removed by 
centrifugation and the plasma stored at -20°C un til analysed.
2. Metabolic investigations -  Following administration of 
14C-ethacrynic acid, each animal was placed in a steep-sided 
metabolism cage f i t te d  with a perspex front panel (to avoid loss 
of urine) and the to ta l urine and faecal collection was made. 
Urine samples were collected into containers cooled in solid  
carbon dioxide so that the urine samples would be immediately 
frozen. Urine samples were obtained during the periods 0-8 h,
8-24 h and thereafte r at 24-h in terva ls  up to 144 h a fte r  dosing. 
The cage was washed with a small amount of d is t i l le d  water 
(100-200 ml) a fte r  8 and 24 h, and with 5 l i t r e s  of d is t i l le d  
water a t the end of the collection period. Faeces were collected  
at 24-h in tervals  throughout the study.
Col 1 ection of samp! es : Oral doses___________________________________
Following oral administration of 14C-ethacrynic acid blood samples 
were obtained a t pre-dose, 0 .5 , 1, 1 .5 , 2, 2 .5 , 3 , 4, 5, 6 , 7 , 8 , 24, 
48, 72 and 96 h a fte r  dosing. Plasma was separated and stored as 
described above. Urine and faeces samples were also collected as 
detailed above, but without the 8-h cage wash,-
B ile collections
The b ile  produced by each animal was collected during the 48 h a fte r  
the intravenous administration of 1IfC-ethacrynic acid. B ile from 
th.e rhesus monkey was collected at 15-min in tervals  up to 3 h post­
dose, and then at 4 , 5, 6 , 24 and 48 h. The b ile  from the baboon 
was collected at 5-min in tervals  up to 30 min, at 45 and 60 min, 
and then at hourly in tervals  u n til 6 h post-dose, and at 24 and 48 h. 
A ll b ile  samples were collected d ire c tly  into containers cooled in  
solid carbon dioxide to immediately freeze the b ile  samples.
Measurement of rad io ac tiv ity
Radioactivity was measured with a Philips liq u id  s c in t il la t io n  analyser 
(P h ilip s , N .V ., Eindhoven, Holland). A fter choosing the optimal 
settings, quench correction curves using the "external standard" 
method were prepared from radiochemical standards ( llfC-hexadecane, 
Radiochemical Centre, Amersham, U.K.) (Kobayashi and Maudsley, 1969). 
The coeffic ien ts  of a quadratic quench curve function were calculated  
by computer and entered in the analyser data processors, which 
autom atically calculated d isintegration rates. The v a lid ity  of the 
ca lib ra tio n  curves was checked at in terva ls  of approximately 20 
working days. A "background" disintegration rate (ca. 30 dpm) was 
measured, and subtracted from the sample disintegration ra te . The 
minimal detectable count rate was considered to be twice background 
levels in the  portions of samples taken fo r analysis. With equal 
counting times fo r "background" and standard, the counting erro r  
at the lim it  of detection was 8% of the net count ra te .
For measurement of rad io ac tiv ity  in various samples, fo r example, 
plasma, b i le , cagewashings, or methanol extracts of faeces, as well 
as portions of the doses (fo r measurement of specific  a c t iv ity  and to 
quantify the doses administered), e ith e r Packard Ml-31 s c in t i l la to r  
(Packard Instrument L td ., Caversham, U.K.) or S c in t il la to r  Cocktail 
"T" (Fisons, U.K.) were used.
Faeces and cage debris were separately homogenised w ith methanol 
(ca. 400 ml) ,  the homogenates were separated by centrifugation and 
the methanol decanted, and diluted with methanol to 500 ml. The 
residues were dried in a ir ,  weighed, and t r ip l ic a te  samples of these 
residues (ca. 300 mg) were mixed with cellu lose powder and combusted
in oxygen using a Packard 306 Automatic Sample Oxidiser (Packard 
Instrument L td ., Caversham, U .K .}. The 14C02 produced was absorbed 
into Carbo-Sorb and mixed with Permafluor V C^) s c in t il la to r  
(Packard Instrument L td .) . Recovery of ra d io ac tiv ity  by th is  procedure 
was at least 96%, and results were corrected fo r th is  recovery.
Separation of metaboli tes
Urinary and b il ia ry  radioactive metabolites were separated using 
th in -la y e r chromatography. S ilic a  gel plates 0.25 mm (pre-layered  
20 x 20 cm or 5 x 20 cm p lates, type 6QF254S E. Merck A .G ., Darmstadt) 
.were used. The solvent system used was the upper phase of a mixture o f  
butanol:water;acetic acid, 4:5:1 by volume. The plates were 
developed overnight (ca. 16 h ), th is resulted in good separation 
of the radioactive components present. The zones of ra d io a c tiv ity  
were located e ith er by scanning the t ic  plate using a Berthold p late  
scanner (type LB 2722, Camlab, Cambridge, U.K.) or an automatic plate  
scanner with an associated data handling system (Berthold Automatic 
Scanner, type LB 2832 plus a Le Croy data system). In some cases, 
the radioactive areas were also located by apposition autoradiography 
using Si'ngul-X, X-ray film  (J. Blishen and Co., London, U .K .). For 
quantita tive  purposes the radioactive zones were removed from the 
t ic  plates and the ra d io a c tiv ity  present in each zone was counted by 
liq u id  s c in t il la t io n  as detailed e a r l ie r .
Reference compounds of the glutathione conjugate, the cysteine 
conjugate, and the N-acetylcysteine conjugate were prepared by 
reacting aqueous equimolar amounts of e ith er GSH or cysteine with 
ll+C-ethacrynic acid dissolved in 2.5% sodium bicarbonate. The 
reaction was conducted at pH 8.0 at room temperature. The reaction
was allowed to go to completion (30 min) a fte r  which the reaction  
mixture was freeze-dried . Both the glutathione and cysteine 
conjugates contained a small proportion of ethacrynic acid (ca. 5%) 
when examined by t ic  with the butanol:acetic acid:water solvent 
system.
The N-acetylcysteine conjugate of ethacrynic acid was produced by 
treating  a small amount ( 1-2 mg) of the cysteine conjugate of 
ethacrynic acid with acetic anhydride.
High performance liq u id  chromatography (HPLC)
Measurements of plasma concentrations of ethacrynic acid were 
obtained by means of an HPLC method developed fo r th is study. The 
separation was conducted using a reverse-phase C18 column (25 cm x 
4.6 mm i . d . )  of e ith e r an ODS-2 (P a rtis i 1 PX310; Whatman L td ., 
Maidstone, U .K .) or a yBondapak column (Waters Associates, U .K .) 
using a solvent system of 40% acetonitrile:60%  d is t i l le d  water 
containing 0.025 M sodium phosphate (pH 4 .0 ) at a flow rate  of 
2 ml/min. The HPLC equipment used was a Waters pump un it (M6000A) 
and a Waters in jection  unit (UK6 universal in je c to r) . For q u an tita ti 
of plasma ethacrynic acid, the internal standard method was used.
Each plasma sample (0.25 ml) was "spiked" with 10 yg o f 2-m ethyl-4- 
chloro-phenoxyacetic acid (MCPA) (obtained from Aldrich Chemical Co., 
U .K .). To each plasma sample 1 ml of 1.0 phosphate buffer pH 3 
was added and then extracted with diethyl ether (5 ml) (5 min on 
rotating m ixer). A fter centrifugation of the sample the ether phase 
was removed,evaporated to dryness under a stream of nitrogen, and 
the residue dissolved in 100 y l  of the mobile phase. 50 y l  of th is  
solution was in jected onto the chromatograph. The absorbance of
ethacrynic acid and the internal standard were measured a t 230 nm 
using a Perkin-Elmer (type LC 55; Perkin-Elmer, Beconsfield, U.K.) 
variable wavelength detector.
A standard curve was prepared from fresh baboon plasma to which known 
amounts of ethacrynic acid (0.5-40 yg/ml) were added. The retention  
times (under the conditions described above) were ethacrynic acid 
5.4  min, and the in ternal standard 4.0 min. The amount of ethacrynic 
acid present in the samples was quantified by the peak height ra tio  
method. The standard curve of peak height ra tio  vs. concentration 
was lin e a r; Y = a + bx, where a = 0.00074 and b = 0.0174; r 2 = 0.995. .
Organ/tissue preparation
Non-human primates were sedated by intra-muscular administration of 
phencyclidine (Sernylan, Parke-Davis, U .K.) and k ille d  by exsanguination. 
Rats were k ille d  by cervical d islocation. Portions of the 
l iv e r ,  lung and kidney (non-human primate and ra t)  were placed in  
ice-cold phosphate buffer (0 .5  M, pH 7 .4 , containing 1.15% potassium 
ch lo ride). Portions of the gastro -fn testina l tra c t were opened, 
washed free of contents, and s im ila rly  placed in phosphate bu ffer.
Individual tissues were dissected free of connective tissue and 
weighed portions were fin e ly  minced with scissors, and homogenised 
in 4 volumes of ice-cold phosphate buffer. The tissue homogenates 
were prepared in a Potter-Elvehjem type glass homogeniser f i t te d  
with a Teflon pestle,which was e le c tr ic a lly  driven. For the 
preparation of gastro -in testina l mucosal homogenates, the washed 
portion was blotted dry and surface mucous was removed by gentle 
scraping. The mucosal layer was then removed by placing the portion
of the gastro -in testina l tra c t onto a cold 4°C plate and scraping the 
mucosal layer away from the basal muscle layer. Routinely, the 
mucosal samples were homogenised in 2 volumes of phosphate buffer.
Subcellular fractionation
A ll homogenates were centrifuged at 10,000 x G for 20 min at 4°C using 
an MSE superspeed 65 u ltra -cen trifu g e  to remove c e llu la r  debris, 
mitochondria and lysosomes. The post-10,000 G supernatant was 
decanted and recentrifuged at 105,000 G fo r 1 h. The post-105,000 
supernatant fraction (cytosol) was removed and stored either at-20°C or in liquid 
nitrogen u n til used fo r assay of the soluble enzymes. The p e lle t  
(microsomes) was used fo r the determination of N-acetyltransferase  
and in experiments involving “the microsomal glutathione S-transferases. 
For use, the microsomes were resuspended in phosphate KC1 buffer at 
approximately 10 mg microsomal protein/ml (GS-transferase) or tris-H C l 
(0.1 M, pH 7.4) containing 10% of glycerol fo r N -acetyltransferase. 
Tissue homogenates fo r glutathione determination were s im ila rly  
prepared as described above except that the g astro -in testina l mucosal 
samples were homogenised in 4 volumes of phosphate-KCl buffer.
Buffer solutions used in tissue and ce ll studies 
Phosphate buffered saline (PBS) -  Based on Dulbecco's phosphate 
buffered saline pH 7.4 containing NaCl 8.0 g; KC1 0.2 g; K^PO^O.2 g;
Na^PO^* 12H20 2.89 g; phenol red 0.01 g; per l i t r e  of d is t i l le d  water. *
Chelating solution -  PBS plus 0.5 mM ECTA.
Hank's buffered saline -  pH 7.0 containing NaCl 8.0 g; KC1 0 .4  g;
KH2P0it 0.06 g; Na2HP0tf • 12H20 1 .25 g; phenol red 0.01 g; per l i t r e  
of d is t i l le d  water. For use in the iso lation  of ce lls  collagenase 
(5 mg) and hyaluronidase 10 mg, plus 0.2 ml of 250 mM CaCl2 ; 0.1 ml 
of 1 M NaHC03 and 0.1 ml of fresh ly  prepared glucose solution (100 mg/ 
ml) were added.
Cell and tissue incubation medium -  HEPES-buffered s a lt solution
pH 7.45 containing NaCl 8.0 g; KC1 0.4 g; KH^Ot* 0.06 g; Na2HP0if • 12 H20
0.125 g; CaCl2 * 2H20 0.185 g; MgSO^  • 7H20 0.246 g; HEPES (free  acid)
4.76 g; glucose 1 g; 5 N NaOH 2 ml in 1 l i t r e  of d is t i l le d  water.
To 90 ml of th is  solution is added 10 ml foeta l c a lf serum; 1 ml 
MEM (100X) vitamins; 2 ml MEM (50X) amino acids; 1 ml 200 mM 
L-glutamine; 1 ml phenol red (1 mg/ml).
MEM vitamins and amino acid solutions obtained from Gibco-Biocult,
Paisley, Scotland.
Krebs-Henseleit buffer -  pH 7 .4  containing NaCl 6.9 g; KC1 0.3 g;
KH2P04 0.13 g; MgS04 • 7H20 0.292 g; CaCl2 • 2H20 0.374 g; NaHC03 2 g;
25 mM HEPES dissolved in 1 l i t r e  of d is t i l le d  water equilib rated  with  
95% 0 : 5% CO (Carbogen; B ritish  Oxygen Co. L td ., U .K .).
Buffer solutions used fo r iso lation  of parenchymal and non-parenchyma1 
hepatocytes:
(a) PBS as detailed above plus MgCl2 * 6H20 0.1 g; CaCl2 (anhyd.) 0.1 g; 
per l i t r e .  PBS 'A*
(b) Hank's buffer containing NaCl 8.0 g; KC1 0.4 g; CaCl2 (anhyd.) 0.14 g 
MgSOi* • 7H20 0.2. g; Na2HP04 • 2H20 0.06 g; KH^Oi, 0.06 g;
NaHC03 0.35 g; glucose 1.0 g per l i t r e .
(c) PBS/EGTA calcium -free, containing NaCl 8.1 g; KC1 0.2 g;
MgCl2 • 6H20 0.1 g; Na2HP04 1.42 g; KH^Ot, 0.2 g; EGTA 0.19 g 
per l i t r e .
(d) Collagenase-hyaluronidase buffer (modified Hank's bu ffer) -  
solution (b) plus CaCl2 (anhyd.) 0.41 g without MgCl2 * 6H20. 
Enzymes - 0.05% collagenase (Type IV Sigma Chemical Co.).
(e) Pronase buffer 0.25% pronase (Type XIV Sigma Chemical Co.) 
in Hank's buffer.
Procedure fo r preparation of parenchymal hepatocytes and non-parenchymal 
hepatocytes from ra t (methodology of Robens In s titu te , University of 
Surrey, U .K .).
1. The ra t was anaesthetised with ether and pinned out on a dissecting  
board. An ether mask was placed over its  face.
2. A fin e  polythene catheter was connected to a p e ris ta tic  pump 
giving a flow rate  of 4-10 ml/min. The tube to the end of 
the catheter was f i l le d  with PBS 'A ' EGTA (Solution (c } ) .
3. A fter opening out the abdominal cav ity , the catheter was
inserted into the hepatic portal vein.
4. The pump was s tarted , followed immediately by opening the thorax 
and cutting the vena cava.
5. PBS 1A1 EGTA (Solution (c ))  was perfused u n til 50-60 ml had
passed through the l iv e r .
6 . The liv e r  was perfused with collagenase/hyaluronidase fo r about 
15 min, allowing about 50 ml of enzyme to pass through.
* 7. The liv e r  was removed c a re fu lly  from the animal and transferred
onto a glass p late . I t  was 'combed' with a s ta in less-s tee l comb 
to form a s lurry1.
8 . The s lurry  was transferred to a 250 ml conical flask  with 
30-50 ml collagenase/hyaluronidase and incubated a t 37°C fo r  
20 min,
9. The ce ll suspension was f i l te re d  through bolting cloth (Henry 
Simon, Stockport, U .K .).
10. The f i l t r a t e  was centrifuged fo r 2 min at 250 g (1,800 rev/min 
on an MSE Minor).
11. The supernatant and the upper part of the p e lle t were removed 
(and kept) without disturbing the lower part o f the p e lle t.
12. The pelleted ce lls  were resuspended gently in Hank's saline  
(Solution (b ) ) ,  and were again pelleted fo r 2 min at 250 g.
13. The ce lls  were resuspended and pelleted a fu rth er 2 times as in 
step 12. The washes were discarded.
14. A fter discarding any s tria ted  layer at the top of the p e lle t ,  
the p e lle t was resuspended in a small volume of Hank's and 
kept at 4°C. This is  th e ’'parenchymal hepatocyte" preparation.
15. The supernatant and upper layer of the p e lle t, removed and kept
in step 1 1 .) , were now centrifuged fo r 10 min at 400 g (2,000 rev / 
min MSE Minor).
16. The p e lle t was resuspended in PBS 'A' and pelleted again as in 15.
17. The p e lle t was resuspended in pronase and incubated fo r 1 h at 
37°C.
18. The ce lls  were pelleted as in step 15.
19. The ce lls  were resuspended in PBS 'A' and pelleted a fu rth er 2
times as in step 15.
20. The f in a l p e lle t, "non-parenchyma! hepatocytes", was resuspended 
in a small volume of Hank's and kept at 4°C.
21. Cells obtained in steps 14 and 20 were placed in a small tube,
mixed with an equal amount of Trypan blue (0.5% in sa line) and
examined by phase contrast microscopy at x 400 m agnification.
In the current studies the Trypan blue exclusion dye indicated that the
ce ll v ia b i l i ty  was. greater than 80% in both preparations.
G1utathiOne estimation
The method fo r the estimation of glutathione in biological samples was 
based upon the spectrophotometric assay of the formation of 5 -th io -2 -  
nitrobenzoate (TNB), produced by the reaction of glutathione with  
5 ,5 '-d ith io b is (2 -n itro b en zo ic  acid) (DTNB) (Ellman, 1959).
Tissue samples were homogenised in 4 volumes of phosphate buffer 
(pH 7 .4 , 0.1 M). 4 ml of th is  homogenate was mixed with an equal
volume of sulphosalicylic acid (4%). The mixture was centrifuged  
at 2000 g fo r 30 min, and the supernatant decanted. 1.5 ml of the 
supernatant was mixed with 8.5 ml of phosphate buffer (pH 8 .0 , 0 .5  M), 
and aliquots (2 x 3 m l) were removed. To each a liq u o t, 0.2 ml of 
DTNB reagent (39.6 mg 5 ,5 '-d ith io b is (2 -n itro b en zo ic  acid) dissolved 
in 0.1 M 0-phosphate b u ffer, pH 7.0 (100 m l)) , was added, mixed and 
i ts  absorbance measured in a spectrophotometer a t 412 nm 10 min a fte r  
the addition of the DTNB reagent. A sample blank was measured using 
the remaining 4 ml of the pH 8.0 d ilu tio n . A standard curve was 
prepared using 10 mM glutathione (prepared immediately p rio r to
analysis and stored on ice) and taken through the same procedure.
y-Glutamyltranspeptidase (EC.2 .3 .2 .2 )
The method fo r the assay of y-GT a c tiv ity  in homogenates of various 
tissues was based on the methods of Orlowski and Meister (1963) and 
Meister et a l. (1981), in which L -y-g lu tam yl-p -n itroan ilide  was used as 
the substrate in the presence of glycylglycine as the acceptor 
dipeptide.
L -y-g lu tam yl-p -n itroan ilide  (GNA) (5 mM) was prepared by dissolving  
80 mg of GNA in 1 M HC1 (20 m l). When dissolved, the substrate 
solution was d ilu ted with 30 ml of d is t i l le d  water, and tris -base  
(0.73 g) was added to the solution and the pH was adjusted to 8.0  
with 2 M HC1. The resu lting solution was d iluted to 60 ml with  
d is t i l le d  water. Glycylglycine (0.T  M) was prepared by dissolving  
1.32 g of glycylglycine in 80 ml of d is t i l le d  water and the pH was 
adjusted to 8.0 w ith NaOH (2 M) and f in a l ly  d ilu ted  to 100 ml with  
d is t i l le d  water.
0.6 ml (1 .0  mM) of L -y-g lu tam yl-p -n itroan ilide  solution and 0.6 ml 
(20 mM) glycylglycine were added to 1 ml of tris -H C l buffer (0.1 M, 
pH 8 .0 ) and the mixture incubated at 37°C. Varying amounts of 
tissue homogenate (0 . 1- 0 .5 ml) were then added together with the 
required amount of tris -H C l buffer to bring the reaction volume of
3.0 ml. The reaction was allowed to proceed fo r up to 30 min, 
depending on the tissue being assayed, a fte r  which time the reaction  
was stopped by placing the reaction tubes into a boiling water bath 
fo r 2 min. A fter centrifuging the tubes to remove precip itated  
protein , the absorbance of the resulting supernatant was measured
a t 410 nm. Quantitation of the p -n itro an ilin e  was achieved using a 
molar extinction co e ffic ien t of 8,800 M“1 cnr"L
Cystei nylglyci ne dipeptidase
The a c t iv ity  of dipeptidase in tissue homogenates was measured using 
the substrate S -benzylcysteine-p-nitroan ilide -(Tovey e t a l , 1973) 
using the method of (Hughey e t a l , 1978).
S-Benzylcysteine-p-nitroaniTide (10 mM) was dissolved in HC1 (0.01 M) 
at 37°C. For use, the substrate solution was d iluted to 0.2 mM with 0.4 mM 
MnCla.in 50 mM potassium phosphate buffer (pH 7 .0 ). Tissue homogenates 
(0 .2 -0 .5  ml) were added to 2 ml of substrate pre-heated at 37°C and 
incubated for 30 min. The reaction was stopped by heating the reaction  
tubes in a boiling water bath fo r 2 min. The precip itated protein was 
removed by centrifugation and the absorbance of the supernatant 
measured spectrophotometrically a t 410 nm.
N-Acetyltransferase
Microsomal N-acetyltransferase was assayed by a modification of the 
method of Green and Elce (1975).
The microsomes prepared from various tissue were suspended in tris -H C l 
buffer (0.1 M, pH 7.4) containing 10% glycerol. The microsomes were 
diluted to a f in a l concentration of approximately 1 mg protein /m l.
The substrate benzyl-L-cysteine was dissolved in 0.05 M NaOH and then 
the pH was adjusted to 7.5 with HC1 (0.1 M).
11+C-Acetyl CoA was obtained from Amersham International and had a 
specific  a c tiv ity  of 51 Ci/mol. For use, a v ia l containing 10 uCi of
lifC-acetyl CoA (0.159 yg) was opened and 3.15 ml o f a solution of 
non-radioactive acetyl CoA (1 mg/ml) was added. The resu lting  
solution had a specific  a c t iv ity  of 3.022 yCi/mg (2.448 mCi/mM).
For use in the assay, the contents of the v ia l were d ilu ted  to 40 ml 
with d is t i l le d  water. The incubation mixture consisted of 100 yM 
of benzyl-L-cysteine and 100 yM lifC-acetyl CoA in a to ta l volume of 
2 ml which was incubated a t 37°C. The reaction was in it ia te d  by the 
addition of between 50-100 yg of microsomal protein and incubated 
fo r e ith e r 10 or 20 min, depending on tissue, and was stopped by 
the addition of 0.5 M b^ SOi* (2 ml) a fte r  which the mixture was 
extracted twice with ethyl acetate (4 m l). The pooled extracts  
were then washed with a fu rther 2 ml of 0.5 M H^SO .^ A fte r washing 
the ethyl acetate extract was transferred to a glass v ia l and 
evaporated to dryness. To the dry v ia l 7 ml of a s c in t il la t io n  
cocktail was added and the rad io ac tiv ity  measured. A blank 
consisting of heat denatured protein (100 yg) was taken through 
the assay procedure fo r each batch of samples.
Glutathione S-transferases
The a c tiv ity  o f the glutathione S-transferases present in the • 
supernatant fraction  o f various tissues were assayed by 2 main 
methods. In the f i r s t ,  the production of the glutathione conjugate 
was measured spectrophotometrically using the molar extinction  
coeffic ien ts  and absorbance maxima as reported by Habig e t a l . (1974). 
In the second, the amount of GSH reacted during the period of 
incubation was measured by measuring the residual GSH with the 
DTNB reagent of E ll man (1959).
A ll the spectrophotometric estimations of glutathione S-transferase
a c tiv ity  were carried out in a to ta l reaction volume of 3 ml a t 25°C 
in a therm ostatically controlled cell-compartment of a Pye SP 4000 
spectrophotometer, and with the exception as indicated, a l l  estimations 
were conducted a t pH 6.5 in 0.1 M phosphate buffer to minimise the 
chemical reaction of glutathione with the second substrate. The 
fin a l concentrations of glutathione and respective second substrates 
in the assay mixtures are given in Table 1.
TABLE 1
Conditions used fo r the assay of glutathione S-transferase a c tiv ity
(a) Spectrophotometric assays
S u b s t r a t e
S u b s t r a t e
c o n c e n t r a t io n
(mM)
GSH ' 
c o n c e n t r a t io n  
(mM)
W a v e le n g th
(nm )
Ac
(M " 1 c m " ! )
1- C h i o r o - 2 , 4 - d i  n i t r o b e n z e n e 1.0 1.0 3 4 0 9 . 6
1 , 2 - D i c h l o r o - 4 - n i t r o b e n z e n e * 5 . 0 5 . 0 3 4 5 8 . 5
E t h a c r y n i  c a c i  d 0.2 0 .2 5 2 7 0 5 . 0
1 , 2 - E p o x y - 3 - ( p - n i  t ro p h e n o x y )p r o p a n e 5 . 0 5 . 0 3 6 0 0 . 5
pH 7 .5 .
(b) Substrates in which loss of the th io l group was measured by 
reaction o f residual 6SH with DTNB reagent.
Substrate
Substrate
concentration
(mM)
GSH
concentration
(mM)
Diethylmaleate 5.0 5.0
trans-4-Phenyl-3-butene-2-one 2.0 2.0
Cyclohex-2-en-l-one 3.0 3.0
The residual th io l present in the incubated assay mixtures (to ta l  
volume 4 ml) indicated in Table 1 (b) was measured by adding an equal 
volume (4 ml) of 4% w/v  sulphosalicylic acid , and a fte r  mixing, the 
precipitated protein was removed by centrifugation. 1 ml of the 
supernatant was then d iluted to 50 ml in phosphate buffer (0 .5  M,
pH 8 .0 ) and to 3 ml of th is  solution 0.2 ml of DTNB reagent was added 
(see GSH assay). The reaction was allowed to proceed fo r 10 min 
a fte r  which the reaction product (TNB) was measured spectrophotometrically 
at 412 nm. Chemical reaction of glutathione with the second substrate 
under examination was subtracted from the to ta l amount of th io l used 
during the enzyme catalysed reaction.
Solutions of glutathione (50 mMj were prepared immediately p rio r to 
each group of assays and kept on ice . Solutions of the second 
substrates were prepared in ethanol on a weekly basis and stored 
at 4°C. The stock, substrates were 50 mM except fo r diethylm aleate, 
cyclohex-2-en-l-one and 1 ,2-dichloro-4-nitrobenzene which were 100 mM.
The maximum concentration of ethanol in any reaction mixture (to ta l 
volume 3 ml) was not greater than 5%.
The conditions used fo r any assay were such that the rate of conjugation 
of second substrate with glutathione was lin e a r with respect to 
protein concentration and time, and less than 20% of the second 
substrate was conjugated.
Preparation of the g lu ta th io n e^affin ity  matrix (Simons and Vander Jagt, 
1981)
Epoxy-activated Sepharose 6B (Sigma), 4 g, was washed on a Buchner 
funnel with 500 ml of water. The gel was washed w ith 40 ml of a 
44 mM phosphate.buffer, pH 7 .0 , prepared by mixing 8 ml of 0.2  M_ KH2PQi* 
and 28 ml of 0.1 M Na2HP0tt per 100 ml of solution. The gel was 
transferred to a 50-ml flask where the volume was adjusted to 20 ml 
with the same buffer. Nitrogen was passed through the flask, and 
suspension fo r 5 min; 4 ml of a solution of glutathione (400 mg of
glutathione in 4 ml of water, adjusted to pH 7 with KOH) was added to 
the suspension. A fter 24 h at 37°C with gentle shaking on a Dubnoff 
metabolic incubator (ca. 60 rpm), the coupled gel was washed with  
100 ml of water, and the remaining active groups.were blocked by 
allowing the gel to stand in 1 Fi ethanol amine fo r 4 h. The gel was 
washed sequentially with 100 ml each of 0.5 M KC1 in 0.1 M sodium 
acetate (pH 4 .0 ) ,  0.5 KC1 in 0.1 M sodium borate (pH 8 .0 ) ,  and 
the starting  buffer fo r the column.
Protein
The concentration of protein in various samples were determined by 
the method of Lowry e t a l . (1951) using bovine serum albumin as a 
standard.
Iso e lec tric  focusing
Iso e lec tric  focusing was conducted in th in  1 mm agarose gels which 
were prepared on an 11 cm x 22 cm hydrophilic polyester support sheet 
(Gel Bond). The agarose (.0,3 g; TEF grade) was dissolved in 30 ml 
hot d is t i l le d  water (9Q°C) and 3,6 g sorbito l were added. The 
solution was allowed to cool to approximately 75°C and 1,9 ml of 
pharmalyte 3^10 (Pharmacia Fine Chemicals AB, Uppsala, Sweden) was 
added. The solution was poured into a 1 mm deep mold, the base of 
which was the support sheet. When the gel had set the mold frame 
was removed and the gel allowed to harden fo r 1 h at 4°C before use.
The gel was used in a water cooled f la t  bed apparatus constructed
at Huntingdon Research Centre, The electrode solutions were,anode 
0.04 M aspartic acid or 0.05 M \\2 SOb and cathode 1 M NaOH. Samples
of protein 10-20 yl were placed on the surface of the gel on small
(5 mm x 2 mm) f i l t e r  paper. The samples were applied approximately
V 3 of the distance between the electrodes closest to the anode. 
Iso e lec tric  focusing was conducted at a fixed current (10 mA); the 
applied voltage increased (1000 V max) as the pH gradient of the 
ampholytes was produced. At the completion of the protein separation 
(as judged by the migration of coloured proteins of known pi values; 
BDH, Poole, U .K .), The proteins in the gel were fixed in 5% 
sulphosalicyllc acid/1Q% trich lo ro acetic  acid (30 min ) . The gel 
was washed fo r 30 min with methanol:acetic acid:water (3:1:6  by v o l) .  
The gel was then dried between sheets of f i l t e r  paper and f in a l ly  
dried with a hairdryer. A fter drying, the gel was stained with 0.2% 
Coomassie B r i l l ia n t  Blue.in the same solvent mixture (10-15 min) 
and destained in methanol:acetic acid:water (3:1:6  by vol) and dried.
S ta tis tic a l analysis
The s ta tis tic a l comparison of the measured a c tiv it ie s  of the 
glutathione S-transferases were conducted using a m ultiple comparison 
procedure based on the procedures of Newman (1939) and Keul (1952).
Followingthe analysis of variance,the tes t *t* values were calculated
from t  = Xl ~ Xz. The level of significance is  given by comparison 
SE-D
of th is ' t 1 value with 3  where the q, value is  found from standard
CHAPTER 3
PHARMACOKINETICS OF ltfC-ETHACRYNIC ACID IN NON-HUMAN PRIMATES
INTRODUCTION
Ethacrynic acid (E d e c r in ® ) is a loop d iu re tic  which has been in 
c lin ic a l use fo r the treatment of several human disorders including 
ascites, renal oedema and heart fa ilu re  fo r a number of years. The 
doses used vary between 50-150 mg/day in the case of oral administration  
or 50 mg/day when used as an intravenous infusion. Several groups of 
researchers have published renotropfc and pharmacokinetic data of 
ethacrynic acid obtained from studies in the ra t and the dog 
(Beyer et a l , 1965; Klaassen & F itzgera ld , 1974; Wallin e t a l , 1978).
The pharmacokinetics of ethacrynic acid in man have not been extensively  
studied, although there are well documented pharmacological data of 
ethacrynic acid obtained during c lin ic a l use. In the non-human 
primate, only lim ited investigations, using the chimpanzee or the 
"New World" Cebus monkey, have been reported (Fanelli e t a l , 1977). 
Studies u t ilis in g  "Old World" primates ( i .e .  Rhesus monkey (Macacamulatta) , 
Baboon (Papio species), or Cynomolgus monkey (Macaca fa s c ic u la r is ) ) 
had not been reported prio r to 1978 (Fanelli personal communication). 
Since that time, only the prelim inary studies in the rhesus monkey, 
which form part of th is  thesis , have been reported (W aller, 1980).
Ethacrynic acid reacts ( I )  with sulphydryl compounds in vivo and 
in v it r o . Reaction of ethacrynic acid with glutathione is known to 
form a glutathione conjugate ( I I ) .  R eactiv ity  is due to the 
e lec tro p h ilic  ag-unsaturated ketone moiety present in the ethacrynic 
acid molecule ( I )  reacting with the nucleophilic sulphur atom of 
glutathione with the resultant conjugate being formed across the
unsaturated ethylene group.
Cl Cl
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This reaction which occurs chemically can also be catalysed by one or 
more of the glutathione S-transferase isoenzymes (Boy!and and 
Chasseaud, 1967). The glutathione S-transferases are present in the 
various tissues of higher animals (Jakoby, 1974). In addition , 
ethacrynic acid has also been shown to react covalently with ra t  
glutathione transferase C (Yamada and Kaplowitz, 1980).
The following studies were carried out in order to evaluate: (a) the 
pharmacokinetics of ethacrynic acid in both the rhesus monkey (Macaca 
m ulatta), and the baboon (Papio species) ,  (b) the excretion and 
metabolite p ro file , and (c) the kinetics of the mercapturic acid 
pathway in these species of non-human primate.
EXPERIMENTAL
Animals
Mature rhesus monkeys (Macaca m ulatta) and baboons ( Papio hamadryas, 
Papio anubis or Papio papio). were obtained v ia  the Primate Department 
of the Huntingdon Research Centre, from Shamrock Farms Ltd., Sussex, U.K. All 
animals used were passed as normal healthy adults suitable fo r  
experimental purposes by a veterinary surgeon. Animals were between
6-10 kg bodyweight at the time of dosing, and unless specified to the 
contrary, were fed on a standard primate d ie t , containing f r u i t  and 
wholemeal bread, w ith unlimited access to water. Each week the 
animals received a supplement of blackcurrant ju ice  and vitamin Bi2 
(Cytocon,Glaxo L td ., Greenford, Middlesex, U .K .).
Sample collection
During the metabolic studies, individual animals were housed in steep 
sided metabolism cages f it te d  with perspex splash plates which prevent: 
loss of urine. Faeces and urine were separated.by means of a wire 
mesh f lo o r. To minimise degradation of the metabolites present in 
the urine, the urine was collected as voided into containers cooled 
in solid carbon dioxide. At certain times, as specified in the 
various tables of resu lts , the cage floors were rinsed with a small 
volume of d is t i l le d  water. At the completion of the study, the whole 
cage was washed with 5 l i t re s  of d is t i l le d  water. Any waste food 
remaining in the base of the cage was collected and stored as cage 
debris and analysed fo r ra d io ac tiv ity  content separately.
Blood samples (3-5 ml) were withdrawn by syringe from individual 
animals at the times specified in the results tables by d irec t
sampling from a femoral vein. At early  timed co llections, when 
frequent blood samples were required, a closeable b u tte rfly  cannula 
was inserted in to  a femoral vein and secured to the animal's leg.
When a blood sample was obtained via the cannula, a small quantity  
(approx. 2 ml) of physiological saline was flushed back through the 
cannula to prevent c lo t formation w ithin the cannula. The cannula 
was usually removed a fte r  1 h.
B ile duct cannulation
Bile duct cannulation was conducted by a veterinary surgeon w h ils t 
the animal was maintained under general anaesthesia (Saffan Glaxo Ltd; 
Halothane/oxygen). Each animal had a "T" tube cannula (s ize  8 or 9 FG)
inserted into the common b ile  duct and the cannula was then passed
through an incision in the abdominal wall of the animal. A b i l ia r y  
return tube was also passed in through a separate incision in the 
abdominal wall and secured into the fundus of the stomach. These 
tubes allowed the collection and return of b ile  to the animal. A fter
recovery from the surgical procedure, the animals were kept in
restraining chairs in the Primate Department.- To re-estab lish  the 
normal physiological state of the animal, each animal had 95% of 
the b ile  which i t  excreted returned to i ts  stomach via a "stream 
sp littin g "  device connected to the return tube. The b il ia ry  output 
of each animal was monitored by examination of the b ile  (residual 
5% samples) collected during each. 12-h period. The b ile  parameters 
examined were volume, colour, and also whether there was any 
contamination with blood. When the animal had settled  down and 
was producing reproducible amounts of b ile  free from blood, i t  
was dosed with its  respective dose.
Intravenous administration of the dosing material was made via an 
18 gauge cannula inserted into a saphenous vein. Total b ile  
collections were made at various in tervals  as indicated in the 
results tables. A ll b ile  samples were collected d ire c tly  into  
containers cooled in solid carbon dioxide. During each experiment, 
the monkey was supplemented with b ile  which had been excreted 
prio r to dosing. The b ile  was replaced through the indwelling  
stomach tube.
Dose preparation
The- individual doses usfcd during th is  phase of the study were 
prepared from ll*C-ethacrynic acid kindly supplied by Dr. J. Baer 
of Merck, Sharp and Dohme, Rahway, U.S.A. The specific a c t iv ity  
of the 14C-ethacrynic acid supplied was adjusted by the addition  
of non-radioactive ethacrynic acid dissolved in methanol to a 
methanolic solution containing IlfC-ethacryni'c acid. The solvent 
was removed by evaporation under a stream of nitrogen. The 
ra d io ac tiv ity  present in weighed samples (5-10 mg) of the dose 
was measured by liq u id  s c in t il la t io n  counting, and th is provided 
the data from which the to ta l ra d io a c tiv ity  present in an individual 
dose could be calculated. In the studies involving adm inistration of 
ethacrynic acid via the intravenous route, the weighed dose was 
dissolved in aqueous sodium bicarbonate 2.5% w/ v  (2 m l). The 
resultant solution of sodium ethacrynate was administered as a 
bolus in jection  into the saphenous vein over a 10-20 second period. 
For the oral doses, weighed amounts contained in soft ge la tin  
capsules, were administered by the use of a stomach tube. The 
capsules were displaced from the terminal portion of the stomach 
tube by a ir  pressure using a 20 ml syringe.
To investigate the formation and degradation of glutathione conjugates 
in greater d e ta il, radiolabelled GSH and cysteine conjugates of 
ethacrynic acid were synthesised with e ith e r the sulphur atom of 
the sulphydryl compound labelled with 35S or the acetate portion 
of the ethacrynic acid molecule labelled with ll*C.
Radioactivity measurements
Samples of plasma, b ile  and urine were taken, mixed with a s c in t il la t io n  
cocktail, and th e ir  ra d io a c tiv ity  content measured by standard liq u id  
s c in til la t io n  counting techniques (see Chapter 2 ). Faecal 
samples were extracted with methanol by homogenisation and subsequent 
centrifugation. The methanol was removed, d ilu ted to a known volume 
and an aliquot counted. The residual faeces were then a ir  dried and 
sub-samples were combusted in oxygen using a sample oxid iser p rio r to 
liq u id  s c in t il la t io n  counting. *
Measurement of 1IfC-ethacrynic acid
Quantitation of unchanged ethacrynic acid in plasma was achieved 
using a C18 reverse phase high performance liq u id  chromatographic 
procedure (see Chapter 2 ) , incorporating 4-m ethyl-2-chloro- 
phenoxyacetic acid (MCPA) as the in ternal standard. Quantitation  
was by the standard peak height ra tio  method. Representative 
chromatograms showing the separation obtained between ethacrynic 
acid and the internal standard are given in Figure 3-2.
The concentrations of unchanged ethacrynic acid measured in plasma 
(Table 3-4) indicated that the ra d io a c tiv ity  present in the samples 
up to 4 h a fte r  dosing was associated almost e n tire ly  with 14C- 
ethacryni'c acid. A fter th is  time, the accuracy of the individual
determination was poor. This could be due, in p art, to the known high 
binding c o e ffic ien t of ethacrynic acid to serum albumin, or because 
only small samples were availab le . I t  was, therefore, decided to 
u t i l is e  the to ta l rad io ac tiv ity  measurements as a basis fo r the 
pharmacokinetic model as these corresponded closely with the 
concentrations of ethacrynic acid present in the plasma to a t least 
4 h a fte r  dosing.
RESULTS
Plasma rad io a c tiv ity  concentrations 
Intravenous dose
Following an intravenous dose of ethacrynic acid (50 mg), concentrations 
of rad io ac tiv ity  in plasma samples obtained at the f i r s t  sampling time 
of 5 min were 28.6, 31 .0 , 26.8 and 43.0 yg/ml in each of 4 rhesus 
monkeys 525, 526, 527 and 528 respectively (Table 3-1 and Figure 3 -1 ). 
Plasma rad io ac tiv ity  concentrations in i t ia l l y  declined rap id ly  by about 
10-fo ld w ithin 1.5 h, and then more slowly th e re a fte r, since 
concentrations of between 1 and 2 tig/ml were found during 4 h to 24 h 
a fte r  dosing (Figure 3-1). Pharmacokinetic parameters fo r the plasma 
rad io ac tiv ity  concentration-time data were calculated using a curve 
f i t t in g  programme (M .L .P ., Rothampsted, U .K .). In most cases, a 
3-phase exponential curve could be f i t te d  when weighting facto r was 
appl ied to the la te r  samples. The terminal phase was probably due to the 
release of ethacrynic acid from a "deep tissue compartment". Due to the 
small number of samples obtained a fte r  48 h, i t  was considered that a 
bi-exponential model could be applied to the data. The pharmacokinetic 
parameters and the equations by which they are derived are given in 
Tables 3-2 and3-5. There are close agreements within the group with a 
d is trib u tio n  phase h a l f - l i f e  of between 0.29 and 0.34 (h ), and 
also extrapolated time zero plasma ra d io ac tiv ity  concentrations were 
between 27.5 and 31.5 yg/ml (animal 528 had a s lig h tly  higher value 
of 49.2 pg/ml). The h a lf- liv e s  of plasma rad io ac tiv ity  calculated  
from the terminal (beta) exponential phase were more variab le  with 
h a l f - l i f e  values ranging from 29.7 to 72.3 h. The calculated rate  
constants (Table 3-3) indicated that the transfer rate constant 
(K-j_£) from central compartment ( 1 ) to the peripheral compartment ( 2 )
was higher, 1 .63-2.09 h"  ^ than the reverse rate constant that
is from peripheral compartment to the central compartment (0 .15- 
0.18 h“l) ., w h ils t the elim ination rate constant (K-j_q) was between
0.13 and 0.38 h"1 .
The apparent volumes of d is trib u tio n  Vd (Table 3 -3 ), calculated from 
the individual dose (yg) divi'ded by the plasma concentration a t time 
zero, showed that with the exception of animal 528 (1048 m l), the 
results were s im ilar (1671-1826 m l).
Following the administration of an intravenous dose of ethacrynic acid 
(50 mg), the concentrations of ra d io a c tiv ity  present in the blood 
samples obtained at the f i r s t  sampling time of 5: min were 26 .2 ,
24.1 and 25.2 yg/ml in each of 3 baboons respectively, and were 
sim ilar to those in the rhesus monkeys. No sample was obtained from 
animal 993 at 5 min. The plasma rad io ac tiv ity  concentrations 
declined in a ll animals at approximately the same ra te , and appeared 
to follow  a multi-exponential time-course (Table 3-1 and Figure 3 -1 ). 
Pharmacokinetic parameters derived by curve f i t t in g  in the same manner, 
as applied to the plasma samples obtained from the rhesus, monkeys, 
are given in Tables 3-2 and 3-3. Areas under the concentration-time  
curve extrapolated to in f in i ty  were between 146.2 to 211.8 yg.h/ml 
with the exception of animal 111, which was 76.3 yg.h/m l. The alpha 
phase h a l f - l i f e  values were s im ilar in a ll  animals with calculated  
values of between 0.245 and 0.259 h. The calculated h a l f - l i f e  values 
fo r the beta phase showed greater inter-anim al v a r ia b il i ty  and were 
between 23.3 h and 75.3 h.
Transfer rate constants (Table 3-3). again show that the tran sfer
rate constant ( K-j__2 ) ^rom central compartment to the peripheral 
compartment was highest (2 .12-2 .47  h"^). The reverse transfer rate  
constant ( K2- ] )  anc* t i^e elim ination rate constant (K-]_q) were very 
sim ilar (0 .17-0.20  h“  ^ and 0 .15-0.40 h“  ^ respective ly ). The apparent 
volumes of d is trib u tio n  (Vd) were in the range 1462-1735 ml.
Oral dose
Following an oral dose of ethacrynic acid (50 mg), plasma ra d io ac tiv ity  
concentrations reach a maximum at between 2.5 and 5 h a fte r  dosing of 
1 .9 , 1 .43, 2.5 and 1.7 yg/ml in each of 4 rhesus monkeys respectively. 
During the time period 2-8 h a fte r  dosing, the.plasma levels of radio­
a c tiv ity  were re la tiv e ly  constant (Table 3-5 and Figure 3 -3 ). A fter  
8 h post-dose the plasma rad io ac tiv ity  concentrations declined re la tive ly  
slowly. Terminal h a lf- liv e s  (during 24-96 h) were in the range 51.1-
58.0 h (mean 54.9 h) (Table 3-6 and Figure 3 -3 ). The mean area 
under the curve was 96 yg.h/ml (range 87.2-103.4 yg.h /m l).
Concentrations of ra d io ac tiv ity  in plasma samples obtained.from baboons, 
following a single oral dose of ethacrynic acid (50 mg), are given in 
Table 3-5 and Figure 3 -3 . Peak ra d io ac tiv ity  concentrations of 
1 .7 , 2 .0 , 1.8 and 2.0 yg/ml in the 4 animals respectively, occurred 
between 2.5 and 4 h a fte r  dosing.
The concentration of ra d io ac tiv ity  remained re la tiv e ly  constant during 
the period 2-7 h a fte r  dosing. The mean area under the concentration­
time curve was 97.1 yg.h/ml (range 85.6-104) and the mean terminal 
h a l f - l i f e  value of 55.7 h (range 43-73.5 h) (Table 3 -6 ).
Excretion of rad io ac tiv ity  
Intravenous doses
Following a single intravenous dose of 1I+C-ethacrynic acid (50 mg) 
to each of 4 rhesus monkeys, s lig h tly  more of the ra d io ac tiv ity  was 
excreted in the faeces (mean 51% of the dose; range 49-55%) than in 
the urine samples (mean 41% of the dose; range 40-44%) (Table 3 -7 ).
The faecal samples were extracted routinely once with methanol when 
a mean of 17% of the dose was extracted. In order to check that 
the extraction procedure (used prim arily  fo r the iso lation  of faecal 
metabolites), removed radioactive metabolites of ethacrynic acid 
which were, representative of those occurring, in the faeces,.a  
second extraction was carried out on the m aterial.remaining a fte r  
the f i r s t  extraction . This second extract contained a mean of 6% 
of the dose and also a s im ilar pattern of radioactive compounds.
A to ta l of 93% (range 91-96%) was recovered in the urine and faeces.
The proportions of rad io ac tiv ity  excreted in the urine during each 
collection period are given in Table 3-8 . Excretion of ra d io a c tiv ity  
was maximal during the f i r s t  8 h a fte r  dosing (mean 31% of the dose) 
which represents 74% of the to ta l ra d io ac tiv ity  recovered in the 
urine samples. Over 92% (38% of the administered dose) of the 
urinary rad io ac tiv ity  was recovered in the f i r s t  24 h a fte r  dosing. 
Thereafter only small amounts of rad io ac tiv ity  were excreted.
A substantial proportion of the ra d io ac tiv ity  recovered in the faeces 
(Table 3-10) was measured in the f i r s t  2 co llection periods when 31% 
and 17% of the dose was excreted (94% of to ta l faecal excretion).
The remaining amounts of ra d io ac tiv ity  were slowly excreted during 
the subsequent 4 days.
Following administration of ethacrynic acid (50 mg) to each of 4 baboons, 
a mean of 54% of the dose was excreted in the faeces with a fu rther
39% excreted in the urine (Table 3 -7 ). During the f i r s t  24 h a fte r
dosing over 77% of the to ta l rad io ac tiv ity  excreted in the urine was 
recovered, with the 0-8 h co llection  containing 63% of the urinary  
rad io ac tiv ity  (25% of the administered dose). A fter 24 h only small 
amounts of ra d io a c tiv ity  were measured in the urine samples (Table 3 -8 ). 
The largest proportion of faecal ra d io ac tiv ity  was measured in the 
0-24 h and the 24-48 h samples, 32% and 16% respectively, and th is  
accounted fo r >89% of the ra d io ac tiv ity  excreted via th is  route 
(Table 3 -10). The overall- recovery was 94% (range 90-95%).
Oral doses
Following an oral dose of ethacrynic acid (50 mg) to 4 rhesus monkeys,
a mean of 24% of the dose was measured in the urine samples with a
fu rther 68% present in the faeces (Table 3 -7 ). The overall recovery 
of ra d io a c tiv ity  fo r th is  experiment was 93% (range 87-97%). The 
results obtained fo r the individual timed co llection  period fo r  
urine and faeces samples are given tn Tables 3-9 and 3-10. The 
largest amount of rad io a c tiv ity  was excreted in the urine during 
the 8-24 h period (mean 10.6% of the dose), a to ta l of 19.7% being 
excreted during the f i r s t  24 h.
Small amounts of ra d io a c tiv ity  <1.7% of the dose, were excreted in 
the subsequent 24-h urine co llec tio n , and thereafte r only very small 
amounts of ra d io a c tiv ity  were present. As observed with the 
intravenous doses, most (>97%) of the ra d io ac tiv ity  which was 
excreted in the faeces, was recovered in the f i r s t  2 days a fte r  dosing.
Following a s im ilar dose of ethacrynic acid to the 4 baboons, a s im ilar  
d is trib u tio n  of excreted rad io ac tiv ity  occurred (Table 3 -7 ). Means 
of 26% and 67% of the dose were recovered in the urine and faecal 
samples respectively. Tables 3-9 and 3-10 show the amounts of radio­
a c tiv ity  recovered in the various timed urine and faecal co llection  
periods. In the baboon, s lig h tly  more of the administered radio­
a c tiv ity  was excreted in the 0-8 h period (13% of the dose) than 
the 8-24 h period (10%). The to ta l quantity of ra d io a c tiv ity  excreted 
in the urine during the f i r s t  24 h was greater than 82% of the to ta l 
ra d io ac tiv ity  excreted in the urine. The rad io ac tiv ity  excreted in 
the faeces during-the f i r s t  24 b a fte r  dosing was 37%-, and in the 
24-48 h period, 24%. The rad io a c tiv ity  present in the faeces in the 
f i r s t  2 days was approximately 90% of the to ta l amount of ra d io a c tiv ity  
recovered in the faeces.
Excretion of ra d io ac tiv ity  in b ile  duct cannulated animals 
Intravenous administration
The b il ia ry  excretion of rad io ac tiv ity  was studied in 2 rhesus monkeys 
and 2 baboons, each equipped with a b ile  duct cannula in s itu . The 
onset of excretion of ra d io ac tiv ity  into b ile  was very rapid. Within 
the f i r s t  .60 min a fter, dosing a mean of 54% ± 6% of the dose had 
been excreted in the b ile . There was some inter-anim al varia tion  in 
the proportions excreted in the b ile  during the f i r s t  15 min a fte r  
dosing, with 23% and 35% of the dose excreted in animals 525 and 526 
respectively. Thereafter, the proportions of ra d io ac tiv ity  excreted 
during each collection period were s lig h tly  higher in animal 525.
During the 48-h period a fte r  dosing a mean of 68% ± 1% of the dose 
was excreted in the b ile  (Table 3 -11). In the baboons studied, the 
pattern of b ilia ry  excretion of rad io ac tiv ity  was s im ilar to th a t in
rhesus monkeys. A to ta l of 46% to 58% of the dose was recovered in 
the b ile  during the f i r s t  60 min. Again, there was some inter-anim al 
variation  in the rate b il ia ry  excretion of ra d io a c tiv ity . During the 
48-h collection period, 67% ± 3% of the dose had been excreted in the 
b ile  of baboons (Table 3 -12).
Urine produced during the b il ia ry  excretion studies were measured fo r  
th e ir  ra d io ac tiv ity  content (Tables 3-11 and 3 -12). Approximately 30% 
of the dose was present in the urine samples of both species. The 
major portion of the urinary ra d io ac tiv ity  was present in the urine 
excreted during the f i r s t  24 h. In the case of the baboons, in which 
more frequent urine collections were made during the f i r s t  24 h, a 
mean of 28% of the dose was excreted w ithin 6 h. More than 65% of the 
to ta l urinary rad io ac tiv ity  excreted during 0-6 h was excreted within  
2 h of dosing.
An additional baboon (No. 103) was given an intravenous dose of 1IfC- 
ethacrynic acid (Table 3-13). This baboon excreted approximately 63% 
of the dose in the b ile  and 26% of the dose in the urine.
This same baboon was also given intravenous doses of e ith e r the 
glutathione or the cysteine conjugates of ethacrynic acid (Table 3 -13 ). 
Excretion of rad io ac tiv ity  in the b ile  following administration of 
35S-labelled conjugates labelled in the sulphydryl moiety was lower 
(ca. 18%) than that (25-33%) following administration of 14C -labelled  
conjugates. In each experiment, most of the ra d io ac tiv ity  was excreted 
within 60 min of dosing. The to ta l proportion excreted in the urine  
of th is  animal, following administration of the 35S-labelled conjugates, 
was 48% (glutathione conjugate) and 45% (cysteine conjugate) compared
with 55% and 61% following the respective 1IfC-labelled conjugates.
The to ta l recovery of rad io ac tiv ity  was 63-66% following administration  
of 35S-labelled conjugates and 86-89% following the administration of 
the llfC -labelled conjugates. I t  is  probable that the low recovery 
of ra d io ac tiv ity  obtained with the 35S-labelled conjugates indicates  
incorporation of the 35S-cystei'ne, or 35S-glutathione in to  the body 
"sulphur pool" a fte r  in vivo hydrolysis of the conjugates. The 
presence of unchanged ethacrynic acid in the early  b ile  samples (<1 h) 
also indicated that some degradation of the conjugates had taken place.
Oral administration
The b ilia ry  excretion of ra d io a c tiv ity , following oral administration  
of 1I+C-ethacrynic acid (50 mg) to 2 baboons, was approximately 50% of 
the dose, but the rate of excretion was slower than that which occurred 
a fte r  i .v .  adm inistration. During the f i r s t  60 min a fte r  dosing, only 
5% of the ra d io a c tiv ity  had been excreted in the b ile . The rate  of 
excretion declined to between 2-4% of the dose/h fo r the next 8 h.
A fu rther 18-26% of the dose was recovered in the 8-24 h b ile  samples 
(Table 3 -14). Only 21% of the dose was recovered in the urine obtained 
during the 48 h a fte r  dosing. The rate of excretion of ra d io a c tiv ity  
was greatest between 0 and 8 h (Table 3 -14).
Nature of excreted metabolites 
Bile
Following an intravenous dose of ethacrynic acid (50 mg) to a rhesus 
monkey, there was an immediate increase in b ile  flow, which was 
approximately 3 times the normal b ile  flow of 70 yl/m in (Table 3 -1 5 (a )) .  
The metabolite p ro file  (Figure 3-4) shows that the ra d io a c tiv ity  present
in the b ile  was associated with 3 major components; these were the 
cysteine conjugate of ethacrynic acid (C-EA), the glutathione 
conjugate of ethacrynic acid (GS-EA), and unchanged ethacrynic acid 
(EA). A th ird  metabolite (zone 4 Pre-G) with an Rf value lower than 
that of GS-EA was also observed, as well as a trace component located 
between the positions of GS-EA and C-EA. No notable amounts of the 
corresponding mercapturic acid (N-acetylcysteine conjugate (N) of 
ethacrynic acid) was found. Figure 3 -4 (b) shows the excretion rates  
fo r each of the radioactive components present in the b ile  samples. 
During the f i r s t  hour a fte r  dosing, the rate of excretion of the 
glutathione conjugate decreased rap id ly , possibly as a resu lt of * 
its  rapid conversion to the cysteine conjugate. The rate  of. excretion  
of the cysteine conjugate declined at a fas te r rate than that of 
unchanged ethacrynic acid. The rate of excretion of ethacrynic acid 
was approximately 80% of the excretion rate measured fo r  the cysteine 
conjugate (0.1 mg/min).
The b il ia ry  excretion of metabolites was examined in the baboons, 
receiving an intravenous dose of ethacrynic acid (50 mg). B ile  
samples were obtained at 5 min in tervals  so as to investigate the 
in i t ia l  metabolite p ro files  of the experiment. Table 3-16 and 
Figure 3-5 (a ) & (b) show that in the b ile  samples obtained fo r  baboon 
991 (dose 16), the major metabolite was the cysteine conjugate. Only 
a small amount of unchanged ethacrynic acid was present. The 
proportion of the glutathione conjugate declined rap id ly , with  
very low levels present in the 30 min b ile  sample. In b i le ,  obtained 
a fte r  30 min the proportions of the N-acetylcysteine conjugate (zone 
3) increased slowly. The presence of another metabolite (zone 5) 
became apparent in b ile  obtained a fte r  45 min. The peak rate  of
excretion of both the glutathione and cysteine conjugate of ethacrynic 
acid occurred during the period 10-15 min a fte r  dosing; excretion  
rates were approximately 0.36 mg/min and 0.50 mg/min respectively.
The peak rate of excretion of the N-acetylcysteine conjugate did not 
occur u n til la te r  (20-30 min). The results fo r the excretion of 
metabolites in b ile  obtained from a second baboon 993 (dose 16)
(Table 3-17, Figures 3 -6 (a ) & (b))_ were essen tia lly  s im ilar to those 
obtained with the f i r s t  animal ,;butas can be seen from the autoradiographs, 
the glutathione conjugate disappeared fas te r (very low levels were 
present in the 2-0-25 min samples).
In this second animal, the N-acetyl cysteine conjugate was f i r s t  detected 
at an e a r lie r  time (15 min). B ilia ry  excretion of unchanged ethacrynic 
acid was low. The sample of b ile  produced at 25 min a fte r  dosing was 
re la tiv e ly  small which, although s u ffic ie n t to examine the m etabolite 
p ro file , indicated that there was a temporary obstruction to the b ile  
flow. This was regarded as the reason fo r the transient change in the 
rate of metabolite excretion observed a t th is time (Figure 3 -6 (b )) .
The maximum rate of excretion of the glutathione and cysteine conjugates 
occurred at 5-10 min and were 0.74 mg/min and 0.6 mg/min respective ly , 
whereas that of the N-acetylcysteine conjugate (0.11 mg/min) occurred 
between 20 and 30 min a fte r  dosing. At no time did the rate  of 
excretion of ethacrynic acid exceed 0.1 mg/min.
The p ro file  of b ilia ry  metabolites from a th ird  baboon (No. 103) (dose 
7) was also examined (Table 3-18, Figures 3 -7 (a ) & (b )) . In th is  
animal, very l i t t l e  of the N-acetylcysteine conjugate appeared to be 
produced, and although there was a s lig h tly  higher level of ethacrynic  
acid excretion (ca. 0.1 mg/min), the major radioactive component
detected was the cysteine conjugate of ethacrynic acid. The glutathione 
conjugate was only present in 3 of the f i r s t  4 b ile  samples (15-20 min). 
Surprisingly, l i t t l e  of the glutathione conjugate was present in the 
5 min sample of b ile . The maximum rates of excretion of metabolites 
were 0 .7 , 0.19 and 0.02 mg/min fo r the cysteine, glutathione and 
N-acetyl cysteine conjugates respectively, with the rate of excretion  
of ethacrynic acid remaining uniform at about 0.1 mg/min in each 
sample, except fo r the 0-5 min b ile  (0.05 mg/ml).
Baboon No. 103 was also used to study the b il ia ry  elim ination of radio­
a c tiv ity  following'intravenous doses of the glutathione or cysteine 
conjugates of ethacrynic acid. The conjugates e ith er had the sulphydryl 
moiety labelled ( 35S) (103-dose 1 and 103-dose 2 ) , or the ethacrynic 
acid portion labelled ( llfC) (103-dose 8 and 103-dose 9 ).
Following the intravenous administration of the radio!abelled glutathione  
conjugate of ethacrynic acid to baboon 103-dose 1 ( 35S) (Table 3-19, 
Figures 3-8(a) & (b ))  or 103-dose 8 ( ltfC) (Table 3-20, Figures 3 -9 (a ) &
(b )) the vari'ous radioactive metabolites excreted in the b ile  were 
examined, as well as the proportions of unchanged ethacrynic acid.
This was accomplished by elution of the zones of the t . l . c .  p late  
known to contain ethacryni'c acid and the subsequent quantitation by 
means of H .P .L .C .). In animal 103, the major metabolite was the 
cysteine conjugate of ethacrynic acid with only a small amount of 
the glutathione conjugate being present. In addition to the N -acetyl-  
cysteine conjugate (zone 3 ), there were several other minor radioactive  
components present. These zones are labelled in Figure 3 -8 (a ) as 
zones 1, 3 and 6. Zone 5 was possibly the cysteinylglycine conjugate, 
w h ils t zone 1 was probably oxidised glutathione, but the id e n tity  of
the component in zone 6 is unknown. The rate of excretion of the 
cysteine conjugate was maximal (0.38 mg/min) between 10 and 20 min 
a fte r  dosing, a t which time there was a s im ilar amount (0.32 mg/min) 
of unchanged ethacrynic acid being excreted. At times la te r  than 25 
min a fte r  dosing, the rate of ethacrynic acid excretion increased 
above that of the cysteine conjugate.
A s im ilar p ro file  of excreted metabolites was obtained when the R e ­
labelled glutathione conjugate of ethacrynic acid was administered.
The rate of excretion of the cysteine conjugate did not possess any 
d is tin c t maximum; the rate of elim ination showed a plateau* (ca. 0 .2  mg/ 
ml) during 10-15 min. The ; rate of excretion of ethacrynic acid 
(0.24 mg/min) exceeded the rate of excretion of the cysteine 
conjugate at 10 min a fte r  dosing, but declined stead ily  to be <0.01 
mg/min aft.er 60 min. The rate of excretion of the N-acetyl cysteine 
conjugate in la te r  b ile  samples (25-60 min) was s lig h tly  greater than 
that observed a fte r  the administration of the 35S-labelled glutathione  
conjugate.
The cysteine conjugate of ethacrynic acid labelled in e ith e r part 
of the molecule was also administered to baboon No. 103. The results  
obtained are given in Table 3-^ 21 and Figures 3-10(a) & (b ), and 
Table 3-22 and Figures 3-11(a) & (b) respectively. As was observed 
following administration of the 35S-glutathione conjugate, there was 
also a zone of ra d io ac tiv ity  remaining close to the orig in  (zone 1) 
(Figure 3-10(a )) but only one additional zone of ra d io a c tiv ity  (zone 
3) was detected. This zone coincided with the position of the 
N-acetylcysteine conjugate of ethacrynic acid. The maximum rate  
of excretion of the cysteine conjugate (0.27 mg/ml) occurred between
15 and 20 min a fte r  dosing. At th is tim e, the rate of excretion of 
ethacrynic acid (0.12 mg/min) was maximum. The elim ination of the 
rate of excretion of the cysteine conjugate was s lig h tly  greater than 
that observed fo r the rate of excretion of unmetabolised ethacrynic 
acid.
Following administration of the 14C-labelled cysteine conjugate of 
ethacrynic acid, there was, in addition to the cysteine conjugate and 
small amounts of the mercapturic acid, trace amounts of the glutathione  
conjugate in the early  (10-30 min) b ile . The actual maximum rates of 
excretion of the cysteine conjugate (0.26 mg/min) and*ethacrynic acid 
(0.1 mg/ml) were essentia lly  the same (Figure 3-11) as those observed 
following administration of the 35S-labelled conjugate (Figure 3 -10).
B ile flow
The a lterations in b ile  flow measured following the administration of 
ethacrynic acid are presented in Figure 3-12(a ). There was a very 
rapid increase (3-4 times resting le v e l) in b ile  flow with the maximum 
flow being recorded at about 5 min. Following adm inistration of 
eith er of the ethacrynic acid conjugates an increase in b ile  flow , 
although less pronounced, more variab le , and with a slow return to 
normal values, was observed (Figure 3-12(b ) ) .
Excretion of radioactive metabolites in urine
A fter an intravenous dose of ethacrynic acid , the rhesus monkey excreted 
a mean of approximately 40% of the administered dose in the urine. The 
major proportion of the urinary rad io a c tiv ity  (74%) was excreted during 
the f i r s t  8 h a fte r  dosing. The ra d io a c tiv ity  present in the 0-8 h 
urine produced by animal Nos. 525 and 526 was examined a fte r  the
separation of the individual RC-components by t . l . c .  There were 2 
major and 1 minor radioactive components present. Approximately 47% 
of the urinary ra d io ac tiv ity  present in the 0-8 h sample was associated 
with a component which possessed an Rf value which corresponded to 
that of the authentic cysteine conjugate of ethacrynic acid. A 
sim ilar proportion was associated with unchanged ethacrynic acid.
A small amount of ra d io ac tiv ity  (4-6%) was found in the zone corresponding 
to the R f  of the mercapturic (N-acetylcysteine conjugate) (Table 3 -2 3 (a )) .
The urines (0-8 h) produced by baboon Nos. 991 and 993 following an 
intravenous dose were also examined. S im ilar proportions of radio- * 
active components corresponding to both the cysteine conjugate and 
unchanged ethacrynic acid were observed. The proportions of these 2 
components were 39-46% and 41-49% respectively. The N-acetylcysteine  
conjugate was also present in the urine from both animals (4-12%).
The urine obtained from animal 991 contained an additional radio­
active component with an R f  value between N-acetylcysteine conjugate 
and ethacrynic acid. This component accounted fo r some 7% of the 
urinary ra d io a c tiv ity , but its  id en tity  was not established (Table 3- 
23(a))
Following an oral dose of ethacrynic acid to e ith e r the rhesus monkey 
or the baboon, a higher proportion of the urinary ra d io a c tiv ity  was 
due to N-acetylcysteine conjugate than a fte r  intravenous adm inistration. 
The proportions of th is  metabolite were higher in the urine samples 
obtained from the baboon than those obtained from the rhesus monkey 
(26-32% and 9-10% respectively). In a ll  samples, the proportion of 
unchanged ethacrynic acid was s im ilar (27-37%), whereas the proportion 
of the cysteine conjugate was higher in the urine of the rhesus monkey
(56%) than in that of the baboon (37-40%) (Table 3 -23(b) ) .
Although urine samples were obtained from the animals which were used 
to study the b i l ia ry  excretion of ra d io a c tiv ity , i t  was not possible 
to co llec t the urine samples d ire c tly  containers cooled in solid  carbon 
dioxide. Therefore, the individual components present in the urine 
were not determined, as possible degradation of the components may 
have occurred during co llection .
DISCUSSION
Pharmacokinetics
The pi hsma-pharmacokinetics indicate that ethacrynic acid was rapidly  
removed from the plasma, with a d is trib u tio n  phase h a l f - l i f e  of 
approximately 15-20 minutes in both species. The terminal (or 
elim ination) phase had an apparent h a l f - l i f e  of 43 h in the rhesus 
monkey and 51 h in the baboon. Comparisons with the previously 
reported studies (Klaassen and F itzgera ld , 1974) are d i f f ic u l t ,  
because only the ra t and dog were studied and .these studies were of 
short duration (4 h ). Ings and Stevens (1983) recalculated the 
terminal h a lf- liv e s  from the data of Klaassen and Fitzgerald (1974) 
and obtained h a lf- liv e s  of 90 mi'n and 50 min fo r the ra t and dog 
respectively. The corresponding h a lf- liv e s  obtained from the current 
data indicated that an apparent "terminal" phase h a l f - l i f e ,  calculated  
using only the data to 4 h, results in a value of approximately 3.3 h 
fo r both baboons and rhesus monkeys.
The lim ited  data of Wallin e t a l . (1978) fo r the r a t ,  Was re -p lo tted  
and analysed using the same curve f i t t in g  programme as applied to the 
results obtained in the current study, and th is  resulted in a 
"terminal" h a l f - l i f e  of approximately 4 h.
Thus, i t  appears that the d is trib u tio n  of ethacrynic acid from the 
plasma compartment is s im ilar in both the ra t (experiments of Wal1 in e t a l, 
1978) and non-human primates but slower than e ith e r the dog or the 
ra t (as calculated by Ings and Stevens, 1983). Further investigations  
into the calculated rate constants fo r the removal of plasma 
ethacrynic acid into the peripheral compartment (K-|_2 ) was 1.9 fH
and 2.3 h"  ^ in the rhesus monkey and baboon, and was higher than the 
K-|_2 rate constant of 0.8 h"  ^ calculated from the data of Wallin e t a 1.(1978). 
The apparent difference in rate constants, which is  dependent on the 
estimate of the terminal h a l f - l i f e ,  re flec ts  the shorter duration 
(0-4 h post-dose) of the previously reported studies.
The terminal h a l f - l i f e  of elim ination following an oral dose of 
ethacrynic acid was 55 h in the rhesus monkey and 56 h in the baboon.
The s im ila r ity  of the h a l f - l i f e  values obtained from both the 
intravenous and oral dose experiments probably indicates the slow 
release of ethacrynic acid or one of its  metabolites from "deep tissue  
compartment".
Excretion
In both species of non-human prfmate studied b il ia ry  excretion was 
the major route of elim ination fo r ethacrynic acid and its  m etabolites.
In animals which were dosed intravenously approximately 40% of the 
dose was excreted in the urine. This compares closely to 35% 
reported by Beyer e t a l . (1965). However, th e ir  overall recovery 
of ra d io ac tiv ity  was less than measured in the current studies.
Beyer e t a l . (1965) also reported that to ta l urinary excretion was 
independent of dose in the range 1-10 mg/kg, with over 50% of the 
dose recovered in the faeces, and th is  was in close agreement with  
the val uer obtained fo r both the species of non-human primate (51-54%).
In the dog, 20-30% of the urinary rad io ac tiv ity  was due to the 
cysteine conjugate of ethacrynic acfd (Beyer et a l , 1965), whereas in  
the non-human primate, the cysteine conjugate accounted fo r  
approximately 47% of the urinary rad io a c tiv ity . This observation 
indicates a possible difference in the renal handling of th is  
m etabolite, or its  precursors, in these species.
Beyer and co-workers found that in the dog the amount of ra d io ac tiv ity  
excreted in the urine was independent of the route of adm inistration, 
but in the non-human primate the to ta l amount of ra d io ac tiv ity  excreted 
in the urine following an oral dose was only 24% (rhesus) and 26% 
(baboon). Thus, the ra tio  of the oral to intravenous route (0 .65) 
gives an indication that the absorption of ethacrynic acid from the 
gastro -in testina l tra c t in the non-human primate was probably less 
than the absorption in the dog.
The results obtained with b ile  duct cannulated non-human primates 
show that intravenous adm inistration.of ethacrynic 3cid caused a 
transient increase in the rate of b ile  production by a fac to r o f  
approximately 3. Early work by Erlinger e t a l . (1970) showed th a t, 
in ra ts , ethacrynic acid administration decreased the b ile  flow , but 
subsequent investigations by Shaw et a l . (1972), Klaassen and 
Fitzgerald (1974), and Knodell (1978). proved that th is  was incorrect. 
Knodell reported that ethacrynic acid stimulated both the b ile  s a lt  
independent,and b ile  s a lt dependent excretion, although the actual 
mechanisms by which thi's occurred remain uncertain. In the 
results obtained fo r the 2 species of non-human primate investigated, 
the level of stimulation of b ile  production was greater than that 
observed by Klaassen and Fitzgerald  (1974) in e ith e r the ra t or dog, 
although the duration of increased b ile  flow was s im ila r. Intravenous 
administration of the sulphydryl conjugates of ethacrynic acid 
produced a s lig h t but variable increase in b ile  production.
In animals which had to ta l b ile  collection and, therefore, no ex tra - 
hepatic rec ircu la tio n , the proportion of an intravenous dose excreted 
in the urine was approximately 30%. This indicated that more than 10%
of the b ilia ry  excreted dose was re-absorbed from the gastro -in tes tina l 
tra c t in the in tac t animal and then excreted in the urine. The actual 
percentage of b il ia ry  metabolites re-absorbed must, however, be 
considerably greater than th is  as a portion of re-absorbed radio­
a c tiv ity  would probably be re-excreted into the b ile  fo r a second 
time. This re-cycling possibly occurs several times, and may be 
dependent on the individual metabolites of ethacrynic acid excreted 
into the b ile . An indication of the amount absorbed from the gastro­
in tes tin a l tra c t and excreted in the urine was provided by studying 
the urinary output of ra d io ac tiv ity  following an oral dose to a 
baboon with a- b ile -duct cannula in s itu . The results show that 19% 
of the administered dose was excreted in the urine with a fu rth er  
50% of the dose present in the b ile . Thus, the absorption of 
ethacrynic acid from the in tes tin a l tra c t was approximately 70%.
As mentioned above, the b il ia ry  excretion of ra d io ac tiv ity  following  
an intravenous dose of ethacrynic acid was high (66%) in both rhesus 
monkey and baboon. The major proportion (95% of b i lia ry  radio­
a c t iv ity )  being excreted w ithin 4 h. The corresponding values 
obtained in the dog were 57% of the dose, and between 60-70% of 
the dose in the ra t (Klaassen and F itzgera ld , 1974). Thus, the 
non-human primate is  s im ilar to the ra t in th is  respect but d ifferent 
to the dog.
Excretion of metabolites
Measurements of the re la tiv e  proportions of radioactive metabolites 
excreted into b ile  showed that the rhesus monkey excreted approximately 
25% of the b ile  rad io ac tiv ity  as unchanged ethacrynic acid as did one 
baboon (24%). This compares with <20% in the ra t and 38% in the dog
(Klaassen and F itzgera ld , 1974)_. The corresponding proportions of 
unchanged ethacrynic acid excreted by the 2 other baboons was much 
lower (ca. 10%). In a ll animals studied the general trend was fo r  
an increase in the proportion of ethacrynic acid the la te r  the b ile  
samples were obtained. The proportion of the glutathione conjugate 
of ethacrynic acid in the b ile  of a rhesus monkey during the f i r s t  
4 h .a fte r  dosing was ca. 16% compared to 40% found in the ra t and 
9% observed in the dog (Klaassen and F itzgera ld , 1974). The 
corresponding .values fo r the percentage of glutathione conjugate 
present in.the b ile  samples from 3 baboons were 18%, 25% and 8%. In 
both the rhesus monkey and the baboon the cysteine conjugate was 
the major metabolite 43% (rhesus) and 42-58% (baboon). These 
values are greater than those reported fo r the dog (11%). The 
cysteine conjugate was only present in trace amounts in b ile  
obtained from ra ts . In the ra t 18-20% of b ilia ry  rad io a c tiv ity  
was due to the presence of N-acetylcysteine conjugate (c f . dog 25%) 
(Klaassen and F itzgera ld , 1974). In the rhesus monkey and one of 
the baboons, less than 4% of the b il ia ry  rad io a c tiv ity  was due to 
th is  conjugate, but in the other 2 baboons studied approximately 
12% was the mercapturic acid.
Examination of the to ta l mercapturic acid pathway fo r  ethacrynic acid,
i .e .  conjugation with glutathione, the subsequent degradation to the 
cysteine conjugate and f in a l ly  N -acetylation, in each of the species, 
indicated that in the ra t some 60% of the ethacrynic acid entering  
the l iv e r  was metabolised to the glutathione conjugate, a th ird  of 
th is  conjugate was degraded and acetylated. The rate of conversion 
of 6S-EA to C-EA must be less than the rate of N -acetylation , as 
l i t t l e  cysteine conjugate was detected. In the dog, the overall
conjugation with glutathione was less (54%)_, but a higher proportion 
(over 80%) of th is  conjugate was converted to the cysteine conjugate 
and approximately h a lf was then acetylated to the mercapturic acid. 
Thus, compared to the ra t ,  the rate of formation of the cysteine 
conjugate was higher, and the N-acetylation was rate lim itin g . In 
the rhesus monkey, 64% of the ethacrynic acid presented to the l iv e r  
was conjugated with glutathione, of th is over 70% was degraded to 
the cysteine conjugate, but very l i t t l e  was N-acetylated (3%). In 
the baboon, 75-80% of the ethacrynic acid was conjugated with 
glutathione, with 70-85% being degraded to the cysteine conjugate 
with a fu rther 5-15% N-acetylated. ■■■•*
Therefore, in non-human primates conjugation of ethacrynic acid with 
glutathione occurs very rap id ly . The subsequent degradation to the 
cysteine conjugate must occur at an even fas te r rate because the 
glutathione conjugate disappears from the la te r  b ile  samples. The 
overall extent of N-acetylation is less in the non-human primate 
than in the ra t and dog.
TABLE 3-1
Mean plasma rad io a c tiv ity  concentrations measured in samples obtained 
from rhesus monkeys and baboons following intravenous administration  
o f 1£fC-ethacrynic acid (50 mg). Concentrations expressed as yg 
equivalents/ml plasma. For individual data see Appendices 3 and 4.
Time
(h).
Rhesus Baboon
Mean s D 
(ng/ml) *  5 -u’
Mean -  „ 
(yg/ml) ± S' D'
0 — — _  _
0.08 32.4 ± 7.3 25.2 ± 1.1
0.17 24.1 ± 7.4 20.9 ± 0.2
0.25 18.4 ± 3 . 4 17.3 ± 0.5
0.50 12.8 ± 3.6 .8.8 ± 0.3
0.75 7.68 ± 1.60 5.4 ± 0.5
1 5.08 ± 0.69 4.3 ± 0.2
1.5 3.48 ± 0.88
2 2.89 ± 0.57 2.7 ± 0.3
2.5 2.48 ± 0.46 -
3 2.24 ± 0.37 2.1 ± 0.1
4 1.92 ± 0.30 1.8 ± 0.1
5 1.87 ± 0.28 1.7 ± 0.1
6 1.76 ± 0.23' 1.5 ± 0.1
7 1.64 ± 0.30 1.4 ± 0.1
8 1.60 ± 0.31 -
24 1.23 ± 0.48 1.2 ± 0.2
48 0.81 ± 0.32 0.9 ± 0.3
72 0.73 ± 0.38 0.8 ± 0.3
FIGURE 3-1
Plasma rad ioactiv ity  (log concentration) versus time for samples 
obtained from rhesus monkeys ((.a).525, 526; (b) 527, 528) and baboons 
((c) 103, 111; (d) 991 , 993), following an intravenous dose of 14C- 
ethacrynic acid (50 mg).
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TABLE 3-2
Plasma pharmacokinetic parameters of (a) rhesus monkey and (b) baboons 
following an intravenous dose of llfC-ethacrynic acid (50 mg).
(a)
Animal No.
Parameter
a a A B AUC co (yg/m l).h
—1
_—
i
V-j
-M
M m
525 2.05 0.0212 25.66 1.83 98.6 0.339 32.7
526 2.38 0.0096 29.24 2.22 243.6 0.291 72.3
527 2.32 0.0249 29.14 1.81 85.3 0.299 40.2
528 2.42 0.0233 46.61 2.57 129.7 0.286 29.7
Mean 2.29 0.0198 32.66 2.11 139.3 0.304 43.7
± S.D. ±0.17 ±0.007 ±9.45 ±0.36 ±72,'0 ±0.024 ±19.5
(b)
Animal No.
Parameter
a a A B AUC co (yg/m l) .h
T \  a 
0 0
Ti a 
0 0 - '
103 2.76 0.0143 30.82 1.93 146.2 0.251 48.5
111 2.69 0.0298 28.51 1.96 76.3 0.258 23.3
991 2.83 0.0123 30.17 1.83 159.6 0.245 56.3
993 2.75 0.0092 30.40 1.85 211.8 0.252 75.3
Mean 2.76 0.0164 29.98 1.89 148.5 0.251 50.9
± S.D. ±0.06 ±0.009 ±1.01 ±0.06 ±55.8 ±0.005 ±21.5
TABLE 3-3
Derived pharmacokinetic parameters derived by application of a 2- 
compartment model to the plasma data obtained following an intravenous 
dose of llfC-ethacrynic acid (50 mg), to (a) rhesus monkeys or (b) baboons, 
Rate constants were derived as follows:
i/ _ [ C ] °  . » _ A • B (.3 -  a )2 . „ _ A • B •+ B
Kl-0  -  — -------   ’ 1-2  ----------— —   —  * 2-1  -----------------
A/a + B/B £ C ^° * (A • S + B • a) £ C 3 °
Central Vd =  ^ ; and clearance = Vd x 0.593 ^
Cc ]° tj
(a)
Animal
No. Kl-0 Kl-2 K2 -l i—
i
o i—
i c+ o Central
Vd
Clearance 
ml/mi n
525 0.28 1.63 0.16 27.5 1826 509
526 0.13 2.09 0.18 31.5 1589 205
527 0.36 1.82 0.16 30.9 1671 606
528 0.38 1.92 0.15 49.2 1048 397
Mean 0.29 1.87 0.16 34.8 1480 429
± S.D. ±0.11 ±0.19 ±0.01 ±9.8 ±335 ±172
(b)
Animal
No. Kl-0 Kl-2 K2-l i—
i
0  
1_1 c-t- o Central
Vd
Clearance
ml/min
103 0.22 2.38 0.18 32.8 1462 327
111 0.40 2.12 0.20 30.5 1738 693
991 0.20 2.47 0.17 32.0 1562 313
993 0.15 2.44 0.17 32.3 1551 236
Mean 0.24 2.35 0.18 31.9 1578 392
± S.D. ±0.11 ±0.16 ±0.01 ±1.0 ±116 ±204
FIGURE 3-2
R e p r e s e n t a t i v e  c h r o m a t o g r a m s  s h o w i n g  s e p a r a t i o n  o f  M.C.P. ( i n t e r n a l  
s t a n d a r d )  a n d  e t h a c r y n i c  a c i d  (EA).
3.95 M.C.P.
3 . 9 5  M.C.P.
i
3.95 M.C.P.
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TABLE 3-4
Ethacrynic acid concentrations in the plasma of .rhesus monkeys (525 & 
526) and baboons (103 & 111) following intravenous administration of 
llfC-ethacrynic acid (50 mg). Concentrations expressed as yg/ml plasma.
Time
(h)
Animal No.
525 526 103 m
0.08 30.4 31.8 26.3 25.3
0.17 19.9 18.9 19.6 18.5
0.25 15.2 14.5 17.9 17.5
0.50 9.4 11.4 9.1 8.4
0.75 6.0 8.4 5.7 5.0
1 4.6 5.0 4.3 4.3
1.5 3.6 3.6 - -
2 2.9 3.0 3.3 3.6
2.5 2.6 2.6 - -
3 1.9 2.6 2.3 1.9
4 - 1.9 1.6 1.6
5 - - 1.6 1.3
45 EA
4 . 4 5
5 . 4 8 EA
TABLE 3-5
Mean plasma ra d io ac tiv ity  concentrations measured in samples obtained 
from rhesus monkeys and baboons following oral administration  
of lifC-ethacrynfc acid (50 mg). Results expressed as yg equivalents/ 
ml plasma. For individual data see Appendices 5 and 6.
Time
m
Rhesus Baboon
Mean 
C i^g/ral) b S.D.
Mean 
(ng/ml) ± S.D.
0 » _
0.5 0.68 ± 0.12 0.7 ± 0.1
1 1.12 ± 0.30 1.0 ± 0.1
1.5 1.25 ± 0.42 '1 .2 ± 0.2
2 1.36 ± 0.60 1.3 ± 0.2
2.5 1.48 ± 0.68 1.7 ± 0.4
3 1.68 ± 0.47 1.6 ± 0.2
4 1.78 ± 0.35 1.7 ± 0.2
5 1.56 + 0.27 1.6 ± 0.1
6 1.50 + 0.17 1.5 ± 0.1
7 1.41 + 0.21 1.4 ± 0.1
8 1.39 + 0.15 -  ■ . .  ■ _
24 1.33 + 0.08 1.2 ± 0.1
48 0.99 + 0.19 1.1 ± 0.2
72 0.71 + 0.08 0.7 ± 0.1
96 0.54. + 0.02 0.6 ± 0.1
FIGURE 3-3
Plasma rad io activ ity  (log concentration) versus time fo r samples 
obtained from rhesus monkeys ((a ) 525, 526; (B) 527, 528) and baboons 
((c ) 103, 111; (d) 991 , 993), following an oral dose of llfC-ethacrynic 
acid (50 mg).
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TABLE 3-6
Pharmacokinetic parameters derived from plasma data following an oral 
dose of 1IfC-ethacrynic acid (50 mg) to (a) rhesus monkeys and 
(b) baboons.
(a)
Animal
No.
Time
00-
R-squared H a lf - l i fe
0 0
Area under curve 
(vig.h/ml)
525 24-96 0.918 58.0 87.21
526 24-96 0.970 53.7 90.09
527 24-96 0.996 51.1 103.20
528 24-96 0.935 57.1 103.40
Mean 54.9 95.98
± S.D. ±3.2 ±8.54
(b)
Animal
No.
Time
0 0
R-squared H a lf - l i fe
0 0
Area under curve 
(yg.h/m l)'
103 24-96 0.939 50.6 85.75'
111 24-96 0.982 55.8 94.73
991 24-96 0.933 73.5 103.90
993 24-96 0.893
\
43.0 104.00
Mean 55.7 97.10
± S.D. ±13.0 ±8.72
TABLE 3-7
Excretion of ra d io ac tiv ity  {% dose) from rhesus monkeys and baboons 
following e ith er an intravenous or oral dose of 14C-ethacrynic acid 
(50 mg). For individual data see Appendices 7-18,
Sample
Species/Dose route
Rhesus/IV Baboon/IV Rhesus/Oral Baboon/Oral
Urine
Faeces
Total*
41.3 ± 1.8
51.2 ± 2.9
93.2 ± 1 . 9
38.9 ± 1.8  
54.2 ± 2.3
93.9 ± 2.8
23.5 ± 2.5
67.6 ± 5.3 
92.5 ± 4.7
26.3 ± 2.6  
66.5 ± 1.9  
93.8 ± 4.0
*  Including cage debris.
TABLE 3-8
Mean urinary excretion of rad ioac tiv ity  {% dose) in rhesus monkeys 
and baboons following an intravenous dose of ^C-ethacrynic acid (50 mg). 
Table 3 -8 (b) -  Urine samples from 2 baboons collected at 2 hourly 
in tervals between 0 and 8 h a f te r  dosing. For individual data see 
Appendices 8 and 11.
(a)
Time
0 0
Rhesus Baboon
Mean + S.D. Mean + S.D.
0-8 27.01 + 3.38 24.46 ± 1.00
Cage wash 3.78 + 0.67 2.96 + 0.59
8-24 7.48 + 4.16 6.23 + 0.80
Cage wash 1.05 + 0.52 0.64 + 0.26
24-48 1.06 + 0.42 2.83 + 0.23
48-72 0.35 + 0.07 0.85 + 0.25
72-96 0.17 + 0.02 0.20 + 0.10
96-120 0.11 + 0.03 0.09 + 0.12
120-144 0.06 + 0.01 0.04 + 0.05
Cage wash 0.22 + 0.10 0.02 + 0.03
Total 41.28 + T.79 38.3 + 1.87
(b)
Time
(h)
Baboon
Mean ± S.D.
0-2 19.68 ± 1.05
2-4 4.36 ± 1.61
4-6 1.73 ± 0.55
6-8 1.26 ± 0.16
8-24 7.74 ± 1.29
24-48 3.49 ± 2.00
48-72 1.23 ± 0.30
Final cage wash 0.09 ± 0.04
Total 39.56 ± 2.26
TABLE 3-9
Mean urinary excretion of rad ioactiv ity  {% dose) in rhesus monkeys and 
baboons following an oral dose of llfC-ethacrynic acid (50 mg). For 
individual data see Appendices 14 and 17.
0)_ Rhesus Baboon
Mean + S.D. Mean + S.D.
0-8 9.12 + 1.58 12.57 + 2.31
8-24 10.61 + 1.14 9.50 + 0.86
Cage wash 1.73 + 0.83 1.86 + 0.67
24-48 1.67 + 0.18 1.96 + 0.55
48-72 0.25 + 0.10 0.23 + 0.16
72-96 0.07 + 0.03 0.09 + 0.01
96-120 0.05 + 0.03 0.05 + 0.01
120-144 0.05 + 0.04 0.03 + 0.01
Cage wash - - - -
Total 23.54 + 2.53 26.28 + 2.62
TABLE 3-10
Mean excretion of rad ioactiv ity  {% dose) in the faeces of rhesus 
monkeys and baboons following e ither an intravenous or oral dose 
of 14C-ethacrynic acid (50 mg). For individual data see Appendices 
9, 12, 15 and 18.
Species/Dose route
Time
(h)
. - Rhesus/IV Baboon/IV Rhesus/Oral Baboon/Oral
Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean + S.D.
0-24 30.92 ± 5.46 32.26 ± 6.67 40.44 ±10.27 36.55 + 4.68
24-48 17.15 ± 4.44 15.94 ± 3.75 25.45 ±11.13 24.25 + 3.57
48-72 1.98 ± 0.87 3.39 ± 2.56 1.16 ± 0.31 4.49 + 0.72
72-96 0.69 + 0.24 1.01 ± 0.24 0.26 ± 0.09 0.89 + 0.13
96-120 0.23 ± 0.05 0.58 ± 0.25 0.19 ± 0.04 0.22 + 0.11
120-144 0.22 ± 0.03 .0.20.± .0.01 0.13 ± 0 .0 2 0.09 + 0.02
Total 51.18 ± 2.86 54.18 ± 2.32 67.61 ± 5.32 69.49 ± 1.86
TABLE 3-11
Excretion of rad ioactiv ity  in (a) b ile  samples and (b) urine samples 
obtained from rhesus monkeys following intravenous administration of 
14C-ethacrynic acid (50 mg). Results are expressed as % of the dose 
administered.
(a)
Time
(b)
Animal No.
Mean ± S.D.
525 526
0 -  0.25 23.52 35.20 29.36 ± 8.26
0.25- 0.5 15.53 15.42 15.48 ± 0.08
0.5 -  0.75 5.68 5.54 5.61 ± 0.10
0.75- 1 5.24 2.46 3.85 ± 1.97
1 -  1.25 4.56 2.22 3.39 ± 1.65
1.25- 1.5 3.01 1.71 2.36 ± 0.92
1.5 -  1.75 1.28 1.04 1.16 ± 0.17
1.75- 2 1.29 0.98 1.14 ± 0.22
2 -  2.5 0.99 0.63 0.81 ± 0.25
2.5 -  3 0.94 0.44 0.69 ± 0.35
3 -  4 1.39 0.49 0.94 ± 0.64
4 -  5 0.62 0.60 0.61 ± 0.01
5 -  6 0.84 0.38 0.61 ± 0.33
6 -24 1.84 1.42 1.63 ± 0.30
24 -48 0.23 0.21 0.22 ± 0 .0 1
Total 66.96 68.74 67.85 ± 1.26
(b)
Time
(h)
Animal No.
Mean ± S.D.
525 526
0-24
24-48
48-72
72-96
96-120
29.14
1.28
0.32
0.17
0.06
27.26
0.47
0.18
0.16
0.08
28.20 ± 1.33 
0.88 ± 0.57 
0.25 ± 0.10 
0.17 ± 0.01 
0.07 ± 0.01
Total 30.97 28.15 29.56 ± 1.99
Recovery 
(b i le  + 
Urine)
97.93 96.89 97.41 ± 0.74
TABLE 3-12
Excretion of rad ioactiv ity  in (a) b ile  samples and (b) urine samples 
obtained from baboons following intravenous administration of 1I+C- 
ethacrynic acid (50 mg). Results are expressed as % of the dose 
administered.
(a)
Time
Animal No.
Mean ± S.D.
991 -  16 993 -  16
0-5 min 0.18 2.33 1.26 ± 1.52
5-10 min 7.12 15.93 11.53 ± 6.23
10rl5 min 10.87 13.26 12.07 ± 1.69
15t20 min 7.81 6.75 7.28 ± 0.75
20-2.5 min 5.29 3 .5 7 " 4.43 ± 1 .2 2
25-30 min 3.72 5.40 4.56 ± 1.19
30-45 min 8.53 7.31 7.92 ± 0.86
45-60 mi n 2.88 3.73 3.31 ± 0.60
1- 2 h 9.23 4.98 7.11 ± 3.01
2- 3 h 3.97 1.49 2.73 ± 1.75
3- 4 h 0.95 0.54 0.75 ± 0.29
4- 5 h 0.31 0.25 0.28 ± 0.04
5- 6 h 0.18 0.24 0.21 ± 0.04
6-24 h 2.95 3.04 3.00 ± 0.06
. 24-48 h 0.33 0.22 0.28 ± 0.08
Total 64.32 69.04 66.68 ± 3.34
(b)
Time
(h)
Animal No.
Mean ± S.D.
991 -  16 993 -  16
. 0-2 19.82 23.93 _
2-3 1.57 - -
3-4 2.22 - -
2-4 - 7.11 -
4-5 0.34 - -
5-6 0.78 - -
4-6 - 0.79 -
0-6 24.73 31.83 28.28 ± 5.02
6-24 1.43 1.29 1.36 ± 0.10
24-48 0.81 0.74 0.78 ± 0.05
Total 26.32 33.36 29.84 ± 4.98
TABLE 3-13
Excretion of rad ioactiv ity  in (a) b i le  samples and (b) urine samples 
following intravenous administration of llfC-ethacrynic acid or 
ethacrynic acid conjugates, as indicated. Results are expressed 
as % of the dose administered.
(a)
Animal No. 103 111
Dose No. 1 2 7 8 9 1
Conjugate GS-EA Cys-EA EA GS-EA Cys-EA GS-EA
Label 35S 35S 14C i^C 14C 35S
T ime
5 min 
10 mi n 
15 min 
20 min 
25 min 
30 min 
45 min 
60 min
0.17
1.65
5.72
2.96
2.86
2.91
1.16
0
0.07
1.41
3.37
2.58
2.20
4.44
1.15
4.91
10.78
5.98
5.53
8.37
8.94
6.40
0.31
1.72
5.05
4.54
4.35
2.96
5.80
4.32
0.04
0.82
4.40
3.68
2.60
2.88
3.85
2.22
0.63
1.60
3.20
3.61
3.23
2.37
3.74
0.99
Sub-total 17.43 15.23 50.91 29.16 20.49 18.59
2 h
3 h
4 h
5 h
6 h
6-24 h 
24-48 h
0.26
0.14
0.06
0.05
0.01
0.09
0.01
0.82
0.53
0.31
0.20
0.07
0.67
0.01
8.47
0.82
0.37
0.14
0.10
2.41
0.27
1.93
0.72
0.11
0.10
0.08
1.22
0.66
1.37
0.92
0.78
0.48
0.29
1.01
0.03
0.41
0.33
Total 18.05 17.84 63.49 33.00 25.14 19.33
(b)
Dose No. 1 2 7 8 9
Conjugate GS-EA Cys-EA EA GS-EA Cys-EA
Label 35S 35S i**C. 14 c 14C
Time (h) 
0-2 28.25 23.89 19.35 29.03 33.20
2-4 11.65 13.70 NS 14.61 13.44
4-24 6.54 6.33 5.8 8.71 10.50
24-48 1.96 0.83 0.8 2.30 4.10
Total 48.40 44.80 25.95 54.65 61.24
B il ia ry  excretion 18.05 17.84 63.49 33.00 25.14
Recovery {%) 66.45 62.66 89.40 87.65 86.38
TABLE 3-14
Excretion of rad ioactiv ity  in (a) b i le  samples and (b) urine samples 
obtained from baboons following oral administration of llfC-ethacrynic 
acid (50 mg). Results are expressed as % of the dose administered.
(a)
Time
(h).
Animal No.
Mean ± S.D.
991 -  17 993 -  17
0-1 5.08 4.93 5.01 ± 0.11
1-2 4.04 3.85 3.95 ± 0.13
2-3 2.61 3.96 3.29 ± 0.95
3-4 2.72 4.60 3.66 ± 1.33
4-5 1.88 3.62 2.75 ± 1.23
5-6 2.65 3.72 3.19 ± 0.76
6-7 2.30 2.51 2.41 ± 0.15
7-8 1.91 2.82 2.37 ± 0.64
8-24 25.58 17.86 21.72 ± 5.46
24-48 1.48 1.09 1.29 ± 0.28
Total 50.25 48.96 49.61 ± 0.91
Cb)
Time
(h)
Animal No.
Mean ± S.D.
991 -  17 993 -  17
0-6 9.36 7.26 8.31 ± 1.48
6-24 13.14 11.56 12.35 ± 1.12
24-48 0.61 0.37 0.49 ± 0 .1 7
Total 23.11 19.19 21.15 ± 2.77
TABLE 3-15
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from rhesus 
monkey 525 following intravenous administration of ethacrynic acid,and 
(b) percentage of rad ioactiv ity  corresponding to individual metabolites 
present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinylglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic acid.
(a)
Time(mln) % Dose excreted mg equiv. EA
Bile flow 
lil/min
mg equiv. 
EA/mi n
15 23.52 12.83 207 0.86
30 15.53 8.47 193 0.57
45 5.68 3.10 153 0.21
60 5.24 2.86 127 0.19
Sub-total 49.97 27.26 -
75 4.56 2.49 120 0.17
90 3.01 1.64 120 0.11
(b)
Time (min) Pre-G GS-EA Pre-C C-EA N ? EA
15 11 17 0 46 2 0 22
30 12 23 5 38 2 2 18
45 5 15 6 43 2 2 27
60 4 7 3 48 2 2 34
75 3 6 3 43 1 1 43
90 3 0 2 47 1 0 46
(a) Autoradiograph of b i l ia ry  metabolites separated by t . l . c .  in solvent 
butanol:acetic acidrwater, 4:1:5 by v o l, and (b) the rates of excretion 
of the major metabolites following intravenous administration of lt+C- 
ethacrynic acid (50 mg) to rhesus monkey 525. °  Glutathione conjugate;
•  Cysteine conjugate; ±  N-acetylcysteine conjugate; ■ Ethacrynic acid.
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TABLE 3-16
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
991 (dose 16) following intravenous administration of ethacrynic acid, 
and (b) percentage of rad ioactiv ity  corresponding to individual 
metabolites present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinyTglycine 
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic acid.
•(a)
Time(min) % Dose excreted mg equiv. EA
Bile flow  
ill /mi n
mg equiv. 
EA/mi n
5 0.18 0.09 244 0.018
10 7.12 3.43 246 0.69
15 10.87 5.24 198 1.05
20 7.81 3.76 154 . 0.75
25 5.29 2.55 140 0.51
• 30 3.72 1.79 124 . 0.36
45 8.53 4.11 121 0.27
60 2.82 1.36 69 0.91
Total 46.34 22.33 - -
(b)
Time(mi n) Pre-G .GS-EA Pre-C C-EA N ? EA
5 7 32 0 51 1 0 9
10 8 32 0 51 1 0 7
15 9 34 0 47 4 0 7
20 7 22 0 54 9 0 8
25 3 10 4 56 16 0 12
30 0 3 11 51 22 0 13
45 0 0 21 36 26 1 17
60 0 0 26 31 25 2 16
(a) Autoradiograph of b i l ia ry  metabolites separated by t . l . c .  in solvent 
butanolracetic acid:water, 4:1:5 by v o l, and '(b) the rates of excretion 
of the major metabolites following intravenous administration of lt+C- 
ethacrynic acid (50 mg) to baboon 991 (dose 16). O Glutathione conjugate; 
•  Cysteine conjugate; a  N-acetylcysteine conjugate; ■ Ethacrynic acid.
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TABLE 3-17
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
993 (dose.16) following intravenous administration of ethacrynic acid, 
and (b) percentage of rad ioactiv ity  corresponding to individual 
metabolites present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinlyglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic acid.
(a) .. ...
Time(min) % Dose excreted mg equiv. EA
Bile flow 
yl/min
mg equiv. 
EA/mfn
5 2.33 1.12 300 0.23
10 15.93 7.77 240 1.54
15 13.26 6.39 180 1.28
20 6.75 3.25 120 0.65
25 3.57 1.72 80* 0.34
30 5.39 2.60 140 0.52
45 7.30 3.52 87 0.24
60 3.73 1.80 73 0.12
Total 58.28 28.09 - -
(b)
Time (min) Pre-G GS-EA Pre-C C-EA N ? EA
5 0 29 0 61 0 0 10
10 6 49 0 39 2 0 5
15 8 35 0 42 6 1 8
20 5 18 4 52 13 1 8
25 2 7 9 52 19 1 10
30 0 3 15 43 24 1 13
45 0 0 23 33 25 3 14
60 0 0 29 31 21 3 14
*  Temporary obstruction to b ile  flow.
(a) Autoradiograph of b i l ia ry  metabolites separated by t . I . e .  in solvent 
butanol:acetic acidrwater, 4:1:5 by v o l, and (b) the rates of excretion 
of themajor metabolites following intravenous administration of lt+C- 
ethacrynic acid (50 mg) to baboon 993 (dose 16). O Glutathione conjugate;
•  Cysteine conjugate; a  N-acetyl cysteine conjugate; ■ Ethacrynic acid.
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TABLE 3-18
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
103 (dose 7) following intravenous administration of ethacrynic acid, 
and (b) percentage of rad ioactiv ity  corresponding to individual 
metabolites present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinlyglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic acid.
(a)
Time(min) % Dose excreted mg equiv. EA
Bile flow 
yl/min
mg equiv. 
EA/min
5 4.91 2.46 308 0.49
10 10.78 5.39 180 1.08
15 5.98 2.99 120 0.60
20 5.53 2.77 124 0.55
25 - - - -
-30 - 8.37 4.19 131 0.42
45 8.94 4.47 83 0.30
-60 6.40 3.20 95 0.21
Total 50.91 25.47 - -
(b)
Time(min) Pre-G GS-EA Pre-C C-EA N ? EA
5 6 22 0 59 0 0 11
10 5 17 0 64 0 1 11
15 2 9 0 69 1 1 17
20 0 3 0 62 4 6 23
CD
30 0 3 3 60 5 3 25
45 0 0 5 50 6 1 38
60 0 0 5 44 7 1 42
(a) Autoradiograph of b i l ia ry  metabolites separated by t . l . c .  in solvent 
butanol:acetic acid:water, 4:1:5 by v o l, and 0 )  the rates of excretion 
of the major metabolites following intravenous administration of 14C- 
ethacrynic acid (50 mg) to baboon 103 (dose 7). O Glutathione conjugate;
•  Cysteine conjugate; ±  N-acetyl cysteine conjugate; ■ Ethacrynic acid.
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TABLE 3-19
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
103 (dose 1) following intravenous administration of the glutathione 
conjugate ( 33S) of ethacrynic acid, and (b) percentage of rad ioactiv ity  
corresponding to individual metabolites present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinylglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate;
EA, ethacrynic acid.
(a)
Time (min) % Dose excreted mg*EA
Total 
mg equiv. 
EA
Bile flow 
yl/min
mg equiv. 
EA/mi n+
5 0.17 0.05 0.14 140 0.03?
0.02°
10 1.65 0.44 1.29 160 0.26
0.17
15 5.72 1.61 4.52 360 0.91
0.58
20 2.96 0.88 1.93 ‘ 260 0.39
0.30
25 - - - - -
30 2.86 0.80 2,26 180 0.23
0.15
45 2.91 0.58 2.06 193 0.14
0.10
60 1.16 0.38 0.97 227 0.06
0.04
Total 17.43 _  . 13.17
=25.87**
— —
* EA measured separately a f te r  elution from t . l . c .  plate.
* *  Percentage dose excreted as e ither EA or conjugates of EA.
+ a Total expressed as EA;  ^ Metabolites other than unchanged EA.
ihl
Time(min) Pre-G GS-EA Pre-C C-EA N ? EA
5 0 0 0 0 0 0 0
10 47 4 1 44 3 0 0
15 16 5 5 67 6 3 0
20 12 4 4 73 2 2 0
cD
30 38 3 3 49 2 1 0
45 26 3 3 58 4 1 0
60 20 2 2 70 2 0 0
(a) Autoradiograph of b i l ia ry  metabolites separated by t . l . c .  in solvent 
butanol:acetic acid:waters 4:1:5 by v o l , and (b) the rates of excretion 
of the major metabolites following intravenous administration of the 
glutathione conjugate ( 35S) of ethacrynic acid to baboon 103 (dose 1).
O Glutathione conjugate; •  Cysteine conjugate; *  N-acetylcysteine 
conjugate; ■ Ethacrynic acid.
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TABLE 3-20
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
103 (dose 8) following intravenous administration of the glutathione 
conjugate of 1£tC-ethacrynic acid,and (fa) percentage of rad ioactiv ity  
corresponding to individual metabolites present in each sample.
Abbreviations ; Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of  
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinylglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic acid.
t o
Time(mi n) % Dose excreted mg equiv. EA
Bile flow 
yl/min
mg equiv. 
EA/min
5 0.41 0.21 194 0.04
10 1.72 0.86 138 0.17
15 5.06 2.52 138 0.50
20 4.54 2.26 118 0.45
25 4.35 2.16 120 0.43
30 2.96 1.47 82 0.30
45 5.80 2.89 78 0.19
60 4.32 2.15 69 0.14
Total 29.16 14.52 - -
(b)
Time(min) Pre-G GS-EA. Pre-C. C-EA. N ? EA
5 0 0 0 0 0 0 0
10 0 4 1 20 3 0 70
15 0 6 2 39 3 0 48
20 0 5 0 42 6 0 46
25 0 4 0 48 8 0 38
30 0 3 3 33 9 0 48
45 0 2 4 49 10 0 33
60 0 0 7 65 10 0 6
[di) Autoraaiograpn or di nary  metabolites separated by t . l . c .  in solvent 
butanol:acetic acidrwater, 4:1:5 by vol, and (b) the rates of excretion 
of the major metabolites following intravenous administration of the 
glutathione conjugate of li+C-ethacrynic acid to baboon 103 (dose 8).
O Glutathione conjugate; •  Cysteine conjugate; ±  N-acetylcysteine 
conjugate; ■ Ethacrynic acid.
1 0 3 - 8
10 15 2 0  S T D  25 3 0  4 5  6 0
CTi
0.4-
+->
0 . 2 -
6010 20 40 5030
Time (m)
TABLE 3-21
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
103 (dose 2) following intravenous administration of the cysteine 
conjugate ( 35S) of ethacrynic acid, and (b) percentage of rad ioactiv ity  
corresponding to individual metabolites present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinlyglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic acid.
(a)
Time(min) % Dose excreted mg*EA
Total 
mg equiv. 
EA
Bile flow 
yl/min
mg equiv.' 
EA/min+
5 0.01 0 0 8010 0.07 0.01 0.05 180 0.01?o.or15 1.41 0.32 1.02 320 0.200.1420 3.37 0.62 2.29 340 0.460.3325 2.57 0.41 1.69 240 0.340.2630 2.20 0.36 1.43 240 0.290.2245 4.44 0.76 2.96 200 0.200.1560 1.15 0.21 0.78 133 0.050.04
Total 15.23 — 10.2
=20.6**
— - -
*  EA measured separately a fte r  elution from t . l . c .  p late .
**  Percentage dose excreted as e ither EA or conjugates of EA.
+ 3 hExpressed as tota l EA; D Metabolites other than unchanged EA.
(b)
Time(nrin) Pre-G GS-EA Pre-C C-EA N ? EA
5 0 0 0 0 0 0 0
10 0 0 0 0 0 0 0
15 10 0 0 84 5 0 0
20 11 0 0 82 7 0 0
25 12 0 0 82 7 0 0
30 12 0 0 81 7 0 0
45 11 0 0 79 9 0 0
60 10 0 0 84 5 0 0
(a) Autoradiograph of b i l ia ry  metabolites separated by t . l . c .  in solvent 
butanol :acetic acidrwater, 4:1:5 by v o l, and (b) the rates of excretion 
of the major metabolites following intravenous administration of the 
cysteine conjugate ( 35S) of ethacrynic acid to baboon 103 (dose 2).
O Glutathione conjugate; •  Cysteine conjugate; a  N-acetylcysteine 
conjugate; ■ Ethacrynic acid.
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TABLE 3-22
Excretion of (a) rad ioactiv ity  in b ile  samples obtained from baboon 
103 (dose 9) following intravenous administration of the cysteine 
conjugate of llfC-ethacrynfc acid, and (b) percentage of rad ioactiv ity  
corresponding to individual metabolites present in each sample.
Abbreviations : Pre-G, zone of rad ioactiv ity  with Rf value <GS-EA; 
GS-EA, glutathione conjugate of ethacrynic acid; Pre-C, zone of 
rad ioactiv ity  between GS-EA and C-EA (probably due to cysteinlyglycine  
conjugate); C-EA, cysteine conjugate; N, N-acetylcysteine conjugate; 
EA, ethacrynic aci'd.
(a)
Time(min) % Dose excreted ma equiv. EA
Bile flow 
yl/min
mg equiv. 
EA/min
5 0.04 0.02 132 0
10 0.82 0.41 192 0.08
15 4.40 2.16 232 0.44
20 3.68 1.83 170 0.37
25 2.60 1.30 130 0.26
30 2.88 1.43 170 0.29
45 3.62 1.91 118 0.13
60 2.22 1.10 142 0.07
Total 20.49 10.16 - -
(b)
Time(min) Pre-G GS-EA Pre-C C-EA N ? EA
5 0 0 0 0 0 0 0
10 0 0 0 65 5 0 30
15 0 2 0 60 8 0 25
20 0 4 0 63 9 0 23
25 0 4 3 58 9 0 25
30 0 0 2 62 8 0 26
45 0 0 0 66 8 0 24
60 0 0
0
70 2 0 23
(a) Autoradiograph of b i l ia ry  metabolites separated by t . l . c .  in solvent 
butanolracetic acid:water, 4:1:5 by v o l, and (b) the rates of excretion 
of the major metabolites following intravenous administration of the 
cysteine conjugate of 11+C-ethacrynic acid to baboon 103 (dose 9).
O Glutathione conjugate; •C yste ine  conjugate; a  N-acetylcysteine 
conjugate; ■ Ethacrynic acid.
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TABLE 3-23
Proportions of rad ioactiv ity  present in the 0-8 h urine samples in 
rhesus monkeys 525 and 526, and baboons 991 and 993, following 
e ither (a) an intravenous, or (b) an oral dose of llfC-ethacrynic 
acid (50 mg).
(a)
R *  Kf
Animal No.
525 526 991 993
0.35 Cysteine conjugate 48 46 39 46
0.46 N-acetyl cysteine conjugate 6 4 4 12
0.67 ? - - 7 -
0.80 Ethacrynic acid 45 50 50 41
(b)
Rf *
Animal No.
525 526 991 993
0.35 Cysteine conjugate ‘ 56 56 37 40
0.46 N-acetylcysteine conjugate 10 9 26 32
0.80 Ethacrynic acid 30 32 37 27
* R.p value re la tive  to top of t . l . c .  p late.
FIGURE 3 -1 2
Alterations in b ile  flow (a) following intravenous administration of
lt+C-ethacrynic acid (50 mg) to baboons 991 ■; 993 # ;  and 103 0 ,  and
(b) following intravenous administration of e ither the glutathione 
conjugate of ethacrynic acid, •  dose 1; ■ dose 8, or the cysteine
conjugate of ethacrynic acid, O dose 2; a  dose 9.
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CHAPTER 4
IN VIVO MODIFICATION OF THE METABOLISM OF THE GLUTATHIONE 
CONJUGATE OF ETHACRYNIC ACID
INTRODUCTION
As a result of investigating the metabolic fate  of ll*C-ethacrynic 
acid in the non-human primate, i t  was concluded that this animal 
species extensively conjugates ethacrynic acid with GSH. The 
resulting GSH conjugate is rapidly catabolised, presumably via the 
cysteinylglycine conjugate, to the corresponding cysteine conjugate* 
The cysteine conjugate is  subsequently N-acetylated only slowly (rhesus 
monkey < baboon). All these conjugates are excreted in the b i le .  
Several points, however, remain to be c la r i f ie d :  f i r s t ,  is there any 
evidence that the formation and excretion of the glutathione 
conjugate or i ts  metabolic products lead to the depletion of hepatic 
glutathione levels?; second, does the in i t ia l  step in the catabolism 
of the glutathione conjugate proceed e ither by transpeptidation or 
by hydrolysis mediated byy-glutamyltranspeptidase? The results in 
this thesis show that the l iv e r  of the non-human primate can produce 
a ll  the products of mercapturic acid biosynthesis. This contrasts 
with studies of paracetamol metabolism in isolated ra t  hepatocytes, 
in which i t  appeared that the cysteine conjugate was only slowly 
produced from the glutathione conjugate and no N-acetylation of the 
cysteine conjugate occurred (MoldeuS et a l , 1978; Jones et a l , 1978).
Depletion of hepatic glutathione
Rapid non-enzymic or enzymic conjugation of a xenobtotic with, hepatic 
glutathione usually leads to the depletion of hepatic glutathione.
Many xenobiotics are known to produce extensive and rapid depletion 
of hepatic GSH leve ls , fo r  example, administration of methyl iodide 
(75 mg/kg p .o .)  lowered hepatic GSH content to 17% of normal within  
2 h (Johnson, 1965), and diethyl maleate (644 mg/kg i . p . )  lowered 
the hepatic GSH to 10% of normal within a s im ilar time interval 
(Boyland and Chasseaud, 1970).. Compounds such as ethacrynic acid 
which contain ag-unsaturated carbonyl groups can react both non- 
enzymically and enzymically with GSH; other examples include ethyl 
vinyl ketone, trans-4-phenyl-3-butene-2-one, cyclohex-l-en-2-one, a ll  
possess the capacity to deplete hepatic glutathione. One of this  
group, cyclohex-l-en-2-one, when administered in traperitoneally  to 
rats (121 mg/kg) resulted in the hepatic glutathione levels that were 
17% of normal within 30 min (.Boyland and Chasseaud, 1970). With 
regard to the enzymic conjugation of this compound with glutathione, there 
appears to be a species difference between the ra t and non-human 
primate (Down and Chasseaud, 1979). Although the doses of the 
ag-unsaturated carbonyl compounds administered to the ra t were 
greater than the doses of ethacrynic acid used in the present 
investigations, a possible lowering of the hepatic -GSH concentrations 
could occur and this would perhaps a ffec t the rate or extent of 
formation of the mercapturic acid precursors of ethacrynic acid.
To investigate this p o ss ib il i ty , a baboon (No. 993), which had 
previously received ethacrynic acid, was again dosed twice with 
ethacrynic acid (50 mg) separated by an interval of 3 h. The tota l 
bile  output was collected for 3 h a f te r  each dose, and the metabolite 
profiles were examined. The results obtained are described in this  
Chapter.
Metabolism of glutathione conjugates
After formation of the glutathione conjugate of a xenobiotic, i ts  
subsequent metabolism proceeds f i r s t  via the removal of the y- 
glutamyltranspeptidase (EC 2 .3 .2 .2 . ) ,  and the process is e ither one 
of transpeptidation or of hydrolysis. y-Glutamyltranspeptidase (y-GT) 
is widely distributed in the tissues of higher animals (Meister et a l ,
1976), and has been shown to possess 3 possible functions;
(1) hydrolysis -  producing the cystei'nylglycine conjugate and 
glutamate, (2) transpeptidation -  in which the y-glutamyl residue 
is transferred to an acceptor molecule, (3). autotranspeptidation -  
where the residue is transferred to e ither another GSH molecule or 
perhaps even a GSH conjugate. In the la t te r  case, a y-glutamyl-y- 
glutamylcysteinylglycine conjugate may resu lt.
Several compounds have the a b i l i t y  to influence the a c t iv ity  of y-GT.
A group of compounds c lassified  as "y-glutamyl analogues" prevent the 
transpeptidase function of the enzyme. Examples of this group of 
compounds are 6-diazo-5-oxo-norleucine (DON) and azaserine (o-diazo-  
acetyl-L-serine.) both of which in h ib it  y-GT by reacting s p e c if ic a lly ,  
stochiometrically, and covalently with the active s ite  of the enzyme 
(Tate and Meister, 1977; Inoue, 1977). This inh ib ition  has been observed 
with the purified enzyme from ra t and human tissues (Tate and Ross,
1977). More recently another y-glutamyl analogue (aS,5S)-a-amino-3- 
chloro-4,5-dihydro-5-isoxazole acetic acid (AT 125) (Neil et a l ,
1979; Tso et a l , 1980) has been shown to spec if ic a lly  in h ib it  y-glutamyl 
transpeptidase. L-serine in the presence of borate also in h ib its  the 
purified enzyme, and forms the basis of the characterisation of y-GT 
(Tate and Meister, 1978).
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Another modification of y-GT has been observed following administration  
of maleate. Maleate stimulates the hydrolytic function of y-GT whilst  
inh ib iting  transpeptidation (Tate and Meister, 1974). Several analogues 
of hippurate produce similar effects (Thompson, 1979). In the present study 
because of the re la t iv e ly  large size of the experimental animals 
(=•8 kg), and also the limited a v a i la b i l i ty  of AT 125, the more 
read ily  available DON was used as an in h ib ito r  of y-GT fo r  the in vivo 
studies. As hippurate (benzoylglycine) occurs endogenously, i t  was 
employed in.an attempt to enhance the inh ib ition  of transpeptidation.
To investigate the p o ss ib il i ty  that the l iv e r  of other, species 
can produce each of the .metabolites resulting from in i t i a l  conjugation 
of ethacrynic acid with glutathione, experiments were devised in which 
the hepatic metabolism of ethacrynic acid would be studied, without 
any inter-organ interaction which may occur in the in tact animal.
The ra t was used for these experiments.
EXPERIMENTAL
Animals
Baboon 99 36  was used to study the e ffec t of the intravenous administration 
of 2 separate doses of 1I+C-ethacrynic acid (50 mg). This experiment was 
conducted in order to examine the possible depletion of hepatic 
glutathione. The second dose of ltfC-ethacrynic acid was administered 
at 3 h a fte r  the f i r s t  dose. Prior to and during dosing the production 
of b ile  was monitored as described previously.
During the experimental period the baboon was restrained in a primate 
chair, and maintained on the standard primate d ie t. Water was supplied 
ad libitum.
Two additional male baboons (204 and 205; bodyweights 8.2 and 8.4 kg 
respectively) were selected from stock. Whilst under general 
anaesthetic, each was f i t te d  w ith an indwelling b ile  duct "T" tube 
cannula and stomach return tube as previously described. These 
animals were maintained as described above. These baboons were used 
fo r in h ib itio n  studtes and were dosed with 6-diazo-5-oxo-L-norleucine  
and hippurate as indicated below.
Four male rats (CD -  Sprague-Dawley, Charles R iver, U .K ., of body- 
weight ca. 200 g) were used to investigate the b ilia ry  excretion of 
llfC-ethacrynic acfd with and without in tac t renal c ircu la tio n . A fter  
cannulation of the animalrs b ile  duct, and when normal b ile  production 
had been established, the rats were each dosed with llfC-ethacrynic 
acid at a dose level of 5 mg/kg. Prior to the insertion of the b ile  
duct cannula into rats 11 and 13, the renal blood vessels were ligated  
using surgical s ilk . These rats were held under general anaesthetic 
(Etorphtne/methotrimeprazine; Imobilon) during the 4 h experiment, 
a fte r  which time they were k ille d  by cervical d islocation.
Doses
Doses of llfC-ethacryntc.acid fo r e ith e r baboons or rats were prepared 
as previously described. The specific  a c t iv ity  of each dose was 
measured and the purity  (>98%) was checked immediately p rio r to dosing. 
The individual doses administered were as follows: baboon 993, f i r s t
dose -  50 mg, 19.55 y C i,  and second dose -  50 mg, 19.55 yCi (a t 3 h 
a fte r  the f i r s t  dose); baboons 204 and 205 -  50.5 mg, 5.56 yCi 
administered at 4 h a fte r  pretreatment with in h ib ito rs . Rats 10 and 
11, 1 mg, 4.059 y C i, and rats 12 and 13, 1 mg, 3.95 y C i .
For the study of the in h ib itio n  of hepatic y-GT, baboon 204 was 
pretreated by intravenous administration of DON (10 mg/kg) and 
hippurate (200 mg/kg). Baboon 205 only received DON (10 mg/kg).
These compounds were administered 4 h p rio r to the administration  
of 14C-ethacrynrc acid.
Samples
B ile samples were obtained from each baboon at 5 min in tervals  up to 
and including the 30 min sample, at 45 and 60 min post-dose and there­
a fte r  at hourly in terva ls . B ile  samples from rats were collected at 
30 min in tervals  up-to 4 h., post-dose. A ll b ile  samples were 
collected into containers cooled in solid carbon dioxide so as to 
ensure that the b ile  samples were immediately frozen.
Measurements
Measurements of ra d io a c tiv ity  were made as previously described. 
Radioactive metabolites present in b ile  samples were separated by 
th in -la y e r chromatography on s ilic a  gel p lates, using a solvent 
system of butanollacetic acidrwater (4 :1:5  by v o l) , and were quantified  
byusing a lin ea r t . l . c .  analyser.
RESULTS
Depletion of hepatic glutathione
Following the f i r s t  of 2 successive doses of llfC-ethacrynic acid, 55% 
of the administered ra d io ac tiv ity  was excreted into baboon b ile  during 
T h. This is  s im ilar to 58% obtained when the animal was previously 
studied, and to 46% and 51% obtained from 2 other baboons (Nos. 991 
and 103). An increase in b ile  flow, up to 4-times the base-line  
value, was observed soon a fte r  dosing, 5-15 min (Figure 4 -1 ). The 
time of maximum secretion of b ile  occurred s lig h tly  before the highest 
rate of excretion of ra d io ac tiv ity  (Table 4 -1 ). A fter the second dose 
of llfC-ethacryntc acid, a s im ilar proportion of the radioactive dose 
(51%) was excreted in the b ile  during 1 h. During 30 min a fte r  dosing 
the rate of excretion of rad io ac tiv ity  following the second dose was 
slower (except in.the f i r s t  sample) than that observed a fte r  the f i r s t  
dose. The rate of excretion of rad io ac tiv ity  during the time period 
30-60 min a fte r  the second dose was greater than that observed 
following the f i r s t  dose. Stimulation of b ile  production was some­
what lower, although the maximum b ile  flow , 240 y l/m in , was 5-times 
the value measured immediately prio r to the second dose (Table 4-1 
and Figure 4 -1 ). The to ta l proportion of the administered dose 
recovered in the urine samples was s im ilar (ca. 20%) in the 3 h 
period following e ith er dose.
Examination of the radioactive components present in b ile  a fte r  the 
f i r s t  or second dose showed that only small amounts of ethacrynic acid 
were excreted unchanged, with s lig h tly  more a fte r  the f i r s t  than a fte r  
the second dose. The glutathione conjugate of ethacrynic acid (GS-EA) 
was most abundant in the 10-min b ile  sample. (31 and 28%), diminishing
to 5% or less at 60 min. The proportion of the cysteine conjugate of 
ethacrynic acid (Cys-EA) was greatest at about 25 min a fte r  dosing 
(69% and 67% resp ective ly ), and declined only s lig h tly  to about 51% 
at 60 min. The proportion of ra d io ac tiv ity  in b ile , associated with 
the N-acetylcysteine conjugate of ethacrynic acid (NAC-EA), was 
in i t f a l ly  very low (3-5% in the 5 and 10 min b ile  samples), but then 
Increased to a maximum 29% at 45 min a fte r  the f i r s t  dose, and 31% 
at 60 min a fte r  the second dose (Table 4 -2 ).
Figure 4 -2 (a) shows the time-course of the rates of excretion of the
major radioactive components present in the b ile  following the f i r s t  
dose of llfC-ethacrynic acid. The maximum rates of excretion fo r  
unchanged ethacrynic acid, GS-EA and Cys-EA occurred at 12.5 min, and 
were 0.08, 0.5 and 0.9 mg/min respectively. At 22.5 min or more 
a fte r  dosing, the rates of excretion of both ethacrynic acid and 
its  glutathione conjugate were low, <0.05 mg/min. At 52.5 min a fte r  
dosing, the excretion rate of the cysteine conjugate was s im ila r to  
that observed at the time of the peak excretion of ethacrynic acid. 
The rate of excretion of the N-acetylcysteine conjugate reached a 
maximum at 22.5 min a fte r  dosing (0.11 mg/min), a fte r  which i t
slowly declined to 0.07 mg/mtn at 52.5 min.
Following the second dose of I4 C-ethacrynic acid, the maximum rates  
of excretion of both the cysteine conjugate and the glutathione  
conjugate were lower (0 .7  and 0.25 mg/min respectively) than those 
a fte r  the f i r s t  dose. The rate of excretion of the N-acetylcysteine  
conjugate was also lower during the f i r s t  30 min a fte r  the second 
dose, but a fte r  th is  time increased to 0.09 mg/min at 52.5 min 
(Figure 4 -2 (b) ) .
In h ib ition  studies using DON and hippurate
In a baboon pretreated with DON (an in h ib ito r of y -G T ), the cumulative 
excretion of ra d io a c tiv ity  during 60 min a fte r  a single intravenous 
dose of llfC-ethacryntc acid was 52%, s im ilar to that observed in an 
untreated animal. However, the proportion of rad io ac tiv ity  excreted 
at the time of peak excreti'on of ra d io ac tiv ity  (15 min) was approximately 
two th irds of that excreted in an untreated baboon, w hilst a t la te r  
time (25 to 60 min) the proportion of rad io a c tiv ity  excreted was 
s lig h tly  greater than that observed with the untreated animal (Table 4-3). 
The maximum stim ulation of b ile  flow (206 pi/m in) was only approximately 
twice the base-line value and occurred'at 10 min a fte r  dosing.
When both the y-GT in h ib ito r (DON) and the y-GT modulator (hippurate) 
were used together in the pretreatment regimen in the baboon, the 
proportion of ra d io ac tiv ity  excreted in the b ile  during 60 min a fte r  
dosing was only 38% of the administered dose. In the baboon receiving 
the pretreatment regimens, the to ta l amount of rad io a c tiv ity  excreted 
in the b ile  during 6 h a fte r  dosing was 60% and 57% respectively , and 
during the 24 h a fte r  dosing was very s im ilar (approximately 62%)
(Table 4 -4 ). The b ile  flow observed a fte r  the administration of both 
DON and hippurate was markedly reduced with a peak value of 152 yl/m in. 
Peak b ile  flow was measured at 20 min a fte r  dosing (Table 4 -4 ).
The urinary excretion of ra d io ac tiv ity  was s lig h tly  higher following  
pretreatment with DON and hippurate (31%) than that observed following  
pretreatment with DON alone (25%) (Tables 4-3 and 4 -4 ).
Examination of the proportions of the major radioactive components 
present in the b ile  samples of baboons pretreated with DON showed
th a t, in contrast toan untreated animal a notable proportion of the 
ra d io ac tiv ity  was present as ethacrynic acid (>20%). The samples 
which contained the highest proportions (46% and 40%) of unchanged 
ethacrynic acid were the 60 and 10 min samples respectively. The 
proportion of the glutathione conjugate was highest (43%) fn'the 15 min 
sample. At la te r  sampling times, the proportion of the glutathione  
conjugate declined and was 3% at 60 min a fte r  dosing. The proportion 
of the ra d io a c tiv ity  present as the cysteine conjugate was low (<32% 
in a ll  samples), with the highest proportion being measured in the 
45 min b ile  sample (Table 4 -5 }. The proportions of N-acetylcysteine  
conjugate was low (between 1-5%) during the f i r s t  20 min a fte r  dosing, 
but slowly increased to a peak value of 20% at 45 min, and showed a 
s lig h t decline to 17% by 60 min a fte r  dosing.
The proportions of rad io ac tiv ity  present in the b ile  samples following  
pretreatment with both DON and htppurate show that the excretion of 
ethacrynic acid was greater (>33%) in a ll samples except in the sample 
obtained at 20 min a fte r  dosing (12%). As observed in the b ile  samples 
obtained a fte r  pretreatment with DON the maximum proportion of 
ethacrynic acid excreted occurred at 10 and 60 min a fte r  dosing 
(54% and 57% respectively) (Table 4 -5 ). The highest proportion of 
the glutathione conjugate (38%) was measured in the 20 min b ile  sample, 
a fte r  which time the proportion stead ily  declined u n til a t 60 min only 
5% of the rad io ac tiv ity  was associated with the glutathione conjugate 
of ethacrynic acid. The proportion of cysteine conjugate present in  
the b ile  samples was lower at a ll times, with the exception of the 
20 min sample, than when the animal was treated with DON alone. 
S im ila rly , the proportion as the N-acetylcysteine conjugate was 
also markedly reduced. The highest proportion excreted as N -acety l-
cysteine conjugate occurred in the 60 min sample (11%) (Table 4 -5 ).
Following pretreatment with DON, the glutathione conjugate had the 
highest rate of excretion of any metabolite studied (4 .2  mg/min), and 
the maximum rate of excretion occurred at 12.5 min a fte r  dosing. The 
rate of excretion of the glutathione conjugate declined rapid ly  with  
time. The maximum rate of excretion of the cysteine conjugate was 
0.2 mg/min (12,5 min) and rates of excretion close to th is  value were 
recorded up to 37.5 min a fte r  dosing. A fter 37.5 min, the rate of 
excretion declined to be <0.05 mg/min in the fin a l b ile  sample 
analysed. The rate of excretion o f:the N-acetylcysteine conjugate 
was low <0.05 mg/min in the f i r s t  4 b ile  samples, a fte r  which the 
rate of excretion rose to approximately 0.1 mg/min before f in a l ly  
declining to 0.05 mg/min at 52.5 min, Ethacrynic acid was excreted 
at a rate of between 0.15 and 0.2 mg/min during most of the f i r s t  
hour a fte r  dosing. Only in the la s t sample analysed did the rate  
of excretion of ethacrynic acid f a l l  to approximately 0.1 mg/min 
(Figure 4 -3 ).
Following pretreatment of a baboon w ith both DON and hippurate, 
the maximum rate of excretion of both the glutathione and cysteine 
conjugates occurred la te r  (17.5 min) than when DON was used alone.
The maximum rates measured were 0.32 mg/min (GS-EA) and 0.3 mg/min 
(Cys-EA). The rate of excretion of ethacrynic acid was s im ila r to 
those obtained a fte r  DON pretreatment. A major difference in the 
rate of excretion of the N-acetyl cysteine conjugate was observed as 
the excretion rate remained low (<0.02 mg/min) fo r the duration of 
the experiment (Figure 4 -3 ).
The to ta l amounts of ethacrynic acid and the conjugates derived from 
the in i t ia l  conjugation of ethacrynic acid with glutathione are 
presented in Table 4-6 . When 1IfC-ethacryni’c acid was intravenously 
administered to an untreated baboon, 1.4 mg of ethacrynic acid was 
excreted unchanged. A to ta l of 26 mg of the administered ethacrynic 
acid was excreted as the glutathione conjugate during the f i r s t  hour 
a fte r  dosing, 77% (20 mg) of which was catabolised to the cyste iny l- 
glycine conjugate, most of which (19 mg) was fu rther metabolised to 
the cysteine conjugate. Approximately 15% (3 .7  mg) of the cysteine 
conjugate was converted into the N-acetyl cysteine conjugate.
Foil owing the pretreatment of the baboon With DON, the amount of 
unchanged ethacrynic acid excreted into the b ile  during the f i r s t  
hour was greater (7 .2  mg). 17.2 mg of the administered ethacrynic 
acid was conjugated with glutathione during the same time period.
Of the to ta l glutathione conjugate formed only 9.5 mg was fu rther  
catabolised to the cysteine conjugate, and 32% (3 mg) of the cysteine 
conjugate was acetylated. When the pretreatment regimen also included 
hippurate, the amount of unchanged ethacrynic acid excreted was 
sim ilar to the amount excreted a fte r  DON pretreatment, but the 
amount conjugated w ith glutathione was lower (10.7 mg). The glutathione 
conjugate was metabolised fu rther to the cysteinylglycine conjugate 
(1 mg), and the cysteine conjugate (5 mg) being produced. 16% of the 
cysteine conjugate underwent fu rther metabolism to form the N -acetyl-  
cysteine conjugate.
Examination of the urine samples produced by the baboon follow ing both 
pretreatment regimens showed that approximately 25% of the rad ioactiv ity  
was due to unmetabolised ethacrynic acid with an additional 50-65% 
present as the cysteine conjugate.
Only 10-15% of the urinary ra d io a c tiv ity  was associated with the 
N-acetylcysteine conjugate. In the urine, sample produced at 30 min 
by the baboon, following pretreatment with both DON and hippurate, 
a trace of the glutathione conjugate of ethacrynic acid was detected 
(<1.5% of the administered dose) .
Hepatic metabolism of the glutathione conjugate of ethacrynic acid in 
the ra t
Following administration of 14C-ethacrynic acid to ra ts , each with an 
indwelling b ilia ry  cannula, over 66% of the administered dose was 
excreted in the b ile . The major portion of the b il ia ry  excreted 
rad io ac tiv ity  was measured in the 0-30 min sample (36%) and 17% in 
the 30-60 min sample. Thereafter the proportion excreted in the b ile  
declined to be less than 1% of the dose between 3 and 4 h. During the 
experiment, the flow of b ile  was increased over the base-line value, 
with the maximum flow being recorded between 30 and 60 min a fte r  
dosing. Because the normal b ile  production in the ra t is  low (7 ul/m in) 
the b ile  samples were only collected during 30 min periods; therefore, 
the actual time at which bTle flow was maximal could not be determined. 
The amount of ra d io ac tiv ity  excreted in the urine during the 4 h 
experiment was 15% of the administered dose (Table 4 -7 ).
In a ra t in which a ll  the renal blood vessels were ligated  the largest 
proportion of ra d io ac tiv ity  was excreted in the b ile  during the 0 -3 0 min 
period a fte r  dosing (55%), and 19% in the subsequent sample collected  
(30-60 min). The proportion excreted declined rapid ly  a fte r  60 min 
to be less than 1% between 3 and 4 h a fte r  dose adm inistration. Although 
b ile  flow was increased during the whole of the experimental period, the 
highest b ile  flow occurred between 0 and 30 min; th is  was e a r l ie r  and
of greater magnitude than that observed in the ra t with normal renal 
function (Table 4 -7 ).
The proportions of radioactive components excreted in the b ile  samples 
obtained from a ra t with normal renal function are given in Table 4-8. 
Only a small proportion (2-6%). was present as unmetabolised ethacrynic 
acid in any sample. The glutathione conjugate was the major metabolite 
in the f i r s t  b ile  sample (0-30 min) and represented 67% of the b il ia ry  
ra d io a c tiv ity . The proportion due to the glutathione conjugate 
declined to 28% a fte r  1 h, but did not decline fu rther during the 
experiment. In samples of b ile  produced by the ra t a fte r  30 min, the 
N-acetylcysteine conjugate accounted fo r more than 41% of the b i l ia ry  
ra d io a c tiv ity . The time at which the highest proportion of rad ioactiv ity  
in the b ile  was due ,to the N-acetylcysteine conjugate occurred between 
30 and 60 min a fte r  dosing. The remaining portion of the rad io a c tiv ity  
comprised both the cystetnylglycine and the cysteine conjugates of 
ethacrynic acid. The rates of excretion of the individual components 
are given in Figure 4-4 .
In the ra t in which the renal blood vessels had been ligated  a s im ila r  
p ro file  of metabolites was observed, but the proportion present as the 
glutathione conjugate was higher in both the 0-30 and 30-60 min samples. 
With the exception of these 2 samples, in which the N-acetylcysteine  
conjugate accounted for 7 and 19% of the rad io ac tiv ity  respective ly , 
the proportion of ra d io ac tiv ity  present as the N-acetylcysteine 
conjugate was between 35 and 43% (Table 4 -7 ). The rates of excretion  
of the various radioactive components show that the glutathione  
conjugate was excreted approximately 10-times fas te r than that o f any 
of the other metabolites during the f i r s t  30 min a fte r  dosing, although 
the rate of excretion of the glutathione conjugate declined rapidly-with time 
(Figure 4 -4 ).
DISCUSSION
In the baboon following the intravenous administration of 2 separate 
doses of 14C-ethacrynic acid (50 mg), separated by an in terva l of 3 h, 
there was l i t t l e  in d irec t evidence to suggest that any depletion of 
hepatic glutathione had occurred. Assuming that the weight of the 
baboon liv e r  was ca. 100 g and that the concentration of glutathione  
was ca^ . 6.5 nM (see Chapter 6 ) , then the l iv e r  should contain 
approximately 200 mg of glutathione. I t  can be calculated that i f  
the synthesis of hepatic glutathione was slow, a reduction in the 
level of hepatic glutathione could occur before the second dose of 
ethacrynic acid was administered. The results obtained following the 
second dose of 1I+C-ethacrynic acid showed th a t there was no reduction 
in the to ta l amount of the glutathione conjugate formed. The major 
differences which occurred concerned the actual rates of excretion 
of the b i l ia ry  excreted conjugates of ethacrynic acid. The rates of 
excretion of both the GS-EA and the Cys-EA were reduced. Thus, the 
l iv e r  of the baboon was able to conjugate in excess of 50 mg of 
ethacrynic acid with glutathione w ithin 4 h. However, the production 
of the N-acetylcysteine conjugate was markedly reduced following the 
second dose of ethacrynic acid which could indicate some lim ita tio n  
in the capacity of l iv e r  mtcrosomal acetyl-CoA dependent, N -acetyl-  
transferase. The observation that the b ile  flow was reduced following  
the second dose, although a transient increase in b ile  production 
occurred, could be due to the p a rtia l depletion of the b ile  s a lt pool 
despite the re-introduction of baboon b ile  (v ia  the stomach return  
tube) during the experiment.
The administration of the y-glutamyltranspeptidase in h ib ito r , DON, 3 h
prio r to the administration of llfC-ethacrynic acid (50 mg) caused only 
a s lig h t reduction in the to ta l amount of the glutathione conjugate 
formed, but as expected markedly reduced its  catabolic conversion to 
the cysteine conjugate. Only 55% of the glutathione conjugate was 
metabolised to the cysteine conjugate following pretreatment with DON, 
compared to 77% in the untreated baboon. The co-administration of DON 
together with hippurate, a compound which is known to a lte r  the 
transpeptidation and hydrolytic function of y-GT (Thompson and M eister, 
1980; Welbourraand Dass, 1982), caused a pronounced drop in the 
formation of the glutathione conjugate, but only a s lig h t decline in 
i ts  conversion to the cysteine conjugate (47%). Hippurate may also 
d ire c tly  in te rfe re  with the conjugation of glutathione with ethacrynic 
acid or modify the active transport of the glutathione conjugate into  
the b ile . The production of the cysteine conjugate of ethacrynic acid 
was not completely prevented by DON and hippurate, and th is  could 
possibly be due to e ith er the hydrolysis of the glutathione conjugate 
by y-GT or incomplete in h ib itio n  of the transpeptidase a c tiv ity  of the 
hepatic y-G T.
A surprising observation was that only 16% of the cysteine conjugate 
of ethacrynic acid, produced a fte r  pretreatment with both DON and 
hippurate, was N-acetylated, compared to 32% N-acetylated when DON 
was used alone.
Although the urinary excretion of rad io ac tiv ity  was s im ilar following  
both pretreatment regimens, only a small amount (1.5%) was present in  
a single urine sample as the glutathione conjugate of ethacrynic acid, 
namely in the 30 min urine sample obtained from the hippurate 
supplemented study. DON in the presence of hippurate is probably a
specific  in h ib ito r fo r hepatic y-GT due to the fac t that DON contains
an L-amino acid which would be expected to be rapidly removed from
the systemic c ircu la tio n  by the liv e r  (M il le r , 1962). The hepatic
removal of DON could resu lt in only a small amount of DON being
availab le fo r the in h ib itio n  of the renal y-GT (Inouee ta l, 1979). In the
non-human primates in which the renal y-GT a c tiv ity  is considerably
greater than the hepatic y-GT a c tiv ity  (see Chapter 6 ) ,  very l i t t l e  
in h ib itio n  of renal y-GT may take place.
The observations reported here indicate that the liv e r  of the non-human 
primate is  probably capable of providing the complete mercapturic acid 
pathway fo r the elim ination of ethacrynic acid. There is the- 
p o ss ib ility  that the glutathione conjugate formed in the l iv e r  could 
be transported to the kidney where i t  could undergo catabolism, and 
the metabolites thus produced returned via the systemic c ircu la tio n  
to the l iv e r  fo r excretion into the b ile . However, th is seems 
unnecessary since the l iv e r  is  capable of conducting a ll  the stages 
of the mercapturic acid pathway.
The possible inter-organ exchange of glutathione conjugates or the 
various metabolites of the glutathione conjugates was investigated using 
the ra t as the experimental model. In one study in the ra t ,  the 
contribution from the kidney was prevented by the in terruption of 
the renal blood supply and venous drainage throughout the experiment.
ATI the metabolic products resulting from the in i t ia l  conjugation of 
ethacrynic acid with glutathione were present in the b ile  with over 
93% of the dose being excreted w ithin 4 h. Indeed, a large proportion 
of the b il ia ry  excreted rad io ac tiv ity  (>41%) was the N-acetylcysteine 
conjugate of ethacrynic acid, which indicates that complete metabolism 
of the glutathione conjugate to the mercapturic acid was accomplished
in the ra t l iv e r .
The l iv e r  contains a mixed population of ce ll types with varying 
metabolic functions. The results of Moldeus et a l . (1978) were 
obtained using an isolated hepatocyte (parenchymal c e ll)  preparation. 
This preparation would be devoid of the c e llu la r  interactions which 
would occur in vivo, and this could provide the possible explanation 
fo r the observation that only a small amount of the glutathione 
conjugate of paracetamol was converted into the cysteine conjugate, 
which was not apparently fu rther metabolised. This observation 
highlights one of the 1 im itations, in the use of isolated ce ll . 
preparations to predict the fa te  of a xenobtotic in v ivo .
TABLE 4-1
B ilia ry  and urinary excretion of ra d io ac tiv ity  in the baboon (No. 993) 
following an in i t ia l  ( f ir s t ) ,  intravenous dose of 14C-ethacrynic acid 
(ca. 50 mg), and following a second intravenous dose of llfC-ethacrynic 
acid (ca. 50 mg) given 3 h la te r .
F irs t dose Second dose
Time
(min) Dose Cumulative Bile Dose Cumulative B ileexcreted dose f l  ow excreted dose flow
(%) m (y l/m in ) (%). (%) (y l/m in)
(a) B ile  
5 . 0.01, 0.01 80 0.32 . 0 , 3 200
10 6.92 6.94 320 8.51 8.8 240
15 16.63 23.6 300 11,26 20.1 160
20 10.73 34.3 200 5.59 25.7 80
25 6.19 40.5 160 4.36 30.0 70
30 4.17 44.6 140 3.42 33.5 60
45 7.66 52.3 140 10.85 44.3 87
60 3.05 55.4 127 6.45 50.8 73
120 3.86 59.2 120 4.60 55.4 62
180 0.80 60.0 52 2.45 57.8 55
(b) Urine
30 15.08 15.1 - 13.11 13.1 —
60 3.76 18.8 - - - -
180 1.90 20.7 - 6.68 19.8 . -
TABLE 4-2
Proportions of radioactive metabolites excreted in the b ile  of a baboon 
(No. 993) fo llow ing, (a) an in i t ia l  intravenous dose of 14C-ethacrynic 
acid,and (b) a s im ilar intravenous dose of llfC-ethacrynic acid 3 h 
la te r .
Time
(min)
Conjugate
GS-EA Cys i m NAC-EA EA
(a). (b). Cal (b). (a ) (b) (a) (b)
10 31 28 53 60 3 3 7 2
15 29 23 54 64 5 4 5 2
20 18 18 60 67 11 6 4 • 2
25 6 16 69 67 19 9 2 2
30 6 14 59 67 25 7 4 3
45 7 5 50 66 29 18 7 3
60 5 2 51 50 26 31 7 6
TABLE 4-3
Excretion of ra d io ac tiv ity  in the b ile  and urine of a baboon (No. 
following an intravenous dose of 14C-ethacrynfc acid at 4 h a fte r  
pretreatment with DON (10 mg/kg).
Time
Dose
excreted
m
Cumulative
excretion
(%)
B ile flow 
(y l/m in)
(a) B ile
5 min 0.01 0.01 90
10 min 4.24 4.2 206
15 min 9.75 14.0 168
20 min 6.89 20.9 146
25 min 7.19 28.1 146
30 min 5.86 33,9 140
45 min 12.73 46.7 153
60 mfn 5.14 51.8 133
2 h 5.20 57.0 79
3 h 1.63 58.6 41
4 h 0.85 59.5 34
5 h 0.55 60.0 43
6 h 0.26 60.3 40
24 h 1.10 61.4 27
(b) Urine
30 min 16.33 16.4 -
60 mfn 2.78 19.1 -
120 mfn - - -
360 min - -
.1440 mi n 5.38 24,5
TABLE 4-4
Excretion of ra d io a c tiv ity  in the b ile  and urine of a baboon (No.204) 
following an intravenous dose of llfC-ethacrynic acid at 4 h a fte r  
pretreatment w ith DON (10 mg/kg) and hippurate (200 mg/kg)
Time
Dose
excreted
m
Cumulative
excretion
. . ( * )
B ile flow  
(pi/m in)
(a) B ile
5 min 0.68 0.7 114
10 min 2.74 3.4 118
15 min 5,10 8.5 126
20 min 8.47 17.0 152
25 min 5-. 04. . .22.0 84
30 min 3.20 25,2 62
45 min 7.54 32,8 62
60 mfn 5.56 38.3 57
2 h 10.24 48.6 39
3 h 3.79 52.4 28
4 h 2.11 54.5 21
5 h 1.31 55.8 18
6 h 0.80 56.6 21
24 h 6.00 62.6 29
(b) Urine
30 min 17.99 18.0 -
60 min 3.16 21.2 -
120 mfn 3.74 24.9 -
360 min 4.47 29.4 -
1440 min 1.70 31.1 — .
TABLE 4-5
Proportions of radioactive metabolites excreted in the b ile  of 
baboons following the intravenous administration of llfC-ethacrynic 
acid (ca. 50 mg) 4 h a fte r  (a) pretreatment with DON (10 mg/kg) or
(b) pretreatment with DON (10 mg/kg) and hippurate (200 mg/kg)
Time
(min)
Conjugate
GS-EA Cys-EA NAC-EA EA
(a) (b) (a) (b) (a) '(b ) (a) (b)
10 30 27 16 7 1 2 40 54
15 43 37 20 12 3 1 19 37
20 35 .38 25 36 5 2 20 12
25 24 31 26 19 12 2 25 33
30 16 21 26 19 17 4 28 44
45 8 12 32 24 20 7 27 48
60 3 5 20 17 17 11 46 57
TABLE 4-6
Hepatic metabolism of the glutathione conjugate of ethacrynic acid 
in the baboon following various pretreatment regimes.
Abbreviations : GS-EA, glutathione conjugate; CysGly-EA, cysteinylglyci 
conjugate; Cys-EA, cysteine conjugate; NAC-EA, N-acetylcysteine 
conjugate of ethacrynic actd.
Dose
No.
Total
conjugates
(mg)
Conjugate* Ethacrynic
acid
(mg)GS-EAfrig)
CysGly-EA
(mg)
Cys-EA
(mg)
NAC-EA
(mg)
* -Ca) 27.7 26.3 20.4 19.3 3.7 1.4
( b ) 25.4 24.2 20.2 18.6 2.8 0.7
(c) 19.0 17.3 11.4 9.5 3.0 7.2fd) 12.2.. 10.7 6.0 5.0 0.8 7.2
*  Total mg of ethacrynic acid conjugate metabolised via th is  step 
of the mercapturic acid pathway.
(a) Single dose of I4 C-ethacrynic acid (baboon 993).
(b) Second dose of IlfC-ethacrynic acid (ca. 50 mg) at 3 h a fte r  the
f i r s t  dose (a} (baboon 993}.
(c ) Pretreatment with DON 0 °  nig/kg) 4 h p rio r to administration  
of IlfC-ethacrynic acid (baboon 205).
(d) Pretreatment with both DON (10 mg/kg) and hippurate (200 mg/kg)
at 4 h prio r to administration of 14C-ethacrynic acid (50 mg) 
(baboon 204).
TABLE 4-7
Excretion of rad io ac tiv ity  in the b ile  of rats following an intravenous 
dose of ll+C-ethacrynic acid (5 mg/kg). The renal blood vessels were 
ligated immediately prio r to dosing.
T i me 
0 0
Dose excreted 
i%)
Cumulative 
excretion  
(% dose}
Bile flow  
(pl/m in)
Normal Ligated Normal Ligated Normal Ligated
0.5 35.6 55.4 35.6 55.4 13.3 16.0
1 16.9 18.8 52.5 74.2 20.0 13.3
1.5 6.6 7.7 59.2 81.9 17.3 10.3
2 3.1 4.4 62.3 86.3 16.7 10.0
2.5 1.4 3.8 64.1 90.7 16.7 13.7
3 1.3 1.7 65.4 91.8 17.0 10.0
3.5 0.7 1.2 66,1 93.0 12.0 10.0
4 0.6 0.8 66.8* 93.8 13.7 9.7
*  A fu rther 15.3% of the dose was recovered in the urine 
from th is  animal.
TABLE 4-8
Proportions of ethacrynic acid and conjugates of ethacrynic acid 
excreted in the b ile  of rats fo i l  owing an intravenous dose of 14C- 
ethacrynic acid (5 mg/kg); (a ) normal ra t ,  and (b) ra t with renal 
blood supply liga ted .
Time
(h)
Conjugate
GS-EA Cys-EA NAC-EA EA
(a). (b) (a) (b) (a) (b) (a) (b)
0.5 67 83 16 8 15 7 2 21 28 69 18 10 52 19 3 21.5 26 39 22 17 49 41 4. . 3 .2 26 36 24 17 45 43 4 42.5 27 35 25 20 44 41 4 43 26 35 28 22 41 35 4 53.5 26 29 28 28 41 37 5 64 24 19 29 38 41 36 6 7
FIGURE 4-1
A lterations in baboon b ile  flow following a f i r s t  intravenous dose 
of 14C-ethacrynic acid (50 m g )# -# 9 and second dose of 14C-ethacryni 
acid (50 mg) 3 h la te r  (see Table 4 -1 ).
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FIGURE 4 -2 (a)
Rate of excretion of ethacrynic acid and its  conjugates in the b ile  o f 
baboon fNo. 993), (a ) following the f i r s t  dose of llfC-ethacrynic acid 
(50 mg/kg), and (b) following the second dose of 1IfC-ethacrynic acid 
administered 3 h a fte r  the f i r s t .
Abbreviations : O Glutathione conjugate; •  Cysteine conjugate; 
±  N-acetylcysteine conjugate; ■ Ethacrynic acid.
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FIGURE 4 -2  (b V
Rate of excretion of ethacrynic acid and its  conjugates in the b ile  of 
baboon (No. 993) , (a} following the f i r s t  dose of llfC-ethacrynic acid 
(50 mg/kg), and (b) following the second dose of ll+C-ethacrynic acid 
administered 3 h a fte r  the f i r s t .
Abbreviations : O Glutathione conjugate; •  Cysteine conjugate; 
±  N-acetylcysteine conjugate; ■ Ethacrynic acid.
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FIGURE 4-3
Rate of excretion of ethacrynic acid and its  conjugates in the b ile  
of baboons following an intravenous dose of ^C-ethacrynic acid 
(50 mg/kg) 4 h a fte r  e ith e r , (a) pretreatment with DON, or (b) pretreatment 
with DON and hippurate.
Abbreviations : O Glutathione conjugate; •  Cysteine conjugate;
±  N-acetyTcysteine conjugate; ■ Ethacrynic acid.
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FIGURE 4-4
Rate of excretion of ethacrynic acid and its  metabolites in the ra t 
b ile  following an intravenous dose of lifC-ethacrynic acid (5 mg/kg)
(a) normal ra t ,  and (b) ra t with renal blood supply liga ted .
Abbreviations : O Glutathione conjugate; •  Cysteine conjugate;
*  N-acetylcysteine conjugate; ■ Ethacrynic acid.
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CHAPTER 4(b)
Id e n tific a tio n  of the major metabolites of ltfC-ethacrynic acid
In the b ile  of non-human primates,following an intravenous dose of 
14C-ethacrynic acid, there were 3 major m etabolites. The radioactive  
metabolites co-chromatographed on t ic  with synthetic reference 
compounds, and were assumed in order of decreasing p o la rity  in the 
solvent system butanol :aceti.c acidiwater (4:1:5  by v o l.} ,  to be the 
glutathione conjugate, cysteine conjugate, and the N-acetylcysteine 
conjugate (mercapturic acid,) of ethacrynic acid. Another un identified  
metabolite of greater p o la rity  than the glutathione conjugate was also 
observed (Zone 4) in the b ile  of both rhesus monkey'and baboon. This 
radioactive metabolite tended to "mirror" the disappearance of the 
glutathione conjugate, p a rtic u la r ly  in the baboon,
To confirm the id e n tit ie s  of the major b il ia ry  metabolites the 
radioactive components present in the b ile  samples from baboon 991 
(dose 16) were separated by t ic  using preparative plates ( 2mm;60F254 
E. Merck, Darmstadt, W. Germany), developed in the butanol:acetic acid 
water solvent system.. The s ilic a  gel containing each radioactive zone 
was separately removed from the backing plate and placed into small glass 
columns which contained a fin e  sintered glass f i l t e r  at the lower 
end. The rad io ac tiv ity  was eluted with 50% aqueous methanol and 
concentrated by evaporation of the eluant. Each radioactive  
metabolite was fu rther purified  by HPLC separation using a 
yBondapak C18 column (Waters Associates) eluted with a lin e a r  
gradient of 0^40% a c e to n itr ile  in water containing sodium acetate  
buffer (pH 5 .0 , 0.05 M), at a flow rate of 2 ml min"! with a gradient
time lapse of 30 min. Fractions of eluate (2 ml) were collected and 
the ra d io a c tiv ity  present in each fraction  determined. A single 
radioactive component was isolated from each of the 3 t ic  zones and 
corresponded to the glutathione conjugate (retention time * 11 m in), cysteine 
conjugate v« 19 min) and the N-acetyl cysteine conjugate (*2 6 m in ). The 
HPLC fractions containing ra d io a c tiv ity  were pooled and freeze-dried . 
Samples of the freeze-dried fractions were subjected to d irec t probe 
mass spectrometry, but apart from the N-acetylcysteine conjugate, no 
conclusive evidence of id e n tity  of the conjugates was obtained.
Additional samples o f each radioactive component were treated with  
acetic anhydride containing methane sulphonic acid, following the 
method of Bakke (1982), to y ie ld  the S-acetates of ethacrynic acid.
The S-acetates thus formed were subjected to d irec t probe mass 
spectroscopy, from which id e n tifia b le  mass fragments were obtained.
Samples of the glutathione conjugate and the cysteine conjugate were 
also examined by fast-atom-bombardment (FAB) mass spectrometry 
(Dr. N. Haskins, M-Scan L td ., Ascot, Berkshire, U .K .), and the 
spectra obtained confirmed the id e n tit ie s  of both the glutathione  
and cysteine conjugate.
Mass spectrometry
Mass spectra were obtained using a VG 7070E double-focusing mass 
spectrometer (VG Analytical L td ., Manchester, U.K.) linked to a 
VG 11-250 data system (VG Analytical L td .) fo r control and data 
processing. Samples were introduced into the mass spectrometer 
using the d irec t insertion probe and subjected to a lternate  
electron impact/chemical ionisation (ACE) conditions. Mass spectra
were recorded every 3 seconds as the sample was slowly heated to 
400°C. Electron impact spectra were obtained with an electron  
energy of 70eV, and a trap current of 100 yA, while chemical 
ionisation spectra were obtained with an electron energy of 50 eV, 
an emission current o f 200 yA and isobutane as the reactant gas.
In each case the ion source temperature was 200°C.
FIGURE 4(b)-1
Mass spectra of ethacrynic acid, 
and (b) Cl mode of ion isation .
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FIGURE 4 (b )-2-
Mass spectra of the glutathione conjugate of ethacrynic acid isolated  
from baboon b ile  (991). Chemical modification by treatment of the 
conjugate with acetic anhydridermethane sulphonic acid to y ie ld  the 
S-acetyl conjugate of ethacrynic acid Bakke (1982). Fragmentation 
produced by (a) El and (b) Cl mode of ion isation .
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FIGURE 4 (b )-3
Mass spectra of the cysteinyl conjugate of ethacrynic acid isolated  
from baboon b ile  (991). Chemical m odification by treatment of the 
conjugate with acetic anhydridermethane sulphonic acid to y ie ld  
the S-acetyl conjugate of ethacrynic acid Bakke (1982). Fragmentation 
produced by (a) El and (b) Cl mode of ionisation .
FIGURE 4 (b )-4
Postulated mass spectral'fragm entation pathway fo r the S-acetates of 
ethacrynic acid. Figures 4(Bj-2&3.
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FIGURE 4(b )-5
Fast-atom-bombardment spectra of glutathione conjugate of ethacrynic 
acid isolated from baboon b ile .
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FIGURE 4 (b)-6
Fast-atom-bombardment spectra of cysteinyl conjugate of ethacrynic 
acid isolated from baboon b ile .
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FIGURE 4 f b ) - 7
Mass spectra of N-acetylcysteine conjugate of ethacrynic acid isolated  
from baboon b ile  (991). Fragmentation produced by (a) El and (b) Cl 
mode of ionisation .
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FIGURE 4fE?)-8
Postulated mass spectral fragmentation pathway for the N-acetylcysteine 
conjugate of ethacrynic acid.
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CHAPTER 5
THE IN VITRO METABOLISM OF ETHACRYNIC ACID AND ITS GLUTATHIONE
CONJUGATE
INTRODUCTION
I t  is evident from the results contained in Chapters 3 and 4 that the 
in vivo metabolism of ethacrynic acid in non-human primates proceeds, 
via the glutathione conjugate, to the mercapturic acid (N-acetylcysteine 
conjugate. In the non-human primate, however, the formation of 
mercapturic acid was not extensive.
Some questions a rise , such as, are a ll the l iv e r  ce lls  (parenchymal, 
non-parenchymal and other), capable of conjugating ethacrynic acid 
with. GSH, and does the metabolism of ethacrynic acid proceed at 
d iffe r in g  rates in various ce ll types? In an attempt to provide 
some of the answers to these questions, isolated ce lls  from various 
tissues ( l iv e r ,  kidney and gastro -in testina l mucosa) were examined 
to evaluate th e ir  respective capacity to metabolise ethacrynic acid.
As mentioned e a r l ie r ,  the liv e r  is an inhomogeneous organ and, 
therefore, isolated hepatic ce ll populations were examined.
Isolated hepatocytes, renal c e lls , and e p ith e lia l ce lls  from the 
gastro -in testina l tra c t are of major importance in studying 
metabolism at the c e llu la r  le v e l, without the physiological 
in teraction of e ith er the whole organ or the whole animal.
There are, of course, some lim itations  on the use of these "cell 
populations", but in most cases they possess some advantages over 
tissue homogenates. In isolated ce lls  the ce lls  themselves control
the synthesis of co-factors (Fry, 1981), and the c e llu la r  structure is  
maintained as a viable u n it.
Tissue s lic e s , i . e .  th in ly  sliced portions of the p a rticu la r organ 
under investigation , have been used fo r a number of years to study 
tissue metabolism. The tissue s lic e  technique was used by Barnes e t a l . 
(1959) and Bray e t a l . (1959), to study the metabolism of 
S-(p-chlorobenzyl )-g lutath ione in the liv e rs  of several species, 
including the guinea pig, ra t and ra b b it, and also the mucosal 
epithelium from the ra t. The use of tissue slices is  to be preferred 
to 'th e  u'sfe of whole ti'ssue homogenate as c e llu la r  disruption is  less. 
Tissue homogenates have been successfully used to study the metabolism 
of the glutathione conjugate of benzylfsothiocyanate (Brusewitz e t a l , 
1977).
• EXPERIMENTAL
Due to the physical size of the major organs, i .e .  l iv e r  and kidney, 
in the non-human primate, f t  was decided that perfusion of the whole 
organ w ith collagenase and hyalurontdase (Seglen, 1972) would require  
the use of large quantities of these enzymes. Therefore, the isolation  
of ce lls  from the non-human primate l iv e r ,  kidney and mucosal 
epithelium was carried out using the methods of Fry (1981), in 
which small portions of sliced tissue are incubated with collagenase/ 
hyalurontdase to lib era te  isolated c e lls . P rior to the removal of 
the organs of in teres t from the non-human primate (baboon) the 
animal was sedated with pencyclidine (Sernylan, Parke Davis U .K .), 
and k ille d  by exsanguination. The abdominal cavity and the chest 
was opened and the decending aorta was located. A 4 mm polythene
cannula was inserted into the aorta and tied  in place with the t ip  
facing away from the heart. The vena cava was then cut and the 
abdominal organs were perfused with ice-cold phosphate-buffered 
saline (PBS) (Chapter 2 ). Perfusion normally took between 5 and 
10 min, a fte r  which: time most of the blood had been removed from the
organs. When the organs appeared pale and "blood-free" the individual
organs, a portion of small in testine  (10-15 cm d ista l to the
Sphincter of Odd!1 was removed and placed in fresh PBS. Tissue 
slices approximately 0 . 2- 0 .4 mm were prepared by placing a small 
portion of the respective organ onto a cold glass plate (4°C) and 
sliced using a m ultiple blade tissue s lic ing  apparatus. The 
apparatus, which was constructed at Huntingdon Research Centre, 
consisted of 12 demountable single edged disposable microtome 
blades (8 cm long[ mounted side by side, with an 0.3 mm spacer 
between each blade. Approximately 2-3 g of l iv e r  could be sliced  
at once, and tissue slices were then washed from the apparatus with 
PBS and placed into small beakers (100 m l). The same technique 
was used fo r the preparation of kidney slices a fte r  the outer 
capsule and the connective tissue of the renal pelvis had been 
removed by dissection, For the preparation of the in tes tin a l 
ep ith ia l c e lls , the mucosal surface was washed with PBS and the 
mucosal layer gently separated from the basal tissue by scraping 
(using a glass microscope s lid e ). The mucosal ce ll layer was also 
cut into thin s lices , but due to its  fra rb le  nature did not produce 
uniform s lices.
For the preparation of isolated hepatocytes, renal ce lls  and ileum 
mucosal c e lls , the tissue slices obtained above were placed in a 
conical flask  (250 ml) and incubated at 37°C fo r 10 min with gentle
agitation (in  a shaking water bath). The ce lls  were allowed to 
s e ttle  and the supernatant care fu lly  removed. This wash procedure 
was repeated twice. A fter the second wash a fresh quantity of PBS 
solution , containing 0.5 mM EGTA, was added to the tissue slices  
and incubated fo r a fu rther 10 min. This stage was repeated using 
fresh EGTA/PBS solution, a fte r  which the PBS/EGTA solution was 
removed and replaced w ith a solution of collagenase/hyaluronidase 
(0.1% and 0.05% respectively! in Hanks buffer (pH 7 .0 ) containing 
glucose. The tissue was incubated with enzyme solution fo r 30-40 min. 
The resulting ce ll suspension was then f i l te re d  through a single  
thickness of bolting c loth . The m aterial passing through the cloth  
was then mixed gently, the v iab le  ce lls  were allowed to s e tt le , and 
the supernatant decanted and replaced with fresh buffer. The ce lls  
were then separated by very low-speed centrifugation ( -  50 g, 1 min). 
This wash procedure was repeated twice. The fin a l ce ll p e lle t was 
resuspended to Liebowitz-L15 medium, to which an tib io tics  and foeta l 
c a lf serum (10%) were added. V ia b ility  of the ce ll preparation 
(usually 80-85%) was established by the a b il ity  of the ce lls  to 
exclude trypan-blue.
Kidney ce lls  were prepared in the same manner as described above, 
although the kidney cells  isolated were much more irreg u la r in shape 
than the hepatocytes. The fin a l suspension of kidney ce lls  were 
expressed in terms of ce ll numbers, but due to the irreg u la r ce ll 
sizes the estimation was inaccurate.
The preparation of small in testine mucosal ce lls  was accomplished by 
a modification of the method of Grafstrom e t a l . (1979). A small 
segment of ileum ( -  10 cm) was flushed through with PBS to remove
residual faecal m atter. One end of the in tes tin a l segment was tied  
o ff and the segment f i l le d  with a solution of Hanks buffered saline  
(pH 7 .5 ) , containing CaCl2 (4 mM), NaHC03 (25 yM), glucose (5 yM), 
heparin (25 i .u . /m l ) ,  0.1% collagenase and 0.05% hyalurontdase, and 
the other end was tie d . The in tes tin a l segments were incubated fo r  
15 min at 37°C. A fter incubation the in tes tin a l segment was opened 
and the solution containing isolated ce lls  poured into a conical 
flas k  and washed (x 2) with, a Krebs-Henseleit medium (pH 7 .4 )  
containing Hepes (25 mM), glucose (5 mM[ and p e n ic illin  (500 i .u . /m l ) .  
The isolated c e lls  had a low v ia b i l i ty  C~ 70-75%) which declined
rapidly (50% v ia b i l i ty  a fte r  1 h]> .
Isolated hepatocytes, and non-parenchymal hepatocytes from ra t l iv e r ,  
were prepared using the methodology developed at the Robens In s t itu te ,  
University of Surrey, and the author g ra te fu lly  acknowledges the help 
of Drs. D. Benford and M. Dobrota in these preparations (Chapter 2 ).
The l iv e r ,  kidney and gastro -in testina l "tissue slices" were incubated 
at 37°C in the suspending medium (5 ml) to which l l fC-ethacrynic acid 
was added. The incubations were continued fa r  30 min, w ith portions 
Cl ml) Being removed at 0, 20 and 30 min a fte r  addition of the 
ethacrynic acid. The tissue fragments were removed by centrifugation  
and the soluble protein was precip itated by the addition of an equal 
volume of sulphosalicylic acid (4% w /v). Aliquots of the p ro te in -free  
supernatant were examined by t . l . c ,  using the solvent system butanol:
acetic acid:water (40:10:50, v/v ) .  The areas of the t . l . c .  plates
corresponding to the positions GSH-EA and Cys-EA were removed and 
the rad io ac tiv ity  measured by liq u id  s c in t il la t io n  spectroscopy.
Isolated ce ll preparations were used to study the conversion of GSH-EA 
into Cys-EA. For these experiments the 35S-labelled glutathione  
conjugate of ethacrynic acid was synthesised. Each ce ll preparation 
(10 ml) contained between 2 and 4 x 106 c e lls /m l, and was incubated 
at 37°C in the presence of 10 yM 35S-GSH-EA. The incubations were 
conducted fo r 30 min, during which time portions (1 ml) were removed 
as 5-min in tervals  and examined fo r the presence of GSH-EA, as 
detailed above.
With one preparation of kidney c e lls , an in h ib ito r of y-GT was also 
added. The in h ib ito r used was DON (see Chapter 4 ) , 'a t  a concentration 
of 5 yM. The liv e r  ce ll preparation was also examined a fte r  the 
addition of methionine (5 yM ).
RESULTS
Liver slices
When l iv e r  slices from 2 baboons (A and B) were incubated with 1£f'C- _ 
ethacrynic acid (5 yM), 2 major radioactive metabolites of ethacrynic 
acid were observed. These metabolites co-chromatographed on t . l . c .  
with the reference glutathione conjugate (GS-EA) and the cysteine 
conjugate (Cys-EA}. A fter 10 min baboon A had metabolised
i
approximately 7% and baboon B 6 .7%  of the ethacrynic acid to Cys-EA, 
with a fu rther 11% and 7% present as GS-EA. A fter 20 min incubation 
the proportions of Cys-EA bad increased to 1T% and 13% respectively , 
with 19% and 14% present as GS-EA. At the end of the experimental 
period (30 min) the respective figures fo r Cys-EA were: A, 23%
B, 19% and fo r GS-EA 18% and 20% respectively (Table 5 -1 ).
Kidney slices
The kidney s lic e s , a fte r  10 min incubation, had metabolised between 
25% and 27% of the I l *C-ethacryntc acid to Cys-EA, with a fu rth er  
7 .3 -9 .6% present as GS-EA. The proportion of GS-EA in the incubating 
medium remained between 3,6% and 5,6.% by the end of the 30-min 
experiment. The corresponding values fo r Cys-EA were 38-42% 
at 20 min, and 51-57% a fte r  30 min (Table 5 -2 ).
In tes tin a l mucosa
The in tes tin a l mucosa metabolised JIfC-ethacrynic acid at an intermediate 
level between the kidney and liv e r . At 10 min a fte r  the addition of 
14C-ethacrynic acid, between 18% and 20% was present as Cys-EA, 
with 8.8-12% as GS-EA. The amount of GS-EA continued to increase 
during the experiment, and the proportions of Cys-EA were between
25-30% (20 min), and between 37-42% (30 min). The
corresponding values fo r GSH-EA were 14-16% (20 min), and 18-
21% (30 min) (Table 5 -3 ). With a ll tissue s lice  incubations,
l i t t l e  (<0.2%) N-acetylcysteine conjugate was detected.
Isolated ce ll preparations
The results presented in Table 5-4 are calculated on the basis o f the 
proportion of 35S-GS-EA converted to Cys-EA during a 30-min incubation 
The results are expressed both in terms of the proportion per 106 ce ll 
and the amounts (nmols) converted to Cys-EA.
The kidney ce lls  were the most active of the ce ll types examined, 
with approximately 40% of the GS-EA being metabolised to Cys-EA.
When the in h ib ito r of y - G T  was present th is  proportion of Cys-EA 
declined to 4.8% during the same time in te rv a l. The in tes tin a l 
mucosa metabolised 9.8%, and the l iv e r  3.3% of the GS-EA during a 
30-min incubation. The liv e r  ce ll preparation, which also contained 
L-methionine. ( 5  yM.) showed that the proportion metabolised had 
increased approximately 2-fo ld  when compared to the hepatocytes*. 
which received no methionine supplement.
The amount of 35C-GS-EA metabolised, calculated in terms of nmols 
of Cys-EA produced per minute, resulted in values of 0 . 12 , 0.01 and 
0.029 nmol/min fo r the kidney c e lls , l iv e r  ce lls  and mucosal ce lls  
respectively. The corresponding ra tio s , when kidney ce lls  = 100, 
were: l iv e r  8.3 and mucosal ce lls  24.2. In the kidney ce ll
preparation, containing DON (the y - G T  in h ib ito r) the value was 11.6.
The. incubations were also examined at 5-min in te rv a ls , and the
proportion of Cys-EA present at each time in terval for kidney c e lls , 
with and without the y-GT in h ib ito r (DON), are given in Figure 5-1.
The conversion of GSH-EA to Cys-EA was approximately lin e a r with 
kidney c e lls . However, in the presence of DON the kidney ce lls  show 
that the conversion was. possibly bi/phasic, with the preparation 
metabolising GS-EA fas te r towards the end of the period of 
incubation (20-30 min). Both l iv e r  and mucosal ce lls  produced 
Cys-EA at an approximately lin ea r rate  (Figure 5 -2 ).
Rat I jy e r  ce ll preparations
The 3 populations of ra t hepatocytes, i . e .  parenchymal hepatocytes, 
non-parenchymal hepatocytes, and the "residual c e lls " , were separately 
incubated fo r 1 h with ltfC-GS-EA. The results showed that the residual 
m ateria l, i . e .  fraction  rich in b ile  duct e p ith e lia l ce lls  and 
c e llu la r  debris, produced the fastest rate of conversion of GS-EA 
to Cys-EA (25% in 1 h ). The parencymal hepatocytes produced 13% 
and the non-parenchymal 8.2% in the same time in terval (Table 5 -5 ).
The rate of formation of Cys-EA in a ll  3 ce ll type Dreparations 
appeared to decline during the incubation, although a lin e a r portion  
occurred in the f i r s t  30 min a fte r  following the addition of the 
GS-EA. The reason fo r th is  observation is not known, the c e llu la r  
v ia h il i ty  at the end of the experimental period showed l i t t l e  change 
(<5%). The "residual cells" were not tested for v ia b i l i ty  using 
trypan blue exclusion.
DISCUSSION
The results support the in vivo observations which indicate that the 
l iv e r  can produce the cysteine conjugate of ethacrynic acid without 
any interorgan exchange of e ith e r the glutathione or cysteinylglycine  
conjugate. In the tissue s lice  experiments, the rate of metabolism 
of ethacrynic acid occurred fas te r in the kidney, where over twice 
the amount of EA was converted to Cys-EA than observed with the l iv e r  
in the same time in te rv a l. In the liv e r  preparation the level o f ’. 
GS-EA produced increased during the experiment, indicating that the 
production of GS-EA occurred a t a fas te r rate than that a f the 
metabolism of the GS-EA to the cysteine conjugate. In the kidney 
the conversion of GS-EA to Cys-EA occurred at a fa s te r ra te , and 
the level GS-EA declined during the experiment. The amount of 
glutathione conjugate produced by the mucosal tissue slices was 
sim ilar to that in the l iv e r ,  although the conversion to the cysteine 
conjugate was greater, which indicated that the to ta l production of 
the glutathione conjugate was greater in the mucosal c e lls . The 
p o ss ib ility -e x is ts  that the production of the cysteine conjugate 
of ethacrynic acid in the l iv e r  could be lim ited  by e ith e r the 
access ib ility  of the enzymes responsible fo r the metabolism of the 
GS-EA, or by various factors which may reduce the metabolic 
capacity of the l iv e r  s lices .
The results of the isolated ce ll preparations support the conclusion 
that kidney ce lls  are better able to metabolise the glutathione  
conjugate of ethacrynic acid than the l iv e r  or the mucosal c e lls .
The concept that the fu rther metabolism of GS-EA is dependent on 
y-GT was c learly  demonstrated by the use of DON as the a c tiv ity  of
kidney ce lls  were only 10% of normal in the presence of th is  y-GT 
in h ib ito r . The reason why methionine produced an increase in the 
metabolism of GS-EA is not known but could be due to stim ulation of 
GSH production. Methionine is known to increase the production of 
glutathione in isolated ce lls  (Reed and Beatty, 1978), which in turn 
could result in higher, a c t iv it ie s  of the enzymes responsible fo r  
glutathione metabolism.
Both parenchymal and non-parenchymal hepatocytes can produce Cys-EA 
from GS-EA, although the major portion of hepatic a c t iv ity  in th is  
respect probably resides in the e p ith e lia l c e lls  of the b ile  ducts. 
I t  is  not known to what extent the isolated non-parenchymal ce ll 
preparation contained c e lls  of th is  type, although the presence of 
b ile  duct lin in g  ce lls  could possibly explain the higher level of 
metabolic conversion of GS-EA to Cys-EA observed with the 
non-parenchymal hepatocyte preparation.
Comparison of the results of the studies reported in th is  thesis
with the results of Moldeus- e t a l . (1978), using the glutathione
conjugate of paracetamol, possibly indicate some species differences
in the metabolism of the glutathione conjugates, Ethacrynic acid
can be metabolised to the cysteine conjugate in both non-human
primate and the ra t ,  although the p o s s ib ility  exists that various
glutathione conjugates are metabolised to a d iffe re n t extent,
dependent on the p articu lar tissue used. As observed with
benzyli'sothiocyanate (Brusewitz e t  a l , 1977), both ra t l iv e r  and
kidney have the capab ility  to metabolise the glutathione conjugate
and th is  would suggest that perhaps the glutathione conjugate of
paracetamol is a typ ica l. This aspect requires fu rth er study using 
several d ifferent glutathione conjugates before any d e fin ite  
conclusion as to the apparent differences in metabolism can be made.
TABLE 5-1
Formation of (a) glutathione conjugate of ethacrynic acid and 
(b) cysteine conjugate of ethacrynic acid by baboon liv e r  s lices  
incubated with ltfC-ethacrynic acid (5 yM]
0 1
O L
TABLE 5-2
Formation of (a) glutathione conjugate of ethacrynic acid and 
(b) cysteine conjugate of ethacrynic acid by baboon kidney slices  
incubated with llfC-ethacrynic acid (5 yM)
(a)
(b)
Sample
Time
10 min 20 min 30 min
Baboon A ( i ) 8.6 8.0 5.3 '
( n ) 7.3 7.6 5.6
Baboon B ( i ) 9.6 7.9 4.3
( 11) 8.9 6.7 3.6
Baboon A ( i ) 27.1 40.3 57.2
( 11) 26.6 41.7 55.3
Baboon B ( i ) 24.8 39.2 56.2
( 11) 25.1 37.5 51.3
Sample
Time
10 min 20 min 30 min
Baboon A ( i ) 11.1 19.6 23.4
( I D 11.6 18.4 21.9
Baboon B ( i ) 6.2 13.2 18.7.
( 11) 7 .8 13.9 19.7
Baboon A ( i ) 7.2 11.1 18.2
( 11) 6.8 11.5 17.2
Baboon B ( i ) 6.4 12.1 19.8
( 11) 7.1 14.2 20.6
TABLE 5-3
Formation of (a) glutathione conjugate of ethacrynic acid and 
(b) cysteine conjugate of ethacrynic acid by baboon ileum mucosa 
incubated with 14C-ethacrynic acid (5 pM)
Sample
Time
10 min 20 min 30 min
Baboon C ( i )
( i i )
12.2
11.5
16.3
15.5
21.4
20.2
Baboon D ( i )
(H )
9.0  
. 8.8
14.2
14.7
18.6
17.9
Baboon C ( i )  
( ” )
18.4
19.6
29.7
30.2
42.1
40.8
Baboon D ( i )  
( 11)
17.9
17.8
26.4
24.9
38.2
37.2
TABLE 5-4
Formation of the cysteine conjugate of ethacrynic acid by isolated  
cells  from various baboon tissues incubated with 35S-glutathione 
conjugate of ethacrynic acid.
Tissue
Cysteine conjugate of 
ethacrynic acid Ratio to 
kidney
%/106 c e lls * nmols nmol s/min
Ki dney 40.1 3.59 0.12 100
Kidney + DON 4.8 0.43 0.014 11.6
Liver 3.3 0.30 0.010 , 8.3 .
Liver *  Methionine (5 6.1 0.55 0.018 15.0
Ileum mucosa 9.8 0.88 0.029 24.2
*  % of 35S-glutathione-ethacrynic acid conjugate formed in 30 min 
incubation.
FIGURE 5-1
Formation of the cysteine conjugate of ethacrynic acid from 
35S-glutathione conjugate of ethacrynic acid by isolated kidney 
ce lls  • ,  and kidney ce lls  incubated in the presence of DON a . 
35S-glutathione conjugate of ethacrynic acid added at time 0. 
Cells prepared from baboon tissues.
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Time (min) a fte r addition of 35S-GS-EA
FIGURE 5-2
Formation of the cysteine conjugate of ethacrynic acid from 
35S-g1utathione conjugate of ethacrynic acid by isolated liv e r  
ce lls  a ,  and isolated ileum mucosal ce lls  • .
35S-glutathione ethacrynic acid conjugate added at time 0. 
Cells prepared from baboon tissues.
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TABLE 5-5
Formation of the cysteine conjugate of ethacrynic acid by isolated  
l iv e r  ce lls  -  parenchymal, non-parenchymal and residual ce lls  
obtained from ra t l iv e r .
Cells (2 x 106/m l) incubated with the glutathione conjugate of 
14C-eth.acrynic acid (10 yM).
Time Cell population
(min) Parenchymal Non-parenchymal Residual c e lls *
10 4.5 2.2 6.8
20 7.2 4.3 11.2
30 8.9 6.5 16.0
45 11.0 7.6 21.2
60 13.4 8.2 25.2
* Residual ce lls  mainly composed of duct c e lls ,  
connective tissue and tissue fragments.
CHAPTER 6
THE ENZYMES OF MERCAPTURIC ACID SYNTHESIS 
INTRODUCTION
The trip ep tid e  glutathione (GSH; y-L-glutam yl-L-cysteinylg lycine) is 
the major non-protein th io l in most ce lls  of higher animals. GSH 
partic ipates in many reactions within the c e l l ,  and as fa r  as the 
subject of th is  thesis is  concerned, the detoxication of xenobiotics. 
This detoxication process occurs by mercapturic acid biosynthesis 
(Boy!and and Chasseaud, 1969}. The in i t ia l  step in the formation of 
a mercapturic acid is the conjugation of an e lec tro p h ilic  xenobiotic 
with the sulphur atom of the endogenous nucleophile GSH. This 
conjugation is  usually catalysed by the glutathione S-transferase  
(EC 2 .5 .1 .1 8 ). The presence of several glutathione S-transferase 
isoenzymes has been demonstrated in the tissues of higher animals 
(Pabst e t a l , 1973; Askelof e t a l , 1975; Kamisaka e t a l , 1975;
Asaoka et a l , 1977}.
In any p articu la r species the re la tiv e  abundance of each of the 
isoenzymes may vary with the p articu la r organ or tissue examined,and 
in an individual tissue a p articu la r isoenzyme may be absent 
(Guthenberg e t a l , 1983 a,b; Hales et a l , 1978). Many of the 
isoenzymes have a broad and overlapping s p e c ific ity  fo r a range of 
substrates, i . e .  l-ch loro-2,4-din itrobenzene. However, some compounds, 
fo r example menaphthyl sulphate, seem to be substrates for a single or 
a very restric ted  number of the isoenzymes.
I t  is reported that organs or tissues lik e ly  to be exposed to 
xenobiotics, or th e ir  "activated" metabolites, contain re la tiv e ly  
high levels of the glutathione S-transferases, prim arily  operating 
as a detoxication system. Such organs would be those at "portals" 
of entry of xenobiotics into the body, such as the g astro -in testina l 
t ra c t , l iv e r ,  or lungs. The present study was designed to examine 
concentrations of glutathione, and the a c tiv it ie s  of the glutathione  
S-transferase isoenzymes in various organs or tissues of non-human 
primates. The tissues examined were prim arily  the tissues which 
could be involved in the in i t ia l  exposure or subsequent excretion of 
xenobiotics, i . e .  l iv e r ,  kidney, lungs and gastro -in testina l tra c t  
(stomach, ileum and colon). For comparative purposes, the a c t iv it ie s  
of the glutathione S-transferases present in the soluble fractions of 
the same tissues obtained from the ra t ,  and those present in the 
soluble fraction  of human liv e r  were measured. Whilst there are 
numerous reports of glutathione S-transferase a c t iv ity  in ra t tissue  
(fo r a review see Chasseaud, 1979), re la tiv e ly  l i t t l e  has been 
published concerning such a c tiv ity  in the non-human primates.
The immunological s im ila r ity  between the human and non-human primate 
glutathione S-transferase was also examined using an antibody raised 
against purified  human basic transferases.
Investigations with the microsomal glutathione S-transferases of 
non-human primate and the ra t are detailed elsewhere in th is  thesis  
(Chapter 7 ).
Glutathione, in addition to its  reactive sulphydryl group, also 
contains a y-glutamyl moiety linked to the cysteinylglycine through
a peptide bond. As stated e a r l ie r ,  th is  bond is the s ite  of action 
of y-glutamyltranspeptidase (y-GT; EC 2 .3 .2 .2 ) .  The removal of the 
y-glutamyl residue from the glutathione conjugate of a xenobiotic 
compound, results in the formation of the respective S-cysteinylglycine  
conjugate. The y-glutamyl group is transferred e ith er to an acceptor 
molecule (amino acid or peptide) or to water. y-GT is also responsible 
fo r the catabolism of glutathione i t s e l f ,  and thus assists in the 
regulation of in tra c e llu la r  sulphydryl concentrations. /
As observed w ith the glutathione S-transferases, y-GT is  widely 
distributed in animal tissues, al-though the actual s ite  of location  
d iffe rs  (Meister et a l , 1976). In general, the highest levels o f 
y-GT have been observed in tissues with an active secretory or 
absorptive function such as the e p ith e lia l ce lls  of the b ile  duct, 
jejunum, lung and renal tubules, as well as the hepatic c a n ilic u li -
(Meister e t a l , 1976).
Following the action of y-G T , the resultant cysteinylglycine conjugate 
can be fu rther cataboltsed by a specific  dipeptidase to y ie ld  the 
corresponding S-cysteine conjugate (Stetson, 1975). This enzyme, 
in common with y-G T , has also been located in both the brush border 
and plasma membranes of the kidney and in tes tin a l mucosal c e lls .
The fin a l enzyme involved in the formation of a mercapturic acid 
( i . e .  an N-acetyl cystei ne conjugate), N-acetylates the cysteine 
conjugate produced as detailed above. The N-acetyltransferase is a 
microsomal, acetyl CoA dependent, enzyme (Green and Elce, 1975).
The enzyme is present in both the liv e r  and kidney of rats as shown 
by the tissue s lice  incubation experiments of (Bray et a l , 1959).
The same tissues which were used to study the glutathione S-transferases 
were examined fo r y -G T , dipeptidase, and N-acetyltransferase a c tiv ity  
in order to elucidate the completeness of mercapturic acid biosynthesis 
in p a rticu la r organs or tissues in the non-human primate, in comparison 
with the ra t.
EXPERIMENTAL
Tissues were removed from individual animals as soon as possible a fte r  
death (w ithin 5 min), and placed in ice-cold phosphate buffer . . 
(0.1 M^, pH 7 .4 ). The homogenisation of each tissue was carried out 
as detailed  in the main methods section (Chapter 2 ). Due to the 
membrane lo ca lisation  of some of the enzymes, the assay fo r both y-GT  
and dipeptidase were conducted using whole (uncentrifuged) homogenates. 
The GSH concentration was also estimated in whole homogenates using 
the 5,5-dith iobis-C 2-nitrobenzoic ac id ) (DTNB) reagent of Ellman (1959). 
Glutathione S-transferases were measured in the soluble (c e ll supernatant) 
frac tio n , w hilst N-acetyltransferase a c tiv ity  was determined in the 
respective microsomal fractions.
The immunological id e n tity  of the glutathione S-transferases present 
in various tissues of the non-human primate with those of the human 
basic transferases was investigated using the double immuno d iffusion  
technique of 0uchterlony.(1958). Antibodies to the human basic glutathione 
S-transferases, raised in the rab b it, were a generous g i f t  from 
Dr. B. Mannervik, Department of Biochemistry, Arrhenius Laboratory, 
University of Stockholm, Sweden.
Enzyme assays
The fu l l  experimental procedures are given in Chapter 2, but b r ie f ly  
the a c tiv ity  of y-GT was determined by measuring the production of 
p -n itro an ilin e  from the substrate y-g lu tam yl-p -n itroan ilide  (Meister e t a l, 
1981), and cystetnyldipeptidase a c t iv ity , by the release of 
p -n itro an ilin e  from S -benzylcyste inyl-p -n itroan ilide  (Hughey, 1978) 
both at 37°C. The p -n itro an ilin e  produced was quantified by 
spectrophotometry at 410 nm.
Glutathione S-transferase a c t iv ity  towards the several substrates 
was measured using the substrates and conditions indicated in the 
tab le .
Conditions used fo r the assay of glutathione S-transferases
Substrate
(abbreviation)
Concentration
(mM)
Molar extinction  
co e ffic ie n t  
(mM”1 cim l) a t 
wavelength 
ind icated**
1-C hioro-2 ,4-d in i trobenzene (CDNB) 1.0 9.6 340
1,2-Dichloro-4-nitrobenzene (DCNB) 5.0 8.5 345
Ethacrynic acid CEAi 0.2 5.0 270
Diethyl maleate (DEM) 5.0 *
trans-4-Phenyl-3-butene-2-one (t-PBO) 2.0 *
Cyclohex-2-en-l-one (CHO) 3.0 *
1,2 Epoxy-3-(p-nitrophenoxy)_propane (ENPP) ........5.0 0.5 360
GSH was present in a ll  assays at an equimolar concentration to the second 
substrate used, with the exception of the assays with ethacrynic acid 
where GSH concentration was 0.25 mM.
*  Reaction with these substrates was determined by calculating the to ta l 
th io l reacted a t the end of the incubation period from measurement of 
residual unreacted GSH using the DTNB reagent (Ellman, 1959).
* *  Values taken from Habig et a l . (1974).
The a c tiv ity  of the microsomal N-acetyltransferase present in various 
tissues was measured by the method of Green and Elce (1975) using 
benzyl-L-cysteine (100 mM) and 1^C-acetyl CoA (100 mM). The 
radioactive N-acetyl deri va ti ve was extracted with ethyl acetate and 
quantified by liq u id  s c in t il la t io n  counting.
RESULTS
Tissue glutathione
As has been observed with most mammalian species, glutathione (GSH) 
was present in concentrations of between 1.6 and 6.8 mM in the various 
organs and tissues obtained from the 3 non-human primate species 
studied. Among the tissues and organs examined, in each species the 
l iv e r  contained the highest concentration of GSH except fo r the eye 
(len s). The concentration of GSH in baboon liv e r  was 6.8 mM, s lig h tly  
more than that (6 .2  mM) in the liv e r  of the cynomolgus monkey, and 
that (6.1 mM) in the l iv e r  of the rhesus monkey. There was no notable 
difference in the concentration of GSH between these species. The 
concentration of GSH in the gastric  mucosa was between 4.5 and 4.9 mM 
fo r a ll  the non-human primates studies, and exceeded those found in  
the kidneys of the same animals (3 .4 -3 ,8  mM). Concentrations of 
glutathione in the remainder of the gastro -in testina l tra c t showed 
a gradual decrease in concentration from duodenum to ileum to colon.
In the gastro -in testina l tra c t there were no notable species 
differences in the GSH concentrations, although those in the 
cynomolgus monkey were m arginally greater (Table 6 -1 ). Other organs 
examined were testes, pancreas, spleen, heart and eye (le n s ), and 
with the exception of the eye (le n s ), possessed concentrations of 
GSH between 1 .8 -2 .8  mM. In the eye (le n s ), of the 2 non-human 
primates examined, the concentrations of glutathione were 6.9 and 
6.3 mM in rhesus monkey and baboon, respectively (Table 6 -1 ), and 
sim ilar to those in the corresponding liv e r
Glutathione S-transferases (GS-transferases)
The a c tiv it ie s  of the GS-transferases present in the soluble fractions
(cytosol) obtained from various tissues of ra t and non-human primates 
are given in Tables 6-2 to 6-8 . A ll figures are expressed in the tex t 
as mU/mg, th is  is nmol .min“l .mg protein"^.
1-C hioro-2,4-d i ni trobenzene (CDNB)
Table 6-2 shows the a c tiv it ie s  of the glutathione S-transferases 
towards 1-chioro-2,4-dinitrogenzene (CDNB). In the tissues obtained 
from the ra t ,  the l iv e r  had the highest level of a c t ic ity  (613 mll/mg) 
with the mucosal ce lls  of the stomach and the ileum containing 160 and 
157 mU/mg respectively. The gastro -in testina l mucosal preparations 
contained approximately twice the a c tiv ity  measured in the kidney 
cytosol, w h ils t the lung contained 56 mU/mg. The a c tiv it ie s  of the 
GS-transferases towards CDNB in the l iv e r  samples of the various 
species of non-human primate examined, were between 4 and 5-times 
higher than that observed in ra t l iv e r . No s ig n ific an t differences  
in hepatic GS-transferase a c t iv ity  were observed between the various 
primate species. The mean hepatic GS-transferase a c t iv it ie s  were, 
rhesus 2552 mU/mg, baboon 2849 mll/mg, cynomolgus 3052 mU/mg. The 
next most active tissue in the rhesus monkey was the mucosal cytosol 
obtained from the ileum (498 mU/mg), the kidney cytosol was s lig h tly  
less active (384 mU/mg), Contrary to the results obtained in the 
r a t , the a c tiv it ie s  of the GS-transferases towards CDNB were 
s ig n ific a n tly  lower in the stomach mucosa (264 mU/mg) than the 
ileum mucosa (498 mll/mg).. The respective values fo r the GS-transferase 
a c tiv it ie s  in the other tissues of the rhesus monkey assayed were, 
lung 258 mU/mg and colon 77 mU/mg. The GS-transferase a c tiv it ie s  
measured in the baboon tissues were marginally lower in the kidney 
(277 mU/mg) and lung (171 mU/mg) when compared to the rhesus monkey 
(384 and 258 mU/mg resp ective ly ). The GS-transferase a c t iv it ie s
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towards CDNB measured in the various portions of the gastro -in testina l
tra c t mucosa were not s ig n ific a n tly  d iffe re n t from those of the rhesus
monkey. The results obtained in the various tissues obtained from the
cynomolgus monkey were, in general, s im ilar to those of the rhesus
monkey, although the liv e r  GS-transferase a c tiv ity  was s lig h tly  higher, 
3052 mU/mg (c f. 2552 mU/mg).
1 ,2-Dichloro-4-nitrobenzene (DCNB)
The a c tiv it ie s  of the glutathione S-transferases towards DCNB in ra t 
tissues were highest in the l iv e r  36,1 mU/mg, and the a c tiv it ie s  in 
the stomach and ileum mucosa were 3.5 mU/mg and 6.9 mll/mg respectively. 
The kidney, lung and colon had a c tiv it ie s  of 3 .2 , 2.8 and 1.6 mll/mg 
respectively (Table 6 -3 ).
In the various tissues obtained from the non-human primate, the 
a c tiv it ie s  of the glutathione S-transferases towards DCNB were lower 
than those observed in the ra t. The a c tiv ity  in the l iv e r  of the 
rhesus monkey was s ig n ific a n tly  higher, 24 mU/mg, than e ith e r of the 
other 2 non-human primates (14 and 16 mll/mg respective ly). In the 
ra t the GS-transferase a c tiv ity  in the ileum towards DCNB was 
approximately twice that in the kidney, whereas in the non-human 
primate such a c tiv it ie s  were s im ilar.
Ethacrynic acid (EA)
In the ra t both the renal cytosol and the ileum mucosa cytosol contained 
s lig h tly  greater GS-transferase a c tiv it ie s  (25 and 24 mll/mg respectively) 
towards EA than the liv e r  (20 mU/mg). The remaining tissues of the 
ra t examined contained the following GS-transferase a c t iv it ie s ,  
lung 16.7, stomach 11.5 and colon 3,2 mll/mg (Table 6 -4 ). No 
s ig n ifican t difference in the a c tiv it ie s  of the GS-transferases
towards ethacrynic acid were observed between any of the individual 
tissue obtained from the 3 primate species examined. In a ll primates 
the GS-transferase a c tiv ity  in the liv e r  (10-13 mU/mg), was s ign ifican tly  
higher than the a c tiv ity  in the kidney (5 .8 -9 .1  mU/mg). The highest 
levels of GS-transferase a c tiv ity  in the gastro -in testina l tra c t  
mucosa examined in the non-human primate were found in the ileum 
(7 .2 -8 ,3  mU/mg). The colon mucosa had low levels (0 .9 -1 .1  mU/mg) of 
GS-transferase a c tiv ity .
Diethyl maleate (DEM)
In the ra t , GS-transferase a c tiv ity  towards DEM was highest in the 
l iv e r  100.8 mU/mg, and a c tiv it ie s  in ileum mucosa were 86.5 mU/mg, 
kidney 56.9 mll/mg, stomach mucosa 50.5 mU/mg, lung 40.5 mll/mg and 
colon mucosa 28,9 mU/mg.
In the tissues from the non-human primates, a c t iv it ie s  were considerably 
lower: those measured in the various tissues obtained from the rhesus 
monkey were l iv e r  39.2 mll/mg, iluem 21,5 mU/mg, kidney 12.9 mll/mg, 
lung 10.2 mll/mg, stomach 9.7 mll/mg and the colon mucosa 6.2 mll/mg.
In the baboon, the hepatic GS-transferase a c t iv ity  with DEM (30.2 mll/mg) 
was s ig n ific a n tly  lower than that in rhesus monkey (Table 6 -5 ).
trans-4-Phenyl-3-butehe-2-one (t-PBO)
Hepatic cytosol from the ra t had the highest GS-transferase a c t iv ity  
towards t-PBO (44.0 mU/mg}, w h ils t that in the ileum was approximately 
50% less (22.8 mU/mg). Other tissues e ith er had lower levels of 
GS-transferase a c t iv ity , i . e .  kidney 5.2 mU/mg, lung 4.0 mll/mg, or 
the a c tiv it ie s  were below the lim it  of detection (stomach and colon).
The various tissues obtained from the non-human primates had levels  
of GS-transferase a c tiv ity  which were s im ila r, 4 -7 .2  mU/mg, in a ll  
tissues examined,with the exception of those of the ileum mucosa 
(10.0 mll/mg) and kidney (9 .0  mll/mg) of the rhesus monkey.
Cyclohex-2-en-l-one (CHO)
With th is  substrate, there was a marked species difference in 
GS-transferase a c tiv ity  (Table 6 -7 ], In the l iv e r  of the non-human 
primate, GS-transferase a c tiv ity  towards CHO was less than 2% of 
that in ra t hepatic cytosol. No measurable a c tiv ity  was detected in 
e ith er the kidney or ileum mucosa of the non-human primate (c f. ra t  
329 mU/mg and 194 mU/mg resp ec tive ly ).
1 ,2-Epoxy-3-(p-nitrophenoxy)propane (ENPP)
The respective a c tiv it ie s  of the GS-transferases towards ENPP in the 
l iv e r ,  kidney and ileum mucosa of the ra t were 8 .6 , 4.8 and 2.6 mU/mg.
In both the rhesus monkey and the baboon, the a c tiv it ie s  
towards ENPP were lower ( l iv e r  1.8 and 2.6 mll/mg, kidney 1.7 and 2.3 
mU/mg, and ileum 1.0 and 1.4 mU/mg respectively) (Table 6 -8 ),
Immunological id en tity
The results obtained with the double immuno-diffusion experiments 
indicated that there was a good degree of s im ila r ity  between the 
cytosolic GS-transferases of the 3 species of non-human primates 
studied and man. Of the tissue cytosols examined, the l iv e r ,  kidney, 
stomach mucosa and ileum mucosa of both the baboon and rhesus monkey 
produced notable p rec ip itin  lines . The samples of duodenal cytosol 
did not react (rhesus) or resulted in a doubtful positive reaction  
(baboon). The l iv e r  cytosol preparations from 2 cynomolgus monkeys
were also examined, and in both cases a positive reaction was obtained 
(Figure 6 -1 ). In contrast, no reaction was observed with ra t or mouse 
hepatic cytosol fractions.
Human 1iver GS-transferases
The results in Table 6-9 show the data obtained fo r the a c tiv it ie s  of 
the GS-transferases present in human liv e r  cytosol towards various 
e lec tro p h ilic  substrates. The group of substrates studied were the 
same as used to measure the non-human primate GS-transferase a c tiv it ie s  
and assayed under identical conditions. The a c t iv it ie s  of human l iv e r  
GSrtransferases towards the halogenated nitrobenzenes were lower than 
those observed in non-human primate l iv e r . A c tiv it ie s , when CDNB was 
the second substrate, were 993 mU/mg 6  and 763 mll/mg ?, and the 
a c tiv it ie s  were 3.2 mll/mg <J and 4 mll/mg ? when DCNB was used. 
GS-transferase a c tiv ity  towards the ag-unsaturated d iu re tic  ethacrynic 
acid (3 ,0  mU/mg $  and 3.4 mll/mg ?) was approximately 30% that in the 
hepatic cytosol of the non-human primates. The same proportion of 
a c tiv ity  was observed towards diethyl maleate (10.6 mll/mg and
11.4 mU/mg ? ). GS-transferase a c tiv ity  measured towards the other 
ag-unsaturated compounds in the human liv e r  was s im ilar to that in 
non-human primate l iv e r  with respect to trans-4-phenyl-3-butene-2-one  
but there was no detectable a c tiv ity  towards cyclohex-2-en-l-one, and 
very l i t t l e  GS-transferase a c t iv ity  towards the epoxide l,2 -epo xy-3- 
(p-nitrophenoxy)propane.
The enzymes of glutathione S-conjugate metabolism 
Once the glutathione conjugate of an e lec tro p h ilic  compound has been 
produced, metabolism to produce a mercapturic acid (an N-acetylcysteine  
conjugate) proceeds via the loss of both the v-glutamyl and glycine
m oieties, followed by N-acetylation of the resu ltant cysteine conjugate. 
The results obtained (Table 6-10) show that in the non-human primate, 
the kidney contained the highest a c t iv ity  of y-glutamyltranspeptidase, 
398-505 mU/mg (18-23% of the ra t renal a c t iv ity ) .  y-GT a c tiv it ie s  
in non-human primate l iv e r  was 42 to 74 mU/mg, which was 3 to 5 -fo ld  
higher than that in ra t l iv e r . In the ra t a c t iv it ie s  of y-GT in the 
in tes tin a l mucosa, (111, 136 and 60 mU/mg) in duodenum, ileum and colon 
respectively were higher than those of ra t l iv e r  (14 mU/mg), whereas 
in the non-human primate the a c tiv it ie s  were lower than those o f the 
corresponding l iv e r .
Measurement of cysteinlyglycine dipeptidase a c tiv ity  in ra t tissues 
showed that ra t kidney (26 mU/mg) had higher a c t iv ity  than the ileum 
mucosa (15 mll/mg) and liv e r  (5 mll/mg) (Table 6 -11). The a c t iv ity  in 
kidney of non-human primates was between 12 and 17 mll/mg, w h ils t that 
of the liv e r  was lower (3 .6  to 4.7 mll/mg). Mucosa from the ileum of 
non-human primates contained approximately 50% (baboon and rhesus 
monkey) of that of the ra t ileum (14.7mll/fng), although the cynomolgus 
monkey was lower (28%). No detectable a c tiv ity  of e ith e r y-GT or 
cysteinylglycine dipeptidase was obtained in the gastric  mucosa of 
the species examined.
The a c t iv ity  of microsomal N-acetyltransferase was highest in the 
kidney of a ll species examined; ra t kidney contained 31.3 mU/mg.
The respective a c tiv it ie s  measured in the.rhesus monkey, baboon and 
cynomolgus monkey were 19.6, 22.7 and 23.8 mU/mg respectively. The 
a c tiv ity  of N-acetyltransferase in ra t l iv e r  was approximately 30% 
of that in ra t kidney, which was s im ilar to the proportion in the 
hepatic microsomes of the non-human primates (22-30%). The duodenal
and ileum mucosa samples from rats contained a c tiv it ie s  of 6.4 and 
5.0 mU/mg respectively. S lig h tly  lower levels of N-acetyltransferase  
a c tiv ity  were observed in in tes tin a l mucosa preparations in the 
non-human primate. Low levels of microsomal N-acetyltransferase  
a c tiv ity  were measured in the colon mucosa, w h ils t no detectable 
a c tiv ity  was found in the gastric  mucosa in a ll the species examined 
(Table 6 -12).
DISCUSSION
Glutathione
Glutathione (GSH) was present at concentrations between 1.6 mM and 
6.8 mM in a ll the tissues of the 3 non-human primate species examined. 
The highest level of GSH measured in any tissue was recorded in the 
eye lens ( 6 .8 'mM), and'this is in general agreement with the high 
levels of GSH present in the eye lens of other mammalian species 
(Saneto, 1980), where GSH serves to maintain the transparency of the 
lens (Bellows and Shoch, 1950; Kinoshita and Masurat, 1957). 
Concentrations of GSH. in the l iv e r  and kidney of the non-human 
primates studied were rhesus 6 .1 , 3 .6 , baboon 6 .8 , 3 .8 , and cynomolgus
6.4 and 3.4 mM. These values in the d iffe re n t primate species are 
very s im ilar. The mean k idney:!iver GSH concentration ra tio  was 
0.56. Values of this ra tio  in the ra t were 0.36-0.57 (Jocelyn,
1959), 0.59 (Waelsch, 1952) and 0.41 (Akerboom and Sies, 1981), 
in the mouse 0.58, and in the' hamster 0.34 (Heinonenand Vainio, 1980).
The various portions of the gastro -in testina l tra c t examined in the 
current study had concentrations of GSH between 1.8 and 4.9 mM; 
highest in the mucosal cells  of the stomach in a ll non-human primate 
species (4 .5 -4 .9  mM). Concentrations of GSH apparently decreased 
with increasing distance from the stomach along the remainder of 
the in tes tin a l t ra c t , perhaps re flec tin g  a diminishing need fo r GSH. 
Representative values of 2.2 and 1.9 mM were obtained in the mucosa 
of the terminal ileum and colon mucosa respectively.
The re la tiv e ly  high levels of GSH which are present in the gastro-
in tes tin a l t ra c t , p a rtic u la rly  in the stomach, of the non-human primate 
may be there to serve in the immediate detoxication of many exogenous 
compounds. Boyd e t a l . (1977) has shown that the stomach mucosa of 
the ra t contains high levels of GSH (6 .8  mM), which were >94% of the 
corresponding hepatic concentrations. This may be interpreted as 
providing a f i r s t  lin e  of defence against the toxic effects  o f  ingested 
xenobiotics (Boyd et a l , 1979),
The concentrations of GSH in the lung of non-human primates were 
between 1.7 and 2.2 mM, which are s im ilar to the values reported by 
Waelsch (1952) fo r the ra t (1 .0 -2 .3  mM). The studies of Moron e t a l . 
(1979), where glutathione S-transferase was used to quantitate the GSH 
present in lung samples, yeilded s im ilar values, although they draw 
attention to the problems caused by comparing the concentrations of 
GSH expressed in terms of the wet weight of tissue examined in 
morphologically d iss im ilar tissues.
Glutathione concentrations in other tissues of the rhesus monkey and 
baboon were measured (testes , pancreas, heart and spleen), and the 
concentrations found were approximately 2 mM. Concentrations of GSH 
in heart tissue were s im ilar to those reported by Harisch and Mahmoud (1980), 
although the GSH content of the spleen of the non-human primate was 
lower than that in the ra t (3 .3  mM) (Jocelyn, 1959).
Thus, i t  can be concluded that the tissues of the non-human primate, 
which are most l ik e ly  to be e ith er the in i t ia l  or main point of 
contact fo r ingested or inhaled xenobiotics, or are at the s ites of 
metabolic ac tiva tio n , contain concentrations of GSH s u ffic ie n t to 
provide a normal amount of protection. The levels of GSH in these
tissues are such that the glutathione S-transferases should also 
function e ff ic ie n tly ,a s  the concentration of GSH would be a t,o r  near, 
saturating levels .
Glutathione S-transferases
In the investigation of the tissue d istrib u tio n  of the isoenzymes 
of the glutathione S-transferase system (GS-transferases), several 
substrates were used in order to provide an overall picture of the 
detoxication capacity of each tissue examined. The results of the 
enzyme assays reported in the lite ra tu re  are d i f f ic u l t  to compare 
d ire c tly -w ith  the present data, due to the range of m olarity (1-10 mM.), 
fo r e ith e r GSH or the second substrate (e lectro ph ile ) used, and the 
temperature (20-37°C) and pH at which the enzyme assay has been 
conducted.
The halogenonitrobenzene substrates, 1-chioro-2,4-dinitrobenzene (CDNB) 
and 1 ,2-dichloro-4-nitrobenzene (DCNB) were chosen because the former 
has become the "universal substrate" fo r the glutathione S-transferase  
isoenzymes, and i t  is  the substrate most often used to monitor 
GS-transferase p u rifica tio n  procedures. A cautionary note is  that 
ra t transferase 5-5 (Jakoby, 1984; Transferase E) has a very low 
a c tiv ity  towards CDNB. DCNB was also used, as i t  has provided a means 
of p a rtia l d iffe re n tia tio n  of GS-transferase isoenzymes, because 
transferases 3-3 and 3-4 are p a rtic u la rly  active towards th is  substrate 
previously called transferases A and C respectively (Jakoby, 1984).
1-ChiOro-2,4-dinitrobenzene (CDNB)
The a c tiv it ie s  ofthe GS-transferases in the liv e r  of the non-human 
primates towards CDNB as the substrate were several-fo ld  (4 -5) higher
than those obtained with ra t l iv e r  (613 mll/mg). Several research 
groups have reported s im ilar values fo r the GS-transferase a c tiv ity  
against CDNB in ra t liv e r  cytosol, fo r example, Guthenberg e t a l .(1980) 
930 mll/mg, Dogra et a l . (1982) 574 mll/mg, Meyer e t a l . (1983) 950 mU/mg, 
Oesch et a l . (1983) 964 mU/mg, Kraus and K1 o ft (1980) 307 mll/mg, and
Baars et a l . (1981) 708 mU/mg.
Summer and Greim (1981). in a comparative study of the rhesus monkey 
and ra t ,  lim ited  to hepatic subcellular frac tio n s , reported much 
greater a c t iv ity  in ra t l iv e r  (1826 mU/mg) and correspondingly higher 
a c tiv ity  (6482 mll/mg} fo r the rhesus monkey hepatic “S100" cytosol 
fraction  than the results shown in Table 6-2 . This represents a
rhesus monkey l iv e r : r a t  l iv e r  ra tio  of 3 .5 :1 , which is ,  however,
s im ilar to that obtained during the current investigation.
Using CDNB as the substrate, ra t kidney GS-transferase a c t iv ity  was 
only 14% (86 mU/mg) of that in the liv e r . This proportion was s im ilar  
to the results of Chasseaud and Down (1982, unpublished data). Several 
groups have reported kidney GS-transferase a c t iv ity  to be approximately 
10% of the hepatic level (Baars et a l . (1981); Oesch et a l . (1983);
Kraus and K lo ft (1980)}. C lifto n  and Kaplowitz (1978) reported that 
the renal a c tiv ity  was 5% of the hepatic a c t iv ity . As observed with  
the hepatic cytosol, the primate renal cytosolic GS-transferase 
a c tiv ity  towards CDNB were 3.5 to 4.5-fold higher than that in ra t renal 
cytosol preparations (rhesus 384, cynomolgus 366 and baboon 277 mU/mg).
The a c tiv it ie s  of the GS-transferases of the mucosa of the gastro­
in tes tin a l tra c t in the ra t were stomach 160, ileum 157 and colon 35mU/mg. 
Thus, both the stomach and ileum a c tiv it ie s  were higher than the
a c tiv ity  measured in ra t kidney (86 mU/mg). These results are in 
general agreement with those of C lifto n  and Kaplowitz (1978) who 
studied various portions of ra t ileum and colon. Baars et a l . (1981) 
reported GS-transferase a c tiv it ie s  in the ileum and colon which were 
both below those in the kidney, although Baars et a l . (1981) also 
reported that the a c tiv ity  in the gastric  mucosa was higher (40 mll/mg) 
than that in the ileum mucosa (29 mU/mg), which in turn was higher 
than that in the colon (34 mll/mg).
In the non-human primates, GS-transferase a c tiv ity  in the mucosa of the 
• ileum was 496-508 mU/mg, which w§sf.somewhat higher than in the gastric  
mucosa (251-266 mU/mg).
The mucosal ce lls  obtained from the colon of each of the non-human 
primate species studied had the lowest values of a ll the parts o f the 
gastro -in testina l tra c t examined when CDNB was used as substrate (77- 
90 mll/mg).
The results obtained fo r the GS-transferase a c tiv it ie s  in various 
portions of gastro -in testina l t ra c t , p a rtic u la rly  the stomach, probably 
p ara lle l the differences in the dietary exposure to exogenous compounds 
that occur between rodents and non-human primates.
1 ,2-Dichloro-4-nitrobenzene (DCNB)
The second halogenonitrobenzene substrate used in the current 
investigation was 1,2-dichloro-4-nitrobenzene (DCNB). In the ra t ,
DCNB has been reported to be the preferred substrate fo r e ith e r the 
homodimertc GS-transferase isoenzyme 3-3 (Transferase "A", Habig e t a l , 
1974) or the heterodimeric glutathione S-transferase isoenzyme 3-4
(Transferase "C", Habig e t a l , 1974).
The re la tiv e  a c tiv it ie s  of the glutathione S-transferases towards DCNB 
as substrate in the various tissues of the ra t were s im ilar to those 
previously reported with the liv e r  possessing the highest level 
(31.6 mU/mg). The next most active tissue was the mucosa of the 
small in testine  (ileum 7.0 mll/mg). The GS-transferase a c tiv it ie s  
present in the cytosolic fractions of the kidney, lung and stomach 
were s im ilar 3 .2 , 2.8 and 3.5 mU/mg respectively, w hilst the colon 
mucosa was the least active of the tissues examined. In the lite ra tu re  
the absolute values reported fo r the hepatic G S -transferase.activ ity  
towards DCNB are rather variab le , due to the numerous assay conditions 
used. C lifton  and Kaplowitz (1978) reported values some- 2 to 3-times 
higher than those indicated above (Table 6 -3 ), but th e ir  assay 
conditions included GSH at a concentration of 10 mM. Values approaching 
those measured in the hepatic cytosol during the current investigation  
that have been reported are: 28 mll/mg (L it te rs t  e t a l , 1975); 31 mll/mg 
(Guthenberg et a l , 1980). The a c tiv ity  (31 mU/mg) reported by 
Guthenberg et a l . (1980) was in close agreement with the values 
obtained by Spearman and Leibman (1984), and Oesch et a l . (1983).
The ra tio  of the GS-transferase a c tiv it ie s  present in the l iv e r  and 
kidney gives an index for the re la tiv e  abundance of the GS-transferase 
isoenzymes 3-3 and 3-4. Calculations using tissue a c tiv it ie s  expressed 
in terms of mU/mg protein , results in a value of 40:1 fo r the 
liver:k idney ra tio  (Booth, 1961), 24:1 (C lifto n  and Kaplowitz, 1978) 
and 20:1 (L it te rs t  et al, 1975): the ra tio  was 11:1 from the results obtained 
during the current investigations. GS-transferase a c tiv it ie s  measured 
in the kidney cytosol were s im ilar to those present in the cytosol of
both the lung and ileum mucosa. These observations were in general 
agreement with those of L it te rs t  et al. (1975) and, therefore, 1t would appear 
probable that the s tra in  of rats used in the current study may be 
s lig h tly  lacking in one or more of the GS-transferase isoenzymes.
The a c tiv it ie s  of the glutathione S-transferases towards DCNB in the 
cytosolic fractions of various tissues of non-human primates were 
s im ilar in each tissue with the exception of the l iv e r . In the l iv e r  
of the rhesus monkey, the a c tiv ity  was 65% of that in the ra t hepatic 
cytosol, w h ils t in the cynomolgus monkey and baboon, the a c t iv ity  was 
lower (45 and 40% respective ly). The lower l iv e r  GS-transferase 
a c tiv ity  is re flected  in the c a lc u la te d 'liv e r to kidney a c tiv ity  
ra tios  obtained in the non-human primates. These were 6:1 (rhesus),
4:1 (baboon), and 3:1 (cynomolgus). The ra tio  obtained with the 
rhesus monkey compares closely w ith  a ra tio  of 8:1 calculated from 
the data of Asaoka et a l . (1977), using the same species of non-human 
primate. The lower liv e r  to kidney GS-transferase a c tiv ity  ra tio  
obtained with the non-human primates could possibly indicate a more 
s im ilar isoenzyme composition in both the liv e r  and kidney of the 
non-human primate than that which occurs in the ra t. The p a rtia l 
absence of transferase 3-3 in ra t kidney has been reported (Hales et a l , 
1978). The p ro file  of the various glutathione S-transferases may be 
less organ specific  in non-human primates than in the ra t. Another 
p o ss ib ility  is that the whole "family" of isoenzymes present in the 
primate may more closely resemble the isoenzyme p ro file  reported fo r  
man (Warholm et a l , 1983), In the human glutathione S-transferases, 
there is l i t t l e  d istinction  in the substrate s p e c ific itie s  of the 
basic GS-transferases (Jakoby and Habig, 1980).
The differences in GS-transferase a c tiv it ie s  which occur in individual
tissues in man are due, in part, to the presence of variab le amounts of 
neutral and acidic GS-transferases with th e ir  d iffe rin g  substrate 
s p e c if ic it ie s .
ag-Unsaturated compounds 
Ethacrynic acid (EA).
Ethacrynic acid is a commonly used second substrate fo r the GS-transferases 
and is an active substrate with sub-unit 2 of the ra t GS-transferases. 
("AA" Habig e t a l , 1974). I t  is also a substrate fo r the acidic  
GS-transferases in man (Marcus et al, 1978; Guthenberg and Mannervik, 1981). 
The use of EA as a second substrate, therefore, provides additional 
information on the isoenzyme composition of the various tissues. EA 
has a high rate of non-enzymic reaction with GSH: in the current 
investigation , th is amounted to approximately 25% of the to ta l rate  
of.enzymic conjugation.
In the ra t, the a c tiv it ie s  of the GS-transferases towards EA in both 
the l iv e r  and kidney cytosolic fractions were approximately equal 
(20.4 mll/mg and 24.9 mll/mg re sp ec tive ly ); these are s im ilar to 31 mll/mg 
and 39 mll/mg respecti vely, reported by C lifton  and Kaplowitz (1978).
These workers also reported that GS-transferase a c tiv ity  present in 
various parts of the gastro -in testina l tra c t varied between 33 and 
21 mll/mg, decreasing progressively between the duodenum and the 
terminal ileum. In the ileum mucosa cytosol of the rats examined 
during the current investigation , a lower mean value (24 mll/mg) was 
obtained than that of C lifton  and Kaplowitz (1978). The overall 
d istrib u tio n  of GS-transferase a c tiv ity  towards EA in l iv e r ,  kidney 
and ileum, although lower in terms of the absolute leve ls , was s im ila r  
to previous reports. The GS-transferase a c tiv ity  of the gastric
mucosa was approximately 50% of that present in the ileum mucosa which, 
in turn , was approximately 6 -fo ld  greater than that in the colon mucosa. 
The dimethyl analogue of ethacrynic acid (2 ,3-dimethyl-4 - [ _  2-methylene- 
butyryl ]phenoxyacetic acid, [D M E A ]) was used as a substrate fo r the 
GS-transferases by Boy!and and Chasseaud (1968) on account of its  
slower non-enzymfc reaction, and the l iv e r  to kidney a c tiv ity  ra tio  
was reported in terms o f a c t iv ity  per gram of tissue as 2 .2 :1 . Although 
DMEA is less reactive with GSH than is EA, the enzyme-catalysed reaction  
was only approximately 20% of that observed with EA (Boyland and 
Chasseaud, 1967), and as a consequence th is substrate was not used 
in the current investigations'.
In the tissues obtained from the various species of non-human primate, 
GS-transferase a c tiv ity  towards EA were lower than those measured in 
the corresponding ra t tissues. A greater difference was observed 
between the liv e r  and kidney GS-transferase a c tiv it ie s  which produced 
l iv e r  to kidney a c tiv it ie s  ratios of 1.4:1 (rhesus and cynomolgus 
monkey) and 1.7:1 (baboon). With the exception of the rhesus monkey, 
the a c t iv it ie s  of the GS-transferases in the cytosol of the gastric  
mucosa were s im ilar to those present in the renal cytosol. S lig h tly  
higher GS-transferase a c tiv ity  levels were measured in the ileum.
The non-human primates can, therefore, conjugate a xenobiotic 
containing an ag-unsaturated ketone in the l iv e r ,  lung, kidney and 
gastro -in testina l tra c t. However, in terms of species differences  
which may ex is t between the ra t and the non-human primate, the 
position of the ag-unsaturated ketone moiety in the molecule may 
be important.
Diethyl maleate (DEM)
The a c t iv ity  of the GS-transferases towards diethyl maleate (DEM)
(which can be regarded as an ag-unsaturated c is -e s te r) in various 
tissues of the non-human primate were, in general, between 20-30% of 
those in the respective tissues of the ra t. GS-transferase a c tiv it ie s  
in the stomach mucosa and colon mucosa were only approximately 20% of 
those in the ra t.
Boy!and and Chasseaud (1969) reported the a c tiv it ie s  of the 
GS-transferase a c tiv ity  towards DEM in the cytosol o f ra t l iv e r  at
7.5 yM SH lost/m in/g tissue, which i f  a value o f 60 mg cytosolic  
protein per gram tissue is  assumed, results in a calculated value 
of 125 mU/mg. The a c tiv ity  in the ra t hepatic cytosol in the current 
investigation (100 mU/mgl was s im ilar, Chasseaud (1979) presented 
data concerning GS-transferase a c tiv it ie s  towards DEM fo r some ex tra - 
hepatic tissues which were 23% (kidney) and 29% (lung) of the hepatic 
a c tiv ity . These figures were derived from the results published 
e a r lie r  by Boyland and Chasseaud (1967), which were 9 .3 , 2.1 and 
2.7 yM SH lost/m in/g tissue fo r l iv e r ,  kidney and lung cytosol 
respectively. The respective values fo r the cytosol protein  
condensations in these tissues used in the current study were 
l iv e r  (61.5 mg/g), kidney (49.6 mg/g) and lung (55.4 mg/g). These 
protein concentrations were s im ilar to those reported by L it te rs t  e t a l. 
(1975, 1976). I f  the results of Boyland and Chasseaud (1967) are
recalculated using these protein values, then the respective 
a c tiv it ie s  obtained are approximately l iv e r  (150 mU/mg), kidney 
(42 mU/mg) and lung (49 mU/mg). In the current study, the GS-transferase 
a c tiv it ie s  measured in ra t kidney were approximately 57% of those in  
the l iv e r  but s lig h tly  greater than those in the lung (41% of the
hepatic le v e l) . Hepatic GS-transferase a c tiv ity  in the rhesus monkey, 
baboon and cynomolgus monkey was 39, 30 and 32% respectively o f that 
in the ra t. The results fo r the hepatic cytosol fractions of both 
the rhesus monkey and the baboon are in close agreement with the 
resu lts  of Down and Chasseaud (1979). The a c tiv it ie s  of the 
GS-transferases present in the kidney and lung using DEM as substrate 
were s im ilar in each of the 3 species of non-human primate studied, 
although s lig h tly  greater in the cynomolgus monkey.
In the gastro -in testina l tra c t of the non-human primate, the ileum 
had the.highest GS-transferase a c t iv ity  in each of the species, and 
although a c tiv it ie s  in the baboon and cynomolgus monkey were 75 and 
80% o fth e ir  respective hepatic leve ls , that in the rhesus monkey was 
lower (55% of the hepatic le v e l) . The d is trib u tio n  of g astro -in tes tin a l 
GS-transferase a c tiv ity  towards DEM was s im ilar in both rodent and 
non-human primates, and as observed with other substrates, a c t iv ity  
decreased d is ta l from the duodenum.
Other ag-unsaturated compounds
Two other ag-unsaturated substrates were used in the current 
investigations to delineate any differences in the conjugation of 
these types of exogenous compounds. One of the substrates, tran s -4 - 
phenyl-3-butene-2-one (t-PBO), contains an ag-unsaturated carbonyl 
group and the other substrate cyclohex-2-en-l-one (CHO) is an 
ag-unsaturated cyclic  ketone.
The a c tiv it ie s  of ra t hepatic GS-transferases towards t-PBO were 
sim ilar to those previously reported by Boyland and Chasseaud (1968), 
but s lig h tly  higher a c t iv it ie s  were measured in the hepatic cytosol
fraction  of both the rhesus monkey and the baboon than previously 
reported (Down and Chasseaud, 1979), The ra t renal cytosol a c t iv ity  
was lower (5 .2  mU/mg) than the results (8 .0  mU/mg) calculated from 
the data of Boyland and Chasseaud (1968). The major differences in  
the GS-transferase a c tiv ity  p ro file  with t-PBO when compared to 
that obtained with other substrates was observed in the gastro­
in tes tin a l tra c t where values of less than 1 mU/mg were measured in 
the gastric mucosal cytosol from each species of non-human primate.
The GS-transferase a c tiv ity  of the primate ileum mucosa was not 
s ig n ific a n tly  d iffe re n t from that in the respective hepatic cytosol.
A ra tio  o f  2:1 fo r the ra tio  of l iv e r  to ileum GS-transferase ac tiv ity  
was observed in the ra t during th is  study.
Thus, although both ethacrynic acid and trans-4-phenyl-3-butene-2-one  
are ag-unsaturated ketones they exh ib it d iffe rin g  GS-transferase 
substrate a c t iv ity  p ro files  in individual tissues of the non-human 
primate, presumably due to differences in individual isoenzyme 
a f f in i t ie s .  The non-human primate also d iffe rs  from the ra t in the 
re la tiv e  extent of GS-transferase a c tiv ity  towards these 2 substrates. 
In a ll the tissues examined, a c tiv it ie s  towards EA were some 3 to 5-times 
those in the non-human primate. With t-PBO as substrate, ra t  l iv e r  
and ileum a c tiv it ie s  are approximately 2 to-5-times those in.the non­
human primate, whereas a c tiv it ie s  in the ra t and non-human primate 
kidney were approximately equal.
Species differences are more apparent when cyclohex-2-en-l-one (CHO) 
was used as a substrate fo r the GS-transferases. The ra tio  of 
a c tiv ity  between the liv e r  and kidney of the ra t was s im ilar to the 
results of Boy!and and Chasseaud (1968) and Chasseaud (1979), although
absolute levels were approximately 50% of those previously reported.
The cytosolic fraction  of the ra t ileum mucosa also contained 
appreciable GS-transferase a c tiv ity  towards CHO (60% of kidney; 40% 
of l iv e r ) .  When the same tissues from the non-human primate were 
examined, only the l iv e r  had any detectable GS-transferase a c tiv ity  
towards CHO, and th is  was only 2% of that present in the ra t hepatic 
cytosol. Low levels of GS-transferase a c tiv ity  towards CHO have been 
observed previously with non-human primates (Down and Chasseaud, 1979), 
but these observations were confined to l iv e r  samples fo r which the 
a c tiv ity  was given as <1 ymol SH lost/h/mg protein . In the current 
investigation , none of the other tissues o f.th e  non-human primate 
contained any detectable a c tiv ity  even when the protein concentration 
in the assay reaction mixture was increased severa l-fo ld . A very 
pronounced species difference therefore exists with th is  type of 
ag-unsaturated cyclic  ketone, and GSH conjugation with th is  class of 
compound warrants fu rther detailed examination.
1 ,2-Epoxy-3-(p-nitrophenoxy)propane (ENPP)
The epoxide substrate ENPP has been reported as the major substrate 
fo r transferase 5-5 (Transferase "E"; F je lls te d t e t a l , 1973), and is  
also a minor substrate fo r sub-units 3 and 4 in the ra t. ENPP is  
also a substrate for the acidic GS-transferases, and to a lesser extent, 
the neutral GS-transferases in man (Warholm e t a l , 1983). No 
measurable GS-transferase a c tiv ity  towards ENPP has been detected 
with the basic GS-transferases of man (Jakobyand Habig, 1980) or the rhesus 
monkey (Asaoka and Takahashi, 1977). The results obtained during the 
current investigation show that the levels of GS-transferase a c t iv ity  
in hepatic cytosol towards ENPP in the primate were between 20 and 30% 
of those in the ra t. In the ra t renal cytosol, GS-transferase a c t iv ity
was 56% of that in the l iv e r ,  whereas in the baboon and rhesus monkey, • 
renal and hepatic values were s im ila r. GS-transferase a c tiv ity  in 
the mucosa of the ileum of the ra t was lower (30% the hepatic value), 
but in the non-human primates examined,the ileum mucosa had a c tiv ity  
which, was as much as 60% of that in the l iv e r .  These results could 
possibly indicate that in the tissues of the non-human primate 
examined, s im ilar amounts of the acidic plus neutral GS-transferase 
isoenzymes were present.
Human GS-transferases
The results obtained fo r the re la tiv e  a c tiv it ie s  -of the GS-transferases ' 
of human liv e r  cytosol towards several substrates gives an indication  
of the.isoenzyme composition of human l iv e r .  Comparison of the 
s im ila r it ie s  and differences in the a c tiv ity  towards the same substrate 
in both the non-human primate and man should provide insight as to the 
"species equivalence" of the non-human primate and man in respect of 
the GS-transferase p ro file .
l-Chloro-2,4-dinitrobenzene was conjugated with GSH at approximately 
the same rate by human liv e r  cytosol and ra t liv e r  cytosol, but th is  
represents only 30% ofthe a c tiv ity  measured in the hepatic cytosol 
of the non-human primates. The isoenzyme s p e c ific ity  towards CDNB 
in man is such that a ll  the basic isoenzymes have very s im ilar  
a f f in it ie s  and reaction rates; the neutral isoenzymes are approximately 
3 -times as ac tive , w h ils t the acidic GS-transferases have intermediate  
values (Warholm, 1983). Therefore, when compared to man the non-human 
primates e ith er contain more GS-transferase per se, or the liv e r  
contains higher levels of the more active neutral or acidic  
GS-transferases.
Previous reports (Boyland and Chasseaud, 1969) indicated that 
GS-transferase a c tiv ity  towards 1,2-dichloro-4-nitrobenzene in the 
hepatic cytosol of man was approximately 8% of that in ra t l iv e r .  
Grover and Sims (1964) also reported an essen tia lly  s im ilar  
proportion (5%). In the current investigations a value of 
approximately 9% o f the ra t hepatic a c t iv ity  was obtained from 
human liv e r  (male). A s lig h tly  higher proportion (11%) was measured 
in the samples of liv e r  obtained from human females. The values 
observed in man were much lower than those measured in the hepatic 
cytosol of the non-human primates, p a rtic u la rly  in the rhesus monkey. 
The fa c t that DCNB is a general substrate fo r the basic and neutral 
GS-transferase isoenzymes and an e ffec tive  substrate fo r  the acidic  
isoenzymes, suggests that an increased proportion of the acidic  
GS-transferases may ex is t in the non-human primate, p a rtic u la r ly  
in the rhesus monkey.
Ethacrynic acid (EA) has also been reported as a characteris tic  
substrate fo r the acidic human transferase (Marcus e t a l , 1978), 
and the results obtained with the hepatic cytosol of the non-human 
primates indicate that the liv e r  of the non-human primate may 
possibly contain a higher proportion of acidic GS-transferases than 
the l iv e r  of man. The measured hepatic GS-transferase a c t iv ity  in 
man towards EA was approximately 25-30% of that in the non-human 
primates. In man, no obvious sex-related differences in respect of 
the GS-transferase a c tiv ity  towards th is substrate were observed.
As observed with some of the substrates detailed above, the 
GS-transferase a c tiv ity  of human liv e r  was about 30% that of the 
non-human primate l iv e r ,  A s im ilar resu lt was obtained when 
diethyl maleate was employed as the e le c tro p h ilic  substrate, with
human liv e r  possessing 25% of the a c tiv ity  of that in rhesus monkey 
l iv e r ,  and 30% of that in the l iv e r  of both the baboon and cynomolgus 
monkey. No detailed GS-transferase s p e c ific ity  with diethyl maleate 
has been reported, so the assumption that DEM is probably a general 
substrate indicates a higher concentration of GS-transferases in the 
non-human primates.
The a c tiv ity  of the human liv e r  GS-transferase towards trans-4-phenyl- 
3-butene-2-one show s im ilar low levels (4 .6  mU/mg) to those present 
in both the baboon (6.3 mU/mg) and the cynomolgus monkey (6 .5 .mU/mg). 
GS-transferase a c tiv ity  in the rhesus monkey liv e r  was 9 mll/mg.
The hepatic cytosol of the baboon was the most active (2 .6  mU/mg) of 
the non-human primate tissue cytosols examined when the epoxide
1,2-epoxy-2-(p-nitrophenoxy)propane was used as a substrate.
GS-transferase a c tiv ity  towards th is  substrate in the rhesus monkey 
was (1 .8  mU/mg), w hilst in the human hepatic cytosol i t  was very low 
(male 0.2 and female 0,3 mU/mg J_: some samples had no detectable 
a c tiv ity . In common w ith the non-human primates, no detectable 
GS-transferase a c t iv ity  was obtained in human l iv e r  when cyclohex-2- 
en-l-one was used as substrate. These results indicate that the 
non-human primate should be considered closer to man than to the 
ra t ,  with respect to the range and a c tiv it ie s  of various GS-transferases.
The non-human primates, although possessing greater GS-transferase 
a c t iv it ie s  than man, appear to have a s im ilar a c t iv ity  p ro file  
towards d iffe re n t substrates, and the;species differences between 
man and non-human primate may be explained in terms of the re la tiv e  
amounts of the GS-transferase isoenzymes present, rather than the
present or absence of any p articu la r GS-transferase isoenzyme.
Immunologically, the basic isoenzymes of the non-human primate and 
man are re lated . Fleischner et a l. (1976) reported that cytosol fractions  
of rhesus monkey liv e r  and kidney cross-reacted with antibodies to 
the basic human transferases. These observations were confirmed in 
the current investigations, and extended to other tissues of the 
rhesus monkey as well as several tissues of both the baboon and 
cynomolgus monkey. Tissues including stomach, ileum, kidney and 
l iv e r  from a ll  non-human primates showed cross-reactiv ity  with the 
antibody to human basic GS-transferases used in th is  study. The 
lung cytosol fractions of the non-human primate did not cross-react. 
Asaoka and Takahashi (1977) detailed the amino acid composition of 
the major basic GS-transferase present in the rhesus monkey l iv e r ,  
which was s im ilar to the amino acid composition of human liv e r  basic 
GS-transferases (Warholm 1983)_.
Further examination of the glutathione S-transferase in tissues of 
the.non-human primates and th e ir  comparison with the GS-transferases 
of man involve the separation of the individual isoenzymes and are 
presented in Chapter 8.
Metaboli sm of glutathione S-Conjugates
Measurement of y-GT and dipeptidase in a ll 3 species of non-human 
primate studied shows that the kidney, l iv e r  and in tes tin a l mucosa 
have the capacity to convert glutathione conjugates to the 
corresponding cysteine conjugate. In the event that the glutathione  
conjugate has a molecular weight large enough to favour b il ia ry  
excretion, as a route of excretion,then assuming uptake by the b ile  
duct lin in g  c e lls , the conjugate would be in close proximity
to high concentrations of the enzymes responsible fo r its  catabolism.
In the ra t ,  y-GT comprises about 1.5% of the to ta l membrane protein  
(Glossman and N e v ille , 1972; George and Kenny, 1973). Hepatic 
a c tiv ity  in the ra t in the current investigation was less than 0.7% 
of that measured in the kidney. Hepatic y-GT a c tiv ity  in the 
non-human primates, in common with the observations of Goldbarg et a l . 
(1960) with human l iv e r 5 were 3 to 5-times higher than that in the ra t.  
Hepatic y-GT a c tiv ity  in an individual non-human primate species was 
between 10 and 17% of that in the corresponding kidney. Hepatic y-GT  
has been shown to be* localised in the b ile  duct epithelium with some 
a c tiv ity  in the periportal hepatocytes (M eister, 1976), and also a 
soluble form of the enzyme has been reported (Szewczuk, 1966). 
In tes tin a l y-GT a c tiv ity  in the non-human primate was 5-7% of that 
in the corresponding kidney, and s im ilar in ra tio  to that measured 
in ra t in tes tin a l and kidney preparations. These results are in 
general agreement with the.observations of ^Goldbarg et a l . (1960) 
and Tate (1980).
In common with the results ohtatned fo r y-G T , the a c tiv it ie s  of 
cysteiriylglycine dipeptidase (CG-DP) measured indicated that the 
kidney from a ll  species examined contained the highest a c t iv it ie s .
The CG-DP a c tiv ity  in the l iv e r  was less in the non-human primate 
than that in the ra t,b u t represented a higher proportion (27-32%) 
of that in the corresponding kidney (c f. ra t 19%). In the mucosa 
of the ileum, dipeptidase a c tiv ity  was approximately 50% of that 
in the kidney in a ll species examined; th is  resu lt is  in agreement 
with the reported specific  lo ca lisation  of th is  enzyme in the 
gastro -in testina l tra c t (Kim and Brophv, 1976; Kim et a l , 1976).
No d is tinc tion  has been made in the current investigations between 
the membrane-bound and soluble dipeptidases, which have been reported 
to ex is t in the human (Stetson, 1975) and non-human primate (Das and 
Radhakrishnan, 1972).
The fin a l step in the mercapturic acid synthesis, that of N-acetylation  
of the cysteine conjugate, has been shown to occur in ra t l iv e r  and 
kidney slices (Elce, 1970). As seen with the catabolic enzymes which 
act on the glutathione S-conjugates, the N-acetyltransferase is more active in. 
the kidney than in the l iv e r  (Green and Elce, 1975). N-acetyl transferase is a 
microsomal enzyme (Green and Elce, 1975; Hughey et a l , 1978), and has 
been reported to be la b ile  (Tate, 1980); th is may resu lt in lower 
in v itro  a c tiv ity  than the "actual in vivo" a c tiv ity  present in the 
tissue being assayed. The results indicate that the kidney microsomes 
of the non-human primate contained similar N-acetyl transferase ac tiv ity  to that 
in the ra t kidney microsomes. The results obtained for the ra t are, 
however, lower than those reported by Duffel and Jakoby (1982), although th e ir  
preparation contained the non-ionic detergent, N ,N -b is-(3-D - 
gluconamidopropyl)-3a,12a-dihydroxy-5p-cholan-24-amide, which could 
cause release of bound enzyme from the microsomal membranes.
N-acetylase a c tiv ity  in the liv e r  microsomes was between 23-30% of 
that in the kidney microsomes, whereas they were s im ilar to those in the 
in tes tin a l mucosa of the rhesus monkey. S light lower N-acetyl transferase  
a c tiv ity  were observed in the in tes tin a l mucosa from both the baboon 
and cynomolgus monkey.
When the overall size of the organs of the non-human primate are 
considered, the levels of a c tiv ity  are consistent with a large capacity 
fo r the production of mercapturic acids. In the current investigations
the non-human primate did not appear to read ily  N-acetylate the 
cysteine conjugate of ethacrynic acid which was formed in the l iv e r ,  as 
only small amounts of the mercapturic acid were excreted in to  the b ile .  
This observation could be explained in terms of a lower substrate 
s p e c ific ity  fo r the cysteine conjugate of ethacrynic acid than the 
substrate S-benzylcysteine used fo r the assay of microsomal 
N-acetyltransferase. In th is  respect i t  may be pertinent that 
microsomal N-acetyltransferase has a high a c tiv ity  towards low 
p o la rity  S-substituted cysteines(Duffel and Jakoby, 1982).
The p o s s ib ility  exists that a deacetylase could be present in the 
l iv e r  which has a higher substrate s p e c ific ity  fo r the mercapturate 
of ethacrynic acid than that produced from the synthetic substrate.
TABLE 6-1
.Mean concentrations (± S .D .) of glutathione (mM) in the various 
tissues and organs of the non-human primates.
Tissue
Species
Rhesus (n = 2 ) Baboon (n = 5) Cynomolgus (n -  5)
Liver 6.10 6.84 ± 0.79 6.24 ± 0.89
Kidneys 3.60 3.80 ± 0.71 3.44 ± 0.63
Lungs 1.65 2.42 ± 0.58 2,28 ± 0.33
Stomach+ 4.50 4.50 ± 0.49 4.86 ± 0.63
Duodenum+ 2.25 3.00 ± 0.26 3.14 ± 0.30
Ileum+* 2.20 2.60 ± 0.43 3.02 ± 0.43
Colon* 1.85 2,02 ± 0.26 2.55 ± 0.62
Testes 2.30 2.84 ± 0.34 NA
Pancreas 2.05 2.04 ± 0.62 NA
Spleen 2.10 1.76 ± 0,18 NA
Heart 2.15 1.76 ± 0.44 NA
Eye (Lens) 6.85 6.32 ± 0.46 NA
NA = Not assayed.
+ = Mucosa.
*  = Sample from middle portion.
TABLE 6-2
Mean a c tiv it ie s  (± S.D .) of glutathione S-transferases towards
l-chloro-2,4-d in itrobenzene in various tissues of non-human primates
and the ra t. Results are expressed as nmol/min/mg protein.
Species
Tissue Rat Rhesus Baboon Cynomolgus
Cn = 5) (n = 4) (n = 5) (n = 5)
Liver 613 ± 4 5 2552 ± 256 2849 ± 214 3052 ± 504
Kidney 86 ± 12 384 ± 69 277 ± 58 366 ± 37
Lung 56 ± 4.0 258 ± 47 171 ± 47* 300 ± 81
Stomach 160 ± 3 0 264 ± 31* 251 ± 54* 266 ± 76*
Ileum . 157 ± 2 3 498 ± 34 496 ± 64 . 5Q8 ± 66
Colon 34.7 ± 4.2 77.1 ± 15.7 79.2 ± 13 90.4 ± 15.3
A ll primate results are s ig n ific a n tly  d iffe re n t (P <0.001) from the 
respective ra t tissues except those marked *  P <0.05.
TABLE 6-3
Mean a c tiv it ie s  (± S.D .) of glutathione S-transferases towards
1 ,2-dichloro-4-nitrobenzene in various tissues of non-human primates
and the ra t. Results are expressed as nmol/min/mg protein.
Species
Tissue Rat Rhesus Baboon Cynomolgus
(n = 5) ii (n -  5) (n = 5)
Liver 36.1 ± 5.0 23.7 ± 3 .Of 14.4 ± 0.9+ 16.2 ± 1.2+
Ki dney 3.2 ± 0.4 4.0 ± 0.5 3.4 ± 0.6 5.0 ± 0.7+
Lungs 2.8 ± 0.5 3.2 ± 0.2 3.5 ± 0.8 4.0 ± 0.7*
Stomach 3.5 ± 0.4 4.4 ± 0.3 4.8 ± 1.3 6.1 ± 0.9+
Ileum 6.9 ± 0 .4 5,7 ± 0.3* 5.5 ± 0.9+ 6.7 ± 0.8
Colon 1.6 ± 0 .5 . 1.1 ± 0 .3 1.7 ± 0.3 1.9 ± 0.7
t  Results s ig n ific a n tly  d iffe re n t (P <0.001) from ra t. ■ 
*  Results s ig n ific a n tly  d iffe re n t (P <0.05) from ra t.
TABLE 6-4
Mean a c tiv it ie s  (± S.D.) of glutathione S-transferases towards
ethacrynic acid in various tissues of non-human primates and the
ra t. Results are expressed as nmol/min/mg protein .
Species
Tissue Rat 
(n = 5}
Rhesus 
(n = 4)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 20.4 ± 3.8 13.0 ± 1.1 10.1 ± 1.0 10.6 ± 1 .7
Kidney 24.9 ± 3.6 9.1 ± 0.2 5.8 ± 0.5 7.8 ± 0.8
Lung 16.7 ± 4.5 4.4 ± 0.5 3.6 ± 0.5 5.5 ± 0.7
Stomach 11.5 ± 1,1 6.4 ± 0.7 5.6 ± 0.6 7.3 ± 1.1
Ileum 24.0 ± 1.5 8 .O' ± 1.2 7.2 ± 0.8 8.3 ± '1.4
Colon 3.2 ± 1.1 0.9 ± 0.3 1.1 ± 0.2 1.1 ± 0.4
All primate results s ig n ific a n tly  d iffe re n t (P <0.001)
from ra t.
TABLE 6-5
Mean a c tiv it ie s  (± S.D .) of glutathione S-transferases towards
diethylmaleate in various tissues of non-human primates and ra t.
Results are expressed as nmol SH reacted/min/mg protein.
Tissue
Species
Rat 
(n = 5)
Rhesus 
(n = 4)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 
Ki dney 
Lung 
Stomach 
Ileum
100.8 ± 5.3 
56.9 ± 11.4
40.5 ± 7.5
50.5 ± 18,0
86.5 ±. 9.2.
39.2 ± 4.3  
12.9 ± 2.0
10.2 ± 1.0 
9.7 ± 1.6
.2 1 .5 .± 4 .3
30.2 ± 4.1 
9.9 ± 3.4 
11.1 ± 3.1 
10.5 ± 2.5 
22.8 ± 3.3
32.9 ± 3.7 
1 5 .4 '± 4.2
14.3 ± 2.9
26.4 ± 5.5
A ll primate results s ig n ific a n tly  d iffe re n t (P <0.001)
from ra t.
TABLE 6-6
Mean a c tiv it ie s  (± S.D.) of glutathione S-transferases towards
trans-4-phenyl-3-butene-2-one in various tissues of non-human
primates and ra t. Results are expressed as nmol SH reacted/min/mg protein.
- Species
Tissue Rat
(n = 5)
Rhesus 
(n = 4)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 44.0 ± 4.1 9,0 ± 2 .Of 6.3 ± 1.3+ 6.5 ± 1.4+
Kidney 5.2 ± 1.0 7.1 ± 1.7 4.0 ± 1.1 4.6 ± 1.5
Lung 4.0 ± 0.8 4.6 ± 1.1 ND ND
Stomach ND ND ND ND
Ileum 22.8 ± 3.0 10.0 ± 1.4+ 4.6 ± 3.8+ 7.2 ± 1.4+
Colon ND ND ■ ‘ ND ND •
ND = Less than 0 .8  nmol/min/mg.
A ll primate results indicated + are s ig n ific a n tly  d iffe re n t  
(P <0.001) from ra t.
Kidney and ileum results from rhesus monkey s ig n ific a n tly  
higher (P .<0.05) than baboon.
TABLE 6-7
Mean a c tiv it ie s  (± S.D .) of glutathione S-transferases towards
cyclohex-2-en-l-one in various tissues of non-human primates and
ra t. Results are expressed as nmol SH reacted/min/mg protein.
Tissue
Species
Rat 
(n = 51
Rhesus 
(n = 4)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 507 ± 45 8.3 ± 1.5 8.4 ± 1.2 7.9 ± 1.5
Ki dney 329 ± 27 ND ND ND
Ileum 194 ± 31 ND ND ND
ND = No a c tiv ity  detected.
A ll primate results s ig n ific a n tly  d iffe re n t (P <0.001)
from ra t.
TABLE 6-8
Mean a c tiv it ie s  (± S.D.) of glutathione S-transferases towards
1,2-epoxy-3-(p-nitrophenoxy)propane in various tissues of non-human
primates and ra t. Results are expressed as nmol/min/mg protein .
Tissue
Species
Rat 
In = 4).
Rhesus 
(n = 3)
Baboon 
(n = 5)
Liver 8.6 ± 2.9 1.8 ± 0.5+ 2.6 ± 0.8+
Kfdney 4.8 ± 1.6 1.7 ± 0.5 2.3 ± 0.9
Ileum 2.6 ± 0.8 1.0 ± 0.4 1.4 ± 0.5
Colon ND ND ND
ND = No a c tiv ity  detected.
Primate results indicated t  are s ig n ific a n tly  
d iffe re n t (P <0.001) from the ra t .
TABLE 6-9
Mean a c tiv it ie s  (± S.D.)of~the human hepatic glutathione S-transferase
towards various substrates. Results are expressed as nmol/min/mg protei
Substrate Male (n = 5)
Female 
(n = 5)
1-C hioro-2,4-d i ni trobenzene 933 ± 207 763 ±1 36
192-Chloro-4-nitrob'enzene 3.2 ± 0.6 4.0 ± ' 0.5
Ethacrynic acid 3.0 ± 0.4 3.4 ± 0.4
Diethylma leate 10.6 ± 0.5 11.4 ± 0.7
trans-4-Phenyl-3-butene-2-one 9.6 ± 0.5+ 3.7 ± 0.6+
Cyclohex-2-en-l-one ND ND
1,2-Epoxy-3-(p-nitrophenoxyipropane 0.24* 0.32 ± 0 .2 * *
*  Three subjects had no detectable a c tiv ity  with th is substrate. 
* *  Two subjects had no detectable a c tiv ity  with th is  substrate.
A ll human results with the exception of a c t iv ity  towardsCDNB are 
s ig n ific a n tly  d iffe re n t (P <0.001) from the ra t.
A ll human results with the exception of the a c tiv ity  towards t-PBO 
and ENPP are s ig n ific a n tly  d iffe re n t (P <0.001) from the non-human 
primate.
t  S ign ificant d iffe re n t (P <0.001),
TABLE 6-10
Mean a c tiv it ie s  (± S.D.)  of y-glutamyltranspeptidase in various
tissues of non-human primates and ra t. Results are expressed as
nmol/min/mg protein.
Tissue
Species
Rat
Cn = 3}
Rhesus 
Cn = 2)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 14,3 ± 6 42 ± 4 74 ± 5 61 ± 4
Kidney 2195 ± 255 398 ± 37 452 ± 34 505 ± 64
Stomach ND ND ND ND
Duodenum 111 ± 29 28 ± 1 23 ± 5 26 ± 10
Ileum 136 ± 44 . 30 ± 8 18 ± , 7 17 ± 7
Colon 60 ± 1 7 12 ± 6 20 ± 7 16 ± 4
ND = No a c tiv ity  detected.
A ll primate results s ig n ific a n tly  d iffe re n t (P <0.001) 
from the ra t.
TABLE 6-11
Mean•a c tiv it ie s  (± S.D.) of cysteinylglycinedipeptidase in various
tissues of non-human primate and ra t. Results are expressed as
nmol/min/mg protein .
Species
Tissue Rat 
(n = 3)
Rhesus 
(n = 2)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 4.8 ± 0.9 3.6 ± 0 .3 4.7 ± 0.7 4.4 ± 0.8
Ki dney 25.8 ± 6.4 11.7 ± 0.4 + 17.3 ± 2.0+ 13.7 ± 1.6+
Stomach <1 <1 <1 NA
Ileum 14,7 ± 1.3 7.2 ± 0.4 + 7.4 ± 0.7+ 4.1 ± 7 +
NA = Not assayed.
t  Results s ig n ific a n tly  d iffe re n t (P <0.001) from the ra t.
TABLE 6-12
Mean a c tiv it ie s  (± S.D.) of microsomal N-acetyltransferase in various
tissues of non-human primates and ra t. Results are expressed as
nmol/min/mg protein .
Tissue
Species
Rat 
(n = 5)
Rhesus 
(n = 2)
Baboon 
(n = 5)
Cynomolgus 
(n = 5)
Liver 11.0 ± 1.2 4.5 ± 0 .2f 6.0 ± 0 .6t 7.1 ± 0 .5 t
Ki dney 31.3 ± 2.6 19.6 ± 0 .9 t 22.7 ± 2 .2t 23.8 ± 3.8*
Stomach ND ND ND ND
Duodenum 6.4 ± 0.6 3.4 ± O .lt 3.6 ± 0.2t 4.2 ± 0.7*
Ileum 5.0 ± 0.4 3.5 ± 0.3* 3.2 ± 0 .7t .3.6 ± 0..2*
Colon 1.7 ± 0.2 0.6 ± O .lt 1.4 ± 0.5 1.7 ± 0.4
ND = No a c tiv ity  detected.
f  Results s ig n ific a n tly  d iffe re n t (P <0.001) from the ra t.  
*  Results s ig n ific a n tly  d iffe re n t (P <0.05) from the ra t .
FIGURE 6-1
Double immuno d i f fus ion  of  samples of cytoso l ic  fract ions of various 
tissues of non-human primate against antibodies to human basic 
GS-transferase isoenzymes.
Iff
B
Each "p late" consists of 8 grouDS of wel ls punched in agar in groups of 
6 wells equid istant  from a central we l l .  The central well contained
antibodies to human basic GS-transferase isoenzymes and each of  the outside
1 1 1 1  l
wells contained e i ther  neat cytosol (marked *) or a 8» 16 or 32
d i lu t io n  of cytosol in clockwise sequence from well *.
Sample sequence - Species.Tissue
PI ate
Well Group Nos. Control Wei 1 s
1 2 3 4 5 6 7 8
A B. K B.Lu B.D B. St B. I Rh.Lu Sali ne + vfc
B Rh. K Rh.I Rh. Lu C.L C.L H.L < u 11
C R.l R. K M.L H.L Rh.L Rh. K \« * »
D Rh. D B.L B.K B.D B. St B.Lu I * u
Abbreviations : Species - B, baboon; Rh, rhesus; C. cynomolgus; R, r a t ;  
M, mouse; H, human. Tissues - L, l i v e r ;  K, kidney; Lu, lung;
St, stomach mucosa; D, duodenal mucosa; I ,  ileum mucosa.
1 4 7
2 5 8
3  6
A
1 4 7
2 5 8
3 6
CHAPTER 7
MICROSOMAL GLUTATHIONE S-TRANSFERASES 
INTRODUCTION
In the previous Chapter the a c tiv it ie s  of the glutathione S-transferases 
(GS-transferases) towards several d iffe re n t substrates were measured 
in cytosolic fractions prepared from various tissues of the non-human 
primate. The levels of a c t iv ity  were compared to those measured in 
the tissues of the ra t and also the liv e r  cytosol of man. GS-transferase 
a c tiv ity  has also been shown to be present in other sub-cellu lar 
fractions of ra t l iv e r  including microsomes (Morgenstern et a l , 1979,
1980; Freidberg et a l , 1979), and mitochondria (Morgenstern et a l , 198Q; 
Wahllander, 1979; Kraus, 1980); although recently, studies have 
indicated that the mitochondrial GS-transferase a c tiv ity  may be 
due to loosely bound cytosolic enzymes (Ryle and Mantle, 1984); and 
nuclei (Morgenstern, 1980). Microsomal GS-transferases also occur in 
the liv e r  of fish (Nimmo .et a l , 1981) and rhesus monkey (Summer and 
Griem, 1981), and in other tissues in the ra t (DePierre and Morgenstern, 1983). 
As with other drug metabolising enzymes, i t  is important to quantify  
the contribution of the microsomal GS-transferase to the overall organ 
glutathione S-transferase capacity. This information may be useful 
when assessing the susceDtibi1ity  of a p articu lar tissue to xenobiotic 
damage. In addition, sub-cellu lar d istrib u tio n  studies may indicate  
a possible localised function for individual GS-transferases.
One notable characteris tic  of the ra t hepatic microsomal GS-transferases 
is that the microsomal enzyme a c tiv ity  can be stimulated in v itro
several-fo ld  by addition of sulphydryl reagents such as N-ethylmaleimide 
(Morgenstern, 1979), and iodoacetamide (Nimmo et a l , 1981), this e ffe c t  
is not seen with the cytosolic isoenzymes. The degree of activation  
has been reported as occurring to d iffe rin g  extents in various 
tissues; for example, ra t l iv e r  microsomal GS-transferase a c tiv ity  
was stimulated more than 5 .5 -fo ld , lung microsomal a c t iv ity  1 .2 -fo ld ,  
w hilst kidney microsomes were not stim ulated, and the in tes tin a l 
microsomal GS-transferases were inh ib ited  by the in v itro  addition  
of N-ethylmaleimide (DePierre and Morgenstern, 1983). The researchers also 
reported results fo r other ra t tissues including adrenal, testes , 
spleen, brain , heart and thymus, but of these tissues only the thymus 
microsomes were stimulated (1.5-fold)_, whereas the brain and heart 
GS-transferase a c tiv ity  were markedly inh ib ited  (>93% in h ib it io n ).
One objective of this section of the current investigation was to 
examine the activation characteristics of the GS-transferases of 
various tissues in the 3 species of non-human primate (rhesus monkey, 
baboon and cynomolgus monkey). Another objective was to compare the 
microsomal GS-transferases of non-human primates with the respective 
microsomal GS-transferases prepared from ra t tissue.
EXPERIMENTAL
The microsomal pelle ts  of various tissues which remained a fte r  the 
preparation of cytosolic fractions (post-105,000 g) had been decanted 
(see Chapter 2 and Chapter 6 ), were resuspended in 100 mM 
sodium phosphate buffer (pH 7.0 containing potassium chloride 0.15 M, 
by gentle hand homogenisation in a Potter-Elvehjem homogeniser 
(3 passes). The volume of suspending buffer was s im ilar in magnitude
to that of cytosol previously removed. This microsomal suspension 
was then centrifuged at 105,000 g fo r 60 min. This wash procedure 
removed most of the cytosolic GS-transferases, as judged by the level 
of GS-transferase a c tiv ity  present in the wash buffer. Lactate 
dehydrogenase a c tiv ity  in the wash fraction  was also monitored 
using the method of Bernstein and Everse(1975). Lactate dehydrogenase 
is a characteris tic  cytosolic "marker1 enzyme. The wash procedure 
was repeated 3 times, and a fte r  the th ird  wash no lacta te  dehydrogenase 
or GS-transferase a c tiv ity  was detected in the washings. The washed 
microsomes were then resuspended Tn buffered isotonic potassium 
chloride to a f in a l concentration of approximately 10 mg microsomal 
protein per ml. Protein was measured by the method of Lowry e t a l . 
(1951). This washed microsomal preparation is referred to as 
"microsomes" throughout th is Chapter.
Microsomes were prepared in the same manner fo r the l iv e r ,  kidney 
and lung,and also 2 portions of the gastro -tn testina l tra c t from 
each of the 3 non-human primate species and the ra t. The 2 portions 
of the gastro -in testina l tra c t examined in each species consisted of 
the proximal portion of the tleum (plus duodenum) and the d is ta l 
portion of the ileum.
The treatment of the microsomes with sulphydryl reagents was carried  
out as follows: microsomes (5-10 mg protein) were incubated with an 
equal volume of 0.5 mM N-ethylmaleimide fo r 3 min at 22°C. The 
period of incubation was chosen following in i t ia l  experimentation 
to ascertain the "activation rate p ro file "  fo r the hepatic microsomes 
of the non-human primates and the ra t. In these experiments, 
incubations were continued fo r up to 20 min. S im ilar activation
studies were also conducted using 1 mM iodoacetamide in place of 
N-ethylmaleimide. To terminate the activation process e ith e r GSH 
or d ith io th re ito l, at an equimolar concentration to the activation  
reagent,was added to h a lt the activation and remove excess sulphydryl 
reagent. GS-transferase a c tiv ity  was routinely assayed using 
1-chioro-2,4-dinitrobenzene (XDNB} as the second substrate.
Pretreatment of the microsomes with detergent p rio r to the addition  
of the activation reagent was also examined using Triton X-100,
Lubrol PX, or the non-ionic detergent "Zwittergent 3-14“ (Calbiochem 
•L td .} . .  These experiments were only conducted using baboon or ra t  
l iv e r  microsomes. Solubilisation of the microsomal glutathione  
S-transferases was attempted using the same detergents. To examine 
the pi characteristics of the activated microsomal proteins 
iso e lec tric  focusing was carried out using Triton X-100 solubilised  
microsomal GS-transferases.
Prior to the iso e lec tric  focusing experiments using baboon hepatic 
microsomes, the detergent (Triton X-100),.was removed by d if fe re n tia l  
ammonium sulphate precip ita tion  at 50% saturation, followed by 
prec ip ita tion  of the microsomal GS-transferases at 85% ammonium 
sulphate saturation. The precipitated proteins were removed by 
centrifugation and redissolved in phosphate buffer and desalted on 
a small (20 ml) Sephadex G-25 column. Iso e lec tric  focusing 
experiments were conducted in 1 mm thick agarose gels containing 
sorbitol togetherwith ampholytes in the pH range 3-10.5 (see Chapter 2 ). 
The pH gradient was established over a distance of approximately 
10.5 cm. A fter separation the protein bands were not sharp, presumably 
due to th'e presence of small amounts of residual detergent; therefore,
fo r the measurement of the GS-transferase a c t iv ity , the gel was sliced  
in to 4 mm sections. Each section was eluted with phosphate buffer 
(1 ml, pH 7 .0 ) , and the GS-transferase a c t iv ity  in each eluate towards 
CDNB was measured.
For comparative purposes a sample of hepatic cytosol (5 ml) from the 
same baboon was treated with Triton X-100 detergent. The detergent 
was removed and the protein prepared as described above. A fter the 
iso e lec tric  focusing of a sample of the cytosolic protein , the gel was 
sliced and eluted, and the GS-transferase a c tiv ity  determined.
RESULTS
In a l l  3 species of non-human primate and the ra t , microsomal 
GS-transferase a c tiv ity  was highest in the l iv e r ,  where the respective 
values were 90, 86, 72 and-63 mU/mg microsomal protein in the rhesus 
monkey, baboon, cynomolgus monkey and the ra t. In the microsomes 
prepared from the 2 portions of the ra t ileum the GS-transferase 
a c tiv ity  was measured in the kidney and lung microsomes (7 and 12% 
respectively}. In a ll the species of non-human primate examined, 
microsomal GS-transferase a c tiv ity  in the extrahepatic tissues were 
between 14 and 36 mU/mg (Table 7 -1 ). When the extrahepatic 
GS-transferase a c tiv ity  was expressed in terms as a percentage of 
hepatic a c t iv ity , the lung contained the greatest proportion in each 
non-human primate species [28%, rhesus; 30%, baboon; 50%, cynomolgus). 
In the non-human primates, the greatest a c tiv ity  in g astro -in testina l 
microsomes was between 37 and 39% (cynomolgus monkey) of that in the 
l iv e r . In 2 of the non-human primates, the kidney microsomes 
contained the lowest proportion of GS-transferase a c tiv ity  (13-33% 
when compared to the liv e r )  (rhesus-and cynomolgus monkey).
When the a c tiv ity  of the microsomal GS-transferases are expressed as 
a percentage of the corresponding cytosolic GS-transferase a c t iv ity ,  
the 2 sections of ra t ileum had the highest a c tiv ity  (15-22%); 
whereas in ra t lung microsomes i t  was 14%, and the ra t l iv e r  10%.
In the rhesus monkey, lung microsomes had 10% of the cytosolic  
GS-transferase a c t iv ity , whereas the other tissues examined contained 
between 3 and 4% of the corresponding cytosolic a c t iv ity . The 
results obtained with the microsomes of the baboon tissues were 
s im ila r; the proportion of hepatic microsomal a c tiv ity  contained
in the microsomes of other tissues were lung 15%, kidney 10%, and 
between 3-5% in the remainder. In the tissues obtained from the 
cynomolgus monkey, the respective proportions were lung 12%, kidney 
7%, ileum 6% and liv e r  2%. When other substrates of the cytosolic  
GS-transferases were investigated as substrates fo r the microsomal 
GS-transferases, no measurable a c tiv ity  was obtained with ethacrynic 
acid, 1 ,2-dichloro-4-nitrobenzene, 1 ,2-epoxy-3-(p-nitrophenoxy)propane 
or trans-4-phenyl-3-butene-2-one.
The time-course of microsomal activation by N-ethylmaleimide was 
studied. Activation was in it ia te d  at time zero by the addition o f . . 
0.5 mM N-ethylmaleimide and stopped by treating  aliquots o f the 
incubation mixture with 0.5 mM d ith io th re ito l at various timed 
in te rva ls . Microsomal GS-transferase a c tiv ity  towards CDNB was 
measured in each sample and the results obtained are presented in 
Figure 7-1. A fter 10 mtn (resu lts not shown), the extent of 
activation began to decline slowly. The rate of activation was 
greatest in the ra t ,  in which species the extent of activation  was 
also greatest (6 .3 -fo ld } .
There was no s ig n ifican t difference in the activation p ro files  
between any of the non-human primate hepatic microsomes studied.
The maximal level of activation was attained a fte r  3 min ( ra t  and 
baboon), and a fte r  4 min in the other 2 species of non-human primate.
A decline in the extent of activation was observed shortly a fte r  the 
time of occurrence of the peak activation in both the ra t and 
cynomolgus microsomes.
Microsomal GS-transferases were "activated" in the l iv e r  microsomes,
but not to any s ig n ifican t extent in any of the other tissues, by 
treatment with N-ethylmaleimide. The respective GS-transferase 
a c tiv it ie s  measured a fte r  3 min treatment with N-ethylmaleimide 
are given in Table 7-2. The maximal extent of activation observed 
with ra t l iv e r  microsomes was 6 .3-times the non-activated (control) 
value. In the non-human primate, the extent of activation was lower, 
3 .7 -fo ld  [rhesus), 4 -fo ld  (baboon) and 4 .1 -fo ld  in the cynomolgus 
monkey. In the other tissues examined, occasionally a s lig h t  
in h ib itio n  of GS-transferase a c tiv ity  was observed (both ra t and 
cynomolgus-distal ileum; and also baboon lung), but in most samples 
there was a s lig h t stim ulation of a c t iv ity  of between 1.03-1.43 of 
the control values (Table 7 -2 ).
Iodoacetami.de pretreatment also stimulated microsomal GS-transferase 
a c t iv ity , but to a lesser extent than was observed with N-ethylmaleimide. 
When expressed as a percentage of the activation achieved with  
N-ethylmaleimide the ra t l iv e r  microsomes were 65% activated with 
iodoacetamide; the corresponding values in the non-human primate 
species were 44, 47 and 55% in cynomolgus monkey, rhesus monkey 
and baboon respectively (Table 7 -2 ).
Activated ra t and baboon liv e r  microsomal GS-transferases were 
solubilised by treatment of the microsomes with detergent. When the 
ra t hepatic microsomes were incubated with Triton X-100, 91% of the 
GS-transferase a c tiv ity  was so lub ilised , w h ils t Lubrol PX treatment 
resulted in somewhat less "solubilised" a c tiv ity  (80%). The non-ionic 
detergent "Zwittergent 3-14" produced s lig h tly  more solubilised  
a c tiv ity  (85%). Treatment of the baboon microsomes with any o f the 
detergents resulted in approximately 60% of the a c tiv ity  being
released. L i t t le  activation of baboon hepatic microsomal GS-transferases 
occurred when the microsomes were pretreated with detergent p rio r to 
addition of the sulphydryl reagent (Table 7 -3 ).
Following so lu b ilisa tion  of baboon hepatic microsomal GS-transferases 
with Triton X-100, the proteins were separated by iso e lec tric  focusing 
in an agarose gel. The results are shown in Figure 7-2. The baboon 
microsomes show 3 d is tin c t zones of a c tiv ity  with approximate pi values 
of 7 .0 , 8.5 and 9 .2 , with some general non-specific a c tiv ity  between 
pH 7 .0 -9 .5 . Iso e lec tric  focusing conducted on the Triton X-100- 
treated cytosolic GS-transferases, resulted in 5 main regions of 
GS-transferase a c tiv ity . Two small zones of a c tiv ity  were observed 
with approximate pi values, 4.9 and 6 .5 , and 3 main zones with  
approximate pi values of 7 .5 , 8.3 and 8.9 (Figure 7 -3 ).
DISCUSSION
Microsomes prepared from various tissues of non-human primates, in 
common with the corresponding cytosolic fractions, contain GS-transferase 
a c tiv ity  towards l-ch loro-2 ,4-d in itrobenzene. Conversely, the microsomal 
preparations from the liv e r  o f e ith er the ra t or any o f the non-human 
primate species did not possess any measurable a c tiv ity  towards 
several other substrates of the GS-transferases, such as 1 ,2 -d ich loro - 
4-nitrobenzene, ethacrynic acid, l,2-epoxy-3-(p-nitrophenoxy)propane 
or trans-4-phenyl-3-butene-2-one. These results are in general 
agreement with those reported by Morgenstern et a l . (1983) using ra t  
hepatic microsomes. Measurable levels of GS-transferase a c t iv ity  
were obtained w ith some of the substrates lis te d  above only when the 
microsomal GS-transferases were pu rified  approximately 20-fo ld  
(Morgenstern et a l , 1983). GS-transferase a c tiv ity  towards the 
other substrates used in the current investigation were also reported 
as not being activated by treatment of ra t l iv e r  microsomes with  
sulphydryl reagents. This appears to hold with the hepatic microsomes 
of non-human primates, as there was no detectable activation  a fte r  
activation  with N-ethylmaleimide. P urifica tion  o f the hepatic 
microsomal GS-transferases, other than by iso e lec tric  focusing, 
was not attempted during the current study.
The extent of GS-transferase a c tiv ity  towards CDNB in hepatic 
microsomes was increased between 3.7 and 4 .1 -fo ld  in the various 
species of non-human primate, whereas in the ra t hepatic microsomes 
i t  was activated approximately 6 .3 -fo ld . The extent of activation  
observed in the ra t was s lig h tly  higher than that reported by 
DePierre and Morgenstern (1982) (5 .6 -fo l d), or by Morgenstern and Dock (1982)
(4 .0 - fo ld ) , although less than f i r s t  reported by Morgenstern et a l . 
(1979) (8 -fo ld ) . Activation levels in excess of these values have 
been obtained using lip id  vesicles (Boyer et a l , 1982). Not a ll  
species possess microsomal GS-transferases which can be activated , 
fo r example, the hepatic microsomes prepared from the trout (Salmo 
g a ird n e rii) did not show any increase in GS-transferase a c tiv ity  
a fte r  treatment with iodoacetamide (Nimmo e t a l , 1981). A very 
s lig h t stim ulation of hepatic microsomal GS-transferases in man was 
reported by Morgenstern et a l . (1984). These authors stated, however, 
that the tissue samples which were examined had been stored frozen 
fo r several months prio r to assay. Samples of ra t hepatic microsomes 
which had been stored at -20°C gradually, but eventually, completely 
lo st the capacity to be activated by N-ethylmaleimide (Morgenstern 
et a l , 1980). Hepatic microsomes from each o f the species of non-human 
primate used in the current investigation were stored at -70°C, and 
a fte r  a periodof 6 months, although s im ilar levels of microsomal 
GS-transferase a c tiv ity  was measured, no activation  of GS-transferase 
a c tiv ity  could be i l l ic i t e d  by e ith e r N-ethylmaleimide or iodoacetamide 
(resu lts  not shown). I t  is , therefore, probable that the human 
microsomes used in the investigations of Morgenstern et a l . (1984) 
no longer possessed the capacity fo r activation  by sulphydryl reagents. 
I t  would not be unexpected that the human microsomes could lose the 
capacity fo r activation at a s im ilar rate to that observed with the 
hepatic microsomes from non-human primates.
The time-course p ro files  (Figure 7-1) show that the activation of 
microsomal GS-transferase a c tiv ity  was very rapid. Stimulation of 
a c tiv ity  with N-ethylmaleimide reached a maximum within 4 min in the 
ra t and non-human primate. The use of iodoacetamide instead of
N-ethylmaleimide also stimulated microsomal GS-transferase a c t iv ity ,  
but both the extent and rate of activation were lower. The lower 
level of activation observed w ith iodoacetamide could be caused in 
part by.the lower re a c tiv ity  iodoacetamide with sulphydryl groups, 
but i t  could also be due to the in h ib ito ry  e ffec t of th is  compound 
on the GS-transferases,
The observation that none of the extrahepatic tissues of the non-human 
primates examined were stimulated by e ith e r N-ethylmaleimide or 
iodoacetamide is  consistent with previously reported observations 
fo r the ra t (DeRierre and Morgenstern, 1982). However, the reason fo r th is  
lack of activation is not known. I t  can be argued that the microsomal 
GS-transferases present in these extrahepatic tissues could be already 
in a completely "activated" state and, therefore, cannot be activated  
fu rth er.
Using the results of the current investigation , i t  can be calculated  
that in the rhesus monkey the proportions of microsomal to cytosolic  
GS-transferases in extrahepatic tissues were kidney 0.6%, lung 0.7% 
and ileum 0.8%, These proportions are very s im ilar to that fo r the 
GS-transferases of unactivated l iv e r  microsomes (0.9%). The proportion 
of the GS-transferases present in "activated" microsomes represents 
3.6% of the to ta l hepatic GS-transferase a c tiv ity  per gram of tissue.
Glutathione peroxidase a c tiv ity  of the microsomal GS-transferases 
towards cumene hydroperoxide has also been reported to be stimulated 
by sulphydryl reagents (Morgenstern et a l , 1983). This additional 
capacity of the hepatic microsomes fo r both GS-transferase and 
glutathione peroxidase a c tiv ity  could be regarded as an added protective
mechanism against hepatic membrane peroxidation.
As mentioned e a r l ie r , the activation of hepatic microsomal 
GS-transferases can also be achieved using unilam ellar phosphatidyl­
choline vesicles. The extent of activation  using the vesicles was 
approximately the same as that observed with sulphydryl reagents, 
but was additive i f  used in conjunction with sulphydryl reagents 
(Boyer et a l , 1982). The lip id  activation  process was shown to be 
due to the selective removal of an in h ib ito r of GS-transferases from 
the microsomal membrane. The same study indicated that both palmitate 
and lysophosphatidylcholine reversibly inh ib ited  the GS-transferases. 
I t  is  possible, therefore, that modulation of the GS-transferase 
a c tiv ity  in microsomes is  d ire c tly  controlled by the local l ip id  
environment; th is aspect requires fu rther study.
The results of the is o e lec tric  focusing of microsomal GS-transferase 
indicated that the microsomal a c t iv ity  could probably be a ttrib u ted  
to more than a single GS-transferase isoenzyme (possibly 3 ). There 
appears to be some degree of s im ila r ity  between the is o e lec tric  
focusing pattern of both the microsomal and cytosolic GS-transferases. 
However, no GS-transferase a c tiv ity  was detected in fractions  
corresponding to pi values between 7 and 3 in the microsomal 
GS-transferase separation. S im ilar findings, in as much as no 
neutral or acidic GS-transferases were observed, were obtained with  
the hepatic microsomal preparations reported by Lee and McKinney 
(1982).
Thus, in conclusion, the non-human primates possess microsomal 
GS-transferase a c tiv ity  in several tissues. . In the liv e r  microsomes,
the GS-transferase a c tiv ity  can be activated by treatment of the 
microsomes with sulphydryl reagents, and the pi characteristics  
indicate that microsomal GS-transferase a c t iv ity  is probably due to 
at least 3 d is tin c t basic proteins. The importance of these microsomal 
GS-transferases has yet to be determined, but i t  is possible that they 
could be more active towards highly lip o p h ilic  substrates than those 
present in the cytosol. The p o ss ib ility  also exists that as the 
formation of “active metabolites" can take place in the microsomes, 
then the presence of a GS-transferase in close proximity would be a 
" f ir s t - l in e "  detoxication system.
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TABLE 7-3
Activation of ra t and baboon (Papio anubis) hepatic microsomal 
glutathione S-transferase by sulphydryl reagents and detergents.
Activation agent*
Species
Rat Baboon
N-ethylmaleimide (0 .5  mM} 398 346
N-ethylmaleimide (0 .5  mM, 
then 0,5% Triton X-100} 362 212
N-ethylmalei mi de (0 .5  mM, 
a fte r  0.5% Triton X-100J 85 72
N-ethylmaleimide (0.5 mM, 
then 0.5% Lubrol PX} 319 214
N-ethylmaleimide CO*5 mM, 
then 0.5% Zwittergent 3-17T} 338 249
Iodoacetamide (1 mM} 257 189
Control 63 86
* Activation was stopped at 3 min a fte r  
addition of activation agent.
FIGURE 7-1
The rate of activation of hepatic microsomal GS-transferase by 
sulphydryl reagents.
Activation achieved by incubation of hepatic microsomes with 0.5 mM 
N-ethylmaleimide (solid  Tines), or 1.0 mM iodoacetamide (dashed lines). 
The reaction stopped by addition of equimolar d ith io th re ito l at the 
time indicated.
Species studied indicated by •  r a t ,  O baboon, A rhesus monkey and 
■ cynomolgus monkey.
Ratio of a c tiv ity  
as a function of 3 
in i t ia l  a c tiv ity  
towards 
h io ro -2 ,4 -d i ni trobenzene
0 2 4 6 8 10
Minutes
FIGURE 7-2
la tiv e
t iv i t y *
Glutathione S-transferases of baboon hepatic cytosol separated by 
iso e lec tric  focusing on Agarose gel.
r 10
100
30 -
40-
Fraction
* A c tiv ity  of glutathione S-transferases toward l-c h lo ro -2 ,4 -  
dinitrobenzene (.not corrected fo r protein concentration).
* *  Points on pH scale by reference to known proteins, extrapolation  
and in terpo lation assumed to be lin e a r.
FIGURE 7-3
Glutathione S-transferases of baboon hepatic microsomes separated by 
iso e lec tric  focusing on Agarose gel.
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*  A c tiv ity  of glutathione S-transferases toward l-c h lo ro -2 ,4 -  
dinitrobenzene (not corrected fo r protein concentration).
* *  Points on pH scale by reference to known proteins, extrapolation  
and in terpo lation assumed to be lin e a r.
CHAPTER 8
THE GLUTATHIONE S-TRANSFERASE ISOENZYMES OF THE NON-HUMAN PRIMATES
INTRODUCTION
The results presented in Chapter 6 demonstrated that the non-human 
primates* studied possessed considerable glutathione S-transferase  
a c tiv ity  in each of the tissues examined. In some non-human primate 
tissues, suchasthe l iv e r ,  the GS-transferase a c tiv ity  towards 
several substrates was 2 to 3 -fo ld  higher than that observed in human 
l iv e r  cytosol. The pattern of substrate s p e c ific ity  .in non-human 
primate tissues appeared to resemble more closely that observed with 
human liv e r  preparations than that found in the ra t.
Various methods have been used to study the individual isoenzymes 
present in ra t l iv e r  (Habig et a l , 1974), and from a consideration 
of the results obtained i t  was evident that the orig inal nomenclature 
which u tilis e d  a pre fix  indicating the class of substrate involved, 
such as aryl (Grover and Sims, 1964); alkyl (Johnson, 1966); alkene 
(Boy!and and Chasseaud, 1268); epoxide (Boy!and and Williams, 1965; 
F je l1stedt e t a l , 1973), was inadequate because the isolated isoenzymes 
had broad and overlapping substrate s p e c ific it ie s . The orig ina l 
c la s s ific a tio n , as applied to the "basic" ra t l iv e r  GS-transferases, 
was based on the order of elution of the GS-transferase a c tiv ity  
from carboxymethyl cellu lose columns (Habig et a l , 1974). The f i r s t  
stage in the p u rifica tio n  of the ra t l iv e r  preparations involved 
chromatographic separation of the basic and acidic proteins by 
DEAE-cellulose chromatography (Habig et a l , 1974 ) . The column
was equilibrated at pH 8.0 with a tris-H C l bu ffer. Approximately 80% 
of the soluble liv e r  protein was adsorbed onto the DEAE-cellulose, 
but 85% of the GS-transferase a c tiv ity  towards l-chloro-2,4-nitrobenzene  
was not retained. One or more of the GS-transferase isoenzymes may 
possibly have been adsorbed onto DEAE-cellulose as there were 
GS-transferase isoenzymes present in ra t l iv e r  which both bound to 
DEAE-cellulose and had low a c tiv ity  towards CDNB, and could thus 
escape detection (Pabst et a l , 1973; G ill ham, 1971). The proteins o f the non­
retained active fractions were then precip itated with ammonium 
sulphate,and a fte r  centrifugation , the precip itated protein was 
redissolved in phosphate buffer (pH 6 .7 ) ,  The.second stage of the 
p u rifica tio n  involved adsorption onto a column of carboxymethyl 
cellulose (CM 52). The CM-cellulose column was then eluted with a 
lin ea r gradient of KC1 (0-200 mM}.; 4 main peaks of GS-transferase 
a c tiv ity  were recovered in the eluate. The f i r s t  active frac tion  
which was eluted (designated"D"and"E"), was subsequently separated 
in to 2 d is tin c t isoenzymes on the basis of the a c tiv ity  of transferase 
E towards epoxides (F je lls te d t, 1973), and the a c tiv ity  of 
transferase D towards o-nitrophenylmethyl bromide. A s im ilar  
fractionation  procedure was employed by Kamisaka et a l . (1975 a&b) to 
separate the isoenzymes of human liv e r  cytosol. The column used 
was also DEAE-cellulose equilibrated with tris-H C l (pH 8 .0 ) ,  and 
the GS-transferases were eluted with the same bu ffer. Following 
prec ip ita tion  of the active fractions with ammonium sulphate, the 
concentrated GS-transferases were applied to a CM-cellulose column 
(CM 52). The "baste" human transferases were adsorbed onto the 
column and sequentially eluted with a lin ea r potassium chloride  
gradient (0-150 mM) in phosphate buffer. This sequential e lu tion  
resulted in 4 active fractions . The fraction  which eluted at the
-  262 -
lowest ionic strength conditions was fu rther resolved into 2 components 
to give a to ta l of 5 id e n tif ia b le  isoenzymes. These fractions were 
designated a ,  3 ,  y > e» in order of pi value (a 7.8 to e 8 .8 ) . The 
following year, Asaoka et a l . (1977). reported the separation of 
several GS-transferase isoenzymes from rhesus monkey l iv e r ,  although 
the method of p u rifica tio n  used involved an in i t ia l  p u rific a tio n  step 
prio r to DEAE-chromatography. The l iv e r  homogenate was f i r s t  treated  
with phosphoric acid to adjust-the pH to 4 .8 . The precip itated protein 
was removed and the pH of the supernatant fraction  adjusted to pH 7.0 . 
This fraction  was 70% saturated with ammonium sulphate, and the 
precipitated GS-transferases were separated and redissolved in 
phosphate buffer. A fter d ia lysis  against the same bu ffer, the 
GS-transferases were subjected to gel f i l t r a t io n  using a column 
containing Sephadex G-100. A fter gel f i l t r a t io n  the pH of the active  
fractions was adjusted to 8 .0 , and then applied to a DEAE-cellulose column.
The eluted frac tio n s , which possessed GS-transferase a c tiv ity  towards 
DCNB, were pooled, and a fte r  adjusting the pH to 6 .0 , the pooled 
fractions were applied to a column of CM-cellulose. A fter washing 
the column with buffer (pH 6 .0 ) ,  the a c tiv ity  was sequentially eluted  
with a lin ea r gradient of 0-200 mM NaCl. The elution resulted in 5 
separate fractions each containing GS-transferase a c tiv ity . A 
previous study where the GS-transferase a c tiv ity  was s im ila rly  
applied to a CM-cellulose column resulted in only one active fraction  
( Ito  et a l , 1974), which was thought to be due to the pH at which 
the chromatography was conducted. Further p u rifica tio n  of frac tio n  IV 
(the fraction  containing the highest GS-transferase a c tiv ity  towards 
DCNB), was conducted using 2 additional CM-cellulose separations and 
one separation stage using hydroxapatite chromatoqraphy. The 
properties of this major rhesus monkey liv e r  GS-transferase have
been reported (Asaoka and Tafcahashi, 1977}.
Evidence that there were other GS-transferase isoenzymes with more 
acidic pi values than the "basic" isoenzymes already separated, was 
provided by Marcus et a l . (1978) (transferase p ) ,  Awasthi et a l . (1980) 
(transferases to and if;}, Mar holm et a l . (1981) (transferase u) and 
Guthenberg and Mannervik (1981} (transferases p and t t ) .
Selective p u rifica tio n  of the glutathione S-transferases by means of 
immobilised ligand chromatography have been investigated by several 
groups. An immobilised GSH-affinfty matrix was used by Simons and 
Vander Jagt (1977). In the preparation of the GSH-affinity matrix 
the GSH was coupled to an epoxy-activated-Sepharose (6B) via the 
sulphur atom of GSH. This a f f in i ty  matrix was successfully used to 
purify  the GS-transferases from human liv e r  cytosol, and subsequently 
from ra t and porcine liv e r  (Simons and Vander Jagt, 1981).
S-Hexylglutathione coupled to epoxy-activated-Sepharose (6B) by the 
a-amino group of the y-glutamyl group of GSH was reported by Aronsson 
e t a l . (1978), and used by Guthenberg and Mannervik (1979), and 
Mannervik and Guthenberg (1981). In e a r lie r  work, a glutathione- 
bromosulphthalein conjugate was used and the a f f in i ty  ligand 
immobilised onto cyanogen bromide-activated-Sepharose (4B) (C lark, 
1977). This a f f in i ty  matrix was subsequently used to examine the 
GS-transferases from a variety  of sources (Clark and Dauterman,
1982). The use of a s im ilar a f f in i ty  matrix was reported by 
Wolkoff et a l . (1979), although some d if f ic u lty  was reported in 
the subsequent elution of the GS-transferases due to the high 
binding a f f in i ty  of bromosulphthalei.n with some GS-transferases.
A cholic acid a f f in i ty  matrix was used by Pattinson (1981), to
d iffe re n tia te  the ra t GS-transferase sub-units 3 and 4. Various 
glutathione a f f in i ty  matrices u t ilis in g  various a lip h a tic  diamine 
spacers have been investigated by Inoue et a l . (1981), to 
p re fe re n tia lly  iso la te  various ra t l iv e r  GS-transferases.
The th ird  major method of p u rific a tio n  of the GS-transferases from 
diverse sources involved the technique of iso e lec tric  focusing using 
various in e rt support gels. Clark et a l . (1973), used th is  technique 
to compare the GS-transferase isoenzymes of insect and mammalian l iv e r  
preparations. Subsequently Hales et a l . (1978) u tilis e d  polyacrylamide 
gels (K rig le y ,-1971) to examine the GS-transferase isoenzymes of ra t 
l iv e r  and kidney. A s im ilar approach was employed by Kamisaka et a l . 
(1975), and Askelof et a l . (1975) to study the isoenzymes of human 
l iv e r ,  and also by Koskelo (1983) to study the differences in the 
GS-transferases obtained from human l iv e r ,  kidney, lung, spleen and 
placenta. An additional technique fo r the separation of the various 
isoenzymes, by v irtue  of th e ir  individual pi characteris tics , was 
provided by the development of "chromatofocusing" (Sluyterman and 
Wijdenes, 1978). The method u tilis e s  the princip le  that a pH 
gradient can be produced on an ion exchange resin by taking advantage 
of the buffering action of the charged groups of the ion exchange 
m atrix. Thus, a chromatography column containing a suitable ion 
exchange resin can be equilibrated with buffer at a p articu la r pH,' 
and subsequently eluted with another buffer at a second pH. As the 
charged groups are t it ra te d  with the second b u ffer, an in ternal pH 
gradient is established in the column. As a resu lt of the focusing 
effects which occur within the column, the protein under examination 
is concentrated at its  characteris tic  pi value, and can be eluted  
with very high resolution. This technique has been applied to the
separation of the GS-transferases present in ra t l iv e r  by Jensson et a l . 
(1982), using an ion exchange resin PB-118 (Pharmacia) equibrated at 
pH 11.0, and subsequently eluted using an ampholyte containing bu ffer.
A to ta l of 7 isoenzymes, each possessing GS-transferase a c tiv ity  
towards l-chloro-2,4-d in itrobenzene were iso lated .
For the comparative study of the glutathione S-transferases which 
occur in the various tissues of non-human primates, i t  was decided 
to employ separation procedures which involved a minimum of 
pretreatment of the individual sample. Within the context o f the 
studies described in th is  thesis , the re la tiv e  abundance of the 
various GS-transferase isoenzymes rather than the exhaustive 
characterisation of any particu la r GS-transferase was evaluated.
EXPERIMENTAL
Separation o f the "basic" GS-transferase isoenzymes 
A ll stages in the preparation of the cytosol frac tio n s , and subsequent 
p u rifica tio n  of the GS-transferase isoenzymes were conducted in a cold 
room at 4°C. The various tissue homogenates were prepared as deta iled  
in Chapter 2. To separate the GS-transferase isoenzymes present in 
the various tissues of non-human primate, the prelim inary step was 
adsorption chromatography using DEAE-Sephadex. Chromatography was 
conducted at pH 7.4 in 20 'mM tris-H C l buffer; a t th is  pH, the "basic" 
GS-transferases should not be adsorbed onto the DEAE-Sephadex, whereas 
the "neutral" and "acidic" proteins would be adsorbed. The column 
dimensions were 20 mm x 44 cm, and the flow rate was 0.6 ml/min.
The column was equilibrated with 20 mM tris-H C l bu ffe r, and a fte r  
application of the sample, elution was continued with the same b u ffe r.
The "basic" GS-transferase isoenzymes were present in the early  
eluant fractions (flow-through frac tio n s ). A lin e a r sodium chloride 
gradient 0-200 mM was employed to subsequently e lute the adsorbed 
"neutral" and "acidic" GS-transferase isoenzymes. Both the flow­
through fractions and the sa lt-e lu ted  frac tio n s , showing GS-transferase 
a c tiv ity  towards CDNB, were in d iv id ua lly  pooled and dialysed against 
sodium phosphate buffer (0.01 M, pH 7 .0 ) .  The dialysed fractions  
were concentrated by u l t r a f i l t r a t io n  to approximately 8-12 ml. The 
volume of concentrated eluant was adjusted to 20 ml and applied to a 
chromatography column containing the GSH-affin ity matrix (bed volume 
-  30 m l). The GSH-affinity matrix was prepared as described by 
Simons and Vander Jagt (1977) (Chapter 2 ) , and equilibrated with 
22 mM potassium phosphate bu ffer, pH 7 .0 . The GSH-affinity column 
was washed through with the same Buffer u n til the eluant was protein- 
free . The presence of protein in the eluate was detected by 
monitoring the absorbance at 280 nm using an SP-400 spectrophotometer 
(Pye-Unicam). The GS-transferases which were adsorbed onto the 
a f f in i ty  matrix were eluted with 0.05 M tris-H C l buffer (pH 9 .6 ) 
containing 5 mM glutathione. The eluate ( -  80 ml) which contained 
the "basic" GS-transferase isoenzymes, was rapidly adjusted to 
pH 6.7 and dialysed overnight against 10 l i t re s  of 0.01 M phosphate 
buffer (pH 6 .7 ) . Following d ia ly s is , the proteins were concentrated 
by u l t r a f i l t r a t io n .  The concentrated GS-transferase extract (20 ml) 
was then applied to a column of carboxymethyl cellu lose (CM 52)
20mm x 46 cm (bed volume approximately 150 m l), which had previously 
been equilibrated with 0.01 M phosphate buffer (pH 6 .7 ) a t a flow  
rate of 0.6 ml/min, The adsorbed GS-transferases were eluted with 
a lin ea r gradient of 0-200 mM NaCl in the eq u ilib ra tio n  bu ffer. 
Fractions (6 ml) were collected and assayed fo r GS-transferase
a c tiv ity  towards CDNB (1 .0  mM) and GSH (1 .0  mM). The eluted fractions  
containing GS-transferase a c tiv ity  (5 in to ta l)  were designated as 
fractions "A" to "E", and were each concentrated by u l t ra f i l t r a t io n  
to a small volume (1-2 m l). The designation of the fractions is an 
arb itra ry  designation based on the order of e lu tio n , and does not imply 
any s im ila r ity  to the early  nomenclature used by Habig et a l . (1974). 
The concentrated sample was removed from the dailysis  tubing, which 
was then washed with 2 x 1 ml of phosphate buffer (pH 6 .5 ) ,  and 
f in a l ly  the to ta l fraction  was d iluted to 5 ml using the same bu ffe r.
The 5 ml fractions of specific  GS-transferase isoenzymes were assayed 
fo r GS-transferase a c tiv ity  using CDNB (l-.O-mM), GSH (1 .0  mM) in a 
to ta l reaction volume of 3 ml of phosphate buffer (pH 6 .5 ) .
Separation of the "acidic" and "neutral" GS-transferase isoenzymes 
The "acidic" and "neutral" GS-transferases eluted from the DEAE- 
Sephadex column were pooled, dialysed overnight against 10 l i t r e s  of 
0.01 M phosphate buffer (pH 6 .7 ) and then concentrated by u lt ra f i l t ra t io n  
u n til the volume was reduced to approximately 3-5 ml. The concentrated 
protein was removed from the d ia lysis  tube which was then washed with  
3 ml of phosphate buffer (pH. 6 .7 ) ,  and f in a l ly  d ilu ted to 10 ml with  
the same buffer. The to ta l fraction  was applied to a G SH -affin ity  
column as detailed fo r the "basic" GS-transferases. The subsequent 
elution from the a f f in i ty  m atrix, and the concentration of the active  
frac tio n s , was also as detailed fo r the "basic" transferases. The 
concentrated "neutral plus acidic" GS-transferase fraction  was 
dissolved in 5 ml of phosphate buffer and designated as frac tio n  "F".
Iso e lec tric  focusing
Iso e lec tric  focusing was conducted in 1 mm thick agarose gels, 
containing agarose (IEF grade), sorbitol and ampholytes in the pH
range 3-10.5 (Pharmacia). The apparatus, both the electrophonesis 
chamber and the power supply, were constructed at Huntingdon Research 
Centre fo r the purpose of th is study (Chapter 2 ). The progress of the 
iso e lec tric  focusing experiments were monitored by the migration and 
subsequent focusing of coloured protein markers of known pi 
characteristics (pi ca lib ra tio n  proteins BDH, U .K .).
MoleCula-r weight determination
Molecular weight determination of the GS-transferases was conducted
in a 20 mm x 82 cm column of Sephadex G-100 superfine equilibrated
with tris-H C l buffer (5 .0  mM, pH 7 .5 ) , containing 100 mM potassium
chloride. Proteins of known molecular weight were used to ca lib ra te
the column (aprottnin 6,500; cytochrome c 12,400; carbonic anhydrase
29,000; ovalbumin 45,000; albumin (BSA) 66,000). Blue dextran
(MW >2 x 106) was'used to determine the void volume of the column.
The flow rate was maintained at 0.6 ml/min during the experiments,
the d irection of flow being against g rav ity . Fractions each of 3 ml
were collected. The column volume was 256 ml (V t) , and the void
volume (V0 ) was determined as 84 ml with blue dextran. The respective
Kav values fo r each ca lib ra tion  protein and the GS-transferases from
various tissues (eachconducted separately}, was calculated from
Kav = ^ w h e r e  Ve was the volume of e lution of each p a rticu la r  
Vt “ Vo
protein . For the determination of the molecular weight of the 
GS-transferase proteins, samples of concentrated G SH-affin ity eluates 
were obtained from homoaenates of rhesus monkey, baboon and human 
l iv e r ,  and rhesus monkey and baboon kidney.
ChromatofOcusing
The technique of chromatofocusing was used in an attempt to provide
a rapid separation of the GS-transferase isoenzymes present in the 
G SH-affinity eluates of homogenates of various tissues of non-human 
primate and human l iv e r .  The chromatofocusing experiments were 
conducted using the following conditions. The ion exchange resin  
PB-118 (Pharmacia) was swollen in the primary buffer (0.025 M 
tr ie th y l amine-HCl, pH 1 1 .0 ), and degassed under vacuum p rio r to 
packing the column 10 mm x 15 cm (bed volume approximately 12 m l).
The column was equilibrated with the primary buffer (200 m l), and a 
sample of GS-transferase (approximately 4 mg protein) was applied to 
the column in primary buffer. The column pH gradient was established 
by applying the secondary (e lu tio n } buffer which consisted of 
pharmalyte-HCl, pH 8-10.5 (d ilu ted  1 :45 ), and adjusted to pH 7 .0 . 
Approximately 150 ml of the secondary buffer was required to change 
the column eluate to pH -  7 .2 . Fractions of 3 ml were collected and 
assayed fo r GS-transferase a c tiv ity  towards CDNB. Cytochrome c 
(p i >10.6) was completely excluded from the PB-118 gel and, therefo re , 
was used to indicate where the pH gradient s tarted. Cytochrome c was 
chromatofocused separately at the s ta rt of these experiments, and not 
by inclusion into any individual separation, as non-specific binding 
of proteins to cytochrome C can occur.
Enzyme parameters
To determine the substrate s p e c ific itie s  of the "basic" and "acidic  
plus neutral" GS-transferases, the fractions "A" to "E" (post- 
CM-cellulose chromatography}, and fraction  "F" (post-DEAE-Sephadex 
and G SH-affinity chromatography) were assayed using the various 
GS-transferase substrates, using conditions detailed in Chapter 6.
In addition, the specific  a c tiv ity  of the various fractions towards 
the substrate p-nitrobenzyl chloride (1 .0  mM;, GSH 1.0 mM) was also
determined. The k inetic  constants Km and Vmax were determined using 
CDNB and DCNB and the major "basic" fractions . The data were analysed 
by lin ea r regression analyses of double reciprocal plots (Uneweaver- 
Burk) or S/V vs, S plots (Woolfe}. In h ib itio n  by bromosulphthalein, 
haematin, or S-hexylglutathione were examined at fixed in h ib ito r  
concentrations using fractions "C", "D" and "F" (2 "basic" and the 
combined "neutral and acidic" fra c tio n ).
RESULTS
Separation of GS-transferase isoenzymes
The procedure adopted fo r the iso lation  of the various GS-transferases 
is shown as Figure 8-1 . The chromatographic separation of the 
cytosolic GS-transferases from crude tissue homogenates using DEAE- 
Sephadex chromatography resulted in 2 major fractions being iso lated . 
These 2 frac tio n s , designated I and I I ,  comprised the "basic" 
GS-transferases (frac tio n  I ) ,  and the "neutral plus acidic" 
GS-transferases (frac tio n  I I ) .  Both these fractions were separately  
purified  using aG S H -affin ity  m atrix. The G S -tran s fe rases '(I), a fte r  
elution from the GSH-affinity m atrix, d ia lysis  and concentration, 
were fu rther fractionated using CM-cellulose chromatography. This 
procedure resulted in the sequential elution of 5 fractions which were 
designated "A", "B", "C", "D" and "E". The fraction  of GS-transferase 
isoenzymes eluted from the DEAE-Sephadex column with the sodium 
chloride gradient (frac tio n  I I )  were dialysed and concentrated, but 
were not purified  fu rther a fte r  elution from the GSH-affinity matrix: 
this fraction  was designated fraction  "F",
Hepatic "basic" glutathione S-transferase isoenzymes
Rhesus monkey liv e r
A sample of rhesus monkey liv e r  homogenate 80 ml (= 20 g liv e r )  
containing 3,330 units of GS-transferase a c t iv ity  was applied to the 
DEAE-Sephadex column. (A unit of GS-transferase a c tiv ity  is defined 
as 1 yM of Droduct formed min- "! mg protein""! using 1 mM 1-ch lo ro -2 ,4 -  
dinitrobenzene as substrate unless stated otherwise.) Approximately 
65% of the applied GS-transferase a c tiv ity  was eluted from the DEAE-
Sephadex column in the eq u ilib ra tio n  buffer (frac tio n  I ) ,  and a fu rther 
23% eluted during the sodium chloride gradient (frac tio n  I I ) .  When the 
GS-transferases present in fraction  I were adsorbed onto the GSH-affinity  
matrix and subsequently eluted, 84% of the applied GS-transferase 
a c tiv ity  was recovered [55% of the orig inal cytosol a c t iv ity ) .
Subsequent chromatography of the eluate obtained from the G SH-affin ity  
matrix using CM-cellulose resolved the "basic" GS-transferases into 5 
fractions. The GS-transferase a c tiv ity  (un its ) present in each of 
the fractions were:"“A", 30; "B", 104; "C", 372; " D \  970; "E", 87.
These values corresponded to 1, 3, IT , 29 and 3% respectively of the 
orig inal a c tiv ity  present in the rhesus* l iv e r  cytosol (Table 8 -1 ,
Figure 8-2 (a) and (b )) . These fractions sum to a to ta l of 86% of 
the GS-transferase a c tiv ity  applied to the CM-cellulose column.
Baboon liv e r
The results obtained following the p u rifica tio n  of the GS-transferases 
from an equivalent sample of baboon hepatic cytosol, were s im ila r , 
although the y ie ld  in terms of the orig inal a c tiv ity  were s lig h tly  
lower (84, 46 and 38% a fte r  DEAE-Sephadex, GSH-affin ity and CM-cellulose 
chromatography respective ly). As described fo r the rhesus monkey live r  
cytosol,GS-transferase a c tiv ity  was eluted from the CM-cellulose in 5 
frac tio n s . The GS-transferase a c tiv ity  (un its ) present in each of the 
fractions "A" to "E" were: "A", 64; "B", 120; "C", 549; "D", 675;
"E", 157. These values corresponded to approximately 1 ,5 , 3 , 13, 16 
and 4% respectively of the orig inal a c t iv ity  present in the baboon 
hepatic cytosol (Table 8 -1 , Figure 8-3 (a) and (b ) ) . The major 
difference observed between the purified  hepatic GS-transferases of 
the rhesus monkey and baboon cytosol, was that the y ie ld  of frac tio n  "D" 
from the baboon was 16% of the  orig inal a c t iv ity  whereas in the
corresponding fraction  from the rhesus monkey liv e r  cytosol i t  was 29%.
Human liv e r
The sample of human liv e r  cytosol fractionated using the same procedure 
resulted in 81, 51 and 40% of the to ta l GS-transferase a c t iv ity  being 
recovered a fte r  the DEAE-Sephadex, GSH-affinity and CM-cellulose 
chromatography respectively. The a c tiv ity  was also eluted from the 
CM-cellulose column in 5 separate fractions . The GS-transferase 
a c tiv ity  (un its ) present in each of the fractions "A" to "E" were:
"A", 17; "B", 31; "C", 103; "D", 293; " E \  65. These values 
corresponded to approximately 1, 2, 8, 23 and 5% of the orig inal 
GS-transferase a c tiv ity  present in the human hepatic cytosol (Table 8-1, 
Figure 8-4 (a) and (b)_).
Hepatic "neutral plus acidic" glutathione S-tranSferase isoenzymes 
The GS-transferase a c tiv ity  eluted from the DEAE-Sephadex column with  
the sodium chloride gradient (fractio n  I I ) ,  indicated that approximately 
31% of the orig inal a c t iv ity  present in baboon hepatic cytosol 
comprised the "neutral plus acidic" GS-transferases. In the samples 
of rhesus monkey and human liv e r  cytosol, the corresponding fractions  
accounted for 23 and 22% respectively of the orig inal GS-transferase 
a c t iv ity . As stated e a rlie r,"  the GS-transferase a c t iv ity  comprising 
fraction  I I  was purified  only by G SH-affinity chromatography. The 
subsequent a c t iv ity  eluted from the a f f in i ty  matrix represent 
14% (rhesus), 18% (baboon) and 15% (human) of the orig inal cytosol 
GS-transferase a c tiv ity  (Table 8 -1 ).
Renal GS-transferase isoenzymes
The same fractionation  procedures used fo r hepatic cytosol was applied
to renal cytosol obtained from the rhesus monkey and the baboon 
(Table 8 -2 ). Following DEAE-Sephadex chromatography, frac tion  I 
("basic" glutathione S-transferases) comprised 50 and 46% of the 
a c tiv ity  applied to the column in the rhesus monkey and baboon 
respectively, whereas fraction  I I  (the "neutral plus acidic"  
GS-transferases) represented 25 and 36% respectively. Following 
CM-cellulose chromatography of fraction  I from each renal cytosol, 
as observed with the hepatic cytosol, the "basic" GS-transferases 
could be divided into 5 frac tio n s , although the to ta l GS-transferase 
a c tiv ity  was re la tiv e ly  lower (31% of the orig inal a c t iv ity ) .  The 
respective proportions of GS-transferase a c tiv ity  recovered in each 
fraction  from rhesus monkey and baboon renal cytosol were approximately, 
"A", 2 and 1%; "B", 1 and 2%; "C", 16 and 12%; "D", 10 and 13%;
"E", 2 and 2% respectively. Following p a rtia l p u rifica tio n  using the 
‘G SH-affinity m atrix, the "neutral and acidic" GS-transferases 
represented 18 and 25% of the GS-transferase a c t iv ity  present in the 
orig inal renal cytosol of the rhesus monkey and baboon respectively  
(Table 8 -2 , Figures 8.5 (a ) and (b ), and 8-6 (a) and (b )) .
Protein associated w ith  GS-transferase a c tiv ity
The protein content of the various purified  GS-transferases (fractions  
"A" to "F"), obtained from the hepatic cytosols of the rhesus monkey, 
baboon and human, are presented in Table 8-3. The protein content of 
the "basic" GS-transferase isoenzymes (the to ta l of fractions "A" to 
"E"), purified  from the rhesus monkey hepatic cytosol, was 42 mg.
This amount of protein corresponded to approximately 3% of the to ta l 
cytosolic protein. A fu rther 0.3% of the cytosolic protein was 
recovered in the "neutral plus acidic" fraction  (fractio n  "F").
The amount of protein in the "basic" GS-transferases of baboon hepatic
cytosol was s lig h tly  larger (4%, 58 mg), w hilst the proportion (1.6%,
20 mg) was obtained from human liv e r  cytosol was lower (Table 8 -3 ).
The corresponding amounts of protein associated with the "neutral plus 
acidic" GS-transferases were 0.4% (5 mg) and 0.1% (2 mg) in baboon and 
human hepatic cytosol respectively. The to ta l amount of protein in a ll  
the purified  GS-transferases of hepatic cytosol were 45 mg (rhesus 
monkey), 63 mg (baboon) and 24 mg (human), which corresponds to about 
3, 4 and 2% of the soluble protein present in the orig inal hepatic 
cytosol respectively.
Calculation of the amounts of protein associated with any individual 
"basic" GS-transferase fraction  showed that in the purified  extracts  
of rhesus monkey hepatic cytosol obtained a fte r  CM-cellulose 
chromatography, fraction  "D" contained the largest proportion of 
protein of any "basic" fraction  (13 mg, 33%). The next highest 
proportion was in fraction  "B" (10 mg, 24%). Fractions "C", "A" and 
"E" contained 18, 15 and 11% respectively. In the "basic" 
GS-transferase fractions purified  from baboon hepatic cytosol, 
fraction  "D" contained the largest amount of protein (16 mg, 27% of 
the to ta l "basic" GS-transferase pro te in ). As observed with 
the rhesus monkey, fraction  "B" contained the next highest amount 
of protein (15 mg, 26%). The remaining 3 fractions contained between 
6. mg (10% fraction  "E") and 12 mg (22%, fraction "A"). In the human 
l iv e r  cytosol, the purified  "basic" fraction  "D" contained the 
highest amount of protein (6 mg, 32%), with 4 mg (22%) in fraction  
"B", 4 mg (21%) in fraction  "A" and 3 mg (14%) in fraction  "E"; 
fraction  "C" contained the lowest amount (2 mg, 12% of the to ta l 
"basic" pro te in ). Measurement of the amounts of protein in each of 
the "basic" GS-transferase fractions obtained from non-human primate
renal cytosol, indicated that the protein associated with the "basic" 
GS-transferases was 14 mg (2% of the cytosolic protein) in the rhesus 
monkey, and 19 mg (.2%). in the baboon. In the purified  "basic" 
GS-transferases of rhesus monkey renal cytosol, fractions "A" and "D" 
contained s im ilar amounts of protein , approximately 4 mg, with the 
other fractions containing 3 mg ("B")_, 2 mg ("C") and 1 mg ("E").
These amounts of protein corresponded to 27, 26, 22, 18 and 8% of the 
to ta l protein associated with the "basic" isoenzymes. The corresponding 
amounts and proportions obtained from the baboon renal cytosol were: 
fraction  "D", 6 mg (31%); fraction  "A” , 5 mg (26%); fraction  "B", 4 mg 
(21% );-fraction  "C", 3 mg (16%); fraction  "E", 1 mg.(6%) (Table 8 -4 ).  
The protein associated with the "neutral plus acidic" transferase  
fraction  of renal cytosol was approximately 0.7 mg in both the 
rhesus monkey and baboon.
Specific a c t iv ity  of the isolated "basic" GS-transferase Isoenzymes 
I t  can be seen from Tables 8-1 and 8-2 that each of the 5 "basic" 
glutathione S-transferases isolated from the liv e r  and kidney cytosol 
from both the rhesus monkey and baboon possess GS-transferase a c t iv ity  
towards CDNB, The "basic" isoenzymes isolated from human l iv e r  also 
show a s im ilar pattern of a c t iv ity  towards th is  substrate, although 
the re la tiv e  GS-transferase a c tiv it ie s  probably re fle c t the lower 
specific  a c t iv ity  (1.27 units/mg) present in the orig inal cytosol 
in man than in e ith er the rhesus monkey (2.52 units/mg) or baboon 
(2.89 units/mg).,
1-Chi0ro-2,4-dinitrobenzene
The specific  a c t iv it ie s  fo r the isolated individual isoenzymes obtained 
from the hepatic cytosol of the various species examined are given in
Table 8-6. In the rhesus monkey, the highest specific  a c t iv ity  of any 
of the "basic" GS-transferases was observed in fraction  "D" (72 un its / 
mg), w hilst the specific  a c t iv ity  of fraction  "C" was 48.7 units/mg. 
The specific a c tiv it ie s  of the other fractions from rhesus monkey 
hepatic cytosol were: "A", 4 .9 ; "B", 10.6; "E", 19.1 units/mg. 
Measurement of the individual specific  a c t iv it ie s  of the "basic" 
isoenzymes purified  from baboon l iv e r  cytosol indicated that fraction  
"C" had the highest specific  a c t iv ity  (64.4 units/ma) and that of 
fraction  "D" was 43.2 units/mg. Fraction "E" from the baboon liv e r  
had a specific  a c t iv ity  of 27.0 units/mg w hilst those designated "A" 
and "B" had values of 5.2 and 7,9 units/mg respectively. The specific  
a c tiv it ie s  of the ''basic" GS-transferases isolated from human liv e r  
showed that fo r each isoenzyme the magnitude of the value measured 
was sim ilar to that obtained for the non-human primates. Both "basic" 
fractions "C" and "D" possessed almost the same specific  a c t iv ity ,
45.8 and 46.7 units/mg respectively. The specific  a c t iv ity  of fraction  
"E" was 24.7 units/mg, which was between the values obtained fo r  the 
non-human primates. The 2 other fractions ("A" and "B") had lower 
specific  a c tiv it ie s  (less than 10 units/mg) which was also observed 
in fractions from the rhesus monkey or baboon.
The specific  a c t iv it ie s  of the "basic" GS-transferases isolated from 
the renal cytosol of non-human primates were lower than those 
obtained from the hepatic cytosol. In the purified  fractions from 
both the rhesus monkey and the baboon renal cytosol, the isoenzyme 
comprising fraction  "C" possessed the highest specific  a c t iv ity ,
18.6 and 13.2 units/mg respectively. The specific  a c t iv it ie s  of the 
isoenzymes comprising fractions "D" and "E" from each species were 
s im ila r, 8.0 and 7.5 units/mg (fraction  "D") and 4.0 and 5.1 units/mg
(fraction  "E"). The remaining 2 "basic" fractions ("A" and "B") from 
each cytosol had low specific  a c tiv it ie s  (<1.9 units/mg) (Table 8 -7 ).
Other substrates
The 2 hepatic and 2 renal GS-transferase fractions from each species, 
which contained the most active GS-transferase a c tiv ity  towards CDNB 
(fractions "C" and "D"), were also examined to determine th e ir ;  
specific  a c t iv ity  towards other substrates. The additional substrates 
used were 1 ,2-dichloro-4-nitrobenzene (DCNB), p-nitrobenzylchloride  
(p-NBC), ethacrynic acid (EA)_ and trans-4-phenyl-3-butene-2-one (t-PBO).
1,2-Dichloro-4-nitrobenzene
The specific  a c t iv it ie s  of the "basic" GS-transferases towards DCNB 
were between 0.17 and 0.42 units/mg in the fractions from hepatic 
cytosol of each species, and between 0.06 and 0.11 in the fractions  
from the renal cytosol. The specific a c t iv it ie s  of the isoenzymes . 
towards DCNB appeared to 'toirror" those measured towards CDNB, except 
that they were 2 orders of magnitude lower (Table 8 -6 ).
p-Nitrobenzylchloride (p-NBC\
When p-nitrobenzylchloride was used, the specific  a c tiv ity  was highest 
in fraction  "D" obtained from e ith er the rhesus monkey or human l iv e r  
(0.79 and 0.36 units/mg respectively): the specific  a c t iv ity  from the 
baboon was 0.27 units/mg. Values of between 0.27 and 0.53 units/mg 
were obtained fo r the specific  a c tiv it ie s  of the other major hepatic 
isoenzyme (fractio n  "C").
Ethacrynic acid (EA)
A c tiv ity  towards ethacrynic acid was s im ilar in each fraction  isolated
from e ith e r of the 2 non-human primates or man. The respective specific 
a c tiv it ie s  obtained in frac tion  "G" were 0.18 units/mg (rhesus and 
baboon l iv e r )  and 0.09 units/mg (human l iv e r ) ,  and in fraction  "D" 
were 0.27 and 0.18 units/mg in rhesus monkey and baboon l iv e r  
respectively, and 0.15 units/mg in human liv e r  (Table 8 -6 ).
The substrate s p e c ific ity  of fractions "C" and "D" isolated from 
e ith er rhesus monkey or baboon renal cytosol were s im ilar to that 
obtained using the corresponding hepatic cytosol, but the magnitude 
of the specific  a c t iv it ie s  was lower. The ra tio  of the hepatic specific 
a c tiv it ie s  obtained when p-NBC was used as a substrate to that when 
DCNB was employed, was approximately 2 fo r both fractions "C" and "D" 
in the rhesus monkey, whereas in the kidney the ra tio  was 1.4 fo r  
fraction  "C" and 2.2 fo r fraction  "D", The ra tio  of the specific  
a c tiv it ie s  towards ethacrynic acid and DCNB in the rhesus monkey kidney 
was approximately h a lf that measured in the l iv e r .  In frac tion  "D" 
of the renal cytosol obtained from the baboon, the ra tio  of GS- 
transferase a c tiv it ie s  towards each of the substrates DCNB, p-NBC 
and EA was approximately u n ity , whereas the ratios  calculated fo r  
fraction  "C" more closely resembled those obtained with the same 
frac tion  isolated from the hepattc cytosol.
trans-4-Phenyl-2-butene-2-One (t-PBO)
No enzyme a c tiv ity  was measured towards t-PBO with any of the hepatic 
or renal "basic" isoenzyme fractions (Tables 8-6 and 8 -7 ).
Specific a c tiv it ie s  of the isolated "neutral plus acidic" GS-transferase
isoenzymes
The specific  a c tiv it ie s  of the "neutral plus acidic" GS-transferases 
(frac tio n  "F") obtained from e ith er the l iv e r  or kidney cytosol of the 
rhesus monkey and the baboon, together with fraction  "F" obtained from 
human l iv e r ,  are tabulated in Table 8-8. Using CDNB, the specific  
a c tiv it ie s  obtained fo r the hepatic ’’neutral and acidic" isoenzyme 
fraction  were 130 units/mg (rhesus), 149 units/mg (baboon) and 
113 units/mg (human). The corresponding specific  a c tiv it ie s  fo r  
the p a r t ia lly  purified  fraction  ("F") from renal cytosol were 72 u n its / 
mg (rhesus) and 107 units/mg (baboon),
The specific  a c t iv it ie s  towards the dihalogen-substituted nitrobenzene 
DCNB were much lower; 0.32 units/mg (rhesus), 0.36 units/mg (baboon) 
and 0.12 units/mg (human) in hepatic cytosol, and 0.10 units/mg and 
0.15 units/mg in renal cytosol of the rhesus monkey and baboon 
respectively. The specific  a c t iv it ie s  of the "neutral plus acidic"  
isoenzymes when p-NBC was used as a substrate were between 0.38 and 
0.5 units/mg in the hepatic frac tio n s , and between 0.21 and 0.27 u n its / 
mg i'n the renal fractions , When ethacrynic acid was used as a 
substrate, the corresponding values were between 0,21-0.31 units/mg 
( l iv e r ) ,  and 0.14-0,18 units/mg (kidney).
In contrast to the observations made with the "basic" GS-transferases, 
the purified  "neutral plus acidic" isoenzymes possessed detectable  
a c tiv ity  towards the substrate t-PBO. The specific  a c tiv it ie s  in the 
hepatic cytosol were 0.67 units/mg (rhesus), 0.04 units/mg (baboon) 
and 0.02 units/mg (human), w hilst they were 0.01 units/mg (rhesus) or 
0.02 units/mg (baboon) in the renal cytosol.
Kinetic parameters and in h ib itio n  characteristics
When CDNB was used as a substrate with fraction  "C", the Km obtained
from a Woolfe plot (S/V vs. S ), was 0.48 nM fo r the human isoenzyme.
With the corresponding fractions from the rhesus monkey and baboon 
l iv e r ,  the Km values were 0.37 mM and 0.30 mM respectively. The 
corresponding Km values with fractton  "D" of human, rhesus and baboon 
l iv e r  were 0 .14 , 0.32 and 0.47 mM respectively (Table 8 -9 ). The 
results also show that the Vmax values fo r each fraction  were very 
sim ilar (50-96 yM/min/mg) in a ll  of the species investigated. When 
DCNB was used, the Km values obtained from human liv e r  fractions "C" 
and "D" were 0.60 and 0.82 mM respectively. For.the corresponding 
fractions from the rhesus monkey the Km values were 0.35 and 0.41 mM 
respectively, w hilst the a f f in i ty  in the baboon fraction  was s lig h tly  
lower (1.17 and 0.85 mM respectively) (Table 8 -9 ).
In h ib ition  of the GS-transferase a c tiv ity  towards CDNB was e'xamined in  
the "basic" "C" and "D" fractions and the "neutral and acidic" 
fraction  "F" from each species. The in h ib ito rs  used were 
bromosulphthalein, haematin and S-hexylglutathione. The GS-transferase 
a c tiv ity  measured towards CDNB was reduced with each in h ib ito r . The 
extent of in h ib itio n  of the "basic" fractions was greatest in the 
presence of haematin (1 yM): man, 51% (in h ib itio n  in"both "C" and "D" 
fractions was equal); the extent of in h ib itio n  was greater in the 
rhesus monkey ("C" -  721; "D" -  66%), and baboon ("C" -  74%; "D" -65%) 
(Table 8 -10). The "neutral and acidic" fractions of each species were 
inh ib ited  to a lesser extent; man, 24%; rhesus monkey, 27%; baboon, 37%. 
Using higher concentrations of the in h ib ito r S-hexylglutathione (10 yM), 
GS-transferase a c tiv ity  was reduced by approximately h a lf; the extent of 
in h ib itio n  in man was ("C" -  53%; "D" -  43%), rhesus monkey ("C" -  58%;
"D", 46%) and baboon ("C" -  50%; "D" -  43%). The a c tiv ity  of the 
"neutral plus acidic" fraction  ("F") was, as observed with haematin, 
inhib ited less than that of the "basic" fractions (man -  25%; 
rhesus -  30%; baboon -  26%) (Table 8 -10). Bromosulphthalein (10 yM) 
was the least potent of the inh ib ito rs  examined with a s im ila r level 
of in h ib itio n  in both fractions "C" and "D" from e ith er of the non- 
human primate species (rhesus -  16-21%; baboon -  14-18%); the 
fractions obtained from human liv e r  were inhib ited to a s lig h tly  
lesser extent (8-11%). As observed with the other in h ib ito rs , the 
effects  of bromosulphthalein on the "neutral plus acidic" frac tio n  
was re la t iv e ly  lower (between 7 and 11%) in each of the species 
examined. Bromosulphthalein is  metabolised to a glutathione 
conjugate,and the resulting conjugate could also exh ib it product 
in h ib itio n  of the GS-transferase isoenzymes.
Molecular Weight determination
The estimation of molecular weight of the glutathione S-fransferases 
was achieved by gel f i l t r a t io n  using Sephadex G-100. The Kav values 
obtained fo r reference proteins are given in Figure 8 -7 , which showed 
that the Kav values were inversely proportional to the loge of 
molecular weight. The respective Kav values obtained for the various 
p a r t ia lly  purified  hepatic GS-transferases were 0.31 (rhesus),
0.29 (baboon) and 0.29 (human), and fo r the GS-transferases of 
the renal cytosols were 0,31 (rhesus)and 0.28 (baboon). Thus the 
calculated molecular weights fo r the GS-transferases were between 
47,000 and 53,000.
Iso e lec tric  focusing
Iso e lec tric  focusing of the p a r t ia lly  purified  l iv e r  cytosol
preparations (post-G SH-affin ity chromatography) from rhesus monkey, 
baboon and human liv e r  showed.that each preparation contained a 
sim ilar protein p ro file  (Figure 8 -8 ). Each liv e r  preparation 
contained 2 proteins which migrated the greatest distance towards 
the cathode. The pH at th is  point in the gradient was approximately 
9 .2 . In* the rhesus monkey liv e r  preparation, 3 other proteins were 
focused between-pH 7 .4-and 8 .0 , and a minor protein focused at pH 7 .3 . 
Two proteins were observed at a s lig h tly  acidic pH, one at pH 6.4 and 
the other at pH 6.25. The major acidic proteins, of which in the 
rhesus monkey there were 4, focused between pH 4.6 and 5 .0 . In the 
p a r t ia lly  purified  preparation.from human liv e r  there were 3 "basic" 
proteins (in  addition to the 2 "basic" proteins pi 9.0 and 9 .2 ) and ' 
the approximate pi values were between 7.3 and 8 .3 . (These proteins 
were less d is tin c t than the corresponding proteins of the rhesus 
monkey.) Some s lig h tly  acidic proteins (pi approximately 6 .2 -6 .5 )  
were also present. There were also 4 acidic proteins comprising 3 
major and one minor component.
With the baboon liv e r  preparation iso e lec tric  focusing separated at 
least 11 proteins. As observed with purified  rhesus monkey cytosol 
there were 2 very basic proteins (pi * 9.0 and 9 .2 ) . There were 4 
proteins which had pi values between 7.3 and 8 .0 , and of these the 
protein with pi  ^ 7.6 was the major component and the remaining 3 
were present at s im ilar concentrations. There were 3 proteins with 
pi values of between 6,05 and 7 .0 , and 2 acidic proteins (p i = 4 .6 ) 
present in approximately equal proportions.
The results obtained when samples of p a r t ia lly  purified  non-human 
primate renal cytosol were examined by iso e lec tric  focusing showed
that the proportion of acidic proteins were increased in re la tio n  to 
those proteins which had pi values between 7.3 and 8 .0 . Both 
preparations contained the very basic proteins (pi * 9.0 and 9 .2 ) .
For comparative purposes, a sample of the ileum mucosa cytosol 
(baboon), p a r t ia lly  purified  by GSH-affin ity chromatography, was 
also examined. In th is  sample there appeared to be at least 4
proteins with pi values in excess of 8.3 and one major protein at
pi 7 .4 . There was very l i t t l e  acidic protein and small amounts of
proteins with pi values between 6 and 8 (Figure 8 -8 ).
- Chromatofocusing . -
Following p u rifica tio n  of the glutathione S-transferase isoenzymes 
by G SH-affin ity chromatography, a sample of the purified  preparation 
was applied to a PB-118 chromatofocusing column. The results obtained 
fo r the p a r t ia lly  purified  GS-transferase isoenzymes of rhesus monkey 
and baboon liv e r  are given in Figure 8-9 (a) and (b ). The eluate  
from the chromatofocusing column revealed that there were at least 
6 fractions which contained GS-transferase a c t iv ity  towards CDNB in 
the hepatic cytosol of the rhesus monkey. There were 2 major and several 
minor fractions separated by this technique of which fraction  "C2" 
contained 48% and fraction  "C4" 20% of the eluted GS-transferase 
a c tiv ity . The proportions of GS-transferase a c tiv ity  present in 
each o f the remaining fractions were "Cl" -  15%, "C3" -  1%, "C5" - 
11% and "C6" -  4.6% of the to ta l GS-transferase a c tiv ity  eluted from 
the column. The proportion of the applied a c tiv ity  eluted from the 
chromatofocusing column was low (54%), although an additional 11% 
of the applied GS-transferase a c tiv ity  was eluted with M sodium 
chloride.
When the sample of p a r t ia lly  pu rified  glutathione S-transferases 
from baboon hepatic cytosol was applied to the chromatofocusing column, 
6 fractions containing GS-transferase a c tiv ity  were eluted. The 
position of each of the fractions was s im ilar to those observed 
during chromatofocusinq of the rhesus liv e r  preparation, but the 
proportions contained in each fraction  d iffe red . Fraction "C2" 
contained 41% of the applied GS-transferase a c t iv ity , whereas the 
proportion of a c t iv ity  associated with fraction  "C4" (32%) was higher 
than that observed w ith the rhesus monkey. The a c t iv ity  associated 
with the minor fractions were "Cl" -  15%, "C3" -  2%, nC5" -  8% and 
"C6" -  3% (Figure 8-9. (b )) . The proportion of the tot^T, a c t iv ity  
applieid to the GS-transferase a c tiv ity  which was recovered in the 
eluate was 64%, with an additional 6% being eluted with M sodium 
chloride.
Chromatofocusing resolved the p a r t ia lly  purified  GS-transferases 
(post-GSH-affinity chromatography) of human liv e r  into 5 fractions  
(Figure 8-9 (c ) ) .  The overall e lution p ro file  was s im ilar to that 
observed with the rhesus monkey liv e r  preparation but one minor 
component, "C3", did not appear to be present. The major frac tio n  
of a c tiv ity  was contained in fraction  "C2" which contained 57% of 
the to ta l a c t iv ity  with a fu rther 21% of the to ta l eluted 
GS-transferase a c tiv ity  associated with fraction  "C4". The a c tiv ity  
associated with the minor fractions was "Cl" -  13%, "C3" -  absent,
"C5" -  7% and "C6" -  2%. The overall recovery of GS-transferase 
a c tiv ity  applied to the column was 62%.
DISCUSSION
Separation of the glutathione S-transferase isoenzymes on the basis 
of th e ir  d iffe re n tia l adsorption onto DEAE-Sephadex indicated that 
there were possibly 3 major groups of proteins distinguishable from 
each other, but each displaying glutathione S-transferase a c tiv ity  
towards CDNB. In the hepatic cytosol of the rhesus monkey, there 
appeared to be approximately equal amounts of 2 "basic" isoenzymes. 
These components were less c le a rly  resolved in the hepatic cytosol 
from e ith er the baboon or man. Both the non-human primate renal 
cytosol preparations showed s im ilar elution p ro files  from 
DEAE-Sephadex as those observed with the corresponding hepatic 
preparations, and thus probably contain a s im ilar isoenzyme compositi
The elution p ro file  of the GS-transferases from human liv e r  was 
sim ilar to that reported by Hayes et a l . (1983), although th e ir  
results showed a somewhat larger amount of "neutral and acidic"  
GS-transferase isoenzymes. The to ta l recovery of GS-transferase 
a c tiv ity  in the eluates from the DEAE-Sephadex chromatographic 
separation were approximately 88% (rhesus monkey), 84% (baboon) 
and 81% (human). These values compare favourably with the a c t iv ity  
recovered during the investigations reported by Habig and Jakoby 
(1981) using ra t l iv e r  cytosol (85-87%), or the recovery reported 
by Asaoka et a l . (1977) (94%), using hepatic cytosol from the rhesus 
monkey. Habig et a l . (1976) reported that approximately 20% of the 
GS-transferase a c tiv ity  present in human liv e r  was eluted from 
DEAE-cellulose with 0.4 M KC1. These proteins, which were not 
examined further by Habig^et a l . (1976), probably comprise part 
of the GS-transferase a c tiv ity  eluted with the "neutral and acidic"
isoenzymes in the current investigation. The use of DEAE-Sephacel 
had been reported by Maruyama et a l . (1984), and although they 
reported that only 60-70% of the GS-transferase a c tiv ity  of ra t  
l iv e r  cytosol was eluted, no sodium chloride gradient was employed 
to e lute the more acidic proteins. In a subsequent publication, 
Maruyama and Li stowsky (1984) reported that when a s a lt gradient was 
used, 68% of theorig ina l a c t iv ity  was due to "basic" GS-transferases 
and 32% to anionic Isoenzymes. There are no comparable data published 
fo r the non-human primate, but the results from the current 
investigations show that the DEAE elution p ro file  of the GS-transferase 
isoenzymes present in the hepatic cytosol of the rhesus monkey closely 
resembled the p ro file  obtained with human liv e r  cytosol (73% "basic" 
and 27% "neutral plus acidic" GS-transferases). The corresponding 
values in baboon liv e r  cytosol were 63 and 37%, w hilst in the kidney 
they were 67 and 33% (rhesus monkey) or 56 and 44% (baboon).
"Basic" GS-transferase isoenzymes
Subfractionation of the "basic" GS-transferase isoenzymes u t ilis in g  
d iffe re n tia l absorption onto CM-cellulose has been used by several 
groups since Habig et a l . (1974) used the technique to separate 
the "basic" GS-transferase Isoenzymes of human liv e r  cytosol in to 5 
components (designated a, £, y , d and e ). A s im ilar number of 
isoenzymes were also observed more recently by Hayes et a l . (1983). 
Asaoka et a l . (1977) have also shown the existence of several "basic" 
GS-transferase isoenzymes in rhesus monkey l iv e r .  There are some 
differences between the CM-cellulose e lution p ro files  obtained in 
the current investigation and in the fractionation  studies reported 
by Hayes et a l . (1983). In the study of Hayes et a l . (1983) the la s t  
fraction  eluted from the CM-cellulose column contained the largest
amount of GS-transferase a c t iv ity  towards CDNB, whereas in the current 
study a small additional peak containing GS-transferase a c tiv ity  
(frac tio n  "E") was eluted a fte r  the major peak (fractio n  "D"). I t  
is probable that the in i t ia l  zone eluted by Hayes et a l . (1983) (frac tio n  
a )  was not observed during the current investigation due to the smaller 
quantities of s tarting  material used. I t  is also probable that the 
peaks which have been designated "C" and "D" in th is  study correspond 
with the 6 and e fractions obtained by Hayes et a l . (1983). In the 
rhesus monkey, approximately 62% of the "basic" hepatic GS-transferase 
a c tiv ity  was associated with fraction  "D" with an additional 23% in 
fraction  "C". ■ These proportions are s im ilar to those in human liv e r  
cytosol, "D" -  57% and "C" -  20%, By contrast, the fractions "D" 
and "C" from the baboon liv e r  cytosol contained sim ilar proportions 
of the to ta l "basic" GS-transferase a c tiv ity  (42 and 35% resp ective ly ).
In the renal cytosol, 66% (rhesus) and 56% (baboon) of the to ta l
GS-transferase a c t iv ity  was associated with the "basic" isoenzymes.
In baboon renal cytosol, the elution p ro file  of the "basic" 
GS-transferases from CM-cellulose was s im ilar to that observed with  
the hepatic cytosol although there was less of 2 of the minor fractions.
In the renal cytosol of the rhesus monkey, fraction  "C" contained the
highest amount of GS-transferase a c tiv ity . Fractions "C" and "D" 
together accounted fo r over 82% of the "basic" GS-transferases in 
both species.
The proportion of cytosolic protein which possesses GS-transferase 
a c tiv ity  has been reported to be approximately 10% (ra t)  (Jakoby et a l ..
1976) and about 2% (human) (Habig et a l , 1976). In the current 
investigation the results show that the proportion of cytosolic  
protein in human liv e r  associated with GS-transferase a c tiv ity  was
s lig h tly  less than 2%, and the proportion was s lig h tly  higher in the 
rhesus monkey (3.4%) and baboon (4.4%). The proportion of hepatic 
cytosol protein present as GS-transferases is perhaps s lig h tly  
overestimated due to some non-GS-transferase protein being present. 
Furthermore, no information has been published in re la tio n  to the 
amount of renal cytosolic protein associated with GS-transferase 
a c tiv ity  in the non-human primates. The current investigation  
indicates that th is  proportion is  approximately 2%. As mentioned 
fo r the hepatic proteins, th is  value is probably an overestimate. 
Nevertheless, the GS-transferases can be regarded as a large 
capacity detoxication system in both l iv e r  and kidney of non-human 
primates and man.
Molecular weight
The molecular weight of the glutathione S-transferases isolated from 
ra t l iv e r  have been reported to be between 45,000 and 47,000 with 
transferase 4.4 (transferase E) being lower (ca. 40,000) (Jakoby 
et a l , 1976). The molecular weight range fo r human liv e r  GS-transferase 
isoenzymes has been reported as 48,000-49,000 (Habig et a l , 1976).
The molecular weights of the hepatic and renal cytosolic  
GS-transferases were estimated,by gel f i l t r a t io n  chromatography, to 
be between 47,000 and 53,000, which are s im ilar (w ithin the 
experimental lim its  of the methodology) to the molecular weight 
(45,000) reported by Asaoka and Takahashi (1977) fo r the major 
"basic" GS-transferase isoenzyme obtained from rhesus monkey l iv e r .
This value (45,000) is somewhat lower than the previous value reported 
by the same group (55,000), Ito  et a l . (1974). In the current 
investigation , the sub-unit structure of the GS-transferases was 
not examined in any d e ta il,  but prelim inary experiments indicated
that the major "basic" GS-transferase isoenzyme (fractio n  "D") 
was composed of 2 sub-units of equal s ize . This aspect requires 
fu rther study with p a rticu la r reference to the minor GS-transferase 
isoenzymes.
Substrate s p e c ific ity
The substrate s p e c ific ity  of the GS-transferase isoenzymes prepared 
from ra t l iv e r  showed that the individual "basic" isoenzymes possess 
d iffe r in g  but overlapping substrate s p e c ific ity  (Habig e t a l 1974; 
G ill ham, 1971 (Table A )}, whereas the "basic" isoenzymes isolated  
from human liv e r  had very s im ilar specific a c t iv it ie s  with any 
individual substrate (Table BJ. This observation appeared to 
extend to the rhesus monkey (Table C).
TABLE A
Specific a c tiv it ie s  of the "basic" GS-transferase isoenzymes isolated  
from ra t l iv e r  from Habig et a l . (1974).
Substrate*
Transferase...........................
1-1
1-2
CB)
- 2-2 
m
. 3-3
(A)
3-4
(Cl O 
1 -P* 5-5
(E) (M)
CDNB 11 14 62 10 _ 0.01
DCNB 0.003 0.008 4.3 2.0 - 0 0.004
p-NBC 0.1 0.11 11.4 10.2 - 4.1 0.5
EA 0.26 0.3 0 0,11 - 0 -
t-PBO 0.01 - 0.02 0.4 - - -
*  Abbreviations: CDNB, l-ch loro-2,4-d in itrobenzene; DCNB, 1 ,2-dichloro-
4-nitrobenzene; p-NBC, p-nitrobenzylchloride*, EA, ethacrynic acid; 
t-PBO, trans-4-phenyl-3-butene-2-one.
TABLE B
Specific a c t iv it ie s  of the "basic" GS-transferase isoenzymes isolated  
from human liv e r  from Kamisaka et a l . (1975).
Substrate*
Transferase
a B Y 6 £
CDNB
DCNB
p-NBC
EA
t-PBO
19
0.05
0.17
0.017
0.001
16
0.07
0.22
0.021
0.001
17
0.04
0.02
0.035
0.001
37
0.05
0.20
0.028
.0.001
34
0.04
0.16
0.044
0.002
TABLE C
Specific a c t iv it ie s  of the "basic" GS-transferase isoenzymes isolated  
from rhesus monkey liv e r  from Asaoka et a l . (1977).
Substrate*
Transferase
I I I
I—
I 
I—
I 
l—
I IV V
CDNB 7.3 15 22 90 17
DCNB 0.02 0.11 0.13 0.23 0.03
p-NBC 0.1 0.4 0.6 1.3 0.4
t-PBO 0.002 0.005 0.007 0.008 0.002
*  Abbreviations fo r Tables B and C: CDNB, 1-chioro-2,4-dinitrobenzene
DCNB, 1 ,2-dichloro~4-nitrobenzene; p-NBC, p-nitrobenzylchloride;
EA, ethacrynic acid; t-PBO, trans-4-phenyl-3-butene-2-one.
The substrate s p e c ific itie s  observed with the human liv e r  GS-transferases 
in the current study showed that both the major "basic" isoenzymes 
(fractions "C" and "D") had very s im ilar specific  a c t iv it ie s  towards 
any individual substrate. When CDNB was used as the substrate the 
specific  a c tiv it ie s  obtained were higher than fo r any of the fractions  
previously reported fo r human liv e r  (Table B), although Warholm et a l . 
(1983 ) reported the specific  a c tiv ity  of the human "basic" (a  -  e )  
transferases as 64 ymol/min/mg protein . The specific a c t iv ity  levels
obtained with the minor "basic" GS-transferase isoenzymes were s im ilar  
to those reported by Kamisaka et a l . (1975). When DCNB was used as 
the substrate, the individual fractions ("C" and "D") of human liv e r  
had specific  a c t iv ity  values of between 0.17 and 0.19 ymol/min/mg 
protein. These values are approximately 3 to 5-times higher than 
those of Jakoby and Habig (1980), but very s im ilar to those obtained 
with the most active fraction  of rhesus liv e r  cytosol (Asaoka et a l ,
1977). The specific  a c t iv it ie s  obtained when p-NBC was used as 
substrate were marginally greater, and those when ethacrynic acid 
was used were approximately 2 to 4 -fo ld  higher than those reported 
by Jakoby and Habig. (1980). In the current investigation , no 
GS-transferase a c tiv ity  was detected towards t-PBO with e ith e r of 
the 2 major "basic" GS-transferase isoenzyme frac tio n s , even though 
the l im it  of detectable a c tiv ity  was s im ilar to the levels reported 
by Jakoby and Habig (1980).
In the species of non-human primate examined, the specific  a c t iv it ie s  (CDNB) 
of the "basic" GS-transferase were s im ilar to the values obtained with 
human l iv e r ,  although the maximum specific  a c t iv ity  more closely  
resembled the' human data published by Warholm e t a l . (1983). The 
maximum a c tiv ity  with any "basic" isoenzyme was 72 ymol/min/mg 
protein with fraction  "D" of the rhesus monkey l iv e r ,  which approached 
the specific  a c tiv ity  (9.0 ymol/min/mg protein) reported by Asaoka 
et a l . (1977) in the same spectes.
With each of the other substrates, the specific  a c t iv it ie s  o f.th e  
non-human primate"basic" hepatic isoenzymes were up to about 2 -fo ld  
higher than those observed with human liv e r .
Thus, in terms of th e ir  substrate s p e c ific ity , the GS-transferase 
isoenzymes of the non-human primate more closely resemble those in 
man than those in ra t.
A s im ilar spectrum of specific  a c t iv ity  values.were obtained with 
the "basic" GS-transferase isoenzymes isolated from non-human primate 
kidney. These results indicate that the forms of GS-transferase 
present in renal tissue of non-human primates are s im ilar to those 
in the l iv e r  in the same species. This concept is fu rther supported 
by the protein pattern observed a fte r  is o e lec tric  focusing (Figure 8 -8 ).
The specific  a c t iv ity  values fo r the "neutral plus acidic"
GS-transferase isoenzymes obtained fo r human liv e r  show that the 
most active substrate was CDNB (113 units/m g), whereas the specific  
a c tiv ity  towards DCNB was approximately 100-fold lower (0.12 units/m g). 
These results are of the same orders of magnitude as those of 
Warholm et a l . (1983). The current investigation used a combined 
("neutral plus ac id ic") frac tio n , but separate "neutral" and 
"acidic" fractions were reported by Warholm et a l . (1983). Comparison 
of the results obtained during the current study with the results  
of Warholm et a l . (1983  ^ indicates that in the "neutral plus acidic"  
fraction  examined the "acidic" GS-transferase isoenzymes are 
possibly predominant. This view received fu rther support from the 
observation that the GS-transferase a c tiv it ie s  with 2 of the other 
3 substrates used (EA and p-NBC) were s im ilar to the human "acidic"  
GS-transferase a c tiv it ie s  previously reported by Warholm et a l .
(1983). With a ll of the GS-transferase substrates examined, tfie 
a c tiv ity  in the "neutral plus acidic" fraction  of non-human primate 
hepatic cytosol was greater than that observed with the corresponding
fraction  of human l iv e r . The specific  a c tiv ity  of the "neutral plus 
acidic" fraction  of non-human primate renal cytosol was s im ilar to 
that in human l iv e r .
Close s im ila r ity  was observed between the k inetic  parameters derived 
fo r the major "basic" hepatic GS-transferase isoenzymes. The 
results showed that when using CDNB as a substrate the Km values were 
between 0.14 and 0.48 mM; the Km values obtained using DCNB varied
between 0.35 and 1.17 mM,
There are numerous compounds which in h ib it  GS-transferase a c t iv ity  
(Chasseaud, 1979), and various investigators have used in h ib itio n  
studies to d iffe re n tia te  between the isoenzymes in ra t l iv e r  cytosol 
(Ketley et a l , 1975; Jakoby et a l , 1976; Li stowsky et a l , 1976).
Recent studies by Yalcin et a l . (1983) used a selection of in h ib itors  
which could provide a basis fo r the specific  characterisation of the 
GS-transferase isoenzymes of the ra t. Some of the inh ib ito rs  lis te d  
also cause in h ib itio n  of the GS-transferase a c t iv ity  of human tissues, 
fo r example, S-hexylglutathione and bromosulphthalein (Warholm e t a l , 
1983), b iliru b in  (Koskelo, 1983), and haematin and indocyanine 
green (Kamlsaka et a l , 1975). Three of these inh ib ito rs  of
GS-transferase a c tiv ity  were used in the current study, namely
bromosulphthalein,haematin and S-hexylglutathione. Of these, haematin 
caused the greatest in h ib itio n . The extent of in h ib itio n  of the 
"basic" isoenzymes in the presence of haematin (1 yM) was greater 
in the non-human primate (65-74%) than in man (57%). The "neutral' 
plus acidic" transferases were inhib ited  to a lesser degree and to 
a s im ilar extent in both non-human primate and man. In h ib itio n  of 
the non-human primate GS-transferases by bromosulphthalein (10 yM)
was marginally greater (8-21%) than in man (7-12%). When
S-hexylglutathione was used as the in h ib ito r , there were s im ilar  
levels of in h ib itio n  of the "basic" GS-transferases of non-human 
primate and man (46-58%) w h ils t the "neutral plus acidic" fraction  
was inhib ited  less (26-30%) in a l l  species.
These findings, therefore, provide additional evidence that the 
non-human primate GS-transferase isoenzymes are s im ilar to those 
i n man.
The technique of chromatofocusing had previously been applied to  
the separation of the hepatic transferases; Mannervik and Jensson (1982) 
and Jensson et a l . (1982), in which 7 "basic" GS-transferase 
isoenzymes were separated. Chromatofocusing of the "basic" 
GS-transferase isoenzymes from non-human primate and human liv e r  
resolve 5 or 6 fractions of enzyme a c t iv ity . The separation of 
the GS-transferases was s im ilar in a ll  3 species examined, although 
the concentration of the individual isoenzymes varied. The technique, 
however, suffered from 2 lim ita tio n s : f i r s t ly ,  in order to examine 
a ll the GS-transferases from an individual tissue, 2 separate 
chromatofocusing columns would be required (one fo r pH 7-4), through 
which the "basic" GS-transferases would pass, but which should 
resolve the "acidic" and "neutral" isoenzymes, and a second (pH 11-7) 
to resolve the "basic" isoenzymes; secondly, the recovery of 
GS-transferase a c tiv ity  from the chromatofocusing column used 
in the current study was low (60-65%), but th is could be due to 
the denaturing of the "acidic" proteins at the extreme pH used 
with th is  column at the s ta rt of the separation.
FIGURE 8-1
P urifica tion  of hepatic and renal glutathione S-transferases from
non-human primates and man
Tissue homogenate
DEAE-Sephadex
Flow through / NaCl
I I
GSH-affinity
Sepharose
Dialysis
U lt ra f i lt r a t io n
Dialysis
U lt ra f i l t r a t io n
CM-cellulose
+  upii
"Neutral and acidic" 
GS-transferases
Fractions
eluted
"A" "B" "C" "D" "E"
"Basic" GS-transferases
)
TABLE 8-1
P urifica tion  of the GS-transferases from liv e r  cytosol from non-human
primates and man
Species
P u r if ic a t io n Rhesus Baboon Man
stage* GS-transferase Relative GS-transferase Relative GS-transferase R ela t ive
a c t iv i t y y ie ld a c t iv i ty y ie ld a c t i v i t y y ie ld
(yM/min) ( % ) (yM/min) ( % ) (yM/min) ( % )
Cytosol fraction 3330 100 4155 100 1272 100
DEAE-Sephadex 293.0 88 3490 84 1032 81
Fraction I 2160 65 2210 53 750 59
Fraction I I 769 23 1280 31 282 22
GSH-Affinity I 1816 55 1906 46 652 51
CM-Cellulose 1562 47 1564 38 509 40
Fraction "A" 30 0.9 64 1.5 17 1.3
"B" 104 3.1 120 2.9 31 2.4
"C" 372 11.2 549 13.2 103 8.1
"D" 970 29.1 675 16.3 293 23.0II £11 87 2.6 157 3.8 65 5.1
GSH-Affinity I I 476 14 755 18 186 15
*  Details of each stage are given in the Methods section, and the ' 
separation procedure is described in Figure 8-1 .
TABLE 8-2
P urification  of the GS-transferases from kidney cytosol from 2
non-human primates
Species
P urifica tion Rhesus Baboon
stage* GS-transferase Relative GS-transferase Relative
a c tiv ity y ie ld a c tiv ity y ie ld
(yM/min) m (yM/min) (% )
Cytosol fraction 282 100 320 100
DEAE-Sephadex 212 75 263 82
Fraction I 141 50 148 46
Fraction I I 71 25 115 36
GSH-Affinity I 117 41 129 40
CM-Cellulose 88 31 98 31
Fraction "A" 6.9 2.4 2.0 0.6
"B" 3.4 1.2 5.0 1.6
"C" 45 16.1 41 12.9
«D« 28 9.8 44 13.9
ii 5.0 1.8 5 5 l  7
GSH-Affinity I I 51 18.1 79 25
*  Details of each stage are given in the Methods section, and the 
separation procedure is described in Figure 8-1 .
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•TABLE 8-4
Protein concentrations in GS-transferase fractions obtained from 
kidney cytosol
Fraction*
Species
Rhesus Baboon
Protein
(mg)
Proportion of  
cytosolic  
protein
( % )
Proportion of  
CM-fraction
( 5 5 )
Protein
(mg)
Proportion of  
cytosolic  
protein
( % )
Proportion of  
CM-fraction  
( 5 5 )
"A" 3..67 0.57 27 5.04 0.52 26
"B" 2.91 0.45 22 4.12' 0.43 21
"C" 2.43 0.38 18 3.14 0.33 16
"D" 3.45 0.54 26 5.95 0.62 31II £11 1.05 0.16 8 1.07 0.11 6ll l^l _ II £11 13.51 2.10 - 19.32 2.01 -
II pit 0.71 0.11 - 0.74 0.08 -
Total 14.22 . 2.21 - 20.06 2.08 -
% "F/A"-"F" - - 5.0 - - 3.7
*  Fractions "A"-"E" eluted from CM-cellulose. Fraction "F" 
eluted from GSH-affinity m atrix.
The to ta l amounts of soluble protein present in the renal cytosol 
were rhesus monkey 644 mg and baboon 963 mg.
FIGURE 8-2
Separation of the glutathione S-transferase isoenzymes from rhesus 
monkey hepatic cytosol by (a) DEAE-Sephadex chromatography and 
(b) fractionation  of the "basic" GS-transferase isoenzymes eluted 
from DEAE-Sephadex by chromatography on CM-cellulose.
Sodium chloride gradient 0-0 .2  M indicated by dashed lin e . 
GS-transferase a c tiv ity  towards CDNB
0.2
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• -0.2M
0.1
0.1M
100
Fraction number
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A B C D E
Fraction number (fractions pooled between adjacent arrows)
FIGURE 8-3
Separation of the glutathione S-transferase isoenzymes from baboon 
hepatic cytosol by (a) DEAE-Sephadex chromatography and 
(b) fractionation  of the “basic" GS-transferase isoenzymes eluted 
from DEAE-Sephadex by chromatography on CM-cellulose.
Sodium chloride gradient 0-0 .2  M_ indicated by dashed lin e . 
GS-transferase a c tiv ity  towards CDNB
0.3
oJ-
QO< 0.2
£
>
NaCI*»oia
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Fraction number (fractions pooled between adjacent arrows)
FIGURE 8-4
Separation of the glutathione S-transferase isoenzymes from human 
hepatic cytosol by (a) DEAE-Sephadex chromatography and 
(b) fractionation  of the "basic" GS-transferase isoenzymes eluted 
from DEAE-Sephadex by chromatograhy on CM-cellulose.
Sodium chloride gradient 0-0 .2  M_ indicated by dashed lin e .  
GS-transferase a c tiv ity  towards CDNB
o
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•a
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FIGURE 8-5
Separation of the glutathione S-transferase isoenzymes from rhesus 
monkey renal cytosol By (aJ DEAE-Sephadex chromatography and 
(b) fractionation  of the "basic" GS-transferase isoenzymes eluted 
from DEAE-Sephasex by chromatography on CM-cellulose.
Sodium chloride gradient 0 -0 .2  M indicated by dashed lin e .  
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FIGURE 8-6
Separation of the glutathione S-transferase isoenzymes from baboon 
renal cytosol by (a) DEAE-Sephadex chromatography and 
(b) fractionation  of the "basic" GS-transferase isoenzymes eluted  
from DEAE-Sephadex by chromatography on CM-cellulose.
Sodium chloride gradient 0 -0 .2  M indicated by dashed lin e .  
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TABLE 8-9
The k inetic  constants of the 2 major "basic" glutathione S-transferase  
isoenzymes of the hepatic cytosol obtained from the rhesus monkey, 
baboon and human towards e ith e r, 1-chioro-2,4-dinitrobenzene (CDNB) 
or 1 ,2-dichloro-4-nitrobenzene (DCNB).
Species Proteinfraction
Kinetic coeffic ients
Woolfe plot Lineweaver- Burk n lo t
Km
yM
Vmax 
yM/min/mg
Km
yM
vmax
yM/min/mg
CDNB Rhesus "C" 0.42 66.8 0.37 62.8
monkey "D" 0.33 96.7 0.32 96.2
Baboon "C" 0.29 81.8 0.30 83.6
"D" 0.41 73.4 0.47 80.6
Human "C" 0.43 66.0 0.48 62.5
“D" 0.15 51.7 0.14 50.3
DCNB Rhesus "C" 0.53 0.39 0.41 0.34
monkey "D" 0.40 0.55 0.35 0.51
Baboon "C" 0.81 0.58 0.85 0.60
"D" 0.96 0.37 1.17 0.44
Human ”C" 0.59 0.27 0.60 0.27
"D" 0.89 0.38 0.82 0.34
Values derived from lin ea r regression analysis of data 
expressed as S/V vs. S -  fcfoolfe p lo t.
Values derived from lin ea r regression analysis of data 
expressed as V v  vs. V s  “ Lineweaver-Burk p lo t.
TABLE 8 -1 0
In h ib ition  of the GS-transferase a c tiv ity  of the 2 major "basic" and 
the "neutral plus acidic" isoenzyme fractions from the hepatic 
cytosol of non-human primates and man.
Species and frac tio n *
In h ib ito r Rhesus monkey Baboon Man
"C" "D" up ii ii C" "D" up ii "C" "D" up ii
Bromosulphthalien 
(10 yM ) 16 21 11 14 18 8 11 8 7
Haematin 
0  yM) 72 66 27 74 65 37 57 57 24
S-Hexylglutathi one 
(10 yM) 58 46 30 50 43 26 53 58 25
*  Fraction le t te r  denotes individual frac tio n . "C" and "D" 
"basic" hepatic GS-transferases. "F" "neutral plus acidic" 
hepatic GS-transferases.
FIGURE 8-7
Determination of molecular weights, by gel f i l t r a t io n ,  of pu rified  
glutathione S-transferases obtained from the ,tissues of non-human 
primates.
Arrows indicate the lim its  of estimated molecular weight. 
•  Indicates position of reference pro te in s.*
50,000 -
■r»
CUs
i-ta
Z3U
CU
0.80.60.40.2
Kav
*  Reference proteins were in increasing order or molecular weight: 
aprotin in , cytochrome C, carbonic anhydrase, ovalbumin and 
albumin (bovine serum).
FIGURE 8-8
Isoe lec t r ic  focusing of p a r t i a l l y  Durif ied cytosol ic  GS-transferases 
from (A) rhesus monkey kidney, (B) baboon kidney, (C) human l i v e r ,
(D) and (E) rhesus monkey l i v e r ,  (F) baboon l i v e r  and (G) baboon ileum 
mucosa. Lanes marked * are reference proteins of known pi values.
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CHAPTER 9
GENERAL DISCUSSION AND CONCLUSIONS
Three species of non-human primate were used in the studies reported 
in this thesis: these were the rhesus monkey (Macaca mulatta) ,  the 
baboon (Papio s p .) and the cynomolgus monkey (Macaca fa s c icu la r is ) .
The overall aim of the investigation was to evaluate the comparative 
capability  of these non-human primates to conjugate xenobiotics with 
GSH, since such information is lacking in the s c ie n t if ic  l i te ra tu re .  
Thus, various aspects of GSH conjugation iri the nOn-human primate were 
examined: f i r s t l y ,  by a study of the metabolism and pharmacokinetics 
of ethacrynic acid, a d iuretic  known to be extensively metabolised by 
GSH conjugation in several other species; secondly, by an evaluation 
of the capacity of hepatic and extrahepatic GSH conjugation in 
non-human primates and a comparison with that of the ra t  and man; 
th ird ly ,  by an assessment of the extent of catabolism of the GSH 
conjugate during mercapturic acid biosynthesis; and fourth ly , by 
investigation of the GSH S-transferase isoenzymes involved in the 
conjugation of xenobiotics with GSH.
Pharmacokinetics of ethacrynic acid in non-human primates 
Approximately 70% of the dose of 1IfC-ethacrynic acid was absorbed 
from the gastro-intestinal t ra c t .  Enterohepatic cycling is probably 
between 10 and 20% dose. As the gastro-intestinal mucosa can 
conjugate ethacrynic acid with GSH, and i t  can also further metabolise 
this conjugate, these reactions and rates at which they occur in the 
in vivo mucosa are areas fo r  future investigation.
Ethacrynic acid, when administered intravenously to the non-human 
primate, was very rapidly cleared from the plasma. The h a l f - l i f e  of 
the in i t i a l  phase, which was probably associated with drug 
distr ib u tio n , was s im ilar in both rhesus monkey and baboon (15-20min), 
and compares closely to that observed in the ra t  and dog (18 min) 
(Klaassen and Fitzgerald , 1974; Wallin et a l , 1978). Subsequently, 
plasma drug concentrations declined with a h a l f - l i f e  of 3.3 h in the 
baboon and 4 h in-the rhesus monkey. A value of 4 h in the ra t  can 
be calculated from the data of Wallin et a l . (1978). I t  is probable 
that th is h a l f - l i f e  is associated with drug elimination. However, 
in the current investigation there was an additional phase of decline 
of plasma drug concentrations of a much longer h a l f - l i f e  of 
approximately 44 h in the baboon and 51 h in the rhesus monkey.
A s im ilar phase with a h a l f - l i f e  of 56 h was also observed following 
oral doses of 14C-ethacrynic acid, and was probably associated with 
the removal of drug from a "deep tissue compartment". I t  is less 
l ik e ly  to have reflected enterohepatic cycling of ethacrynic acid, 
since metabolism of the drug appeared to occur re la t iv e ly  rapid ly .  
However, some accumulation of drug could occur in this "deep tissue 
compartment" during the type of dosing regimen used c l in ic a l ly  
for the drug or during to x ic ity  studies.
The pharmacokinetics of ethacrynic acid do not explain i ts  re la t iv e  
lack of d iuretic  potency in these species of non-human primate 
compared to the dog (Beyer et a l , 1965). However, in the case of 
diuretics , i t  is the concentrations of drug (or active metabolite) 
in the kidney that would be a more important determinant of 
pharmacological action than plasma drug concentrations. A worthwhile 
comparative species study would be one which attempted to define the
time-course and correlation between plasma and urine drug 
concentrations and those in the kidneys as well as diuresis 
following ethacrynic acid administration.
Excretion and metabolism of ethacrynic acid in the non-human primate 
Following intravenous administration of llfC-ethacrynic acid, 
excretion of rad ioactiv ity  occurred prim arily in the b ile  (70%), with 
the remainder of the dose (ca^ 30%) in the urine. When enterohepatic 
circulation was not interrupted by b i le  duct cannulation, urinary  
excretion of rad ioactiv ity  was greater, approximately 40% of the 
dose. These values are comparable to 35% of th e 'ra t io  of dose 
in the urine of dogs (Beyer et a l , 1965), and which was independent 
of the route of administration. In the non-human primate only 25% 
of an oral radioactive dose was excreted in the urine and, therefore, 
a species difference in the absorption or disposition of ethacrynic 
acid may ex is t.
Ethacrynic acid caused a greater stimulation of b i le  flow in the 
non-human primates than was reported for the ra t  or dog (Klaassen 
and F itzgerald , 1974). B il ia ry  excretion involved active transport 
as the bile:plasma rad ioactiv ity  concentration ra tio  in the early  
samples was in excess of 300:1. B ile production is regarded as 
having 2 mechanisms of formation. One is b ile  salt-dependent flow, 
which is in it ia te d  by the active transport of b i le  acids into  
the lumen of the b ile  canaliculi (J a v i t t ,  1976), 
and the other is b ile  saltindependentflow, for which the mechanism 
of action is not c lear, but i t  involves active excretion of Na+ , 
and the modulation of Na+-K+ ATPase a c t iv i ty .  Ethacrynic acid is 
known to cause transient changes in the b ile  salt-independent flow
(Shaw et a l , 1972). The transient changes observed in the b i le  flow 
in the non-human primate are l ik e ly  to be due to the b i le  s a l t -  
independent frac tion , although the greater stimulation of b i le  flow 
in the non-human primate may be governed by another mechanism.
The rate of b i l ia r y  excretion of rad ioactiv ity  in the non-human 
primate was rapid, with more than 60% of the dose being excreted 
during 4 'h . This excretion was s lig h t ly  greater than that in the 
dog (57%), but was s im ilar to that in the ra t (Klaassen and Fitzgerald, 
1974).
The differences in d iuretic  a c t iv i ty  observed in dog (Beyer et a l , 
1965), non-human primate (s l ig h t  diuresis) and ra t  (no diuresis)
(Beyer et a l , 1965), cannot be explained by the variation in the 
b i l ia r y  excretion of ethacrynic acid in these species, but could be 
influenced by the extent of enterohepatic c irculation which may occur 
in the d if fe ren t species; this may result in d iffe r in g  concentrations 
of various metabolites in the kidney.
The proportions of ethacrynic acid and the major metabolites of 
ethacrynic acid excreted in the b ile  of d if fe ren t species are given 
in Table 1.
TABLE 1
Proportions of the metabolites of ethacrynic acid excreted in the
b ile  in various species.
Compound*
Species
Rhesus
monkey Baboon Rat Dog
EA 25 10-22 <20 38
GS-EA 16 8-25 40 9
Cys-EA 43 42-58 Trace 11
NAC-EA 4 4-12 18-20 25
*  EA = Ethacrynic acid; GS-EA = glutathione conjugate;
Cys-EA = cysteine conjugate; NAC-EA = N-acetylcysteine conjugate 
(mercapturic acid).
Examination of the p ro fi le  of the metabolites of ethacrynic acid in 
b ile  draws attention to some species differences in metabolism of 
ethacrynic acid. In the ra t ,  very l i t t l e  cysteine conjugate was 
found in b i le ,  although the b ile  contained a substantial amount of 
the mercapturic acid. As the cysteine conjugate is an intermediate 
between the glutathione conjugate and the mercapturic acid, i t  must 
be N-acetylated at a s im ilar rate to i ts  formation in the ra t .  By 
contrast, dog b ile  contains both the cysteine conjugate and the 
mercapturic acid, which indicates that the rate of N-acetylation  
must be slower than the rate of formation of the cysteine conjugate. 
In the non-human primate the amount of mercapturic acid produced is 
much lower (p a rt icu la r ly  in the rhesus monkey) and, therefore, the 
N-acetylation reaction must occur at an even slower rate . The 
p o ss ib ility  also exists that the mercapturic acid, once formed, 
could be de-acetylated, and thus what is observed would be the net 
product of these forward and backward reactions. This aspect is
another possible area fo r further study. The observation that in the 
non-human primate the amount of the glutathione conjugate excreted in 
the b i le  decreases rapidly with time supports the hypothesis tha t,  
once formed, the glutathione conjugate is rapidly catabolised. Two 
successive doses of ethacrynic acid administered to the baboon caused 
no apparent diminution in GSH conjugation, and the baboon l iv e r  (GSH 
concentration c£. 2 mg/g) was able to conjugate over 50 mg of 
ethacrynic acid with glutathione in 4 h. This observation indicates 
the re la t iv e ly  large capacity of this system for the detoxication or 
elimination of xenobiotics.
In the b ile  samples obtained from the non-human primates, another 
metabolite was observed. This metabolite was more polar than the 
GSH conjugate of ethacrynic acid, but i ts  rate of elimination  
appeared to paralle l that of the GSH conjugate from the b i le .
The id en tity  of this metabolite is unknown, but i t  is possible that  
the carboxylic acid moiety of ethacrynic acid may be conjugated with 
an amino acid with or without the conjugation of the a3-unsaturated 
double bond with GSH. A lte rn a tive ly , the metabolite could possibly 
be e ither the sulphoxide of the glutathione conjugate or be a product 
of the further metabolism of the cysteine or N-acetylcysteine 
conjugates, such as deamination or sulphoxidation respectively  
( fo r  examples see, James et a l , 1968; James and Needham, 1973; Sklan 
and Barnsley, 1968)..
Modification of metcapturic acid biosynthesis in the baboon 
Pretreatment of a baboon with 6-diazo-5-oxo-norleucine (DON), an 
in h ib ito r  of y-GT, did not a l te r  the amount of ethacrynic acid 
conjugated with GSH but, as expected, suppressed the subsequent 
conversion of the GSH conjugate to the corresponding cysteine
conjugate. Hippurate (a modulator of y -G T  a c t iv i ty ) ,  when 
co-administered with DON, caused a drop in the amount of ethacrynic 
acid which was conjugated with GSH, but only s lig h tly  altered the 
subsequent metabolism. The role of hippurate in the modulation o f  
in vivo enzyme systems, such as y -G T , is worthy of further  
investigation. Pretreatment with DON did not cause any detectable 
urinary excretion of the GSH conjugate of ethacrynic acid. DON being 
an L-amino acid would be p re fe ren tia l ly  removed from plasma by the 
l iv e r  where i t  would mainly exert i ts  a ffec ts , and thus, very l i t t l e  
DON may reach the kidney to in h ib it  y -G T ; this may be an explanation 
fo r  the absence o f s ign ificant amounts o f 'the  GSH conjugate in the 
urine. Another explanation could be tubular reabsorption of such a 
conjugate i f  present in the glomerular f i l t r a t e .
Glutathione status, and tissue glutathione S-transferase a c t iv i ty  in 
non-human primates
Two requirements for enzymic conjugation of xenobiotics with GSH are 
glutathione (GSH) and glutathione S-transferases (GS-transferase).
The concentrations of GSH measured in several tissues were s im ilar  
to those reported in other mammalian species (Jocelyn 1972); hepatic 
GSH concentrations were between 6,1 and 6.4 mM. Notable concentrations 
(up to 75% of the hepatic leve l)  were measured in the stomach mucosa, 
although this proportion was less than that reported for the ra t  
[95% of l iv e r ) .  The high level of gastric GSH probably acts as an 
"immediate" protective agent. Other tissues, which e ither can be regarded 
as "portals of entry" into the body, or major organs of metabolism 
for  xenobiotics, also contain high levels of GSH. The amounts in 
these organs and tissues should be s u ff ic ien t to saturate the
GS-transferases present in these tissues and thus provide a fas t and 
re la t iv e ly  large capacity detoxication system.
These measurements of concentrations of GSH in various tissues of 
the non-human primate provides background data for these species 
which hitherto has been lim ited in the s c ie n t if ic  l i te ra tu re .
The a c t iv it ie s  of the cytosolic GS-transferases, present in various 
non-human primate tissues, towards a range of substrates, were 
measured, and the results compared wfth those obtained fo r the ra t  
and man so as to highlight s im ila r it ie s  or differences between 
these species. GS-transferase a c t iv it ie s  towards l-c h lo ro -2 ,4 -  
dinitrobenzene (CDNB) and 1,2-dtchloro-4-nitrobenzene (DCNB), 
ethacrynic acid (EA), diethylmaleate (DEM), trans-4-phenyl-3-buten- 
2-one (t-PBO), cyclohex-2-en-l-one (CHO) and 1,3-epoxy-3- 
(p-nitrophenoxy)propane (ENPP) were measured. The mean results  
obtained for l iv e r ,  kidney and in testinal mucosa (ileum) a c t iv i t ie s  
towards individual substrates are given in the following tables.
For comparative purposes, the GS-transferase a c t iv i ty  towards each 
substrate in the respective ra t tissue has been scaled to 100, 
with the mean observed GS-transferase a c t iv i ty  given in parenthesis.
TABLE 2
1-Chioro-2, 4-dinitrobenzene (CDNB)
Tissue
Species
Rat Rhesusmonkey Baboon
Cynomolgus
monkey
Human
?
Liver 100(613) 416 465 498 161 124
Ki dney 100(86) 446 322 425 NS NS
Ileum mucosa 100(157) 317 316 323 NS NS
TABLE 3
1 ,2-Dichloro-4-nitrobenzene (DCNB)
Tissue
Species
Rat Rhesusmonkey Baboon
Cynomolgus
monkey
Human
cJ 9
Liver 100(36) 66 40 45 9 11
Kidney 100(3.2) 125 106 156 NS NS
Ileum mucosa 100(6.9) 83 80 97 NS NS
TABLE 4 
Ethacrynic acid (EA)
Tissue
Species
Rat Rhesusmonkey Baboon
Cynomolgus
monkey
Human
c? ?
Liver 100(20.4) 64 50 52 15 17
Kidney 100(24.9) 36 23 31 NS NS
Ileum mucosa 100(24.0) 33 30 35 NS NS
TABLE 5 
Diethylmaleate (DEM) .
Tissue
Species
Rat Rhesusmonkey Baboon
Cynomolgus
monkey
Human
cJ 9
Liver 100(100.8) 39 30 33 11 11
Kidney 100(56.9) 23 17 27 NS NS
Ileum mucosa 100(86.5) 25 26 31 NS NS
TABLE 6
trans-4-Phenyl-3-buten-2-one ( t-PBO)
Tissue
Species
Rat Rhesusmonkey Baboon
Cynomolgus
monkey
Human
<J 9
Liver 100(44) 20 14 15 21 9
Kidney 100(5.2) 136 77 88 NS NS
Ileum mucosa 100(22,8) 44 20 32 NS NS
TABLE 7 
Cyclohex-2-erv-1 -one (CHO)
Tissue
Species
Rat Rhesusmonkey Baboon
Cynomolgus
monkey
Human-
9
Liver 100(507) 2 2 2 ND ND
Kidney 100(329) ND ND ND NS NS
Ileum mucosa 100(194) ND ND ND NS NS
ND = No a c t iv i ty  detected.
NS = No sample.
In human l iv e r ,  GS-transferase a c t iv ity  towards CDNB was greater 
(males more so than females) than that in the ra t ,  whereas that in the 
non-human primate were approximately 4 to 5-fold greater than that in 
the r a t ,  and 2 to 3-fold greater than that in man. The GS-transferase
a c t iv ity  in both the kidney and ileum mucosa of the non-human primate
were over 3-fold greater than in those tissues in the ra t .  When DCNB 
was used, the rank order was d if fe re n t;  the ra t hepatic GS-transferase 
a c t iv ity  was twice that of the non-human primate and 10-fold that of 
man. Although GS-transferase a c t iv ity  in the kidney of the non-human
primate was s lig h t ly  greater than that in ra t kidney, there appears to 
be a marked species difference in the capacity of the GS-transferases 
to conjugate halogenonitrobenzenes, and this d iffe r in g  capacity 
appears to be tissue-dependent. I t  should be noted that conjugation 
of both these halogenonitrobenzenes occurs by replacement of the 
chlorine atom in position 1 of the benzene ring by GSH.
With the a3-unsaturated compounds, EA and DEM, ra t  l iv e r  GS-transferase 
a c t iv it ie s  were 2 to 3-fo ld  greater than those in the l iv e r  of the 
non-human primate; the a c t iv ity  in human l iv e r  was even less, 
approximately 35% of that in the non-human primate. The GS-transferase • 
a c t iv it ie s  present in.the kidney and ileum mucosa of the non-human 
primate were also between 17 and 35% of the respective tissue a c t iv i ty  
in the ra t .  With these classes of compound, EA (an a3-unsaturated 
ketone) and DEM (an aB-unsaturated c is -e s te r ) ,  the ra t  appears more 
able (on a cytosolic protein basis) to conjugate these xenobiotics.
I t  must be remembered, however, that the re la t iv e  s ize, and thus the 
tota l capacity of the larger species may compensate for th is apparent 
advantage of the ra t to detoxicate this type of xenobiotic.
When the substrate t-PBO was used (another a3-unsaturated ketone), 
hepatic GS-transferase a c t iv ity  with respect to both the non-human 
primate and human males were s im ilar , but a c t iv it ie s  were only 20% 
of those of the ra t .  Human females had only 50% of the hepatic 
GS-transferase a c t iv ity  present in males, but the reason for this  
apparent difference is unknown. No data fo r the hepatic 
GS-transferase a c t iv ity  of female non-human primates was obtained 
during this study and, therefore, this apparent sex-related  
difference could be investigated further. The renal GS-transferase
a c t iv ity  towards t-PBO in rhesus monkey was s lig h t ly  greater than the 
ra t ,  whereas in both the other non-human primates i t  was marginally 
lower (80% of r a t ) .
When the a l ic y c l ic  ketone (CH0) was use.d, very low levels of 
GS-transferase a c t iv i ty  were obtained in non-human primate l iv e r  
(approximately 2% of that in ra t  l i v e r ) ,  and no GS-transferase 
a c t iv ity  was detected in samples of human l iv e r .  This s trik ing  
species-related difference should be investigated in greater d e ta i l ,  
particu la r ly  with compounds which show a structural s im ila r i ty  to 
cyclohex-2-en-l-one, such as parasorbic acid*and i ts  analogues, and 
also with compounds such as prostaglandin A1, which contain a 
cyclopentenone moiety, to determine also whether such compounds 
would exert greater pharmacological or toxicological effects in 
non-human primates and man owing to this re la t iv e  in a b i l i ty  to 
enzymically conjugate such compounds with GSH.
The GS-transferase a c t iv it ie s  of the non-human primate towards 
several substrates more closely, follow the a c t iv ity  profiles observed 
in man than those of the ra t .  Such differences in GS-transferase 
a c t iv ity  which do occur are possibly due to varying amounts of 
individual isoenzymes. This concept received further support from 
the observations that the cytosolic proteins present in non-human 
primate tissues cross-react with antibodies produced against human 
"basic" glutathione S-transferases, whereas those of the ra t  and 
mouse do not. The immunological s im ila r ity  of human "acidic" and 
"neutral" GS-transferase isoenzymes with those of the non-human 
primate were not investigated, but could provide the basis fo r  
further study.
Microsomal glutathione S-transferase a c tiv ity
Hepatic microsomal GS-transferases in one of the species of non-human 
primate (baboon) were examined, and preliminary investigations show 
that this microsomal GS-transferase a c t iv i ty  towards CDNB could be 
"activated" by the sulphydryl reagents such as N-ethylmaleimide and 
iodoacetamide. The extent of activation of these enzymes in the baboon 
wasless than that observed in ra t l iv e r  microsomes. The microsomal 
GS-transferase isoenzymes of the baboon also appear to be s im ilar  
(as judged by isoe lec tr ic  focusing) to those present in the hepatic 
cytosol. The reason for the presence of GS-transferase a c t iv i ty  in 
the microsomes is open to speculation, but they could function as a 
" f i r s t  l ine  of defence" against "active metabolites" such as epoxides, 
produced by other microsomal enzymes. The close proximity of a 
detoxication system in the microsomes would, therefore, be advantageous 
to the animal.
A ctiv it ies  of the enzymes responsible for the catabolism of 
glutathione and glutathione conjugates
Once formed, the glutathione conjugates of xenobiotics can be catabolised 
(.via the cysteinylglycine and cysteine conjugates) to the respective 
mercapturic acid by the same pathway that exists fo r  GSH i t s e l f .  The 
3 enzyme systems responsible for these conversions are y-glutamyl- 
transpeptidase (y-GT), cysteinylglycine dipeptidase (CGDP) and 
N-acetyltransferase (NAT). The a c t iv it ie s  of these enzymes in the 
ra t  and 3 non-human primate species were measured, and for comparative 
purposes the re la t iv e  a c t iv it ie s  of these enzymes are given in 
Table 8. In a l l  cases, the a c t iv ity  of each enzyme system present 
in a particu lar ra t tissue has been scaled to 100.
TABLE 8
Enzymes of the mercapturic acid pathway
Species 
[  Rat = 100']
Enzyme system
y-G T * CG-D P * NAT+
Rh B C Rh B C Rh B C
Liver 300 520 425 75 98 92 41 55 65
Kidney 18 21 23 45 67 53 63 73 76
Ileum mucosa 22 13 13 49 50 28 70 64 72
Rh = Rhesus monkey; B = Baboon; C = Cynomolgus monkey.
*  Tissue homogenate. + Microsomes.
In the l iv e r  of non-human primates, the a c t iv ity  of y-GT was several­
fo ld  greater, whilst that of CG-DP was s im ilar , and that of NAT was 
approximately ha lf  that present in ra t  l iv e r .  The a c t iv it ie s  of y-GT  
in the kidney and ileum mucosa of the non-human primate were 
approximately 20% of those in the respective ra t tissues. The 
a c t iv it ie s  of the dipeptidase in these tissues of the non-human 
primates were mainly 45 to 67% of those in the respective ra t  tissues, 
whilst the a c t iv it ie s  of N-acetyltransferase were s lig h t ly  higher 
(63 to 75% of ra t  a c t iv i ty ) .
When the entire  mercapturic acid pathway in the l iv e r  is considered, 
the non-human primate appears to possess a more active system than 
that of the ra t ,  although the rate of the las t stage would be s l ig h t ly  
lower. Species-related differences in the mercapturic acid pathway 
are apparent in the kidney and ileum mucosa with the ra t being the 
most active for these tissues. Nevertheless, a l l  3 tissues of the 
non-human primate possess the capability  to catabolise glutathione
conjugates of xenobiotics, although i t  is probable that these 
conjugates may be metabolised at d if fe r in g  rates to those of synthetic  
substrates used to assay the enzyme a c t iv it ie s  in the current 
investigations.
In v itro  metabolism of ethacrynic acid using “tissue slices" and 
isolated ce lls
Tissues such as the l iv e r ,  kidney and ileum mucosa have the potential 
capacity to metabolise ethacrynic acid and its  glutathione conjugate, 
and this was confirmed using both "tissue slices" and isolated cells  
from each of these tissues. The highest.rate of metabolic conversion 
of ethacrynic acid to the cysteine conjugate was obtained with kidney 
tissue and with isolated kidney cells  of each of the non-human primates. 
The kidney ce lls  were approximately 10-fold more active than the l iv e r  
cells  whilst the mucosal cells  had an intermediate a c t iv i ty .
The apparent difference between tissue enzyme a c t iv it ie s  (y-GT and 
CG-DP) measured using the release of p -n itroan iline  from "synthetic" 
substrates, and the in v itro  catabolism of ethacrynic acid probably 
re f le c t  differences in the substrate a f f in i t ie s  of each enzyme.
Glutathione S-transferase isoenzymes in non-human primates 
All the non-human primates examined possessed 3 main groups of hepatic 
GS-transferases which can be classed as e ither "basic", "neutral" or 
"acidic" types.
The "basic" isoenzymes of the rhesus monkey contain 2 major subfractions 
designated "C" and "D", which are probably equivalent to the <5 and e 
fractions of human l iv e r  cytosol (Kamisaka e t a l ,  1975), and fractions
I l l  and IV isolated in the rhesus monkey by Asaoka et a l . (1977). The 
"C" and "D" fractions of the rhesus monkey contain 60 and 20% of the 
"basic" isoenzyme a c t iv i ty ,  which is very s im ilar to the fractions "C" 
and "D" isolated from human l iv e r .  In the baboon, both these fractions  
comprise approximately s im ilar proportions of the tota l "basic" 
isoenzyme a c t iv ity  (40% each). This particu lar d istr ibution of "basic" 
GS-transferases suggests that some substrates w i l l  be more readily  
conjugated than others.
The GS-transferases account fo r about 10% of hepatic cytosolic protein 
in the ra t (Jakoby et a l , 1976) and 2% in man (Nemoto et a l , 1975; . 
Habig et a l , 1976). In the current investigation, the corresponding 
proportion in human l iv e r  was s lig h t ly  less than 2%, whilst non-human 
primate livers  were higher, « 3% (rhesus monkey) and « 4% (baboon). 
These values are probably overestimates as the proteins were not 
rigorously purif ied .
The molecular weights of the "basic" GS-transferases isolated in the 
l iv e r  of non-human primates and man were measured in the current 
investigation as approximately.48,000, which is in close agreement 
with published data. Preliminary studies would suggest that the 
"basic" GS-transferases are dimeric proteins, composed of 2 s im ilar  
sub-units (MW * 24,000).
The substrate spec if it ies  of the major "basic" hepatic GS-transferase 
isoenzymes, obtained in the current investigations are compared with 
previously reported values (Table 9 ) ,  and i t  is apparent that they are 
sim ilar in magnitude to the previously reported values. Towards the 
substrates DCNB, p-NBC and EA, the non-human primate GS-transferases
TABLE 9
Comparison of the specific  a c tiv it ie s  of the "basic" GS-transferases
isolated from non-human primate and human l iv e r .
S u b s tr a te
S p e c ie s / f r a c t io n
Rhesus
monkey Baboon Man Mana
Rhesus*3
monkey
"C" " D" "C" " D" ”C" "D“ 6 £ I I I IV
CDNB
DCNB
p-NBC
EA
t-P B O
49
0 .3
0 .5
0.2
ND
72
0 .4
0.8
0 .3
ND
64
0 .3
0 .4
0.2
ND
43
0.2
0 .3
0.2
ND
46
0.2
0 .3
0.1
ND
47
0.2
0 .4
0.2
ND
37
0 .0 5
0.2
0 .0 3
0.001
34
0 .0 4
0.2
0 .0 4
0.002
22
0.1
0.6
NA
0 .0 0 7
90
0.2
1 .3
NA
0 .0 0 8
Abbreviations: CDNB = 1-chioro-2,4-dinitrobenzene; DCNB = 1 ,2-dichloro-4-
nitrobenzene; p-NBC = p-nitrobenzyl chloride  
EA = ethacrynic acid; t-PBO = trans-4-phenyl-3-buten-2-one.
a Data of Kamisaka et a l . (1975). b Data-of Asaoka et a l . (1977).
ND = No a c t iv ity  detected. NS = Not assayed.
possess marginally greater specific a c t iv it ie s  than those of human l iv e r .  
The results obtained for the specific a c t iv it ie s  of the "basic" 
isoenzymes isolated from human l iv e r  towards the substrates DCNB and 
EA were 4-fo ld  higher than previously reported. The reason for this  
is unknown but may re f le c t  e ither the purity  of the isoenzyme 
preparation, or the v a r ia b i l i ty  or v ia b i l i t y  of the individual l iv e r  
exami ned.
"Basic" GS-transferases isolated from the kidney of non-human primates 
had lower specific a c t iv it ie s  towards the substrates examined than 
those of the respective l iv e r  fractions. This is in keeping with the 
notion that the l iv e r  is generally the major location of xenobiotic 
metabolism in the body.
Other areas fo r  further study
Several aspects of the GSH conjugation of xenobiotics in non-human 
primates require further investigation, such as the extrahepatic 
conjugation of xenobiotics, pa rt icu la r ly  with a range of compounds 
which contain an a f t - u n s a t u r a t e d  system so as to determine possible 
s tru c tu re -ac tiv ity  relationships. This aspect should also be 
extended to the hepatic enzymes of various species, as marked species 
differences have been observed in the current investigation.
The further metabolism of the cysteine conjugate of various 
xenobiotics, involving cleavage by CS-lyase, thiomethylation, and 
possibly sulphoxidation require study, p art icu la r ly  as examples of 
these biotransformation reactions are becoming more widely recognised 
(Hawkins, 1983).
The metabolism of various GSH conjugates by isolated cells  may provide 
additional information as to the contribution made by d if fe r in g  ce ll  
types to the overall detoxication of xenobiotics via GSH conjugation, 
and possibly id en tify  specific cell populations which may be 
toxicologica lly  vulnerable in d iffe ren t tissues.
The investigations with ethacrynic acid show that the capacity fo r  GSH 
conjugation in the non-human primate is large, and demonstrate that  
various organs and tissues can simultaneously contribute to the 
detoxication and elimination of this compound. Some of the 
pharmacological properties of ethacrynic acid are less in the 
non-human primate as compared to man, and this may be due to 
differences in the rate of metabolism in these species, or perhaps 
the localisation of the pharmacologically active "metabolites" 
produced in the kidney.
The specific a c t iv i ty  and immunological p ro fi le  of the GS-transferases 
of non-human primates reveal that there is a greater s im ila r ity  
between these species and man than between the ra t  and man. Thus, 
the extrapolation of ra t data to man may be rendered less re liab le  
fo r  many compounds that are conjugated with GSH, and without metabolic 
data to suggest otherwise, the ra t  could be regarded as unsuitable in 
this respect. I t  would be important to also determine the specific  
a c t iv ity  p ro f i le  of the GS-transferases in the dog, since this is the 
alternative  non-rodent species used in xenobiotic safety evaluation. 
Should the dog prove d i f fe re n t ,  the non-human primate could become 
the preferred species fo r the safety evaluation of those xenobiotics 
l ik e ly  to be metabolised by conjugation with GSH.
In conclusion the studies reported in this thesis show:
T. Ethacrynic acid is metabolised by the mercapturic acid pathway in
the non-human primate as in other laboratory species.
2. The concentrations of glutathione in the tissues of the non-human
primate follow a s im ilar d istribution pattern to that of other 
mammals.
3. Glutathione S-transferases of the non-human primate possess
"basic", "neutral and ac id ic" ' isoenzymes, the specific  a c t iv i t ie s  
of which closely resemble those in man.
4. The entire  mercapturic acid pathway can take place in a single  
organ in the non-human primate.
The rhesus monkey, cynomolgus monkey and the baboon are s im ilar  
with respect to ethacrynic acid.metabolism, tissue glutathione 
concentrations, tissue glutathione S-transferase a c t iv i t ie s ,  and 
the specific a c t iv it ie s  of the glutathione S-transferase 
isoenzymes. The rhesus monkey more closely resembles man in 
these respects, but both the other non-human primates are 
suitable for use as a “model1 species for man in metabolic and 
toxicological investigations.
-  335 -  
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APPENDIX TO CHAPTER 3 
INDIVIDUAL DATA USED TO CONSTRUCT TABLES PRESENTED IN CHAPTER 3
The doses of 1I+C-ethacrynic acid administered to non-human primates 
are given in Tables A1 and A2.
Individual tables in this apoendix are referenced to the respective 
table in Chapter 3, in which the data is used.
Appendix 1
Animal Number Ooses mg dpm/106 uCi Specific a c tiv ity  
dpm/ug
525 I.V . 50.20 93.427 42.084 1860.4
526 Pharmacokinetics 49.99 92.999 41.891
527 51.72 96.215 43.340
528 51.56 95.926 43.210
525 I.V . 50.47 93.906 42.300 1860.4
526 Excretion 50.83 94.572 42.600
527 47.95. 89.200 40.180
528 50.17 93.329 42.040
525 Oral 50.00 93.018 41.900 1860.4
526 Pharmacokinetics 50.00 93.018 41.900
527 50.00 93.018 41.900
523 50.00 93.018 41.900
525 Oral 50.60 42.798 19.278 845.8
526 Excretion 50.60 42.798 19.278
527 50.60 42.798 19.278
523 50.60 42.798 19.278
103 I.V . 47.90 44.125 19.876 921.2 .
111 Pharmacokinetics 53.00 48.822 21.992
991 50.00 46.060 20.748
993 50.00 46.060 20.748
103 I.V . 51.91 47.821 21.541 921.2
111 Excretion 52.58 48.440 21.820
991 47.88 44.110 19.869
993 52.97 48.800 21.982
103 Oral 49.70 45.783 20.623 921.2
111 Pharmacokinetics 48.80 44.954 20.248
991 and Excretion 48.10 44.309 19.959
993 49.60 45.692 20.582
525 Bile 54.55 46.141 20.784
526 i .v. 51.95 43.942 19.794
991 Bile 48.17 43.960 19.80 921.2
993 i.v . 48.17 43.960 19.80
991 Bile 48.94 44.660 20.12
993 oral 48.94 44.660 20.12
103 Bile 50.00 32.75 14.75 654.9
i .v .
Appendix 2
Animal
Number Dose No. Conjugate Label
Dose
dpm x 10® uCi mg
mg 
G or 
Cys
mg
EA
Specific a c tiv ity  
uCi/mg
103 1 G-EA 35s 74.765 33.68 101.1 50.8 50.3 0.333
111 1 G-EA 35$ 74.765 33.68 101.1 50.8 50.3 0.333
103 2 Cys-EA 35g 54.35 24.48 68.8 19.6 49.2 0.356
103 7 EA 14C 32.75 14.75 50.0 - 50.0 0.295
103 8 G-EA 14c 51.24 23.08 98.9 49.7 49.2 0.233
103 9 Cys-EA 14C 52.24 23.53 68.9 19.7 49.2 0.342
Appendix 3 : Table 3-1 (rhesus) Appendix 4 : Table 3-1 (baboon)
Time
( h )
Subject No.
525 526 527 528
0 NO NO NO NO
0.08 28.6 31.0 26.8 43.0
0.17 21.7 18.8 20.8 35.1
0.25 16.8 16.0 17.5 23.4
0.5 9.90 12.8 10.7 17.9
0.75 6.33 7.16 7.22 10.00
1 4.78 4.82 4.60 6.11
1.5 3.53 3.20 2.55 4.65
2 2.65 2.70 2.47 3.73
2.5 2.28 2.67 1.95 3.00
3 2.12 2.47 - 1.77 2.58
4 1.91 1.86 1.58 2.31
5 1.73 1.85 1.64 2.27
6 1.62 2.03 1.52 1.86
7 1.36 1.89 1.40 1.90
8 1.37 1.91 1.30 1.81
24 0.89 1.91. 0.90 •1.21
48 0.59 1.23 0.53 0.87
72 0.54- 1.26 0.40 0.73
Time
( h )
Subject No.
103 m 991 993
0 NO NO NO NO
0.08 26.2 24.1 25.2 NS
0.17 21.2 20.8 20.9 20.7
0.25 17.8 16.8 17.1 17.6
0.5 9.1 8.8 8.5 8.6
0.75 5.4 5.2 4.9 6.0
1 4.4 4.4 4.5 4.0
2 2.8 3.0 2.4 2.5
3 2.2 2.1 2.0 2.1
4 1.9 1.7 1.7 1.7
5 1.7 1.6 1.6 1.8
6 1.5 1.4 1.5 1.6
7 1.4 1.2 1.4 1.5
24 1.2 0.9 1.4 1.2
48 1.0 0.5 1.0 1.2
72 0.8 0.3 0.8 1.1
Appendix 5 : Table 3-5 (rhesus)
Time
( h )
Subject No.
525 526 527 528
0 NO NO NO NO
0.5 0.53 0.64 0.76 0.80
1- 0.78 1.30 1.44. 0.97
1.5 0.86 1.35 1.80 0.99
2 0.89 1.25 2.23 1.07
2.5 1.07 1.19 2.49 1.15
3 1.25 1.42 2.32 1.73
4 1.86 1.43 2.22 1.59
5 1.30 1.36 1.83 1.74
6 1.38 1.41 1.75 1.44
7 1.29 1.28 1.73 1.34
8 1.31 1.27 1.61 1.35
24 1.31 1.25 1.43 1.31
48 0.76 0.99 0.99 1.23
72 0.69 0.62 0.71 0.81
96 0.52 0.52 0.54 0.57
Appendix 6 : Table 3-5 (baboon)
Time
Subject No.
( h ) 991 993 i
i
103 m
0 NO NO NO NO
0.5 0.7 0.6 0.8 0.6
1 1.0 1.0 0.9 1.0
1.5 1.0 1.1 1.1 1.4
2 1.1 1.2 1.2 1.6
2.5 1.2 2.0 1.5 2.0
3 1.7 1.5 1.4 1.9
4 1.5 1.6 1.8 1.8
5 1.6 1.5 1.4 1.7
6 1.4 1.5 1.3 1.6
7 1.4 1.5 1.3 1.5
8 NS NS NS NS
24 1.3 1.3 1.1 1.2
48 1.2 1.3 0.9 1.0
72 0.8 0.7 0.7 0.7
96 0.7 0.6 0.4 0.5
Appendix 7 : Table 3-7 (rhesus i . v . )
Sample
Animal dumber
525 526 527 528
Urine 40.25 41.53 39.64 43.69
Faeces M 1 16.19 18.67 14.64 17.70
M 2 8.11 4.72 6.20 5.99
Residue 25.83 27.35 34.52 24.95
Faeces Total 50.18 50.63 55.28 48.63
Cage Debris 0.76 0.76 0.88 0.71
Total 91.20 92.92 95.80 93.03
Appendix 8 : Urine data for Appendix 7
Time ( h ) 525 526 527 528
COCo 27.64 28.75 29.57 22.08
Cage wash 3.98 4.25 2.79 4.09
CM1CO 5.16 5.96 5.11 13.70
Cage wash 1.76 0.79 0.57 1.07
2 4 - 4 8 0.89 1.09 0.64 1.63
4 8 - 7 2 0.36 0.24 0.37 0.41
72 -  96 0.17 0.14 0.18 0.19
96 -  120 0.08 0.12 0.15 0.08
120 -  144 0.04 0.05 0.06 0.07
Cage wash 0.18 0.14 0.20 0.37
Total 40.26 41.53 39.64 43.69
Appendix 9 : Faeces data for  Appendix
(a) faeces
(a)
Animal No.
Time
<h)
525 526 527 528
0 - 2 4 34.94 23.68 35.32 29.72
2 4 - 4 8 11.97 22.78 17.48 16.38
4 8 - 7 2 1.95 3.20 1.54 1.21
72 -  96 0.88 0.43 0.54 0.91
96 -  120 0.24 0.29 0.21 0.18
«OCM 0.20 0.25 0.19 0.23
Total 50.18 50.63 55.28 48.63
(b) Animal No.
Time
Chi
525 526 527 528
0 - 2 4 12.02 9.84 9.06 11.01
2 4 - 4 8 3.15 7.42 4.57 5.76
4 8 - 7 2 0.64 0.97 0.37 0.45
72 -  96 0.14 0.18 0.40 0.37
96 -  120 0.13 0.14 0.13 0.11
120 -  144 0.11 0.12 0.11 0.12
0 -  24* 6.20 3.92 4.76 4.65
24 -  48* 1.87 0.72 1.38 1.29
48 -  96* 0.04 0.08 0.06 0.05
Total 24.30 23.39 20.84 23.81
* 2nd Methanol extraction
Appendix 10 : Table 3-7 (baboon i . v . )
Animal No.
Sample
103 m 991 993
Urine 39.62 36.97 37.96 41.15
Faeces extract 26.52 28.10 18.84 21.74
Faeces residue 29.22 24.48 37.71 30.10
Faeces to ta l 55.74 52.58 56.55 51.84
Cage debris 1.09 0.63 0.91 0.60
Total 96.45 90.18 95.42 93.59
Appendix 11 Urine data for  
Appendix 10
Time ( h ) 103 m
0 -  8 25.17 23.75
Cage wash 3.37 2.54
8 - 2 4 6.79 5.66
Cage wash 0.82 0.45
CO1 2.67 2.99
4 8 - 7 2 0.67 1.03
72 -  96 0.13 0.27
96 -  120 NO 0.17
120 -  144 NO 0.07
Cage wash NO 0.04
Total 39.62 36.97
Appendix 12 : Faeces data for Appendix 
11 (a) faeces
(b) faeces extracts
Animal No.
Time
Ch)
103 m 991 993
0 - 2 4 29.48 38.08 37.34 24.13
2 4 - 4 8 19.35 10.86 15.50 18.05
4 8 - 7 2 4.30 1.67 1.01 6.59
7 2 - 9 6 0.91 0.75 1.04 1.32
96 -  120 0.42 0.39 0.56 0.94
120 -  144 0.19 0.20- 0.19 0.21
Cage debris 1.09 0.63 0.91 0.60
Total 55.74 52.58 56.55 51.84
Appendix 11 : Urine data for  
Appendix 10
Time ( h ) 991 993
0 -  2 20.42 18.94
2 - 4 3.22 5.49
4 - 6 1.34 2.12
6 - 8 1.14 1.37
8 - 2 4 8.65 6.83
2 4 - 4 8 2.07 4.90
4 8 - 7 2 1.01 1.44
Cage wash 0.11 0.06
Total 37.96 41.15
Animal No.
Time
Ch)
103 m 991 993
0 - 2 4 14.56 20.73- 12.81 10.61
2 4 - 4 8 9.44 6.17 5.33 7.98
48 -  72 1.90 0.67 0.21 2.29
72 -  96 0.31 0.30 0.24 0.41
96 -  120 0.22 0.12 0.16 0.34
120 -  144 0.09 0.11 0.09 0.11
Total 26.52 28.10 18.84 21.74
Appendix 13 : Table 3-7 (rhesus oral)
Animal No.
Sample
525 526 527
00CMin
Urine 24.76 20.06 23.43 25.89
Faeces extract 27.11 24.68 17.89 34.54
Faeces residue 44.14 45.31 41.82 34.96
Faeces to tal 71.25 69.99 59.71 69.50
Cage debris 0.71 0.53 3.56 0.50
Total 96.72 90.58 86.70 95.89
Appendix 15
Appendix 14 : Urine data for Appendix 13
N .  Animal No.
Time
00
525 526 527 528
0 - 8 10.04 6.89 9.15 10.40
CM1CO 10.51 9.70 9.98 12.24
Cage wash 2.10 1.20 2.70 0.90
2 4 - 4 8 1.75 1.80 1.40 1.71
4 8 - 7 2 0.23 0.30 0.11 0.34
72 -  96 0.06 0.08 0.04 0.11
96 -  120 0.03 0.06 0.02 0.08
120 -  144 0.04 0.03 0.03 0.11
Cage wash NO NO NO NO
Total 24.76 20.06 23.43 25.89
Faeces data for Appendix 
13 (a) faeces 
(Jb) faeces extracts
Animal No.
Time
(h)
525 526 527 528
0 - 2 4 30.53 40.64 36.04 54.53
24 -  48 39.54 27.29 22.10 12.85
4 8 - 7 2 0.74 1.38 1.09 1.41
72 -  96 0.15 0.32 0.22 0.35
96 -  120 0.17 0.21 0.14 0.22
120 -  144 0.1£ 0.15 0.12 0; 14
Total 71.25 69.99 59.71 69.50
Animal No.
Time
Ch]
525 526 527 528
0 - 2 4 22.05 15.12 11.56 27.10
2 4 - 4 8 4.29 8.7a 5.69 6.33
4 8 - 7 2 0.43 0.42 0.33 0.64
72 -  96 0.11 0.14 0.14 0.22
96 -  120 0.14 0.12. 0.09 0.14
120 -  144 0.09 0.10 0.08 0.11
Total' 27.11 24.68 17.89 34.54
•Appendix 16 : Table 3-7 (baboon oral)
Animal No.
Sample
103 111 991 993
Urine 27.69 29.18 23.45 24.78
Faeces extract 17.91 23.51 18.75 24.50
Faeces residue 48.30 45.49 45.77 41.72
Faeces to ta l 66.21 69.00 64.52 66.22
Cage debris 1.44 0.07 1.00 1.55
Total 95.34 98.25 88.97 92.49
Appendix 18 : 'Faeces data for Appendix 
Appendix 17 : Urine data for Appendix 16 (a) faeces
16 (b) faeces extracts
Animal No.
Time
(h)
103 111 991 993
Animal No.
Time
00
103 111 991 993
0 - 8 12.81 15.65 10.21 11.61 0 - 2 4 40.80 40.26 33.64 31.50
CM1CO 9.85 8.22 9.87 10.05 24 -  48 19.65 23.62 25.65 28.09
Cage wash 2.36 2.40 1.68 0.98 4 8 - 7 2 4.72 3.73 4.13 5.39
2 4 - 4 8 2.11 2.67 1.42 1.65 72 -  96 0.82 1.08 0.85 0.79
4 8 - 7 2 0.41 0.08 0.11 0.32 96 -  120 0.12 0.20 0.17 0.38
72 -  96 0.07 0.09 0.08 0.10 120 -  144 0.10 0.11 0.08 0.07
96 -  120 0.06 0.04 0.Q4 0.04
120 -  144 0.02 0.03 0.04 0.03
Cage wash NO NO ND ’ NO Total 66.21 69.00 64.52 66.22
Total 27.69 29.81 23.45 24.78
Animal No.
Time
Ch}
103 111 991 993
0 - 2 4 13.12 14.42 10.11 15.07
24 -  48 4.00 7.53 7.37 7.21
48 -  72 0.53 0.87 1.09 2.04
72 -  96 0.11 0.46 0.08 0.10
96 -  120 0.08 0.15 0.06 0.08
120 -  144 0.07 0.08 0.04 NO
Total 17.91 23.51 18.75 24.50
